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Abstract 
Injury and illness associated with drugs are major problems in Australia and around the world, 
despite significant developments in the area of adverse drug reaction (ADR) decision support 
technology.  The aims of this thesis are: to investigate the ADR decision domain; to determine 
factors that may assist in the prevention, detection and management of ADRs; and, to inform 
the pre-requirements analysis phase of the development of decision support systems.  
 
An approach has been taken that permits open and grounded study of the decision environment.  
This approach can then be used to frame and inform the design of an ADR decision support 
system. 
 
Fifteen case studies that comprise self selected consumers,  the treating medical practitioner/s 
and expert perspectives of a single instance of an ADR (fifteen in-depth consumer interviews, 
eight in-depth medical practitioner interviews and 30 expert written questionnaires), have been 
collected and analysed using a grounded theory approach, a symbolic interactionist theoretical 
framework and a social constructionist epistemology.  The analysis was performed from three 
perspectives: individual case study analysis (all interviews for an instance of an ADR); group 
analysis (consumer, medical practitioner and expert views) and analysis combining the individual 
case studies and groups of data.  
 
Concepts, themes and theory have emerged from these data in the following areas: 
 
• the contribution of the differences in understanding of the core concepts within this 
domain, to misunderstandings between decision-makers; 
• the consumer as a diagnostic decision-maker in the ADR decision domain; 
• differential diagnostic strategies used by the consumers and medical practitioners; 
• complexities in the ADR decision domain that make diagnosis difficult; 
• the role of ADR information in consumer and medical practitioner decision-making; 
iii 
• decision types used by consumers and medical practitioners in the ADR decision 
domain; 
• resources used by consumers, medical practitioners and experts to inform their ADR 
decisions; 
• decision-making with partial knowledge of the consumer case history, drug behaviour 
and diseases;  
• the impact of suspected ADRs on consumers and on future decision-making; 
• medical practitioner/consumer decision-making models; and, 
• reasons for low ADR reporting and the impact on the development of new ADR 
knowledge. 
 
The results above suggest the following: 
 
• The ADR decision domain is more complex than the current ADR decision support 
focus and that broadening this focus may assist in providing a more complete and useful 
decision support solution. 
• Improving the prevention, detection and management of ADRs requires more than 
providing prescribers with up to date ADR information. Other important factors are 
sharing of information, awareness of the role of the consumer, a collaborative approach 
between the consumers and medical practitioners, and generation of new ADR 
knowledge. 
• A grounded theory analysis of case study data using the theoretical perspectives of social 
constructionism and symbolic interactionism provided insight into this domain from the 
perspectives of multiple decision-makers.  This may be an approach that can be used by 
systems analysts to inform the requirements analysis phases of decision support within 
other domains. 
 
The results of this qualitative work are preliminary.  Future work is required to confirm and 
expand these results. 
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 CHAPTER ONE 
1. Introduction 
Millions of prescriptions for medications are written every year by medical practitioners 
(doctors), providing treatments for consumers (patients).  A proportion of these treatments, 
however, result in further illness or injury, and in extreme cases, death. 
 
The Second National Report on Patient Safety: Improving Medication Safety by the Safety and 
Quality Council of Australia (Roughead & Semple, 2002) reported that in Australia, between 
1999 and 2000, two to three percent of total Australian hospital admissions may have been 
associated with medications. This equates to about 140,000 of the total 5.9 million hospital 
admissions across Australia.  
 
According to Kohn, Corrigan and Donaldson (1999), the number of Americans to die each year 
from medical error is somewhere between 44,000 to 98,000 reflecting 2.9% to 3.7% of 
hospitalisations. Even using the lower estimate, at the time of the report, more people died in 
America in a given year as a result of medical errors than from motor vehicle accidents (43,458), 
breast cancer (42,297) or AIDS (16,516).  Every year, over 6,000 Americans die from workplace 
injuries.  The subset of these errors that are related to medications alone, occurring either in or 
out of the hospital are estimated to account for over 7,000 deaths annually, and two out of every 
100 hospital admissions experienced an error that was considered preventable (Kohn, Corrigan 
& Donaldson, 1999). 
 
The Therapeutics Goods Administration (TGA) in Australia is responsible for the quality, safety 
and efficacy of prescription and over the counter medicines marketed in Australia.  Every 
medication that is approved for general use in Australia is first trialled by between 3,000 and 
10,000 consumers.  As the group of people who trial the drugs are small, medical practitioners 
and consumers can report any additional problems they notice when using these new drugs to 
ADRAC (Adverse Drug Reaction Advisory Committee) at the TGA.  These reports are analysed 
by members of ADRAC and are then stored in a central database.  The database now contains 
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30 years of data.  Warnings about these new medications, which are based on these data, are 
collated by ADRAC and communicated back to the medical practitioners via a publication called 
The Australian Adverse Drug Reaction Bulletin. 
 
Considerable knowledge exists about the properties of therapeutic medications (drugs), and the 
reasons why they may or may not result in unwanted non-therapeutic symptoms (adverse drug 
reactions).  Knowledge may exist that relates to consumers in the general population or in 
specific groups such as women who are pregnant, or people with liver disease.  What is 
unknown or partially known is: how this knowledge is used within a clinical setting when making 
decisions about drugs; and when there is so much information available, why preventable 
adverse drug reactions continue to occur.  These questions provide a focus for this work. 
 
This chapter will define the research problem to be addressed within this work in section 1.1, 
followed by the aims of the thesis in section 1.2.  The research questions that have been posed 
to address the research problem and a rationale for those questions in section 1.3 are followed 
by an introduction to some terminology used within the work (section 1.4). 
 
1.1. Research problem 
The proposal for the research within this thesis arose from a problem raised by the Therapeutics 
Goods Administration (TGA), the central body in Australia for collecting voluntary reports from 
health professionals about suspected ADRs.   
 
In the early stages of the work within this thesis, a General Practice Computing Group (GPCG) 
funded project was conducted to investigate methods of disseminating the ADR information 
collected by ADRAC back to prescribers.  It began with the aim of creating a database from The 
Australian Adverse Drug Reaction Bulletin which contain new adverse drug reaction information, and 
determining where within the GP workflow this information could be incorporated to assist in 
providing up to date information that related to the specific consumer within the consulting 
room, at the time of prescribing.  The results of this preliminary work have been documented in 
the Final Report to Department of Health and Aged Care for Contract for Services GPCG #12: 
Adverse Drug Reactions Improved Decision Support (ADRIDS) (O'Brien, 2001).  An overview 
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of the processes used by the TGA to collect spontaneous reports can be found in section 2.2.5.1 
of this thesis.  
 
Data collected to inform the GPCG funded project included a series of four GP forums, 
interviews with four medical software companies that develop GP desktop software, and a 
forum with GP experts in health informatics from around Australia. 
 
In addition to the work conducted through the GPCG funded project, a hospital pharmacist and 
a consumer who experienced a severe ADR were interviewed.  The results of these interviews 
were documented in a University of Ballarat internal research report (O'Brien & Yearwood, 
2002).  The combined work from the GPCG project and the interviews with the hospital 
pharmacist and consumer form what is referred to in the remainder of this thesis, as the 
preliminary background studies. 
 
Below are the key points that were highlighted from each of the initial data gathering phases in 
the preliminary background studies (O'Brien & Yearwood, 2005). 
 
GP Forums  
The perception of the group was that:  
 ADRs occur infrequently within a community setting; 
 the number of medications on the market is increasing.  As a result, updating their knowledge 
about potential ADRs is also increasingly difficult; 
 a computer program that sits in the background of their prescribing software would be useful.  
Because their perception is that ADRs occur infrequently, they believe it is a high priority to 
prevent them when possible, but a low priority regarding the time spent on ADR prevention 
compared with the other demands within their workload.   
TGA discussions   
The members of the TGA ADR team reported that: 
 their primary role is to discover previously undocumented ADRs, to document them and 
alert the public as to their existence; 
3 
CHAPTER ONE: INTRODUCTION 
 
 background information about how the TGA ADR team operates was recorded.  
Detailed information about this can be found in section 2.2.5.1; 
 a key element in identifying an ADR is to differentially diagnose between an ADR, the 
presenting disease, or a newly presenting disease.  Generally this can be done with only a 
limited level of certainty, particularly if the ADR is one that has not been previously 
documented.  Often it is not possible to do this differential diagnosis at the time the 
ADR occurs, but new ADRs can be discovered if prescribers report suspected ADRs.  If 
there are enough reports from within Australia or around the world to produce a signal, 
ADRAC can be more certain that there is a relationship between a drug or group of 
drugs and a symptom or set of symptoms. 
 
Consumer 
This single case study highlighted the following: 
 medical data for this consumer was stored in many locations.  The consumer was the 
only person who knew where the complete medical history was located, and she was too 
ill to alert medical staff. She had experienced similar symptoms 10 years earlier, but had 
only limited information about that suspected reaction; 
 the consumer made decisions that may have impacted on the outcome of the ADR.  
These decisions included: when to seek medical assistance, who to seek medical 
assistance from; and what information from her past medical history was relevant to 
relay to the doctor; 
 having experienced a life-threatening ADR, she is highly motivated to prevent future 
ADRs. 
Pharmacist 
The pharmacist provided insight into the ADR reporting practices within a single Melbourne 
hospital.  He also highlighted the following: 
 if a person has experienced an ADR, ensuring the person has enough knowledge to 
prevent a second exposure to that medication was a high priority; 
 accurate diagnosis is essential, although often extremely difficult.  He stated that blaming 
a drug for an ADR means the person does not have access to that form of drug therapy 
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in the future.  Not detecting the drug, results in an increased risk of the person being re-
exposed to the same drug a second time. 
 
Whilst conducting the preliminary background studies, a number of factors converged, which 
resulted in a fresh look at this problem, and a new understanding of this problem domain. 
 
 Three key aspects to the ADR decision domain emerged from the preliminary work; 
prevention of ADRs, early detection and diagnosis of ADRs, and management of ADRs.  
Discriminating between the three stages was important. 
 
 The results of the preliminary background work raised the question of the impact a system 
such as ADRIDS would have on prescriber decision-making.  If a prescriber knows that a 
consumer may experience a particular reaction to a specific drug, would it alter their decision 
of what to prescribe?  For example, if a consumer had a one in 10,000 chance of developing 
an ADR from one medication compared with a one in 50,000 chance for a different 
medication, would it alter the decision of which medication to prescribe?  This information 
may be more likely to assist in detecting an ADR if it was suspected, rather than assisting in 
the decision of which drug to prescribe. 
 
 There was an apparent disparity between the concern within the literature of the high 
incidence of ADRs, and the opinion of the GPs who participated in the forums that ADRs 
were sparse within a clinical setting, and so although ADRs are important to avoid and detect, 
they involved a small proportion of a GP workload. 
 
 The hospital pharmacist was interviewed about the ADR data collection and reporting 
processes used within a large metropolitan hospital.  It became clear that different groups 
within the ADR decision environment had different priorities about which aspect of the 
ADR decision domain was most important in the prevention, detection and management of 
ADRs. 
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 A consumer who had just experienced a severe life threatening ADR offered to record her 
story, in the form of a case study, for inclusion in the preliminary work.  This case study 
highlighted a number of issues that indicated some limitations of current knowledge in the 
ADR decision domain. 
 
The culmination of these events resulted in a new understanding of the problem.  The key issues 
highlighted were that the ADR decision domain is more complex than a single decision-maker 
making prescribing decisions, and that there is a limited understanding of the ADR decision 
domain.  In order to develop any decision support solution, a clearer understanding of the 
domain is required, otherwise systems will continue to be developed based on this limited 
knowledge of the domain, resulting in systems that provide only a partial solution.  
 
1.2. Aims of  the thesis 
The overall aims of this thesis, arising from the problem described in the previous section, are to 
develop an understanding of: the ADR decision domain which will add to current knowledge of 
how ADR decisions are made; the problems that arise when making these decisions; and the 
complexities and the impact ADRs have on people.   
 
The work of this thesis has three key purposes: 
 
 to add to knowledge of this domain, so that it can be used by the decision-makers within this 
domain to assist in the prevention, detection and management of ADRs; 
 to provide an understanding of the domain that can be used to inform the requirements 
analysis phase of ADR decision support;  
 to determine the extent that the methodology used within this work can be applied to the 
requirements analysis phase in the field of software and/or systems engineering. 
 
1.3. Research questions 
The following research questions will be addressed within this work.  Each question or group of 
questions will be followed by a rationale. 
6 
CHAPTER ONE: INTRODUCTION 
 
 Who are the decision-makers in the ADR domain?      
 What decisions are made by each decision-maker?     
 
The literature that has been reviewed in chapter two suggests that the majority of ADR decision 
support has been developed for medical practitioners, indicating that they are the primary 
decision-makers within this field.  The preliminary background work (O'Brien & Yearwood, 
2002) suggests that consumers are also involved in the ADR decision domain, and the decision 
types are broader than prescribing decisions.  This work suggest that it is essential when 
attempting to design decision support systems, to know whose decisions are being supported, 
and which decisions need to be supported. 
  
 What do decision-makers understand by the term ADR?  
 Do all decision-makers agree on a definition of an ADR?   
 
Once it has been established who within this domain are the people making ADR decisions, it is 
important to determine if all decision-makers have a similar understanding of the core concepts 
within the domain.  To address these research questions, a symbolic interactionist philosophical 
perspective (discussed in detail in section 3.3) has been used.  From this perspective, it is 
assumed that people from different groups will use the same terminology differently.  In order to 
develop decision support that will be used by people from multiple groups, it is important to 
understand how they use the core terminology, and whether they use it in similar ways. 
  
 How are ADR decisions made? 
 What problems occur when making ADR decisions? 
 What resources are used by decision-makers: information and knowledge sources and 
content? 
 
To determine which decisions need to be supported, knowledge of how decision-makers 
currently make ADR decisions, which resources they use and the effectiveness of those 
resources, and where problems arise, will highlight where within the decision domain, support 
and new understanding is required.  Understanding when and how ADR’s occur, will provide an 
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opportunity to find solutions to the specific problem areas within the domain.  There is likely to 
be a range of possible solutions to various aspects of the problem domain and these solutions 
may or may not involve decision support.   
 
 How do ADRs affect people and how does this impact on decision-making? 
 
ADRs can result in injury and illness from a treatment which is expected to assist consumers.  
Understanding the impact ADRs have on consumers, and understanding how this affects future 
decisions, assists in gathering a holistic understanding of this problem.  It recognises that 
technology developed within this area is to assist humans, and an understanding of their 
experiences, may assist in developing solutions that take this context into account. 
 
 How do decision-makers contribute to the creation of new knowledge at an individual, 
national and international level? 
 
ADR knowledge is gathered by ADRAC from prescribers and consumers.  It is analysed by 
ADRAC, and then fed back to prescribers.  For completeness, this question has been included 
to understand the full cycle of ADR knowledge development and dissemination, rather than just 
understanding how the information is fed back to prescribers. 
 
 To what extent can a grounded theory analysis of ADR case studies which include multiple 
views of a single instance of an ADR, assist in understanding the ADR decision domain to 
inform decision-makers and software and/or systems designers working within this area? 
 
A method adapted from Information Systems (IS) research (discussed in detail in section 3.4.1) 
has been used to develop an understanding of a decision domain prior to developing decision 
support.  This method arose from an awareness that the traditional requirements analysis 
exercise conducted in the preliminary background studies did not fully inform the decision 
domain.   
8 
CHAPTER ONE: INTRODUCTION 
 
1.4. Terminology 
Most terminology within this domain will be defined in chapter two.  A number of terms, 
however, reflect some of the preliminary assumptions underlying this work.  They have been 
described in the following sections.   
 
Consumer versus patient; medical practitioner versus doctor 
Throughout this work, the terms ‘consumer’ and ‘medical practitioner’ have been chosen rather 
than ‘patient’ and ‘doctor’.  A social constructionist epistemology and symbolic interactionist 
theoretical framework, discussed in chapter three, assumes that members of each group within 
society interact using symbols or language to share meaning.  An underlying assumption, 
therefore, is that members of different sociological groups may use terminology based on shared 
understanding within their own group.  It is important, therefore, to use terminology that 
reflects the shared understanding of the sociological groups within this decision domain. 
 
The term ‘doctor’ can be defined by the Macquarie Dictionary as “a person licensed to practise 
medicine, or some branch of medicine; a physician or medical practitioner other than a surgeon” 
(Macquarie University, 2001).  As can be seen by this definition, ‘doctor’ and ‘medical 
practitioner’ are synonyms and therefore can be used interchangeably.   
  
The term ‘patient’ can be defined as “1. one who is under medical or surgical treatment. 2. a 
person or thing that undergoes action (opposed to agent)”, and the term ‘consumer’ can be 
defined as “one who uses a commodity or service (opposed to producer)” (Macquarie University, 
2001).  According to the second part of the definition of ‘patient’, a patient is acted upon, rather 
than someone who uses a service, which is the definition of a ‘consumer’.  The terms ‘doctor’ 
and ‘patient’ have implications within our society, therefore, that the ‘doctor’ is the person who 
acts upon a patient, and the ‘patient’ is the recipient of that expertise, who is acted upon.  The terms 
‘medical practitioner’ and ‘consumer’, imply that ‘medical practitioners’ provide a service, and 
‘consumers’ are the purchasers or recipients of that service.  As will be discussed in depth in 
section 2.3.6, the term ‘patient’ therefore is in line with Emanuel and Emanuel’s (1992) 
paternalistic model of medical decision-making, whereas the term ‘consumer’, is more in line 
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with Emanuel and Emanuel’s (1992) informed and collaborative models of medical decision-
making. 
It is acknowledged that at times a ‘consumer’ is a ‘patient’ in a medical system.  That is, at times a 
health professional acts upon a person in the health care system, as in the case of a procedure 
such as an x-ray.   In the case of ADR decision-making, as will be seen throughout the work of 
this thesis, the person with the suspected ADR may seek advice from a service provider about 
the nature of their symptoms, an act that is in line with the term ‘consumer’ of a health service, 
rather than ‘patient’ of a health service.  The terms ‘consumer’ and ‘medical practitioner’ have 
therefore been used within the body of this work, rather than ‘doctor’ and ‘patient’.  The term 
‘medical practitioner’, has been used for general practitioner, specialist or hospital based medical 
practitioner; it is the person who is being consulted.  When important to discriminate between 
the types of medical practitioners, the terms GP, specialist, or hospital medical practitioner have 
been used. 
 
Expert 
The participants from ADRAC have been designated as ‘experts’.  The reason for this is that 
they work only with the diagnosis of ADRs, and have specialist knowledge in this area.  By using 
this term, it is acknowledged that the experts have implicitly been placed at a higher level of 
importance, over and above that of the medical practitioners and/or consumers.  This may 
appear to be incongruent with a symbolic interactionist theoretical perspective, where the 
emphasis is on accepting multiple perspectives equally.  In the ADR area, it is the members of 
ADRAC who decide which of the reported suspected ADRs are likely to be ADRs, and which 
are more likely to have an explanation other than an association between the suspected drug and 
the newly presenting symptoms.  The term ‘expert’ has been used to reflect this role ADRAC 
plays in the ADR decision domain. 
 
Drug versus medicine 
The term ‘drug’ is used to mean: a therapeutic medication that is available either through 
prescription or over the counter at a supermarket or pharmacy; or a complementary medication, 
such as an herbal remedy.  The terms ‘drug’ and ‘medicine’ have been used interchangeably, as 
there does not appear to be a significant distinction between these terms.  The term ‘drug’ 
however, is the term used by the medical community within the literature, and so it is the term 
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that has been used in this context.  The term ‘medicine’ or ‘medication’ is the term most 
commonly used when speaking with consumers, to avoid the confusion with the use of the term 
‘drug’ in our society to mean illegal drug. 
 
Other terms used within this work have either been defined initially in chapter two, or have been 
informed by the data and have been described in chapter six. 
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 CHAPTER TWO 
2. Adverse Drug Reactions and 
Decision Support 
2.1. Introduction 
This research is about understanding the medical practitioner/consumer decision-making 
environment specific to adverse drug reactions (ADRs).  The context is to broaden 
understanding to assist in the prevention, early detection and management of ADRs, and to 
consider if decision support may assist with this problem.  Literature surrounding ADRs, 
medical practitioner/consumer decision-making, and decision support technologies, will be 
reviewed in this chapter.   
 
The review begins by providing an understanding of ADRs in section 2.2 including ADR 
definitions (section 2.2.1), the incidence of ADRs in Australia and around the world, section 
2.2.2), the reasons ADRs are known to occur (section 2.2.3), the types of ADRs that have been 
classified (section 2.2.4), a discussion of the attempts that have been made to reduce ADRs 
(section 2.2.5), and some national initiatives that will provide the infrastructure required to 
support ADR decision support applications (section 2.2.6).  This will be followed by a summary 
of some of the problems that still need to be addressed within this domain. 
 
The second component of this chapter (section 2.3) aims to provide an understanding of the 
decision processes surrounding ADRs.  This section begins with an evaluation of current ADR 
decision support (section 2.3.1).  This is followed by a discussion of a number of components of 
a decision support system, including: the ADR decision-makers (section 2.3.2), ADR decision 
types (section 2.3.3), the ADR decision environment (section 2.3.4), decision theories and 
technologies that may be applicable to this domain (section 2.3.5), and decision models (section 
2.3.6).  The final section in this chapter, section 2.4, will discuss literature that has used grounded 
theory to analyse case studies to assist in the software and/or systems design process. 
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2.2. Adverse drug reactions 
2.2.1. ADR DEFINITIONS 
There is some confusion within the literature about the definitions of ADRs. Terms used include 
Adverse Events, Adverse Drug Events (ADE), ADRs, Medical Error and Medication Error.  In 
particular, the terms ADE, and ADR seem to be used interchangeably at times (Bates, 2000; 
Bortnichak & Dai, 1999), yet based on the definitions below, there is a significant difference 
between these terms. 
 
2.2.1.1. Definitions of drug related events. 
The Therapeutics Goods Administration (TGA), use the World Health Organization (WHO) 
definition of an ADR (WHO, 2004, Definitions Section)1.   
 
A response to a drug which is noxious and unintended, and which occurs at doses normally 
used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function.  
 
Adverse drug reactions can be defined further.  The Therapeutics Goods Administration (TGA) 
is particularly interested in collecting data about serious and unexpected reactions that have not 
been previously documented, or where the incidence suddenly increases.  Serious and 
unexpected reactions are defined below. 
 
Serious Reaction 
Again, the TGA use the WHO (2004, Definitions Section) of a ‘serious reaction’, below: 
 
 A reaction which results in death, requires inpatient hospitalisation or prolongation of 
existing hospitalisation results in persistent or significant disability or incapacity is life-
threatening. 
 
1 This style of referencing is recommended by the American Psychological Association. (2001, August 1).  APA style 
for electronic sources. Available from http://www.apastyle.org.  This style is used when the electronic source has 
no page numbers. 
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The TGA extend this definition to include birth defects and malignancy (Purcell, 2001). 
 
Unexpected Reaction 
An ‘unexpected reaction’ is defined by WHO (2004, Definitions Section): 
 
An adverse reaction, the nature or severity of which is not consistent with domestic labelling 
or market authorization, or expected from characteristics of the drug. 
 
The underlying implication of each of the above definitions is that the reaction is related to the 
pharmacological properties of the drug. 
 
Woodstock (2000) from the Food and Drug Administration in America describes an Adverse 
Event (AE) as “an undesired outcome that occurs during healthcare”(p. 2). She describes ADRs 
as AEs where there is a relationship between the undesired outcome and a drug.  The definition 
of an ADR used by Woodstock (2000) is broader than the WHO (2004) definition, as it includes 
human error, rather that reactions directly related to the pharmacology of the drug. 
 
Woodstock (2000) describes some of the problems associated with drugs, highlighting that “ No 
drug is 100 percent safe; no pharmacologically active medicine exists that does not have side 
effects” (p. 2). Some of these ADRs, she says, however, are preventable.  These have been listed 
below. 
 
Defective product 
 Error in the manufacturing of the drug 
 
Medication error 
 Prescribing 
o Calculating dosage 
o Prescribing the correct drug 
 Dispensing 
o Reading handwriting 
o Understanding verbal medication errors 
o Dispensing the proper medication 
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Medical error 
 Misdiagnosis 
 Improper choice of treatment 
 Failure to avoid drug interactions 
 Failure to detect if the drug treatment is not working 
 Failure to detect if the drug is causing further injury 
 Failure to avoid allergic reaction 
 
Consumer error 
 Failure to understand instructions 
 Failure to follow instructions 
 Drug taken by someone other than whom the drug was prescribed 
 
An adverse drug event (ADE) can be broadly described as any adverse event that is drug related 
whether it is as a result of a consumer being given the wrong drug or dosage, or related to the 
properties of the drug. Adverse drug reactions (ADR) are a subset of ADEs.  Woodstock’s 
definition above, is more in line with a definition of ADE, rather than the World Health 
Organization (WHO) definition of an ADR. 
 
To re-iterate the key differences in these terms, an Adverse Event (AE), therefore is any medical 
event that results in an adverse outcome, such as surgery on the wrong leg.  An Adverse Drug 
Event (ADE) is any event related to a drug or medication that results in an adverse outcome.  
This may be as a result of human or process errors.  An Adverse Drug Reaction (ADR) is a drug 
related event that is related to the pharmacological properties of the drug that results in an 
adverse outcome. 
 
It is acknowledged that ADEs and ADRs are highly interrelated, in that all ADRs are also 
adverse events and adverse events that are drug related. At times a result of this work may relate 
to an ADE as well as an ADR, however, as the scope of this work is limited to ADRs, 
implications will only be discussed in the context of ADRs.  The following section (section 2.2.2, 
Incidence of ADRs) discusses the literature relating to ADRs.  Due to the confusion in 
terminology within the literature between ADRs and ADE,  it is necessary to highlight the 
inconsistencies within the literature when discussing these terms in an attempt to understand the 
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incidence of ADRs.  The remainder of the work of this thesis will focus on implications that 
relate only to ADRs. 
 
2.2.2. INCIDENCE OF ADRS 
ADRs can cause death and injury, secondary illness, increased hospital stays, and sometimes 
require aggressive treatment to treat the ADR.   In order to know the extent of the problem and 
to be able to measure long-term effectiveness, it is important to have some understanding of the 
incidence of ADRs.   
 
The Second National Report on Patient Safety: Improving Medication Safety by the Safety and 
Quality Council of Australia, by Roughead and Semple (2002), describes ADRs as a particular 
type of adverse drug event (ADE)  which includes side effects associated with medications. 
 
Roughead and Semple (2002) reported that in Australia, between 1999 and 2000, two to three 
percent of total Australian hospital admissions might have been associated with medications 
(refers to ADEs). This equates to about 140,000 of the total 5.9 million hospital admissions 
across Australia. 
 
The landmark report To Err is Human.  Building a Safer Health System edited by Kohn et al. (1999) 
provides incidence figures which have been quoted extensively as a rationale for continuing 
research and development within this field.  They state that the number of Americans to die 
each year from medical error is somewhere between 44,000 – 98,000 reflecting 2.9% to 3.7% of 
hospitalisations.  These figures refer to adverse events (AEs).  A major teaching hospital in the 
USA estimated that two out of every 100 admissions experienced a preventable ADE.  Here the 
definition is of drug events, but the figures reflect preventable events rather than a total figure.  
This indicates that the total number of ADEs is in excess of two percent.  As discussed in the 
previous section (section 2.2.1), ADRs are a subset of ADEs.  ADR figures were not reported 
within this report. 
 
Pirmohamed, Breckenridge, Kitteringham and Park (1998) from the University of Liverpool, 
state that five percent of all hospital admissions are caused by ADRs, and ten to twenty percent 
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of all hospital inpatients experience ADRs. They also state that ADRs are responsible for the 
death of 0.1% of medical and 0.01% of surgical inpatients.  
 
Lazarou, Pomeranz and Corey (1998) reported the incidence of serious ADRs to be 6.7% and 
fatal ADRs 0.32%.  They estimated from their studies that in 1994 in excess of two million 
hospital consumers had serious ADRs and over 100,000 experienced fatal ADRs, making this 
between the fourth and sixth leading cause of death in the USA.  Interestingly, these figures are 
higher than those reported in To Err is Human: Building a Safer Health system (Kohn et al. 1999), 
but use the WHO ADR definition. 
 
Jha, Kuperman, Rittenberg, Teich and Bates (2001) have developed a computer-based 
monitoring system to alert staff when an ADE may be present.  Their aim was to measure 
hospital admissions caused by ADEs and to measure the associated costs.  They concluded that 
1.4% of admissions were caused by ADEs.  They state in their introduction that drugs cause 
20% of ADEs (That is, 20% of ADEs are ADRs).  Using this approximate value, their study 
appears to indicate that 0.28% of hospital admissions are caused by ADRs. 
 
Bates (2000) quoted Lazarou et al.’s article (1998) to emphasise the high incidence of ADRs, but 
then continued to discuss technology that may assist in the prevention of medication errors. 
Some of the suggestions include robots for filling prescriptions and bar coding of medications.  
In this case, Bates is referring to ADEs.  This is a clear example of confused terminology.  The 
incidence figures Lazarou used were in reference to ADRs, but the technologies suggested by 
Bates to assist with the problem relate to ADEs. 
 
Estimating incidence is complicated by a number of factors. In addition to the difficulties 
surrounding ADR reporting, described in O’Brien and Yearwood (2002), there is the issue of 
medical staff recognising ADRs. This issue is important not only for estimating incidence, but 
also because early detection of an ADR and cessation of the medication can reduce the injury or 
illness caused by the ADR.  According to Dormann, Criegee-Rieck, Neubert, Egger, Geise, 
Krebs, Schneider, Levy, Hahn and Brune (2003), four percent of all admissions to the hospital 
were due to ADRs, and in addition, another 4.5% were present. They also showed in their study 
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that over half of the ADRs were not recognised by either the admitting or the attending 
physician. 
 
Between studies, there is a large variation in the estimated incidence of ADRs and ADEs.  One 
study referred to ADRs and ADEs upon admission to hospital (Jha, Kuperman, Rittenberg, 
Teich & Bates, 2001), some to ADRs and ADEs that happen when an inpatient in a hospital 
(Kohn et al., 1999; Lazarou, Pomeranz & Corey, 1998), and some to hospital admission and 
whilst an inpatient in a hospital (Dormann, Criegee-Rieck, Neubert, Egger, Geise, Krebs, 
Schneider, Levy, Hahn & Brune, 2003; Pirmohamed, Breckenridge, Kitteringham & Park, 1998). 
Other reasons may include different definitions, data collection techniques or variations between 
hospitals and countries.  It is clear from all of these studies that the incidence of Adverse Events, 
Adverse Drug Events and Adverse Drug Reactions result in a significant number of injuries and 
deaths, many of which are considered preventable, and that a significant proportion of ADRs are 
undetected, resulting in the injury or illness continuing beyond the initial incident. 
 
As stated in the previous section, from this point forward the discussion will relate only to 
ADRs. 
 
2.2.3. REASONS FOR ADRS 
ADRs are known to occur for a number of reasons. They can be caused by drug properties, 
changes in their properties under certain conditions and drug interactions.  Reactions can also be 
caused by the effects they can have on individuals.  These individual consumers may have 
particular hypersensitivities, idiosyncratic absorption or metabolic characteristics, or particular 
conditions where particular drugs are contra-indicated.   
 
The above reactions are triggered by the drugs themselves.  Another set of reasons contributing 
to the incidences of ADRs may be related to the decisions made by those involved in the 
prevention, detection and management of ADRs in consumers.   
 
2.2.4. TYPES OF ADRS 
ADRs can be classified in multiple ways.  Below, descriptions of Type A to F reactions, drug 
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interactions and contraindications are discussed.   One source of information used in this section 
was an expert in ADRs from the TGA who provided information via personal communication 
(Purcell, 2003). 
 
2.2.4.1. Type A 
Type A ADRs are “predictable events or reactions, pharmacological reactions or expected events 
or reactions.  They are common and are accounted for by a drug’s known pharmacological 
properties” (Kalachnik, 1999).  Purcell (2003) provided the example of respiratory depression 
due to a narcotic drug such as morphine which was used for treating severe pain. 
 
2.2.4.2. Type B 
Type B ADRs are unpredictable events or reactions: Also referred to as “idiosyncratic or 
unexpected events or reactions.  These reactions are uncommon and independent of a drug’s 
known pharmacological properties…They are considered the most serious and are potentially 
life threatening” (Kalachnik, 1999).  This group includes hypersensitive reactions.  A person may 
have a slight reaction the first time they are in contact with the drug, but may react more severely 
with each subsequent contact.   
 
The key characteristics of Type A and Type B reactions have been summarised in Table 2-1. 
 
Type A (augmented) Type B (bizarre) 
Pharmacological Hypersensitivity or idiosyncratic 
Dose related Not dose related 
Predictable Unpredictable 
Common Rare 
Usually not serious Usually serious 
Majority discovered before marketing Majority discovered after marketing 
Relatively low mortality Relatively high mortality 
Generally reversible (rapidly) with cessation 
of drug or decreased dose. 
Generally not quickly reversible. 
Table 2-1 Comparison between Type A and Type B ADRs (Purcell 2001) 
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2.2.4.3. Additional classifications of ADRs 
Type A and Type B are the reaction types most commonly used by ADRAC.  Edwards and 
Aronson (2000) expand these categories.  These include:  
 
 Type C, dose related and time related. Uncommon and related to the cumulative dose;  
 Type D, delayed. Uncommon, usually dose related and usually becomes apparent some 
time after the use of the drug;  
 Type E, withdrawal. Uncommon, occurs soon after the withdrawal of the drug; 
 Type F, unexpected failure of therapy due to the intrinsic properties of the drug in 
question. Common, dose related and often caused by drug interactions.  
 
Purcell (2003) expanded on Edward and Aronson’s (2000) definition of a Type F ADR.  A Type 
F ADR may signify a counterfeit medicine.  A counterfeit medicine looks like a reputable brand 
name drug but has no active ingredient and is simply fraudulent.  Other reasons for therapeutic 
failure include: 
 
ADRs that result in therapeutic failure 
 shortened shelf life due to breach of storage conditions, such as temperature and/or 
humidity; 
 quality control problems during the manufacturing process, which may result in an inadequate 
amount of the active ingredient; 
 the subset of ‘vaccine failures’ which are due to the properties of the drug, a small proportion 
of individuals who have been vaccinated will develop the disease notwithstanding the fact of 
prior vaccination. 
 
2.2.4.4. Drug interactions 
Drug interactions are ADRs that are caused by drug/drug or drug/food interactions (Kalachnik, 
1999).  According to Purcell (2003), reactions can also involve herbal remedies. 
 
Purcell (2003) describes two subtypes of drug interactions, pharmacokinetic and 
pharmacodynamic. 
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Pharmacokinetic 
Absorption, distribution, localisation in the tissues, biotransformation or excretion of one drug 
may result in an increased or decreased blood level or tissue level of the second drug/s.  
 
Pharmacodynamic 
Additive effects:  An example is when two drugs are taken for hypertension, hypotension may be 
the reaction.  
 
An additional complication is that the reaction to one drug may cause problems with a second 
drug.  An example is a drug that causes vomiting may result in the second drug not being 
absorbed.  
 
2.2.4.5. Contraindications (drug-disease interactions) 
A final type of ADR can occur in consumers who have particular pre-existing conditions.  If a 
drug is known to put stress on a particular part of the body, such as the effect of paracetamol on 
the liver, a consumer who has a condition which affects the liver such as cirrhosis, is likely to be 
more susceptible to the possible side effects of the drug, than a person with a healthy liver.  
Purcell (2003) explained that a specific drug is contraindicated by a particular condition.  The 
contraindication is the condition/status which contraindicates the drug.  Some drugs will be 
classified as absolute contraindications for consumers with a particular condition, indicating the 
drug must never be taken by a consumer with a particular condition, whilst other drugs will be 
classified as a relative contraindication for a particular condition, indicating the drug should not 
be taken by consumers with that specific condition.  
 
2.2.4.6. The nocebo phenomenon 
An additional complexity within the area of ADRs is the concept of the nocebo phenomenon, 
or the nocebo effect.  This effect is similar to the placebo effect.  When a consumer experiences 
a placebo effect, s/he takes a substance that has no effect, such as a sugar tablet, believes that 
the tablet will have a positive effect, and so experiences a positive effect.   
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The nocebo effect is when a consumer takes a substance that does not cause harm, again, such 
as a sugar tablet, but the consumer believes it may cause harm, s/he experiences harmful effects, 
which they perceive to be due to the drug.  The complexities surrounding the nocebo effect will 
be discussed further in section 6.2.3.3. 
 
2.2.4.7. Medical error 
It is well documented that even though ADR types A to E are known to occur within the 
population, it is not possible at this stage to predict who will or will not experience a reaction, if 
the person has not previously been exposed to that particular drug and so they are not classified 
as ‘error’.  Preventable errors, such as prescribing a drug that is: contraindicated for a particular 
consumer; that a consumer has previously experienced an allergic reaction to; is known to cause 
a drug interaction; or caused by a manufacturing fault, can be classified, according to 
Woodstock’s (2000) definition, as medical error.  Failure to detect a Type A to E reaction is also 
classified, according to Woodstock’s (2000) definition, as error.   
 
Classifying error in this field however is difficult.  It is clear which ADRs cannot be prevented, 
but defining exactly which ADRs are preventable is complex, and poorly defined.  If two drugs 
are ‘known’ to interact in an adverse way, what is meant by ‘known’?  Generally the term appears 
to be used to mean well described and previously well documented in the literature.  Is it 
assumed a medical practitioner will have access to all documented literature, or is it only 
considered an ‘error’ if it is documented in particular locations such as in product information?  
If a consumer has previously reacted to a particular drug, where is that information stored?  It 
could be in one medical practitioner’s file which is not accessible to a medical practitioner in 
another setting.  The consumer may know about it, but only know it as labelled by a drug trade 
name, and not recognise the name of a newly prescribed drug.   
 
Failure to detect a Type A to E ADR is also classified by Woodcroft (2002) as medical error.  
This definition, again, is problematic:  failure to detect a suspected ADR within what time 
frame?  At what point is it clear that an ADR has not been detected that ‘should’ have been 
detected?  It is clear that this definition provides guidance about problems within the prescribing 
domain, but does not explicitly state at what point an ‘error’ has been made.  
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Several articles (Bates, 1999; Dean, Schachter, Vincent & Barber, 2002) including a report of the 
Victorian Drug Usage Advisory Committee on Drug Error Prevention in Victorian Hospitals 
(Australia) (VDUAC, 2002) called Beyond blame, emphasised that often error is caused by a 
combination or sequence of events, and that fostering a ‘no-blame’ culture with the aim of 
understanding why errors occur and managing them at a systems level that is co-ordinated is 
more effective than an approach at individual level of ‘blame’. 
 
2.2.5. EFFORTS TO REDUCE THE INCIDENCE OF ADRS 
Understanding why ADRs occur, and exploring methods to increase this understanding are the 
first step in finding ways to decrease the incidence and severity of injury caused by ADRs. 
 
Decreasing the severity of an ADR can be achieved by preventing the ADR or in cases where it 
was not possible to prevent the ADR, to detect it quickly to minimize the impact on the 
consumer. 
 
Efforts to decrease the impact of ADRs appear to fall into six major categories: drug surveillance 
at a national and international level; clinical guidelines; desktop prescribing packages with built in 
alerts; hospital based alert systems; and education of both prescribers and consumers.  
 
2.2.5.1. Drug surveillance - Australia 
Drug surveillance assists in the prevention and early detection of ADRs by collecting suspected 
ADRs, documenting previously unknown information about the behaviour of particular drugs, 
and disseminating that information to prescribers.  This can assist prescribers make decisions 
about who is most at risk of experiencing an ADR from a particular drug, and assist in 
identifying ADRs in situations where prevention was not possible. 
 
ADRAC reporting processes 
The ADRAC reporting processes were documented in the GPCG funded work that formed part 
of the preliminary background studies (O'Brien, 2001).  These processes have been described 
below. 
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The TGA receives approx 13000 reports per year, of which approximately 7000 come in blue 
cards or a similar format.  The blue cards include a defined number of fields and often contain 
additional information.  The remainder of the reports arrive via phone,  fax and occasionally by 
email.  Reporting is voluntary, and is from medical practitioners, pharmacists and drug 
companies.  GPs as a group report infrequently compared with the other groups. 
 
Processing ADR Reports 
On arrival, the reports are date stamped, triaged by a professional officer (nurse with Bachelor of 
Applied Science in Psychology).  Reports of more serious reactions are channelled to the 
secretariat within the TGA.  The reports are then annotated, highlighting the suspected drug(s), 
other drug(s), reaction term(s), relevant laboratory data, additional information, and then a 
causality rating is applied according to the committee's guidelines.  If the reaction/interaction is 
'unlabelled' this is drawn to the committee's attention, a check of the database is made to see if 
there are any other similar reports and MEDLARS is searched to ascertain whether the reaction 
has been published.  Often workload is so great that this level of checking is not possible. 
 
The reports are then transferred to clerical staff who number them, enter the data into the TGA 
database and check the data against the original report for accuracy.  Overnight, a validation 
module updates the database by including the validated reports.  For most reports (drugs of 
current interest and all reports mentioning WHO's critical reaction terms) a photocopy is made 
and forwarded to ADRAC for review at the next available meeting. The reports are then filed 
under the drug name(s).  ADRAC meets eight times per year, reviews the more serious reports, 
discusses what action(s) it wants (more information, company comment, WHO data, literature 
search, ADRAC Bulletin item and other publication).   Any corrections to the coding are made 
after the meeting and a subset of the data is then transmitted electronically to the WHO Uppsala 
Monitoring Centre.  
 
Compiling an ADRAC Bulletin item 
ADRAC identifies a drug safety issue from the reports reviewed.  The secretariat then prepares 
an overview and/or a draft item for the ADRAC Bulletin.  This involves looking at a summary 
printout for the drug, identifying the reaction(s) of interest, printing out the individual case 
summaries and aggregating the findings. This involves a 'pencil and paper' exercise to identify 
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such things as age and sex information, onset latencies (date arithmetic), doses, outcomes, 
laboratory data, and recovery times.  The draft compiled by the secretariat is then considered by 
ADRAC at its meeting(s) (sometimes over six months). The draft is then edited and updated 
until accepted by the committee and ready for printing.  55,000 copies of the ADRAC Bulletin 
are distributed to Australian health professionals as well as overseas agencies. 
 
Use of the TGA ADR database 
TGA receives 2400 calls requesting information from the TGA ADR database per year.  Of the 
calls, approx 60% are faxed.  The remainder are phone and possibly once a week via the 
Internet.  Occasionally there will be a request attached to the blue card that has been posted in. 
 
Requests from the TGA ADR database 
The usual question/requests asked are: 
 What is the profile of a particular drug? 
 What drugs are known to cause a particular reaction? 
 Has a particular drug been known to cause a particular reaction? 
 Sometimes they will ask for information about a particular case. 
 When reporting a reaction – has this reaction been reported before? 
 
Requests can come from pharmacists, GPs, pharmacists on behalf of GPs, hospital drug 
information services.  The current database can produce three main reports. 
 
Drug Summary - Type 9 report.   
The report includes the following information; 
 Single (generic) drug – multiple trade names; 
 Reaction (preferred) terms listed alphabetically; 
 Optional listing within system organ class. 
 
This report is a simple line listing.  It includes the number of reports that identify a specified 
reaction with a specific drug and can be generated at the time of a phone query by a doctor. 
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Reaction Summary – Type 19 
 Lists all drugs against single (preferred) reaction. 
 
Individual case report summary - Type 16 report   
 Formatted anonymous details of individual reports. 
 
Drug Surveillance programs both for pre and post marketing exist in many countries (ADRAC, 
2001; Coulter, 2000; Grant, Coulson & Wood, 2000; Hartmann, Koller Doser & Kuhn, 1999; 
Jarernsiripornkul, Krska, Capps, Richards & Lee, 2002; Myhr, 1998; NAPRA, 2003; Orsini & 
Funk, 1995; Sutcliff, McMorran & Morawiecka, 2000).  Once ADRs have been reported, 
collected and analysed, the information is then disseminated back to health professionals.   
 
The pre marketing information is contained in approved product information (PI) available to 
medical practitioners and through products such as MIMS.  Post marketing information is fed 
back to health professionals via The Australian Adverse Drug Reaction Bulletin, and to consumers via 
the Consumer Medicine Information (CMI). 
 
In Australia, ADR reporting is primarily from hospital, pharmacist and general practice 
environments.  Recently a consumer reporting system has also commenced.  There is a 
telephone reporting system for consumers, the AME (Adverse Medicine Events) Line, that can 
be accessed by the National Prescribing Service web site (NPS, 2004).  The line is manned by 
pharmacists who take the calls and make a diagnosis.  The ADRs that are detected and meet the 
ADRAC reporting criteria are passed to ADRAC for processing. 
 
Consumers Report on Medicines, Policy and Practice, (CRM, 2000) a policy that was adopted at the First 
International Conference on CRM in Sweden, talks about the limitations of ADR reporting 
systems that only include pharmacist and medical practitioners reporting. The document states 
that:  
 
…only a small proportion of practising physicians (often less than 5%) and a relatively small 
number of pharmacists (varying from country to country) contribute data to these systems: 
consequently information on suspected adverse effects communicated by a patient to his 
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physician stands a 95% chance of going no further and making no contribution to the 
adverse drug reaction reporting system (section 1.2 para. 1). 
 
This reinforces the need for  consumer reporting such as the AME (Adverse Medicine Events) 
Line, mentioned above. 
 
2.2.5.2. Drug surveillance - World Health Organization (WHO) 
The World Health Organization (WHO) collects data from 72 countries around the world in an 
attempt to detect ADR signals that are too weak for any individual country to detect. (Lindquist, 
Edwards, Bate, Fucik, Nunes & Stahl, 1999; WHO, 2003).  Some of the services WHO (2004) 
provides to the national centres includes:  identifying new signals from the information 
submitted by the national centres; provision of the WHO database; information exchange 
between national centres and WHO; publications of newsletters and reports; provision of 
training and support to the national centres; and annual meetings of the representatives of 
national centres. 
 
2.2.5.3. Clinical information and guidelines 
The use of information and guidelines to assist medical practitioners with clinical decision-
making is not a new concept.  Guidelines for detecting and reporting ADRs exist in many 
countries around the world, and are often included with guidelines on reporting ADRs to the 
national reporting body (American Society of Consultant Pharmacists, 1998; American Society 
of Health-System Pharmacists, 1995; Naranjo, Shear & Lanctot, 1992; VDUAC, 1999; WHO, 
2002).  These paper based guidelines provide advice to medical practitioners and pharmacists 
about processes that can be followed that will assist in determining if the symptoms observed are 
likely to be associated with an ADR, rather than other reasons such as the existence of an ADE.  
An example is “Ensure that the medicine ordered is the medicine received and actually taken by 
the patient at the dose advised; Verify the onset of the suspected ADR was after the drug was 
taken, not before and discuss carefully the observation by the patient” (WHO, 2002, p. 14).  If 
the medicine received was incorrect, or the dosage taken by the consumer was at an incorrect 
dose, the diagnosis is likely to be an ADE rather than an ADR. 
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One set of guidelines, described by the authors as an algorithm for ADR detection and diagnosis 
provided in-depth stepwise procedures to assist in the diagnosis of ADRs.  This system uses 
statistical procedures, a Bayesian adverse drug reaction diagnostic instrument for determining the 
likelihood that the symptoms are an ADR (Naranjo et al., 1992). 
 
The innovation, however, is taking the paper based information and guidelines, building them 
into clinical software, and developing search engines that assist in locating the information that 
relates to the specific consumer in the consulting room, at the time of decision-making (Barnett, 
Famiglietti, Kim, Hoffer & Feldman, 1998; Beliakov & Warren, 2001; Thomas, Dayton & Peter, 
1999).  Clinical information and guidelines have been shown to be most effective when 
integrated into the General Practitioner’s (GP) decision-making process, and are linked to the 
actual consumer data (Beliakov & Warren, 2001). 
 
PRODIGY (Prescribing RatiOnally with Decision-support In General practice studY)  (SCHIN, 
1998), developed at the University of Newcastle in the United Kingdom is one example of a 
clinical guidelines system that has decision support to assist in locating information at the time it 
is required by the consumer and the GP.  The functionality within the system is described below: 
 
Following diagnosis, the GP is presented with clinical advice and therapeutic 
recommendations; information about non-drug treatments and consumer information 
leaflets is also included.  The Phase Two system includes an extended choice of drugs, more 
comprehensive advisory texts and additional features such as Doctor-patient shared advice 
screens (p. 1). 
 
One of the goals of PRODIGY phase two was to ensure the guidelines were based on best 
practice medicine, and that the drugs recommended were based on appropriateness, safety, 
effectiveness and cost.  These guidelines also include advice about potential ADRs. 
 
Therapeutic Guidelines, in Australia, is another organisation working towards incorporating their 
clinical guidelines, previously in textbook format, into GP desktop software with Decision 
support to allow the guidelines to be context dependent (Therapeutic Guidelines, 2004).  
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Information that was previously in text books or journals incorporated into software with 
decision support modules that locate the critical information the health professional requires at 
the time of decision-making is a significant step forward in assisting with medical decision-
making.  These systems are in the early stages of development and need to be highly tuned in 
order to assist in a medical environment. The GPs in ADR discussion forums indicated that if 
the information is too specific, too broad, too many alerts, takes too much time, is not relevant 
to the consumer within the consultation, the system is less likely to be used (O'Brien, 2001). 
 
2.2.5.4. Electronic prescribing with ADR decision support modules 
Electronic prescribing packages are becoming more popular in general practice clinics and are 
beginning to be introduced into hospital environments.  Four packages were reviewed in the 
preliminary work for this project  (O'Brien, 2001). 
 
A GP may use the full features of the software, which often include a full electronic medical 
record, or they may only use the software for prescribing.  Of the group of GPs who 
participated in ADR forums in the preliminary background studies, the majority used their 
desktop software purely for prescribing (O'Brien, 2001). 
 
Decision support features built into these software products include access to product 
information, drug/drug interactions, drugs that are contraindicated for a specific condition and 
allergy alerts.  The drug/drug interactions use a data source such as the MIMS Interact Database, 
or the A-Z Dex database (O'Brien, 2001). 
 
Some of the clinical guidelines decision support systems (DSS) described in the previous section 
are designed to be embedded into clinical prescribing software or electronic medical records.  
GPs who participated in discussion forums in the preliminary work (O'Brien, 2001) discussed 
difficulties in using these products.  Some of the problems they found were: 
 
 Alerts are too frequent. 
 Alerts are not graded according to severity. 
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 ADRs in product information (PI) sheets are conservative making it difficult to know 
during consultation how likely it is that an ADR will affect a consumer. 
 PI that is available within these products discuss ADRs that are primarily from pre and 
post drug trials – spontaneous reporting data are in some of the PIs, but the process of 
including it can take up to a year. 
 
One complexity raised in discussions with a member of ADRAC is that in many cases the 
frequency of a particular ADR is unknown and the information is therefore not available to be 
included within these prescribing packages.  Another problem raised in the GP forums (O’Brien, 
2001) is that the GPs often do not put the key information into these software packages, and so 
the alerts do not have the information they require to become activated. 
 
2.2.5.5. Early warning ADR alert systems 
The electronic prescribing packages mentioned above work with information about the drugs a 
consumer is taking or may take in the future, and limited medical history about the consumer 
such as known allergies, or significant medical conditions. 
 
Hospital based alert systems which have a knowledge based engine use a body of medical history  
based on information collected whilst the consumer is a hospital inpatient. These systems warn 
staff if a consumer is showing early signs of reacting to a drug, or is at higher than expected risk 
of a reaction. 
 
Raschke, Gollihare, Wunderlich, Guidry, Leibowitz, Peirce, Lemelson, Heisler and Susong 
(1998) developed a computer alert system with the aims of correcting prescription errors that 
may lead to ADEs and detecting ADEs before harm occurs. In this paper, the term ADE is 
used, but it fits within the definition of ADR used within the present study. The system they 
developed targeted a set of 37 known reactions.  For each of the reactions, a set of vital signs 
have upper and lower limits.  If a combination of these signs is registered an alert is triggered. 
Primary preventative alerts are triggered when a consumer may be about to have a reaction, and 
secondary prevention alerts are triggered when a consumer is experiencing a mild ADR.  The 
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aim is to prevent ADRs progressing to serious ADRs.  Of the alerts triggered, 54% were true 
alerts.  The alerts identified opportunities to prevent injury at a rate of 64 per 1,000 admissions. 
 
Another group of researchers has developed a clinical event monitor which scans electronic 
messages that contain new clinical and administrative information sent between clinical 
computing systems, or within an individual system, and notifies medical staff of any patterns that 
indicate there may be a problem that requires attention (Payne, Savarina, Marshall & Hoey, 
2000). The system triggers during order processing, admit, discharge and transfer movements.  
The system monitors events such as alerting the ADE coordinator if drugs are ordered that may 
indicate an ADR has occurred, dose checks and drug interactions.  Again, the system works on 
business rules.  The system described by Payne et al. (2000) is limited to eight rules.  Their 
conclusion is that although the system has proven useful, development of the business rules is an 
iterative process that is complex. 
 
Alert is a clinical decision support tool developed by the Baptist Health System (Caldwell, 2000).  
When a consumer is admitted to hospital, admission and demographic information is fed into 
their clinical data repository.  Whilst the consumer is in the hospital, information is collected 
including laboratory results, medications, diet and radiology.  As in the previous two systems, the 
data are passed through a rule-based module and alerts are triggered if certain criteria are met. 
 
These systems are hospital based and require medical records to be electronic.  They are rule-
based, which like any medical rule-based system, requires frequent updates due to the rate of 
change in medical knowledge. Most of these systems have also been used to estimate the 
number of ADRs occurring in a particular hospital setting (Bates, 2000; Caldwell, 2000; Payne et 
al., 2000; Raschke, Gollihare, Wunderlich, Guidry, Leibowitz, Peirce, Lemelson, Heisler & 
Susong, 1998).  These systems are currently in the research stage, and are not fully implemented. 
 
2.2.5.6. Awareness, information and education 
Prevention is primarily about minimizing a consumer’s risk of taking a medication that may 
cause injury.  Prevention also includes the detection of ADRs as soon as possible in order to 
prevent ongoing injury. 
 
CHAPTER TWO: ADVERSE DRUG REACTIONS AND DECISION SUPPORT 
 
33 
Many articles distinguish between preventable and unpreventable ADRs and make suggestions 
about prevention (Bannwarth, Queneau, Carpentier, Guliana, Bouget & Trombert, 2003; Brown 
& Landry, 2001; Cohen, 2000; Dormann et al., 2003; Geyer, 2003; Lachs & Boyer, 2003). 
Strategies include taking a detailed case history of reactions to drugs, awareness of consumers 
who are at high risk (such as the elderly on multiple drugs), the use of databases (electronic and 
manual) to check for interactions, to be aware of which drugs are more likely to cause 
interactions and family history of reactions to medications which may require a tailored approach 
to medication management for consumers (FDA, 2002). 
 
Lachs and Boyer (2003) have produced an article for the consumer titled Seven steps to safer drug 
use.  This article describes the things that a consumer needs to advise his/her health practitioner 
about even if the medical practitioner does not specifically ask.  They discuss the disclosure of all 
medications, prescription, non-prescription and complementary.  They discuss disclosing this 
information even if the medical practitioner is not prescribing a new medication, as the current 
symptoms may be related to a medication they are taking.  They also discuss mentioning all 
allergies they have had in the past, as a drug that is being prescribed may be of the same drug 
class or ‘family’ of drugs, and so should be avoided.  
 
Information to assist with ADR decision-making has been another focus of prevention and early 
detection.  The focus has been on providing up to date newly described ADRs relating to: old 
medications, or medications that are new on the market, product information, drug interaction 
information, drug-disease interaction information primarily to prescribers and consumer 
information sheets for consumers.   
 
2.2.6. THE AUSTRALIAN CONTEXT 
Australia has a number of state and national projects under development that will add 
infrastructure that will assist with this problem. 
 
2.2.6.1. Health Online 
The Health Online is a national plan for health information management for Australia.  The key 
objectives include: achieving national collaboration; laying sound foundations in the areas of 
privacy laws; security and standards; empowering consumers; supporting clinical care; using 
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information to build a more efficient and effective health care system; and to exporting 
telehealth and health informatics services. 
 
Health Online has identified a number of national projects, including electronic decision support, 
electronic health records, HealthInsite, MediConnect, standards and privacy (Health Online, 2004).  
Key projects that relate to drug safety have been discussed in the following sections.  
 
2.2.6.2. Electronic Decision Support 
In 2002, the National Institute of Clinical Studies (NICS) and the National Health Information 
Management Advisory Council (NHIMAC) jointly sponsored the Electronic Decision Support 
Governance Workshop, (Phillips, 2002) which aimed to identify the key issues and priorities for 
governance in the area of clinical decision support, and then to bridge the gap between research 
and clinical practice. This report relates to Electronic Decision Support Systems (EDSS) in 
health.  It is not specific to decision support related to ADRs. 
 
Within the report, the authors stated that although decision support is an important new 
development to assist clinicians who are overloaded with new information, the development has 
been fragmented and uncoordinated leading to problems of accessibility, scalability, duplication 
and lack of integration with existing systems.  This initial workshop resulted in the establishment 
of a National Electronic Decision Support Taskforce to address the key priorities that were 
identified within this initial workshop. 
 
Phillips (2002, p. 5) listed the issues to be addressed by the taskforce.  They included: 
 
 the current activity and expenditure in the electronic decision support sector; 
 evidence of effectiveness of the different EDSS in improving outcomes; 
 consultations with stakeholders in relation to their business needs (e.g. software industry 
and their information needs (e.g. clinicians and other end users); 
 areas of highest priority for national governance in terms of health outcomes, improved 
delivery of research evidence into practice and improved quality and safety of decision 
support systems. 
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The report included within the appendices the responses from 27 organisations to a pre-
workshop survey as well as presentations from five keynote speakers.  The following key issues 
were highlighted by participants within the workshop (Phillips, 2002).  Several of these issues 
have been addressed by the research in this thesis:   
 
 The NSW Health Department stated one of their priories as “Modelling the clinical decision-
making process to identify the business processes that require decision support and 
determine what form of decision support is appropriate” (p. 44). 
 The Health Advisory Committee/NHMRC and University of Queensland included as a 
priority “developing interfaces designed for how people really work – that is not just ‘user 
friendly’ but designed to be intuitive and less rather than more work than non-EDS system” 
(p. 49) 
 The Consumer Health Forum said “ongoing consultation with consumers around ehealth 
initiatives in a more general sense including decision support, integrated health records etc.” 
(p. 64). 
 “The flexibility and facility for consumer empowerment and self-management as well as 
allowance for input from consumers during the health encounter.  The issue of ‘compliance’2 
needs to be reframed in terms of empowerment” (p. 64)  
 
2.2.6.3. Health Connect 
Health Connect (2004) is an electronic medical record that has been proposed and is being 
developed for use in Australia.  It is currently in its second phase of development.  The Health 
Connect concept is that health information would be collected by the health service provider at 
the point of care and stored in a standard format.  Health providers, with consumer consent, 
would be able to access previous episodes of care from health providers, regardless of its 
location.  Consumers would also have access to their records.  The information would contain 
summaries of the episode of care, not all of the details. 
 
 
2 Recently the term ‘concordance’ has begun being used by some medical practitioners in an attempt to recognise 
shared decision making. 
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Advantages of this concept include: allowing consumers to have more control over their 
information; allowing consumers to participate actively in decisions about their health; 
improving the speed of access and accuracy of information enabling more time for direct 
services to the consumer; reduction in the duplication of services; improved portability of health 
records and exchange of information between providers; and better information for research and 
the development of policy and planning (Health Connect, 2004). 
 
Phase one of the project has been completed.  Phase two will occur between 2003 and 2005.  
The key objectives are to demonstrate value and feasibility, develop a robust business case for 
proceeding, finalise the design, select system components, commence the process for integration 
with systems such as MediConnect, continue developing other essential building blocks for an 
electronic health record, ensure stakeholders are informed and ready, and develop a national 
implementation plan. 
 
This is another example of a positive step forward towards integration of medical information.  
An electronic health record that allows access to previous medical records will assist with 
ensuring a full case history is available.  The issue remains that putting all of the information 
together, is a first step.  Knowing what is in a large record, however, and being able to access key 
factors is another issue.  If, within a ten year record of event summaries, there is a record 
highlighting a suspected ADR, the question is whether either the consumer and/or prescriber 
will know it is there, and think to read it.  Having information in textual event summaries, will be 
like having yet another source of data available, such as guidelines or The Australian Adverse Drug 
Reaction Bulletin, for both the consumer and prescriber to access.  The next phase will be to 
develop decision support software that can assist in retrieving critical elements from the episode 
of care summaries, and bringing them to the attention of the decision-maker at the time of 
decision-making. 
  
2.2.6.4. HealthInsite 
Hopkins and Fogg (2002) discussed the issue of accessing health information via the Internet.  
They stated that consumers have concerns over the quality of the information on the Internet, 
however value the convenience and access to such a wide variety of resources that can be 
accessed to provide in-depth health advice.   
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HealthInsite was first piloted in 1999 by the Commonwealth Department of Health and Ageing to 
provide Australians with high quality, relevant information.  According to Hopkins and Fogg 
(2002), the feedback about the site was generally positive, and the concept was well received.  
Issues such as promotion of the site, ensuring all levels of users can access it easily, and in 
particular ongoing review with consumers as the site develops.  
 
An aspect of the HealthInsite project that pertains to ADRs, is that it contains information about 
conditions and diseases, and treatment options. There are plans to include Consumer Medicine 
Information leaflets in the future.   
 
2.2.6.5. MediConnect 
MediConnect (2004) is a project that has the aim of creating summaries of medication records 
which will be available to service providers, with consumer permission, regardless of which 
service provider created the record.  MediConnect aims to reduce the incidence of adverse drug 
events by improving consumer and health care access to complete medical information.   
 
The electronic medical record will be stored with the Health Insurance Commission (HIC).  
Service providers will be able to access these records when necessary.  The only service 
providers to access the records, and new medications will only be added to the record with 
consumer consent. 
 
The record will hold identifying information and also information about previous adverse drug 
reactions.  The record will include not only prescription medications, but also over the counter 
and complementary medicines.  Information about why the medication has been prescribed will 
also be included.  This project is currently being trialled in Ballarat and Launceston.  
 
A centralised medications record will assist with the reduction of adverse drug reactions in areas 
such as drug interactions and a recorded history of previous adverse drug reactions.  This system 
will become significantly more useful in the prevention of adverse drug reactions if it is 
connected to drug interaction databases. 
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This initiative, again, is a significant step forward in the integration of health information.  Again, 
in order for it to be useful to ADR decision-makers, the decision-makers need to think to access 
the information, and they need to consider the possibility that the symptoms the consumer is 
exhibiting may be related to one of the drugs they are taking. 
 
2.2.6.6. Standards and Laws 
There are some key issues that need to be resolved before any form of electronic health 
information exchange can occur.  Unless consumer health information is secure and privacy can 
be ensured, consumers will not be prepared to endorse information sharing.  As of January 2004, 
a proposed privacy code, which has been developed and available for public comment, is before 
health ministers for consideration (Health Online, 2004).  A copy of the code is available at 
www.health.gov.au/pubs/nhpcode.htm. 
 
Without national and preferably international data and technical standards, communication 
between systems is arduous, and information integrity may be compromised.  The Information 
and Communications Technology Standards Committee (ICTSC) has developed a plan Setting the 
Standards: A National Health Information Standards plan for Australia.  This can also be accessed on 
the Health Online web site (Health Online, 2004). 
 
Standard drug names and drug codes, standard methods of transporting clinical and medical 
information between service providers, consumer rights that include privacy and security of their 
information are all building blocks required to allow electronic data to be shared.  The concept 
of shared electronic data is a cornerstone for the development of electronic clinical decision 
support systems, as it will allow the key information to be accessible to the ADR decision-
makers at the time of decision-making.  In addition, in order for a decision support system that 
has been developed to be transportable to other sectors, a standard infrastructure is essential.  
 
2.2.6.7. Clinician’s Health Channel 
The Clinician’s Health Channel (2003) is a Victorian Government initiative with the aim of 
providing clinicians, which includes medical practitioners, nurses and allied health professions in 
the Victorian public health sector, quality information relevant to Australian clinicians.   
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The Clinician’s Health Channel, provides prescribers with access to a wide variety of electronic 
databases including Drug Product Information, the Australian Medicine’s Handbook, Mims, 
Micromedix which includes a drug interaction tool and alternative medicine information, 
Therapeutic Guidelines, and access to the National Prescribing Service.  It also includes access to 
a number of bulletins including The Australian Adverse Drug Reaction Bulletin. 
This is an example of a system, which provides access to a very wide variety of drug information 
and drug safety resources.  The issue remains, however, that in order to access this information 
to prevent and detect ADRs, a prescriber needs to realise that there is information available that 
they need to access, and access the information at the time within their workflow that they need 
it. 
 
2.2.6.8. Better Health Channel 
The Better Health Channel (2003) is the equivalent of the Clinician’s Health Channel, but for 
consumers.  It provides a range of information about medicines, and the consumer Medication 
Information sheets are available via this site. 
 
2.2.6.9. Consumer Medicine Information 
The Consumer Medicine Information (CMI) is information aimed for consumers and is available for 
all prescription medications and some over-the-counter and complementary medications.  This 
leaflet is the consumer equivalent of the product information sheets for medical practitioners.  
These leaflets will soon be available via the NPS web site, but are currently available on the Better 
Health Channel (2003). 
 
In the last year (2003-2004), the National Prescribing Service in Australia (NPS) have continued 
to develop resources to assist consumers make decisions about medications.  These include a 
consumer information line (Medicines Line), general information about medicines (Medimate), and 
a consumer newsletter produced by consumers for consumers (NPS, 2004). 
 
The consumer drugs and information line provides a facility for consumers to ask pharmacists 
questions about medications including prescription, non-prescription and complementary, and 
to report suspected ADRs.  
 
CHAPTER TWO: ADVERSE DRUG REACTIONS AND DECISION SUPPORT 
 
40 
Medimate provides more general information about medicines and is available for consumers to 
print or view over the Internet.  This product encourages consumers to work with their medical 
practitioner and pharmacist, but also assists consumers make their own decisions by providing 
up to date information using non-medical language.   
 
This initiative is a positive step towards providing consumers with access to reliable information. 
Some positive aspects of these sheets are that as well as including specific information about the 
drug, they also include information about consumer behaviour, and information that the 
consumer must tell the medical practitioner and/or pharmacist.  These areas are very 
comprehensive.   
 
Problems with the information sheets are that each of the CMI is four pages in length in fairly 
small print so a consumer would need to be fairly motivated to read it all in detail, and have 
adequate eye sight.  The sheets state that they do not contain all of the available information, 
which raises the questions of how a consumer does access all available information, and what 
other information there is to know about the medication that is not stated on the sheet.   
Although there are many medical terms defined, there remains medical terminology that would 
not be understood by the average person, such as in the information about Tramal.  This sheet 
states that you must tell your medical practitioner if “you are known to be sensitive to opioids” 
(Better Health Channel, 2003, Tramal(R) SR Sustained Release Tablets).  This implies that the 
consumer understands that opioids are a class of drugs, and knows which drugs belong to that 
class. 
 
2.2.7. ISSUES WITH EFFORTS TO REDUCE ADRS 
As can be seen from sections 2.2.5 and 2.2.6, there have been many developments within this 
area to either, directly reduce illness and injury caused by ADRs or indirectly through improved 
infrastructure.  Many of these systems are still at the research or planning stage, and have yet to 
be implemented. 
 
Having reviewed the literature associated with the efforts that have been made to reduce ADRs, 
a number of issues remain including the following: 
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 Drug surveillance systems work on voluntary reporting, and many ADRs go unreported. 
 Drug alerts within GP desktop systems at this time alert too frequently and the drug 
information provided is too broad to be useful. 
 The likelihood of a specific drug causing an ADR for a specific consumer is not known 
if the consumer has not previously taken the drug. 
 Hospital alert systems use rules which need to be updated frequently.  They are useful 
for consumers being monitored in hospitals but do not generalise to community settings. 
 The majority of ADR decision support is for the prescriber, rather than providing 
support for multiple decision-makers. 
 There are many information sources that are now available on the Internet.  The 
information is in multiple locations using a variety of search options.  There is 
duplication between HealthInsite, a commonwealth initiative and the Clinician’s Health 
Channel and Better Health Channel which are state initiatives.  These systems are only useful 
if the decision-makers realise that the symptoms may pertain to an ADR, and think to 
access them. 
  
The preliminary background studies suggested that the current understanding of the ADR 
decision domain used to develop the systems described above is limited, and there are many 
additional sources of information that may be used by prescribers and consumers currently that 
are not included in these systems, (O'Brien & Yearwood, 2002).  It is also not clear how the 
information is used within the prescriber workflow. 
 
Within the work of this thesis, an aim is to learn more about these information sources, 
understand more about how people currently use the information that is available, who the key 
decision-makers are within the domain, the nature of the decisions being made and the 
additional requirements people have that may be able to assist in the prevention, early detection 
and management of ADRs. 
 
Having explored adverse drug reactions in the current section, the next section provides an 
overview of decision-making, including a diagram illustrating the key components involved in 
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developing a decision support system, discussion about who the decision-makers are within the 
ADR environment, the ADR decision environment, key domain characteristics and some 
decision support techniques that may be useful in this domain. 
 
2.3. Decision support  
The work described in this thesis is exploratory in nature.  As the context of this work is 
whether decision support may be able to assist with the prevention, detection and/or 
management of ADRs, a general overview of decision support systems and their potential 
application to this area has been included below. 
 
The development of a decision support system may use a range of building blocks.  These have 
been visually represented in Figure 2-1, below. 
 
2.3-2 2.3-3
Environment
2.3-4
ision
Theory/ies
Decision or set of
Decisions
2.3-6
Decision Support
Technology/ies
Decision Dec+ +
+ = 2.3-7Decision SupportSystem2.3-5Decision Model/s
2.3-1
Decision
of deci
ve been developed for use across many different discipline areas, 
-maker or group
sion-makers +
 
Figure 2-1 Building blocks for the development of a decision support system 
Decision support systems ha
and as a consequence, different people have different understandings of decision support 
concepts.  When discussing decision support with a general practitioner, an example of a 
decision support system raised may be the medical practitioner’s desk top prescribing package 
that has a built in alert signalling when two drugs prescribed may result in an interaction.  In 
contrast, a manager of a company may see decision support as a software package that will utilise 
years of operational data stored in a data warehouse to forecast future trends that may assist with 
decisions about marketing.   
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sing a particular perspective such as from a behaviouralist’s or a 
aturalistic perspective.  A computer analyst from the field of decision support, may be more 
may be more on what do humans currently do.  
he computer analyst’s focus may be more about how can software replicate and ‘improve’ 
su ecision’, and ‘Decide’ 
e remainder are definitions based on 
to do)  
to select as a course of action—used with an infinitive (decided to go) 
t based on 
e most likely possibility, rather than making a definitive choice that ends uncertainty.   
stance may be in the 
rm of technical or non-technical support. Methods may be as simple as a decision flowchart 
on a wall, through to a fully automated system that can make autonomous decisions. 
A psychologist may refer to a decision theory as a theory that has been developed to explain how 
a human makes decisions u
n
interested in prescriptive decision theory, such as Utility Theory, that can be applied to the 
development of a computer system that takes into consideration preferences, risk and 
uncertainty, and utilises probability to determine the ‘best’ decision based on the parameters 
input into the system.  The psychologist’s focus 
T
decision-making processes. 
 
To assist with clarity, an explanation of how these terms have been used within the decision 
pport domain have been described below.  The first two definitions, ‘D
are from the Merriam-Webster (2003) online dictionary.  Th
how the terms have been used within this work: 
 
Decision: the act or process of deciding. 
Decide:  
 to arrive at a solution that ends uncertainty or dispute about (decide what 
 to bring to a definitive end (one blow decided the fight) 
 to induce to come to a choice (her pleas decided him to help) 
 intransitive senses: to make a choice or judgement. 
It is the final component of this definition that is applicable to the ADR decision domain.  The 
medical practitioners in an ADR domain appear to be more likely to make a judgemen
th
 
Decision Support: Assist with the act of deciding.  Based on the definition for decide, the goal 
of decision support is to assist in making a decision to a greater level of certainty than without 
the decision support, or to prompt that a decision needs to be made.  Assi
fo
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t to predict future decisions based on past decisions. 
y. 
ecision-making.  The 
The current strategies that are being used to assist in decreasing the incidence of injury caused by 
ADRs have been evaluated. These strategies were described in section 2.2.5. They included: drug 
surveillance in Australia; drug surveillance world wide; computerised clinical guidelines; 
electronic prescribing with ADR decision support modules; early warning ADR alert systems; 
and increased awareness and education.    In this section they will be reviewed using Figure 2-1 
as a framework for discussion.  The results of this evaluation are in Table 2-2.   
 
Decision Theory: A number of theories of decision-making.  This may include theories to 
describe how humans currently make decisions, theories that attempt to suggest methods of 
increasing the effectiveness of decision-making based on some criteria of ‘effective’, or theories 
that attemp
 
Decision Model: A generic model generally implies a representation of a larger scale real world 
object.  The representation is generally simpler, smaller, and includes the key features.  A 
decision model attempts to provide a similar function.  It describes a series of steps or processes, 
in a simplified form of decision-making based on a specific decision theory or group of decision 
theories.    
 
Decision Support Technology: Tools that have been used in any domain to develop a decision 
support system.  These tools may be in the form of database concepts such as data warehousing, 
tools based on statistical analysis such as probability, Bayesian techniques, neural networks, 
markov models, or systems that use a range of tools such as rule-based systems, expert systems, 
case-based reasoning, agent technolog
 
Decision Support System: A specific group of systems that support d
support can be in the form of providing information at the time the decision-maker requires it 
such as computerised clinical guidelines, or make fully autonomous decisions such as the 
autopilot functionality found within aeroplanes.  A decision support system may or may not use 
technology. 
 
2.3.1. EVALUATION OF CURRENT ADR DECISION SUPPORT  
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  Aim Decision-
maker/s 
Decision 
type/s 
Decision 
environ-
ment 
Assumptions and 
underlying 
decision theory 
Decision 
model 
Decision 
support 
technology 
Drug 
surveillance 
Develop new ADR 
knowledge.  That is 
discover ‘unknown’ 
ADRs so they 
become ‘known’ 
 
Assist in the 
prevention and 
detection of ‘known’ 
ADRs 
Health 
professionals 
via 
newsletters 
and updates 
to product 
information. 
 
Consumers 
via consumer 
medical 
information 
and media 
Prescribing 
and 
diagnosing 
decisions. 
Regulatory 
environment 
Humans need 
information to make 
decisions.  
  
Provides information 
to decision-makers, 
but assumes the 
medical practitioners 
have strategies to 
make the decisions. 
No underlying 
decision model.  
Data mining 
to assist in 
signal 
detection. 
 
No decision 
support 
technology 
used to 
disseminate 
the 
information. 
Clinical 
guidelines 
To provide ADR 
information to 
prescribers in a 
useful format at the 
time of making 
decisions. 
 
Medical 
practitioners 
and 
pharmacists 
Prescribing, 
detecting 
and 
diagnosing 
decisions 
In clinical 
environment 
Cognitive theory: 
Medical practitioners 
and pharmacists 
cannot hold all of the 
essential information 
in their memory, do 
not have time to keep 
up to date with large 
quantities of drug 
information, and may 
not have the time to 
consult a manual. 
 
Decision model 
based on a 
prescriptive 
theory:  
Rule-based 
decision support. 
Provides decision 
rules to decision-
maker at the time 
of prescribing so 
s/he can use 
them if required. 
 
 
 
 
 
 
Paper based 
guidelines 
use no 
technology.  
 
Context 
sensitive 
search 
engines. 
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  Aim Decision-
maker/s 
Decision 
type/s 
Decision 
environ-
ment 
Assumptions and 
underlying 
decision theory 
Decision 
model 
Decision 
support 
technology 
Electronic 
prescribing 
with ADR 
decision 
support 
modules 
Prevent ‘medical 
error’. 
Warn a prescriber if 
s/he is prescribing a 
drug that is known 
to cause harm to a 
consumer: 
 Drug 
interactions 
 Drug 
contraindication 
 Consumer past 
allergies 
 
Product 
information 
available within the 
software package to 
lookup if required. 
Prescribers 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical 
practitioners 
Prescribing 
decisions 
 
 
 
 
 
 
 
 
 
 
 
 
Prescribing 
and 
diagnostic 
decisions3
Clinical 
environment  
 
 
 
 
 
 
 
 
 
 
 
 
Clinical 
environment 
Cognitive theory: 
Medical practitioners 
cannot hold all the 
essential information 
at one time, and may 
make an error.  This 
system attempts to 
assist in the 
prevention of these 
known preventative 
errors. 
 
 
Cognitive theory:  
Medical practitioners 
cannot hold all of the 
essential information 
in their memory and 
may not have the time 
to consult a paper 
based manual. 
No underlying 
decision model 
 
 
 
 
 
 
 
 
 
 
 
 
No underlying 
decision model 
 
Uses simple 
rule-based 
technology 
to interrupt 
work flow if 
drug 
prescribed is 
not allowed 
based on a 
rule in the 
rule engine 
 
 
 
Uses search 
engines to 
facilitate easy 
searching of 
electronic 
source, and 
can be 
updated 
regularly and 
easily. 
 
 
 
 
 
                                                 
3 If a prescriber has a hypothesis that a drug may be associated with the consumer’s symptoms, consulting the product information can assist in strengthening or 
weakening the hypothesis, thus assisting in diagnostic decision-making. 
CHAPTER TWO:   ADVERSE DRUG REACTIONS AND DECISION SUPPORT
 
47 
  Aim Decision-
maker/s 
Decision 
type/s 
Decision 
environ-
ment 
Assumptions and 
underlying 
decision theory 
Decision 
model 
Decision 
support 
technology 
Early warning 
ADR alert 
systems 
Detect a suspected 
ADR before it has 
time to do harm 
Hospital 
staff, medical 
practitioners 
and nurses 
primarily 
Detection 
of 
suspected 
ADRs 
Hospital 
environment 
Heuristics (rule of 
thumb) 
 
If a particular set of 
symptoms occur, 
suspect an ADR. 
No explicit 
decision model 
defined 
Uses a rule-
based 
engine.  If 
the 
consumer 
symptoms 
including lab 
test results 
and 
biometrics 
match a set 
of 
conditions, 
the rule-
based engine 
triggers an 
alert. 
Awareness, 
information 
and education 
To provide 
information to 
medical 
practitioners, 
consumers and 
pharmacists about 
risks of medicines 
Medical 
practitioners, 
consumers 
and 
pharmacists 
Prescribing, 
diagnostic 
and 
information 
sharing  
Non specific No underlying 
decision theory.   
Education model Not 
technology 
based. 
Table 2-2 Decision theories, models and technologies underpinning current ADR prevention and detection strategies
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As can be seen from this evaluation, each system has a specific purpose, and is targeted towards 
a particular group of decision-makers, in the majority of cases, the medical practitioner.  The 
decision theory underlying the systems is implicit, but in most cases has not been explicitly 
stated, although as can be seen, they all have some underlying theory.  The technologies that 
have been used primarily include rule-based engines and advanced search engines. 
 
The analysis of these strategies has also revealed some assumptions underlying the development 
of these systems.  They assumed that: 
 
 the primary decision-maker in the ADR decision domain is the medical practitioner. 
Technology in clinical and hospital environments, therefore, is designed for the medical 
practitioners on behalf of the consumers; 
 that medical practitioners know how to make ADR decisions and have robust strategies.  
These systems, therefore, assist medical practitioners make decisions by providing up-to-date 
accurate information at the time of decision-making; 
 that medical practitioners cannot hold all of the required information about drugs and drug 
safety in their memories, and will benefit from having the information easily available and key 
information provided to them at the time of decision-making; 
 that medical practitioners are likely to use their own drug and ADR knowledge rather than 
access up-to-date information if they are time constrained, and so providing the up-to-date 
information at the time of decision-making will assist the medical practitioners to access this 
up-to-date information; 
 that consumers require some ADR information, but different information to medical 
practitioners; 
 information to consumer is best provided in written format. 
 
The preliminary background studies (O'Brien & Yearwood, 2002) suggest that some of these 
assumptions may not take into account the complexity of the ADR decision domain.  The focus 
of the work of this thesis is to explore the ADR domain in order to understand the complexities. 
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The following sections will, again, use the components of decision support described in Figure 
2-1 , to provide an overview of current knowledge that could be used within this domain, and to 
highlighting the gaps within this area. 
 
2.3.2. ADR DECISION-MAKER OR GROUP OF DECISION-MAKERS 
To develop decision support, an obvious question is, whose decisions require support?  The 
primary decision-maker to use decision support in the ADR decision domain, listed in Table 2-2, 
is the medical practitioner, including GPs, specialists and hospital medical staff.   
 
There is a significant body of research addressing the role of consumer decision-making within a 
medical context, however the decision type is primarily limited to treatment decisions 
(Bankhead, 1999; Benson & Britten, 2002; Bruera, Willey, Palmer & Rosales, 2001; Charavell, 
Bremond, Moumjid-Ferdjaoui, Mignotte & Odile Carrere, 2001; Coulter, Entwistle & Gilbert, 
1999; FDA, 2003; Mcvea, Minier & Johnson Palensky, 2001; Mussi, 1999; Scott & Lenert, 2000).   
 
Another subset of decisions consumers are known to make within this domain, are decisions 
about when to report a suspected ADR.  In some countries, consumers report suspected ADRs 
to health authorities (NAPRA, 2003; Safety and Quality Council, 2003; TGA, 2003)  The 
introduction of the Medicines Line, in Australia (discussed in section 2.2.6.9) encourages 
consumers to report suspected ADRs. 
 
The preliminary background studies (O'Brien & Yearwood, 2002) indicated that the ADR 
decision-makers may be broader than an individual medical practitioner, and may include 
multiple medical practitioners, the consumer and the pharmacist, and consumer decision types 
are broader than treatment and reporting decisions.  An aim of this work is to understand more 
about the decision-makers within the ADR decision domain, and determine the types of 
decisions made by each of these decision-makers. 
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2.3.3. ADR DECISIONS OR SET OF DECISIONS 
The decision types supported by the decision support strategies listed in Table 2-2, included 
prescribing, detecting and diagnosing decisions made by medical practitioners, and assisting 
consumers to know when to share information.   
 
The drug surveillance systems aim to identify previously undocumented ADRs, or ADRs that 
have increased in frequency with the aim of providing information to prescribers at the time of 
prescribing.  These systems assist with the decision of ‘which drug to prescribe?’ and ‘is this set 
of symptoms associated with a particular drug?’ by providing information to prescribers.  The 
computerised clinical guidelines and the drug dictionaries embedded within GP desktop software 
assist, again, with making decisions about which drug to prescribe.  They may also provide 
additional information such as contraindications for particular groups of consumers within the 
guidelines, or the specific consumer within the consultation room in the case of the desk top 
prescribing system.  They add to the information available to make these decisions, however, 
they still address the same two questions.  The hospital based systems which provide an alert if a 
suspected ADR is detected, also assist with the decision ‘is this set of symptoms associated with 
a drug?’ They also provide additional assistance by raising the question initially, without waiting 
for alternative diagnoses to be exhausted prior to considering this decision.   
 
Appendix six of the ADRIDS preliminary work (O'Brien, 2001), lists a number of decision types 
within the ADR decision context.  The following decisions were derived from the decision types 
elicited from the group of general practitioners in the forums from this work.  These include: 
 
Prevention 
 deciding which drug to prescribe; 
 deciding which information to provide when a consumer asks about a specific 
drug;  
 deciding which information to provide when a consumer requests information 
about potential side effects of a drug prescribed for him/herself or a family 
member;  
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 deciding which information to provide when a consumer requests information 
about potential interactions between a newly prescribed drug and a drug s/he is 
currently taking;  
 deciding which information to communicate to a pharmacist when dispensing a 
drug;  
 deciding whether to trial a new drug on the market; 
 
Early detection or management 
 making a differential diagnosis of a disease versus an ADR, either face to face or 
via a telephone consultation when a consumer phones or presents about a 
possible reaction having commenced drug therapy; 
 determining whether to cease a drug, which drug to cease, and when to cease it; 
 deciding whether to report an ADR to the TGA; 
 situations when the consumer is describing symptoms that may be caused by a 
reaction; 
o the GP formulating diagnosis of ADR as a possibility; 
 situations when a drug company asks for information about reactions observed; 
o the drug company formulating diagnosis of ADR as a possibility. 
 
 
As mentioned in the previous section, the primary decision type made by consumers in the 
literature is treatment decisions.  One study that does discuss consumer decision types 
specifically is (Broadstock & Michie, 2000).  These authors identified the following consumer 
medical decisions: when to consult a health professional; what assessment or treatment to 
undergo; whether to comply with a chosen treatment regime; and when and how to change their 
lifestyle.  Each of these decisions may also pertain to decisions surrounding ADRs, in particular 
the first three.  The fourth decision about lifestyle is peripherally related.  A consumer may 
decide, for example, to alter diet in order to manage hypertension, which may result in a no 
treatment decision. 
 
A list of decision-makers and the decision types made by these decision-makers that have been 
documented in the literature have been illustrated in Table 2-3.  As can be seen from this table, 
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there is a limited understanding of the decision types made by decision-makers within the ADR 
decision domain, especially when compared with the decision types identified in the preliminary 
background work.  Another important factor in understanding the requirements for decision 
support is developing an understanding of the decision types made by each decision-maker, and 
determining which of these decisions, if any, would benefit from decision support.   
 
 Consumer Medical Practitioner ADR Expert Pharmacist 
Detecting and 
Diagnosing 
 X X  
Treatment  X X   
Prescribing  X   
Reporting X X  X 
Seek treatment 
(Broadstock & 
Michie, 2000) 
X   X 
Lifestyle 
decisions 
(Broadstock & 
Michie, 2000) 
X   X 
Table 2-3 Decision types made by each decision-maker 
 
2.3.4. ADR DECISION ENVIRONMENT 
Each decision made has a context, and characteristics that define it, for example, a decision or 
set of decisions may have a time dimension.  Time may be unlimited, such as the decision about 
which coffee machine to purchase, versus very limited time such as navigating a fighter plane in 
a conflict situation. The dimension may alter according to certain parameters, such as in the 
situation with a fighter pilot, the time to make a decision is likely to alter according to whether 
the plane is stationary, flying a routine flight, or in combat. 
 
The following characteristics of the ADR decision environment emerged from further analysis 
of the data collected in the preliminary background work of this thesis.  The characteristics of 
the ADR decision environment depend on whether the decision is made by a single decision-
maker, multiple single decision-makers making decisions in isolation, or a collaborative decision 
or set of decisions.  The analysis of current ADR decision support systems indicates that ADR 
decisions are primarily individual decisions.  The description of medical practitioner/consumer 
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decision models (section 2.3.6) suggests that medical decisions may also include various levels of 
collaboration.  It is assumed for the moment, that the set of decisions surrounding an ADR may 
be single decisions by a consumer or medical practitioner, or collaborative decisions.  
 
These domain characteristics are described in the following sections. 
 
2.3.4.1. Decision-maker characteristics  
Medical practitioners:  
 are novice to experienced (new graduates to experienced specialists); 
 each have a different body of knowledge of medications and their potential ADRs.  Each 
medical practitioner has a set of medications s/he is more familiar with than other 
medications. (a specialist may prescribe a drug and have a set of regular medications, a 
general practitioner may have a different set of familiar medications, a consumer may be 
being treated by the general practitioner, but taking a medication prescribed by a 
specialist); 
 vary in use of computers from full electronic consumer records to fully manual 
consumer records. 
 
Consumers: 
 are medically untrained in most cases, however they may know more about their disease 
than a medical practitioner, especially if they have a chronic disease; 
 have varying access to information, from limited access to information to sophisticated 
skills in accessing the Internet. 
 
2.3.4.2. Decision characteristics 
ADR decisions: 
 require unique form of diagnosis.  In many cases they appear to be random, 
unpredictable and sparse; 
 a decision support system may assist with decision-making, but the decision needs to 
remain with the person making the decision. (A tool needs to augment rather than 
replace decision-making); 
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 the decisions include risk, some that have been identified, and some risk factors that 
have not been identified;  
 the need to make a decision may not be identified. A reaction may not be recognised by 
the consumer and or the medical practitioner as a drug reaction, but attribute the 
symptoms to a disease; 
 the differential diagnostic decision between an ADR, pre-existing disease or new disease 
may not result in a decision of 100% certainty.  The decision is likely to remain at a lower 
level of certainty and may be revised over time; 
 the decision is dynamic in nature.  The consumer’s symptoms are likely to change over 
time and test results will be available at varying times; 
 the prescriber may not get feedback.  The consumer may not seek treatment, or may 
seek treatment at another clinic for a suspected ADR. 
 
2.3.4.3. Environment characteristics 
In the ADR decision environment: 
 a medical staff member may have limited time.  A consumer may have more time to 
think about the problem; 
 information must be able to be accessed very quickly; 
 medical staff are generally not required to provide an argument for their decision, but 
may be challenged by a consumer or administrator (in contrast with legal decisions); 
 no preparation time available in many cases; 
 the level of risk associated with an ADR varies from minimal to highly significant.   
 
2.3.4.4. Information and knowledge characteristics 
Information can be defined as knowledge that has been obtained from investigation, study or 
through instruction (Merriam-Webster, 2003).  Knowledge can be defined as knowing 
something, having familiarity that has been gained by experience and that is within a person’s 
range of information (Sykes, 1976).  Based on these definitions, it appears that information is 
what is transferred between people, and knowledge is what is understood from one or more 
sources of information by a particular individual.  Just because information is given to a person, 
it does not mean it automatically becomes knowledge.  The person receiving the information 
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may not agree with the information, or perhaps may not understand the information.  It seems 
reasonable to conclude, therefore, that information received must be integrated with current 
knowledge in order to become new knowledge.   
 
Information characteristics identified include the following: 
 
 the source of ADR information needs to be clear to the prescriber; 
 the applicability of ADR information used to make ADR decisions needs to be specific 
to the consumer; 
 past history information  needs to be accessible to the decision-makers; 
 there can be uncertainty about the accuracy of some of the available information used to 
make the decisions; 
 the consumer may have a medical history that contains individual risk factors but they 
may be lost in a large hand written medical file, various components of the record may 
be in different locations, the information may not be easily accessible to the medical 
practitioner and consumer in the short time frame available; 
 critical information may not have been included or highlighted in the medical history. 
 
Knowledge characteristics identified include the following: 
 
 differing opinions between medical staff on the definition of an ADR versus side-effect; 
 differing opinions on the severity of ADRs; 
 that decisions are made with incomplete knowledge.  Decision-makers inability to realise 
they are working with partial knowledge; 
 may involve negative knowledge: that is, the symptoms may not match to a diagnosis the 
decision-maker is familiar with.  The decision-maker, therefore knows the diagnosis has 
to be from the set of diagnoses s/he has not seen previously. 
 
An understanding of the decision domain will assist in determining which tools would be most 
appropriate when developing decision support.  An aim of this thesis is to develop, further, this 
understanding of the ADR decision domain.    
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2.3.5. DECISION THEORIES AND TECHNOLOGIES USED IN DECISION SUPPORT 
APPLICATIONS 
Understanding the ADR decision domain and an understanding of how decision-makers 
currently make ADR decisions will assist in matching these decision processes to current 
decision theory.  Knowledge of the decision theories that are used within this domain may then 
assist in choosing technology that supports the underlying theory.  The literature does not neatly 
fall into the building blocks suggested in Figure 2-1.  Theories of decision-making such as Utility 
Theory, have been described in the decision theory literature.  Some techniques that have been 
described within the decision support literature, such as case-based reasoning, are based on 
assumptions about human decision-making, but do not rely on formal decision theory or models 
of decision-making.  These theories and techniques, therefore, have been grouped together in 
this one section, to describe an array of methods of supporting decisions.   
 
Carroll and Johnson (1990) classify decision theory into the following categories: 
 
 Descriptive – how humans do make decisions currently – with their limitations 
 Prescriptive – how humans ‘should’ make decisions if decisions are to be effective and well 
thought out. 
 Predictive – how to predict the decisions humans are likely to make based on their individual 
preferences.  
 
These categories are useful when clarifying the role of the decision support to be considered.  Is 
the nature of the decision support to replicate human decisions, prescribe how humans could 
make ‘better’ decisions, and/or access information from experts that can be used to predict 
future decisions, providing support for non-experts. 
 
2.3.5.1. Cognitive Theory 
Cognitive research about human decision-making says that humans cannot make complex 
decisions based on some human limitations.  These are things such as attention, memory and 
arithmetic calculations (Carroll & Johnson, 1990). 
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Attention 
Humans have selective attention.  They attend to things they see as important – not all 
information, and not necessarily all relevant information (Carroll & Johnson, 1990). 
 
Memory 
According to Carroll and Johnson, (1990), humans have a finite number of chunks of 
information they can attend to at any point in time.  Thorough decision-making may require 
more information to be retained for all possible solutions to be considered, and all of the 
knowledge required to make an appropriate decision.  Humans therefore make short cuts such 
as:  
 
 making decisions based on past decisions; 
 choosing the information they see as key information and ignoring the rest; 
 choosing information based on a bias and ignoring the rest; 
 framing the problem in a particular way which biases the information. 
 
A set of decision theories that have been developed to assist humans with some of their 
cognitive limitations is discussed in the following section. 
 
2.3.5.2. Clinical decision-making theories 
Until about 40 years ago, it was assumed that medical education, continuing education, journals, 
individual experience and exposure to colleagues was enough to ensure medical decisions were 
of a high quality.    According to Eddy (2005), in the 1970s there was a growing body of 
evidence to suggest that individual medical practitioners were making different decisions for 
similar problems, and after significant decision analysis, the conclusion was that it is not possible 
for anyone to accurately process all of the information needed for complex medical decisions 
(Eddy, 2005), a conclusion in line with the cognitive issues described in the previous section.  A 
second problem was that there was a gap between clinical research and what was happening in 
clinical practice.  Two methods of addressing this gap emerged: evidence based guidelines and 
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evidence based individual decision-making.  Eddy (2005) discussed the need to combine these 
methods to support clinical reasoning.   
 
Eddy (2005) described evidence based guidelines as having the following four characteristics: 
 
First, in all of them the work of analyzing the evidence and developing a guideline or other 
policy is done by small groups of specially trained people, usually sponsored by an 
organization.  Second, they all use an explicit, rigorous process.  Third for all of them the 
“product” – whether it be an evidence review, a guideline, or another type of policy – is 
generic.  It is intended to apply to a class or group of patients defined by some clinical 
criteria, rather than to an individual patient.  Fourth, their effects on care are indirect.  That 
is, they are intended to enable, guide, motivate, or sometimes force physicians and other 
types of providers to deliver certain types of care to people, they do not directly determine 
the care provided to a particular patient (p. 13). 
 
The focus for evidence based individual decision-making is “on educating physicians to help 
them bring more research and evidence into their individual decisions about individual patients” 
(p. 14).  Clinical based guidelines were discussed in detail in section 2.2.5.3. 
 
Differential diagnosis 
One of the decision types described in section 2.3.3 was differential diagnosis. There are two 
principal methods of clinical decision-making that are discussed in the literature that relate 
specifically to differential diagnosis: making a diagnosis by selecting a hypothesis (hypothetico 
deductive reasoning); and pattern recognition or pattern matching.  Each of these methods have 
strengths and weaknesses that will be reviewed in the following section. 
 
Diagnosis as selecting a hypothesis 
One strategy for making a diagnosis is by selecting a preferred diagnosis from a number of 
hypotheses, a process which is also referred to as hypothetico-deductive analysis (Elstein & 
Schwarz, 2002).  Diagnosis is made by selecting a number of hypotheses.  “Each hypothesis can 
then be used to predict what additional findings ought to be present if it were true, and the 
diagnostic process is a guided search for these findings” (p. 729).  Methods such as Utility 
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Theory (described in section 2.3.5.3), rely on the weighting of each hypothesis based on new 
evidence.  
 
Elstein and Schwarz (2002) found that this method is used by novices and experts, however the 
experts were able to process the information faster.  They stated that it is possible to collect data 
thoroughly, but ignore, misinterpret or misunderstand some of the findings.  Decision-makers 
may also fail to collect enough data, but interpret what they do collect accurately.   
 
Pattern recognition 
A second method of diagnostic reasoning is pattern recognition (Elstein & Schwarz, 2002).  
Pattern recognition relies heavily on a well-organised store of knowledge and the ability to 
recognise new problems in terms of older familiar problems previously dealt with (Crook, 2001).  
Experts who are in familiar situations with cases they see frequently may not regularly use a 
hypothetico-deductive reasoning method, however they may revert to this method for complex 
cases.  Instead they use automatic retrieval.  An old case is retrieved based on memory of a case 
with similar characteristics.  Pattern recognition is now acknowledged as a central feature of 
expert performance (O'Neill, Dluhy & Chin, 2005). 
 
A variation of the pattern recognition theory of diagnostic decision-making is Donald Schon’s 
theory of reflection-in and reflection-on-action (Smith, 2001).  Schon describes this reflective 
process using past situations to inform new situations. 
 
When a practitioner makes sense of a situation he perceives to be unique, he sees it as 
something already present in his repertoire.  To see this site as that one is not to subsume the 
first under a familiar category or rule.  It is, rather, to see the unfamiliar, unique situation as 
both similar to and different from the familiar one, without first being able to say similar or 
different with respect to what.  The familiar situation functions as a precedent, or a 
metaphor, or…an exemplar for the unfamiliar one (Schon 1983: 138, cited by Smith, 2001). 
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The key difference in Schon’s theory is that there is a time of reflection prior to selection of past 
cases, and the concept of choosing a past case or situation that does not have to be the same as 
the current situation, just have some elements that are similar. 
 
Another issue highlighted by Crook (2001) is that when psychiatric nurses are required to make 
decisions in high risk situations, their experience appears to take in a holistic approach which 
includes the ‘nature of knowing’.  Crook’s (2001) belief is that this ‘knowing’ is based on 
significant experience, but as yet is not well understood, and cannot be accounted for by current 
decision-making theories.  The concern he highlighted is that with the increased emphasis on 
evidence to inform practice, the skills being used by experts may be lost to more formal and 
quantifiable methods.  This concern has been expressed in articles which criticize this method 
stating that clinicians may make a diagnosis based on a past pattern which is incorrect.  Making a 
firm diagnosis too early, may result in ignoring symptoms that point to a different diagnosis 
(Hamilton, 2004). 
 
Complexities and need for flexibility in the use of  diagnostic decision making 
Diagnostic decision-making in health may include: serious and complex issues; two or more 
mutually exclusive actions from which to choose; significant risks and benefits; uncertainty about 
the likelihood that risks and benefits will occur in certain situations; no clear-cut choice; personal 
preferences and/or values for each choice, with multiple decision-makers; requires time to weigh 
up the risks and benefits to make a decision (Narayan, Corcoran-Perry, Drew, Hoyman & Lewis, 
2003).  
 
Clinicians alter the diagnostic decision-making strategy used depending on the individual case 
(O'Neill et al., 2005).  This appears to depend on the experience of the clinician and the 
complexity of the case (Elstein & Schwarz, 2002; O'Neill et al., 2005).  O’Neill et al,. (2005) 
developed a model of novice nursing decision-making that involves checking for past case 
information, and either using it as a starting point in the diagnosis, or if there is no case 
information, commencing with a hypothetico-deductive reasoning process. They also stated that 
a limitation of their model is that it is linear, whereas clinical decision-making often has 
components that are serial, dynamic, and overlapping in nature. 
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It is clear from this literature, that any decision theories attempting to explain medical diagnostic 
decision-making need to incorporate a set of complex, parallel and competing factors where 
there is often risk, uncertainty.  In cases where there are multiple decision-makers there is a need 
to reconcile individual preferences, values and beliefs in a context which is dynamic and time 
constrained.  A combination of methods is likely to be required for any diagnostic decision-
support system. 
 
2.3.5.3. Utility, Expected Utility Theory and Multi-attribute Utility Theory  
Some decision theories commonly used within the areas of decision support are Utility Theory, 
expected Utility Theory and multi-attribute Utility Theory.  A brief introduction to each of these 
theories has been included in this section, and will be followed with an explanation of how they 
may be applied within the ADR decision domain. 
 
Utility Theory 
Utility theory is a decision theory that attempts to prescribe a method of decision-making to 
improve decision-making effectiveness. It states that decision-making can be assisted by 
determining human preferences, weighting those preferences and then assisting humans with 
decision-making based on those preferences  (Taylor, 2000). 
 
Each of, Utility theory, expected Utility Theory and multi attribute Utility Theory, are based on 
cognitive theory, and assume that decision-making is a cognitive process that can be articulated. 
They attempt to overcome some of the limitations described in cognitive theory, described in 
section 2.3.5.1. 
 
Utility Theory can also be used as a statistical method for determining preferences (Bankhead 
1999).  In the study reported by Bankhead (1999), utility statistics were used to determine 
consumer preferences for treatment and compare these preferences with factors within their 
history such as prior experience of the treatment options. 
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Expected Utility Theory 
Once utilities have been determined, predictions can be made using Expected Utility Theory 
(EUT).  This theory is therefore a predictive decision-making theory.  These can then be 
compared with actual decisions, and when utilities are made from experts, predicted decisions 
can be used as an expert system (Bankhead, 1999). 
 
Multi Attribute Utility Theory  
Multi Attribute Utility Theory (MAUT) is a method of eliciting and modelling knowledge from 
experts and making it available to non-experts.  MAUT can assist particularly when there are 
multiple conflicting criteria (Mussi, 1999).  Entities which represent real world objects are 
identified.  Each entity has a number of attributes or characteristics. Independent attributes need 
to be identified.  Experts of a particular domain are used to elicit weights of attributes, which 
reflect the relative importance of each attribute.  The weights can be compared, which results in 
a choice, or recommended choice.  By modelling expert choices, a decision aid can be developed 
which can then be available for non-experts. 
Brennan and Anthony (2000) used MAUT to elicit entities, attributes and preferences from a 
group of expert nurses.  The aim was to create an expert model of a nursing practice model, 
which they based on the manner in which nurses accomplish clinical goals.  The aim of this 
study was to develop a model that could be used for benchmarking rather than to assist in 
decision support.  The model could, however, be used to assist non-expert nurses determine 
priorities when developing a nursing practice. 
 
Limitations of Utility Theory, EUT and MAUT 
As stated, this group of theories, assumes that the weighting of preferences is a conscious 
cognitive task, and that the weightings are consistent between cases, and are accessible.  One 
problem of this method is eliciting the respective weights for each preference from experts.   
 
To assist with the difficulty in eliciting knowledge from experts, Mussi (1999) used a medical 
diagnosis example to propose an alternative method of eliciting weights.  Rather than asking the 
experts to state their preferences, Mussi (1999) elicited preferences by studying case examples.  
The domain used within this study was expert’s choice between two alternative tests in order to 
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make a medical diagnosis.  The conflicting criteria were ‘more is better than less’ referring to 
effectiveness of a particular test, compared with the other issue of ‘less is better than more’ 
referring to attributes such as risk or cost.  Mussi (1999) developed a method of automatically 
eliciting the weights based on the case examples. 
 
Another limitation of these theories is the assumption that medical decision-making, either 
follows, or would benefit from following a linear, cognitive model of decision-making.  The 
fundamental assumption, that experts either consciously or unconsciously weight preferences, 
may be true for some types of decisions, and not other types of decisions.  Novice decision-
makers, people learning how to consciously make decisions, may be more likely to use these 
methods.  Experienced decision-makers may ‘know’ how to solve a problem, based on years of 
solving the same types of problems, but may not be able to access this knowledge.  The 
assumption behind this theory is that experts continue to weight preferences, but do so using a 
higher cognitive level and so no longer have access to it consciously.  Other theories of decision-
making may explain the behaviour of experts more effectively. 
 
Application of Utility Theory, EUT and MAUT to the field of ADRs 
Decisions surrounding ADRs have multiple conflicting criteria, such as comparing the risks 
associated with taking a medication and the benefits of taking the medication, and the risks of 
not treating the medical condition.  ADRs also have the characteristic that there are people with 
expert knowledge surrounding ADR diagnosis, however many medical practitioners such as 
general practitioners, although experts in medicine, may not have expert knowledge of particular 
ADRs.   
 
Using MAUT to elicit important attributes and weights from experts may assist medical 
practitioners with differential diagnosis between ADRs and pre-existing diseases.   
 
An advantage of using these techniques within the ADR decision domain may be that decision-
makers are forced to think about their preferences and give careful consideration to their 
weights.  They then have a clearer understanding of their own preferences and make utility 
assessment explicit (Taylor, 2000.).  Once they have a clear understanding, this enables them to 
communicate their preferences more effectively.  Comparisons between decision-makers can 
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highlight disagreements so they can be discussed.  Given the time constraints of the ADR 
domain, this approach may not be practical. 
 
The additional complexities with the ADR domain include the dynamic nature of the decision 
domain, and in particular the increasing awareness that the decision domain is a collaborative 
domain rather than a single decision domain. Each incident of a suspected ADR will have 
different circumstances surrounding it, including different pre-existing diseases, symptoms and 
groups of symptoms that vary from consumer to consumer.  Symptoms throughout the course 
of a diagnostic process change with time. Knowledge of ADR decisions is constantly increasing 
through processes such as spontaneous reporting.  Knowledge of disease is also increasing.  
Developing an expert system about ADRs using MAUT would require significant maintenance 
to update the knowledge, and relies on the assumption that accessing reliable weightings from 
experts is possible.  This group of theories may provide a contribution to this problem, but on 
their own are unlikely to provide a solution. 
 
2.3.5.4. Rule-based systems 
A detailed account of the history of diagnostic systems can be found in Miller and Giessbuhler 
(1999).  Clinical decision support systems can be broad general systems, or systems that are 
specific to a narrow domain.  According to Miller and Giessbuhler (1999), a large number of 
rule-based systems exist, and most have been applied to a narrow domain, due to the extreme 
complexity of maintaining systems with more than a few thousand rules.   
 
The early systems had the goal of replacing the clinician.  According to Miller and Giessbuhler 
(1999), this style of system was abandoned in the 1980s, and the focus moved more towards the 
development of systems that assisted the clinician make diagnoses, rather than make the 
diagnosis for him/her.  They state that issues with the broad based systems include ensuring the 
system is updated to include new knowledge, however it is difficult to know when new 
knowledge becomes fact and the problem with the narrow domain systems is that medical 
practitioners and hospitals may not choose to spend large amounts of money on multiple narrow 
systems. 
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An early attempt at developing an expert medical system was MYCIN. (Cendrowska & Bramer) 
MYCIN is a rule-based expert system that was developed by Edward Shortliffe in the 1970s at 
the Stanford Medical School.  It was designed to assist physicians with diagnostic and treatment 
decisions caused by certain kinds of bacterial infection.  This system interacted with physicians 
collecting information about specific consumers, by conducting an interactive dialogue with the 
physician.  If further information was required throughout the process, the system would 
attempt to infer it, or ask further questions.  Once a reasonable diagnosis could be made, 
MYCIN would provide the diagnosis and then a list of possible treatment alternatives.  Even at 
this early stage in expert software development, MYCIN had the ability to reason with uncertain 
information.   
 
This system had some features designed to increase its acceptability to physicians.  It was easy to 
use, tolerant of spelling errors, and could recognise synonyms.  It was easy to update the rules, 
and at the end of the consultation provided an explanation of the decision.  If an expert felt a 
rule was incomplete or incorrect, s/he was able to update the rule set. 
 
Cendrowska and Bramer (1984) reconstructed the MYCIN system in order to understand its 
processes and to critically evaluate it.  Problems identified included internal integrity problems 
resulting in inconsistency in decision-making.  This appeared to stem from the statistical 
methods used to manage the uncertain information.  MYCIN did, however contribute to many 
issues such as acceptability by an end user group, managed interaction and provided 
transparency of its decision process by providing an explanation of the decision, as well as 
making decisions within a specific domain. 
 
The main problem with rule-based systems is that they require a set of rules that have been 
elicited from a group of experts, but are static in nature, and cannot manage dynamic situations.  
As new knowledge is discovered, the rules need to be updated, which can be a time consuming 
process.  They also generally do not manage uncertain information well. 
 
The ADR domain is one where the knowledge base is constantly changing and where the 
information is uncertain and incomplete.  Rule-based systems have been built for use within 
hospital settings where consumers are being monitored and there are rules about the acceptable 
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range within factors such as blood pressure and the results of liver function tests. These systems 
are generally limited to a small set of inputs, and diagnose a limited set of ADRs.  In this 
domain, the system monitors what is normal, and if the readings become anything other than 
normal, an alert is triggered. 
 
Rule-based systems do not respond to a dynamic environment.  As previously discussed, there 
are many factors within the ADR decision environment that are dynamic.  There is no clear set 
of rules that clearly define when a set of symptoms is more likely or less likely to be an ADR.   
 
Like the Utility Theories, a rule-based decision support system is unlikely to be a feasible 
solution to the issue of ADRs, but may be useful for a component of the domain, as has already 
been suggested and implemented in hospital clinical systems. 
 
2.3.5.5. Case-based Reasoning 
Case-based reasoning is a method of solving new problems by accessing a database of old 
problems.  In the case of ADRs, ADRs that have been previously documented in The Australian 
Adverse Drug Reaction Bulletin are cases that have occurred in the past that have a particular 
diagnosis attached to them by ADRAC.   
 
Case-based reasoning could be used for differential diagnosis, by creating a database of 
previously diagnosed cases.  One source of these cases may be The Australian Adverse Drug 
Reaction Bulletin. The Australian Adverse Drug Reaction Bulletin is an example of particularly 
interesting or unusual cases.  In order to develop a database of case studies of the less common 
ADRs, medical practitioners in areas of specialty who see particular types of ADRs on a regular 
basis could recall either individual cases, or a typical case, describing the key characteristics of 
that typical case.  These cases could then be stored in a database for other’s to access. 
 
The cases could sit in a repository that could be accessed when a medical practitioner or 
consumer requests access to the database.  A more effective solution, however, may be one 
where the cases database sits in the background, but when the medical practitioner or consumer 
inputs symptoms and consumer characteristics, the case-based reasoner searches for identical or 
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similar cases, and if one or more are found, indicate to the decision-makers that these cases have 
been found ready to be referred to if required. 
 
At this stage, an ADR diagnostic decision model, or a set of rules for diagnosis has not been 
found within the literature, which makes this domain less conducive to a rule-based system.  
Also, the knowledge base is constantly changing.  There are new drugs on the market, and there 
are newly recognised ADRs regularly being documented.  Updating a rule-based system to reflect 
these changes would be a significant task, whereas adding new cases to the case database and 
distributing it, would be far less time consuming.  
 
A database of past cases does exist in the form of The Australian Adverse Drug Reaction Bulletins, 
and although an ADR may be a novel diagnosis to one medical practitioner, across medical 
practitioners it is not a novel problem.  Previously undocumented ADRs would obviously not be 
included within the case database, however, the absence of a diagnosis, followed by a suspicion 
of an ADR and temporal knowledge supporting this suspicion, may be enough for the medical 
practitioner to report the suspected ADR to ADRAC.  If enough medical practitioners do this, 
either within Australia or across the world, a new case can be developed which could then be 
added to the database. 
 
Main, Dillon and Shiu (2001), in their tutorial on case-based reasoning refer to several 
components of a case-based reasoner.  There is the database of cases, a problem case, a case 
retriever, a case reasoner, and then a derived solution.  The case retriever searches for identical 
cases within the database of cases.  If no identical case is found, the database searches for similar 
cases.  The case reasoner then attempts to adapt the similar case in order to derive a new 
solution.   
 
If the view is taken that decision support is most powerful if computers do the tasks that 
humans find difficult, but allow humans to do the tasks they do well, it would seem reasonable 
that within the ADR context, searching for identical or similar cases, and the storage and 
indexing of cases is something a computer would do well.  The task of looking at a similar case 
and matching key attributes to the problem case, and determining quickly if the same diagnosis 
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would apply to this new case, is something a human would do well.  The case reasoner, 
therefore, may not be a required component within this domain. 
 
According to Main et al. (2001), a case-based reasoner may develop new cases based on adapting 
old cases.  These new cases then need to be tested in the real world.  Using the ADR domain, 
new cases, hypothesised by the ADR decision-makers could be tested by submitting the new 
cases to ADRAC.  ADRAC would then verify or otherwise the ‘correctness’ of the new case, 
and determine if it were to be added to the database.  If anyone were to update the database, 
there would be a risk that the integrity of the cases would be compromised. 
 
2.3.5.6. Agent-based systems  
Agents have been described by Majewski (1996) in Knapik and Johnson (1998) as having the 
following characteristics: 
 
 Autonomy: Agents have the ability to operate without the direct intervention of humans or 
others.  They have some kind of control over their internal state. 
 Social ability: Agents can interact with other agents and/or humans via an agent 
communication language. 
 Reactivity: Agents can perceive their environment.  They can respond in a timely fashion to 
changes that occur in it. 
 Proactivity: Agents do not simply act in response to their environments, but are also able to 
exhibit goal-directed behaviour and can take the initiative. 
 
Jennings and Wooldridge (1998) define agents as being “a computer system situated in some 
environment and is capable of autonomous action in this environment in order to meet its 
design objectives” (p. 4). 
 
Multi-Agents 
Multi-Agent Systems (MAS) can be seen as a group of entities interacting to achieve individual 
or collective goals (Barber, Han & Liu, 2000).  Agents can have additional characteristics 
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according to the application requirements.  Some characteristics that have been described in the 
literature include the following:  
 
Co-operation 
Agents can co-operate to solve problems that individual agents may not be able to solve.  In 
order to do this they need to know other agent traits or current status via inter-agent 
communication.  Tasks will be assigned based on this information (Katoh, Kinoshita & 
Shiratori, 2000). 
 
Coordination 
Co-ordination techniques may include negotiation, arbitration, voting and self-modification.  
Barber et al. (2000) describe the following coordination techniques. 
 
 Negotiation – assumes agents are rational and intelligent so they consistently manage their 
goals.  They aim for the highest payoff, measured by utilities. 
 Arbitration – a third party makes the final decision when a conflict arises. 
 Voting – based on the human experience of voting. 
 Self-modification – a technique used when agents do not want to interact with other 
agents. 
 
Risk and Uncertainty 
Agents can be designed to work in conditions of risk and uncertainty.  Methods such as 
probability and utility, from decision theory, can assist in dealing with uncertainty.  A utility can 
be assigned to a belief factor of how certain the agent feels the information may be (Russell & 
Norvig 1994, in Knapik & Johnson 1998). 
 
Adjustable autonomy 
A recent expansion of agent ability has been the concept of adjustable autonomy.  Scerri, 
Pynadath and Tambe (2004) developed a method of adjusting the level of autonomy that an 
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agent used.  When necessary, the agent would transfer control of a task to a human, other times 
working in the background. 
 
ISAs (Intelligent software agents) have been used in a number of domains.  The two that most 
closely align with the goals of this work are medical applications and applications for 
information management. 
 
ISAs can be used in medical applications for patient monitoring.  This may be in an intensive 
care unit where frequent readings can be made and interpreted.  Multiple agents may be working 
as an intensive care unit team. Each ISA may have the responsibility for some component of the 
management of the consumer.  They need to co-operate, negotiate, compromise and work 
together for the overall benefit of the consumer.  If necessary, ISAs can then alert medical staff 
for their intervention (Haynes – Roth et al. 1989 in Jennings and Woodridge 1998). 
 
ISA systems have been developed in the domain of information management, for filtering and 
gathering information that is stored on the world wide web.  
 
Amalthaea from the MIT media laboratory is a multiagent system that discovers, monitors and 
filters information.  The basis of this system is that people have overlapping and competing 
interests.  Their preferences change over time.  Their system is a society of agents that monitor 
for new information, determine the information that fits within the person’s preferences.  Over 
time the person may change their preferences.  Systems such as this would modify their search 
criteria based on these different purposes. 
 
ISAs assist in solving complex problems, and therefore might be useful within the ADR domain. 
As discussed, ADR decision-making involves multiple decision-makers, each decision-maker 
with varying amounts of knowledge, different beliefs and goals.  They have the shared goal of 
avoiding harm from drug therapy, and maximizing the consumer’s health. 
 
It is not feasible for agents to replace decision-makers due to the constant change in priorities, 
symptoms and information sources; however they may have a role in augmenting information 
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sharing and decision-making by sitting between the decision-makers.  It may be possible to use a 
single agent, or an agent may represent each of the parties. 
 
2.3.5.7. Argumentation 
Argumentation is particularly concerned with domains which include argumentative discussion, 
persuasion dialogue or critical discussion.  In particular situations where there is a difference of 
opinion, conflict or dispute (Norman, Carbogim, Krabbe & Walton, 2003). 
 
The ADR decision domain is less about resolving a conflict, and more about obtaining a shared 
goal of a feasible diagnosis, or a treatment option that is satisfactory to each party involved.  The 
decision-makers generally are not adversarial, but co-operative. 
 
An assumption underlying the classical methods of representation and reasoning is that the 
information is complete, certain and consistent.  Argumentation is a method that uses the 
inconsistency to offer insights into rational processes, by using imperfect information by 
constructing and weighing up arguments relevant to alternative conflicting conclusions 
(Carbogim, Robertson & Lee, 2000).  The ADR decision domain, like most medical decision 
domains has incomplete and uncertain information. 
Girle, Hitchcock, McBurney and Verheij (2003) discuss the decision domain of asking an expert 
for advice to assist with decision-making, a domain characteristic that is more in line with ADR 
decision-making.  They state that: 
 
When faced with difficult decisions about what to do, decision-makers benefit from good 
advice.  Good advice comes most reliably from advisors with relevant expertise.  As well, 
good advice has at least three other essential features.  First the advice should be presented 
in a form which can be readily understood by the decision-maker.  Second there should be 
ready access to both the information and the thinking that underpins the advice.  Third, if 
decision-making involves details which are at all unusual, the decision-maker needs to be 
able to discuss those details with her advisors (p. 56). 
 
The idea of explanation, rather than argumentation, is more in line with the ADR domain.  
Explanation of reasoning, when two or more parties are attempting to come to a joint mutually 
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beneficial decision, can assist in joint understanding.  It also can lead to clarification of an idea, 
and it can allow another person with a different set of knowledge, to point out inconsistencies, 
or additional information that needs to be used in order to make the decision. 
 
Shared decision-making between, in particular, the medical practitioner and the consumer 
involves each party having partial, and incomplete knowledge, each needs an understanding of 
the other’s perspectives and reasoning in order to make a decision. 
 
Given the fact that this is a co-operative decision domain, rather than putting resources into 
decision support to assist with sharing knowledge, preferences, beliefs, priorities, again, it may be 
more beneficial to train both groups of people in performing this task via conversation.  In 
conflict situations, conversation is more difficult and so decision support may be more useful.  
In co-operative situations, education may assist in developing the skills that develop this level of 
shared decision-making. 
 
2.3.5.8. Decision theories and the choice of theoretical framework 
At the commencement of this work, a discussion took place about the use of the positivist 
theoretical perspective as the basis for the majority of ADR decision support, and decision 
support generally.  This is also reflected in the decision theories, and decision support techniques 
that have been discussed above.  In particular, theories such as Utility Theory, rule-based 
methods and to some extent case-based reasoning, are situated in the idea that knowledge is 
objective.  Each of these methods attempts to find the most effective solution to a problem, 
based on a set of criteria for ‘effective’.   
 
This work has been based in the area of social constructionism.  This shifts one of the basic 
assumptions of decision support.  Rather than attempting to find the most reliable and 
consistent objective solution, an attempt is being made to reconcile the perspectives of a number 
of decision-makers.  Each of these decision-makers will have their own understanding, 
preferences and priorities of the factors within the problem that are most important, to find a 
solution which is satisfactory to the decision-makers, and is likely to be unique to the case in 
question. 
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The last two techniques discussed, multi-agent technology and argumentation, may be applicable 
to decision support designed from a social constructionist perspective, as they each consider 
multiple individual perspectives and attempt to reconcile these. 
 
2.3.6. DECISION MODELS 
A set of models of decision-making that relates to this domain is Emanuel and Emanuel’s (1992) 
medical practitioner/consumer decision-making models.  These models have been discussed by 
a number of authors, and developed further by Charavell et al. (2001).  A discussion of this 
model and it’s application to this domain will be discussed in this section. 
 
Clinical-decision-making models 
Scott and Lenert (2000) discuss the issue of decision support systems for patients.  They refer to 
four possible models of medical practitioner/consumer decision-making. Paternalistic; 
Informed, Collaborative, and Deliberative models were originally described by Emanuel and 
Emanuel (1992).  Paternalistic decision-making is defined as a model where by the clinician has 
complete authority to make decisions on behalf of the consumer.  Scott and Lenert (2000) stated 
that the proportion of consumers who prefer a Paternalistic model is three to eight percent. 
Informed decision-making is defined as a model whereby the consumer makes completely 
autonomous decisions.  The role of the clinician is to provide medical information, but it is 
assumed that the consumer is responsible for determining their own preferences, and making the 
final decision. 20% to 30% of consumers preferred the Informed model. Collaborative decision-
making is defined as a model where the consumer relies on the health provider to provide 
information, but also to facilitate the decision-making processes.  50% to 60% of consumers 
preferred the Collaborative model. The final model is described as Deliberative.  In this model, 
the health provider attempts to convince the consumer of the best outcome for their health, 
based on what the medical practitioner believes is in the consumer’s best interests.  Ten to 20% 
of consumers prefer the deliberative model.  
 
Scott and Lenert (2000) stated that although consumers may want to participate in medical 
decision-making, they have limitations such as education, numeracy, problem solving skills, and 
understanding their own preferences.  They believe that there are two key ways to improve 
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consumer decision-making.  Firstly to assist consumers with their limitations, and then to 
provide decision support that can accommodate multiple if not all of the clinical decision 
models. 
 
Some authors in England have found that consumer participation in medical decision-making 
can have improved health benefits for the consumer (Stewart, Brown, Donner, McWhinney, 
Oates, Weston & Jordan, 2000; Stewart, Meredith, Brown & Galajda, 2000). The results from 
Stewart et al. (2000b) were that: 
 
Patient-centred communication was correlated with the patients' perceptions of finding 
common ground. In addition, positive perceptions were associated with better recovery 
from their discomfort and concern, better emotional health 2 months later, and fewer 
diagnostic tests and referrals (p. 796). 
 
Stewart et al. (2000a) gave an example of how consumer involvement in decision-making 
assisted in improved outcomes:  
 
For example, concordance between patient and physician expectations and patient 
participation in the decision-making process affects older patients. Communication is also 
linked to patient recall, adherence, and satisfaction. Furthermore, communication impacts 
emotional and physical outcomes of older patients, although evidence of improved physical 
outcomes remains under-investigated in this population. Dimensions of communication, 
such as continuity of relationship, seem to be important in decreasing hospitalization of 
older patients (p. 25). 
 
Charavell et al. (2001) also begin with Emanuel and Emanuel’s (1992) models of decision-
making.  They see the paternalistic and informative models as reducing the exchange of 
information, where as the collaborative and deliberative models attempt to increase the 
exchange.    They then suggest an alternative definition of shared decision-making, which sits 
between the collaborative and deliberative models.  This shared decision-making model includes 
the physician conveying information about the condition, including risks and benefits of various 
options.  The physician would elicit preferences from the consumer and assist in the decision-
making process, and also state their own preferences for the consumer.  Charavell et al. (2001) 
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state that although this appears to be a more effective model of decision-making it remains open 
to interpretation regarding how much each party contributes to the sharing of information. 
 
Charavell et al. (2001) stated that physicians include information that consumers do not have, 
and that it is not until the information has been conveyed, and the risks and benefits have been 
weighed, can a consumer contribute to the decision-making process.  In the domain of ADRs, 
the consumers also have information that the medical practitioners do not have access to, 
authors continually refer to consumer preferences, however consumers also have access to their 
history, their knowledge of their own bodies, and knowledge of past decisions they have made, 
all of which also need to be included in order to make informed decisions.  This shared decision-
making model could be expanded further to include the additional information available to 
consumers that needs to be exchanged to enhance ADR decision-making. 
 
The idea that consumers use information other than the information perceived as key factors by 
the prescriber, is supported by a study by Benson and Britten (2002).  These authors conducted 
a qualitative study to understand consumer decisions about whether or not to take 
antihypertensive medications.  They concluded that consumer decisions may include preferences 
around issues other than the pharmacology of the drug, such as a desire to use a treatment other 
than drugs, a belief that drugs are signifiers of ill health, the consumer was brought up to avoid 
drugs, and a belief that medical practitioners prescribe drugs too readily.  They stated that 
consumers make decisions in ways that make sense for them personally, and for medical 
practitioners to assist their consumer’s to make informed decisions, they need to first understand 
the factors that the consumers perceive as important, factors which may not even be considered 
by the medical practitioner.   
 
Another study on medical practitioner-consumer decision-making about drugs (Stevenson, 
Barry, Britten, Barber & Bradley, 2000) studied medical practitioner/consumer interactions in a 
clinical setting, and found little evidence that both medical practitioners and consumers 
participate in decision-making.  This same group of authors in a different study (Britten, 
Stevenson, Barry, Barber & Bradley, 2000) investigated misunderstandings in prescribing 
decisions.  They identified 14 categories of misunderstandings including patient information 
unknown to the medical practitioner, medical practitioner information unknown to the patient, 
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conflicting information, disagreement about attribution of side effects, failure of communication 
about medical practitioner’s decision, and relationship factors.  They stated that all 
misunderstandings were related to a lack of consumer participation in the consultation, and they 
were all associated with either potential or actual adverse outcomes. 
 
Another group of authors recognised that for shared decision-making to be a realistic option, 
medical practitioners need training (Towle & Godolphin, 1999).  A set of competencies required 
by medical practitioners to engage in shared decision-making include: development of a 
partnership with the consumer; establish consumer’s preferences; review the consumer’s 
preferences and determine their level of certainty; ascertain and respond to the consumers ideas 
and/or concerns; identify choices; provide evidence to support each choice and help the 
consumer reflect on the options available to them, negotiate a decision; and agree to a plan.  The 
competencies identified that are needed by a consumer include: defining a preferred doctor-
consumer relationship; find a medical practitioner and develop a partnership; identify own health 
problems, feelings, beliefs and expectations; communicate these factors to the medical 
practitioner; access information; evaluate information; and negotiate decisions.   
 
As discussed in section 2.2.5, drug surveillance programs, and providing information about 
drugs, the pharmacology of drugs, drug interactions, guidelines about drugs, contra-indications 
etc, are all about providing evidence to the prescriber at the time of prescribing.  The preliminary 
background studies (O'Brien & Yearwood, 2002) indicate that decision-making processes 
surrounding ADRs may be a contributing factor to the incidence of ADRs, an idea which is 
supported by Britten et al. (2000).  As stated previously, misunderstandings were associated with 
adverse outcomes, and training in shared decision-making competencies is an important 
component.  
 
2.4. The use of  grounded theory to analyse case studies in 
systems engineering 
Researchers in the Information Systems (IS) domain, have been exploring the usefulness of 
qualitative methods in their domain for the past two decades:   
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In Information Systems (IS), there has been a general shift in IS research away from 
technological to managerial and organizational issues, hence an increasing interest in the 
application of qualitative research methods (Myers, 2004, Introduction section, para. 1).   
 
The problem of gathering the requirements before building software or developing information 
systems, is ongoing.  Alvarez and Urla (2002) emphasise this point:   
 
A plethora of approaches have been developed over the last few decades to improve the 
quality of information elicited from users during requirements analysis.  IS researchers have 
spent a great deal of time comprehensively reviewing requirements analysis methods (p. 39).  
 
Another group of authors state that one rationale for this is that “Incomplete and inconsistent 
requirements are a major cause of the failure of computer based projects” (p. 1) (Richards, 
Boettger & Britt Fure, 2002). 
 
Three papers have been described below that discuss the use of grounded theory to analyse case 
study data to inform either the requirements analysis phase of systems design, or the processes 
used by information systems analysts to gather requirements analyses.  Grounded theory is 
explained in detail in section 3.4. 
 
Hughes and Wood-Harper (1999) investigated the use of grounded theory to analyse two 
organisational case studies as a component of the requirements analysis phase of systems design.  
The first case study was a three site veterinary practice.  They used Miles and Huberman’s 
(1994), modified form of grounded theory, beginning with ‘seed categories’ as a focus to the 
interview questions.  The categories were, “…understanding of job roles and responsibilities, 
decision-making processes and communication between the three sites” (p. 88). 
 
Hughes and Wood-Harper (1999) found that the recommendations arising from the analysis that 
were given to management were acted upon with satisfactory results.  Although the process 
yielded positive results, the time taken to interview, transcribe, code and categorise the data took 
what they described as excessive time.   
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In their second case study, a small manufacturing company, Hughes and Wood-Harper (1999) 
shortened the analysis process by using the NUDIST qualitative software package, and listening 
to each tape recording, but only transcribing components.  Any themes that had already been 
saturated by previous interviews were not transcribed.  They found that this adapted method was 
also successful in achieving the systems analysis goals and provided a satisfactory outcome for 
the organisation’s management team.   
 
Hughes and Wood-Harper (1999) state that the primary advantage of this method is that 
research and practice can be performed concurrently, producing research to develop new theory, 
at the same time as producing business outcomes. 
 
Orlikowski (1993) used grounded theory to analyse case study data from two organizations that 
used CASE (computer assisted software engineering) tools over time.  The paper presented the 
findings of a grounded theory study into the adoption and use of CASE tools, and developed a 
theoretical framework for conceptualizing this as a process of organizational change. Orlikowski 
(1993), unlike Hughes and Wood-Harper (1999), above, used this approach to investigate the 
usefulness of a methodology of gathering requirements, rather than using the grounded theory 
analysis of case studies as a method in the way Hughes and Wood-Harper (1999) did. 
 
Bryant (2002), in his critique of grounded theory research, points out the strength of 
Orlikowski’s work; in particular “its extensive detail and the ways in which the differing accounts 
of the two case studies illustrate general and specific aspects of the experiences of CASE tool 
introduction” (p. 8). 
 
Goede and De Villiers (2003), like Orlikowski (1993), used grounded theory to investigate IS 
practitioner’s thinking about IS methodologies in order to improve the quality of work 
conducted by IS practitioners.  They define quality as “the finished artefact is used by the users 
to solve the problem intended to be solved and that it was developed within given budget and 
time constraints” (p. 208).  
 
Information systems researchers refer to two levels of analysis, those that involve ‘hard systems 
thinking’ and those that involve ‘soft systems thinking’.   
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2.4.1. HARD AND SOFT SYSTEMS THINKING 
Bell, Cooper and Qureshi (2002), discuss the role of hard systems thinking and soft systems 
thinking in the area of software and/or systems design.  Discussing the work of (Checkland, 
1981), they said:  
 
…the distinguishing characteristic of all hard systems thinking is the belief that real world 
problems can be investigated in this way.  It is argued that most hard methodologies are 
goal centred or goal oriented in that they assume the problem i.e. ‘the what’ is given for 
[a goal state].  For example, to build a product to meet certain requirements, the usual 
objective is to find the best way of building the product to meet the requirements, i.e. ‘the 
how’ (p. 61). 
 
Bell et al. (2002) continue to say that they agree that this assumption of ‘the what’ is a significant 
limitation of hard systems thinking.  They then talk about the importance of including soft 
systems thinking: 
 
When investigating social situations, systems theorists realized that the problem, i.e. ‘the 
what’, could not be assumed as a given.  Stakeholders may have different views of what are 
the most important problems to be solved in order to improve the situation.  Soft 
methodologies have emerged with the aim of attempting to assist in understanding the 
perspective of the stakeholder; leading it is hoped, to relevant improvements in the area of 
concern (p. 61). 
 
Bell et al’s (2002) discussion of the need for ‘soft systems thinking’ supports observations within 
this work that beginning with ‘the what’ pre-defined, as in the initial requirements analysis 
project conducted at the commencement of this work, left out some key features.  These 
features were only revealed when considering ‘the why’ and the purpose of the software or 
system, which resulted in standing back and conducting an analysis of the decision domain, 
which then allows ‘the what’ to be more clearly defined. 
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2.5. Conclusion 
Injury and illness arising from adverse events within the medical domain is a significant problem 
within Australia and around the world.  One aspect of this problem, the occurrence of adverse 
drug reactions, is the focus of this work. This chapter has provided some background to the 
domain of adverse drug reactions. 
 
Efforts to reduce the incidence of ADRs include drug surveillance systems, computerised clinical 
guidelines, electronic prescribing with ADR decision support modules, early warning hospital 
based systems, and methods to increase awareness and provide information and education to 
people within this domain. 
 
Within Australia, there are a number of initiatives currently under development that will assist in 
providing the infrastructure required for the development of medical decision support in the 
future. 
 
The second part of this chapter outlined some aspects of decision support that may be useful to 
consider when designing a decision support system.  These include knowledge of who the 
decision-makers are, the decisions to be supported, the decision environment, decision theories, 
decision models and techniques and technologies that have been found useful within the field of 
decision support.   
 
Although it is encouraging that significant effort is underway to address the problem of ADRs 
within Australia and around the world, when comparing current knowledge of the ADR decision 
domain, with knowledge of a domain that assists in the development of decision support, there 
are some gaps.  There is significant knowledge about the mechanisms underlying ADRs, 
however, there is minimal understanding of how the information and knowledge within this 
domain is used by the decision-makers, who the ADR decision-makers are and the types of 
decisions they make.  There is little understanding of how ADR decisions are made and the 
decision theories that may assist in explaining these decisions.  Although there are many 
techniques for developing decision support within the literature, determining which techniques 
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would be most useful within this domain, requires an in-depth understanding of the decision 
environment.   
 
The final section in this chapter was a discussion that relates to methodology.  Literature was 
reviewed where authors have used a grounded theory approach to the analysis of case study data 
to assist in the development of information systems.  These methods may be useful to assist in 
understanding the pre-requirements analysis phase of systems design within this domain, as they 
encourage collecting real world data, and performing an in-depth analysis, using a technique that 
encourages stepping back from pre-existing assumptions about the domain.  Rather than 
beginning the systems analysis process with a scoped project in mind, stepping back and taking a 
fresh look at the domain, may result in a more complete understanding of this decision domain, 
which will provide fertile ground for specifying requirements for the development of an 
information system. 
 
As will be explained in the following chapter, these methods will be expanded by moving from a 
positivist theoretical framework to a social constructionist view of knowledge, and a symbolic 
interactionist theoretical framework.  This movement of theoretical position, in combination 
with the collection of case study data from multiple perspectives of a single instance of an ADR, 
may provide an understanding of the domain that assists in understanding the complexities of 
this domain, adding to the knowledge that can be used prior to specifying one or more solutions, 
as well as contributing to the overall understanding of the ADR decision domain. 
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 CHAPTER THREE 
 
3. The Research Process 
3.1. Introduction  
This chapter discusses the research processes followed and the underlying philosophical 
perspectives and theoretical perspectives that informed this work.  This chapter is structured 
according to four stages of the research process described by Crotty (1998).   
 
Crotty (1998) defines each of these stages as follows: 
 
Methods: the techniques or procedures used to gather and analyze data related to some 
research question or hypothesis. 
 
Methodology: the strategy, plan or action, process or design lying behind the choice and use of 
particular methods and linking the choice and use of methods to the desired outcomes. 
 
Theoretical perspective: the philosophical stance informing the methodology and thus providing 
a context for the process and grounding its logic and criteria. 
 
Epistemology: the theory of knowledge embedded in the theoretical perspective and thereby in 
the methodology (p. 3). 
 
Rather than choosing a methodology, analysing the results using this methodology, and then 
describing the epistemology that informs the methodology, Crotty’s (1998) approach encourages 
the analysis of the data through the combined views of the epistemology, theoretical framework 
and methodology. 
 
Using this structure, the epistemology behind this work, social constructionism, is described in 
section 3.2, followed by the theoretical perspective of symbolic interactionism in section 3.3.  
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The methodology used within this work is grounded theory, which is described in section 3.4, 
and the methods are described in section 3.5.  Due to the sensitive nature of the data collected, 
there were ethical considerations to be considered which have been described in section 3.6. 
 
This work crosses multiple research communities: medicine; the requirements analysis end of 
information technology; health informatics; and sociology.  One challenge, therefore, is to 
present this work so that it accommodates each of these audiences.  For a designer of a clinical 
decision support system, the theory behind the methodology introduces a number of new 
concepts.  For a reader well versed in qualitative methods, exploration of the arguments that 
exist within each of the philosophical and theoretical perspectives, and providing a detailed 
rationale for an approach is an essential element.  Too much detail may be a barrier to a software 
designer or medical practitioner.  Too little detail may be a barrier to a qualitative researcher. 
 
The primary aim of this work was to add insight into the ADR decision domain to inform the 
pre-requirements analysis phase of decision support systems.  The epistemology, theoretical 
framework and methodology used within this work were the theories chosen to inform the 
research questions.  To accommodate a wide audience, this chapter provides an introduction to 
the concepts, followed by a more detailed discussion of the position taken.  Although there are 
major arguments between schools of thought at each theoretical level, an exploration of these 
arguments has not been included. 
 
The underlying epistemology of traditional scientific research is objectivism, with a positivist 
theoretical perspective.  As a consequence, the majority of medical research, and previous 
research investigating ADRs, is conducted using these philosophical perspectives.  The key 
characteristic of both objectivism and positivism is that knowledge can be discovered by 
studying an object or behaviour, with a significant level of impartiality or objectivity.  Research 
of this type is often reported without explicitly stating the epistemology and theoretical 
perspective, because within the community of readers of this paradigm, these theoretical 
assumptions are a given. 
 
Researchers in the social sciences, however, make explicit the theoretical perspective behind 
their work.  They acknowledge objectivism as one theory of knowledge, but argue that other 
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theories of knowledge are just as valid. This process of making the epistemology and theoretical 
perspectives behind this work explicit has been used within this work. 
 
As discussed in the introductory chapter, ADR decision support that has been developed from a 
positivist perspective is based on the understanding that the concepts behind the ADR decision 
domain have a single understanding for all decision-makers.  ADR decision-making is primarily 
concerned with and focused on the decision domain of the medical practitioner and is generally 
directed towards one or two decisions within this decision domain.  This single perspective that 
underpins current ADR decision support is based, on limited knowledge of the ADR decision 
domain. 
 
Rather than using this traditional positivist theoretical perspective, this work has been based in 
the epistemology of social constructionism, and used a symbolic interactionist theoretical 
perspective.  This philosophical perspective, which will be discussed in detail in sections 3.2 and 
3.3, is that people belong to social groupings and that each group has an understanding of 
concepts within their environment and use symbols and language to label and share ideas about 
these concepts.  Based on this view each group of decision-makers within the ADR decision 
domain will have different understandings of each of the key concepts. Three decision-makers 
from this domain have been interviewed, the consumers, medical practitioners and experts, with 
the aim of understanding the decision domain from these three perspectives.  Considering these 
multiple perspectives is important when developing decision support for this domain. 
 
In order to explore these multiple perspectives, and to gain additional insight into ADR decision 
domain to inform the requirements analysis phase of systems design, case studies have been 
collected from the perspectives of the consumer, medical practitioner and expert that focus on a 
single instance of an ADR.  These case studies have been analysed using a grounded theory 
approach.  The grounded theory approach was used so that pre-conceived ideas about the 
decision domain could be set aside, as much as possible, to allow new insights into this domain 
to emerge, that have been grounded within the data.  The methodology of grounded theory and 
the methods surrounding the collection and analysis of the case studies are described in detail in 
sections 3.4 and 3.5. 
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This combined approach of using a different theoretical perspective, in combination with a 
grounded theory analysis of case studies has resulted in additional insight into the decision 
domain.  
 
3.2. Epistemology – Social constructionism  
Positivism, as stated in the previous section, is a theoretical perspective that comes from the 
epistemology of objectivism.  This philosophy is that all knowledge is contained in an object, 
and it is the researcher’s role to discover that knowledge about the object or entity.  Interpretivism, 
which comes from subjectivism, is the view that all knowledge and understanding of objects and 
the world is created by the observer.  This paradigm assumes knowledge is culturally derived and 
historically situated.  Constructionism sits between these two views.  Constructionism is the view 
that knowledge is constructed by the observer, about a particular object or entity.  Social 
constructionism explains constructionism from a social context.  The view is that an individual 
does not construct reality randomly, but that an individual is born into a social environment with 
rules, expectations and behaviours, that existed prior to the birth of the individual and which is 
used as a basis for the construction of the individual’s understanding and knowledge of the 
world around him or her (Crotty, 1998). 
 
George Herbert Mead, a philosopher and social psychologist described the differences between 
behaviouralism and understanding behaviour using a social context (Mead, 1934).  
Behaviouralism he described, as the study of humans and animals through behaviours observed 
by the researcher.  The meaning of those behaviours is determined by the researcher.  Mead 
(1934) discussed a limitation of the behaviouralist approach; that it is not possible to determine 
the inner thoughts of the person being studied.  He believed that one approach that allows 
researchers to access the inner thoughts, begins with the understanding of society, and then 
seeks to interpret behaviours based on the meanings attributed to those behaviours by the 
society in which they belong. 
 
The philosophy of social constructionism is that meaning is constructed by society, and is 
adopted by each of the members of that society.  A set of behaviours may have a meaning within 
one society and the same set of behaviours may have a different meaning within another society.  
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Society can relate to any social grouping including a country, city, race, religion, organisation, 
role, or any combination of these.   
 
Green (2000), whose work is based in the epistemology of social constructionism, illustrates this 
influence of society, in this case a profession, on the meaning of evidence based practice.  The 
background to her work is the increased emphasis on evidence based practice within a multi-
disciplinary team.  One issue raised by Green, was that there was an underlying assumption that 
there was a single understanding of ‘evidence’.  She found, however, that each discipline had a 
different understanding of this concept: 
  
Rather than being a neutral tool used to inform decision-making, evidence was both 
constructed through professional practice and contributed to the construction of 
professional identity (p. 453). 
 
Green (2000) recommended that in order to work within a multi-discipline decision 
environment, any effort to use evidence based practice requires acknowledgment that different 
groups understand these concepts in different ways, and explicit discussion of the core concepts 
within this domain; evidence, practice and knowledge is a required initial stage.  
 
Another aspect of social constructionism is the influence a social group can exert on its 
members.  An example of the impact of social construction on behaviour is the work conducted 
by Dick (2000).  She studied the influence of the organisational culture of the police force on 
work related stress using a social constructionist epistemology.  She performed a qualitative 
analysis on field notes of counselling sessions to understanding the beliefs the staff members 
placed on their experience of stress.  She said that: 
 
…not only do these constructions influence the ways in which officers perceive themselves 
and their environments, but they also operate at the collective level to ‘normalize’ some 
emotional responses and ‘pathologize’ others… (p. 226). 
 
In this example, the beliefs of the social group became the beliefs of the individuals who joined 
that group. Behaviour of the members enforced these concepts within its members.  Some of 
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the beliefs identified in the participants that perpetuated the stress related to the incongruence 
between the organisational belief system and the individual’s belief system.  This work illustrates 
that not only are beliefs adopted by the participants within a group, they can be imposed by 
other members of the group, to maintain the group identity.  
 
Within the ADR decision domain, an example of a concept that has meaning for one group and 
minimal meaning for another group is the word ‘compliant’.  As will be discussed further in 
section 5.3.4.2, the term ‘compliant’ was a term used by the medical practitioners, but was not 
used by the consumers.  The term ‘compliant’ has meaning within the language of medical 
practitioners and some other health professionals.  This word, not only is a construct of the 
medical community, it implies the person using this word has a particular understanding of the 
respective roles of the medical practitioner and consumer.  It implies that the medical 
practitioner has the role of recommending a treatment (possibly following a discussion with the 
consumer about their preferences), and the role of the consumer is to ‘comply’ with that 
recommendation. 
 
In the same way that Green (2000) found that different professionals working together have a 
different understanding of ‘evidence’, it is the expectation of the researchers that the medical 
practitioner is likely to have different meanings for some of the core ADR concepts to that of 
either an expert, or a consumer.  
 
It is from a social constructionism perspective that the data within this thesis will be interpreted.  
This will allow the meaning of the concepts within the ADR decision domain to be understood 
from a group and individual level.  It is expected that the result will be a richer understanding of 
this domain by embracing the multiple understandings of the underlying concepts. 
 
3.3. Theoretical perspective – Symbolic interactionism 
Symbolic interactionism originally stems from constructionism, but has also been used by those 
who subscribe to interpretivism.  The basic premise of this theoretical framework is that 
meaning is shared between people within a social grouping, via the use of symbols that are used 
within social interactions.   
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George Herbert Mead was the instigator of this philosophical perspective, although he did not 
label his thinking as symbolic interactionism at the time.  Mead wrote scholarly papers from his 
work, but did not publish this work in a language that was accessible to a more general audience.  
Posthumously, his students gathered lecture materials and memories of conversations, and wrote 
of his work  (Lauer & Handel, 1977).    
 
Blumer was one author who wrote extensively about Mead’s work.  Blumer stated three basic 
interactionist assumptions: 
 
‘that human beings act toward things on the basis of meanings that these things have for 
them’; 
‘that the meaning of such things is derived from, and arises out of the social interaction that 
one has with one’s fellows’ 
‘that these meanings are handled in, and modified through an interpretive process used by 
the person in dealing with the things he encounters’ (Crotty 1998, p. 72). 
 
Mead (1934) used a simple example of an exchange between two dogs to illustrate this basic 
theoretical perspective: 
 
The act of each dog becomes the stimulus to the other dog for his response.  There is then a 
relationship between these two: and as the act is responded to by the other dog, it, in turn, 
undergoes change.  The very fact that the dog is ready to attack another becomes a stimulus 
to the other dog to change his own position or his own attitude.  He has no sooner done 
this than the change of attitude in the second dog in turn causes the first dog to change his 
attitude.  We have here a conversation of gestures (p. 42-43) 
 
The gestures used by the dogs had meaning for other dogs.  The exchange of meaning occurred 
through an interaction.  Each dog interpreted the sequence of gestures and body movements, 
which resulted in a shared meaning, the intention to fight. 
 
The basic premise behind this theoretical framework is that symbols are used by people (or 
animals) within a social group, and the symbols have shared meaning.  People outside of the 
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group may or may not understand the meaning.  One example is language.  Each nationality uses 
a language and some subgroups within a culture may use a dialect of that language.  The symbols 
(vocabulary and syntactic structures) are understood by members of the group.  In order to have 
an interaction with a member of that group, an understanding of the language is required. 
 
Research using this framework, therefore, is not to determine which set of symbols, or which 
definition of a particular concept is ‘correct’, but to understand the symbols or language used by 
members of a group, and discover from the members of the group the meaning that has been 
attributed to the symbol set, by the members.  It is not the role of the researcher, within this 
framework, to determine the meaning of the symbols, but simply to understand the meanings 
that have been attached by the members of the group. 
 
The application of symbolic interactionism to this work allows the case studies, which include 
multiple perspectives, to be analysed with the aim of understanding the meaning the members of 
each group have given to the concepts within the ADR domain.  This will provide insight into 
whether the decision-makers within the ADR domain have similar or different understandings of 
these concepts.  Triangulation of the data will assist in revealing these similarities and 
differences. This theoretical perspective is non-critical, and so does not attempt to evaluate the 
appropriateness of these understandings, but seeks to understand them.  We are interested in 
understanding the impact, if any, of these differences and similarities on the prevention, 
detection and management of ADRs, and incorporating this understanding when considering 
the requirements of ADR decision support. 
 
3.4. Methodology – Grounded theory 
The grounded theory methodology draws on the symbolic interactionist theoretical perspective 
(Ezzy, 2002).  This section will provide an overview of grounded theory and explain how it will 
be used within this work, and discuss the rationale for using this approach to assist in the 
requirements analysis phase of systems design. 
 
Grounded theory is a qualitative research methodology.  Strauss and Corbin (1998) define 
qualitative research, as: 
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…any type of research that produces findings not arrived at by statistical procedures or 
other means of quantification.  It can refer to research about persons’ lives, lived 
experiences, behaviours, emotions and feelings as well as about organisational functioning, 
social movements, cultural phenomena, and interactions between nations (p. 11).   
 
Grounded theory is one of many methodologies used within the qualitative paradigm. 
 
Grounded theory, developed by two sociologists, Glaser and Strauss in the 1960s, is a 
methodology that assists in the development of theory, and grounding that theory in data 
(Strauss & Corbin, 1998).  Ezzy (2002) describes grounded theory as a methodology that 
“explicitly rejects the logico-deductive method of theory building and verification” (p. 7).  Ezzy 
(2002) continues to explain the logico-deductive method as one where theories are 
conceptualised and then tested with data.  The concept behind the grounded theory approach is 
that the data gathering should not be influenced by pre-existing theory, but the theory should be 
derived from the data.  
 
A primary aim of this work is to go back to the beginning of the information systems design life-
cycle, or even to a pre-systems design phase of understanding more about the decision-making 
domain, prior to even considering the requirements of the end-users of a decision support 
system.   
 
The issue that was highlighted by the single case study documented in the background studies 
(O'Brien & Yearwood, 2002) is that even though information may exist about the potential risks 
of drugs, and even though this information may be available to the prescriber at the time of 
decision-making, and the medical practitioner at the time of diagnosis, ADRs continue to occur.  
Part of the problem is known to be caused by an inability to predict who is likely to experience 
an ADR to a particular drug.  Based on this initial case study, the preliminary background 
studies, and previous literature, it appears that the decision-making environment surrounding the 
incidence of ADRs is more complex than a prescribing decision-making process, and that 
without understanding the interrelationships between the key actors in this decision-making 
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environment, decision support technology will continue to meet the perceived needs of the 
decision-makers, but not necessarily meet the actual needs. 
 
In order to explore this decision-making environment, case studies of ADRs were collected 
including the consumer, the medical and the expert views.  A grounded theory approach used to 
determine the factors within the decision-making environment that have an impact on the 
prevention and early detection of ADRs, and were seen as important from the participant’s 
perspective rather than the researcher’s perspective, is consistent with the symbolic interactionist 
theoretical perspective. 
 
When collecting case studies, the definition of the ADR was provided by the person answering 
the advertisement.  There were no entry criteria that defined the features of an ADR. 
 
The interview (as described in the methods section below) was semi-structured in nature.  Some 
initial questions were asked to place some boundaries around the scope of the data that were 
collected, however the interview moved to the aspects of the ADR experience that were viewed 
as important by the participant.  A grounded theory approach towards the analysis of the data, 
has allowed the individual participant’s understandings, expectations, decisions, reasoning behind 
their decisions, and interactions to be explored, and then integrated with current theory, or to 
develop emerging theory based on the data. 
 
Grounded theory as described by Strauss and Corbin (1998), requires the detailed consideration 
of the data and analysis, to assist in thinking as laterally as possible about the possible meanings 
of each segment.  This process has the goal of attempting to put aside the researcher’s 
immediate interpretation, and determine the understanding of the participant, by going back to 
the participant and questioning further.  They acknowledge and see as a healthy approach, that 
individual researchers will use the components of the methodology and modify and develop the 
methodology to meet individual circumstances.  
 
Although the purpose of this research was to conduct an exploratory study and derive new 
concepts and theory from grounded data, the focus of the study was a specific application, one 
of developing decision support to assist in reducing the impact of ADRs.  A modified form of 
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grounded theory described by Miles and Huberman (1994) was therefore chosen, that allows the 
analysis of the data to begin with an initial focus, rather than being completely open, as in the 
purest form of grounded theory. Miles and Huberman state that their preferred method of 
generating codes (the first stage in analysis), is to begin with a ‘start list’ of codes which came 
from prior fieldwork, research questions, hypotheses and the literature.  The ‘start list’ came 
from the preliminary work described in O’Brien and Yearwood (2002) and O’Brien (2001), the 
literature and the research questions.  This list evolved as cases were analysed, allowing the data 
to expand and develop the code set.  The codes were then clustered and finally linked to form 
emerging theory. 
 
Miles and Huberman (1994) declare themselves to be realists, in the positivist’s school of 
thought.   The aim of their approach is to be as objective as possible.  Aspects, therefore, of 
their approach have been useful for this work, such as the idea of a ‘start list’ of codes, however 
some of their analysis techniques that are more focused on finding an objective reality have been 
less useful.   
 
Strauss and Corbin (1998) describe three stages of theory development: description, conceptual 
ordering and theorizing: 
 
In brief, describing is depicting, telling a story, and sometimes a very graphic and detailed one, 
without stepping back to interpret events or explain why certain events occurred and not 
others.  Conceptual ordering is classifying events and objects along various explicitly stated 
dimensions without necessarily relating the classifications to each other to form an 
overarching explanatory scheme.  Theorizing is the act of constructing (we emphasize this 
verb as well) from data an explanatory scheme that systematically integrates various 
concepts through statements of relationship.  A theory does more than provide 
understanding or paint a vivid picture, it enables users to explain and predict events, thereby 
providing guides to action (p. 25). 
 
The analysis of the interview data began by generating codes, the codes were developed into a 
hierarchy or to use Strauss and Corbin’s terminology (above), conceptual ordering, which 
resulted in themes.  Some of the themes were combined with each other, or with pre-existing 
knowledge from the literature to form emerging theory.   
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The epistemology of social constructionism, with a theoretical framework of symbolic 
interactionism provides a lens when using a grounded theory form of analysis.  The data were 
collected in the form of a series of case studies, and these case studies were analysed using three 
different methods of case study analysis.  Section 3.5 describes these methods, and how they 
were applied to this research. 
 
3.4.1. RATIONALE FOR THE USE OF GROUNDED THEORY ANALYSIS OF CASE 
STUDIES WITHIN THE ADR DECISION DOMAIN 
 
Grounded theory has been used to analyse case study data to inform the requirements analysis 
phase of ADR decision support systems design.   
 
Hughes and Wood-Harper (1999) used this form of analysis to understand business needs of 
two organisations.  Gathering accurate requirements is important within the business domain to 
ensure the systems developed meet the needs of the business owners and the cost of the systems 
design is proportional to the financial benefits to the organisation.  
 
The ADR decision domain is about preventing injury to humans.  Decision support software 
that meet the needs of decision-makers and facilitates decision-making can assist in the 
prevention of injury.  Decision support that is poorly designed has the potential to exacerbate 
the problem.  Understanding the requirements, therefore, is more than providing a financial 
solution to assist in public health; it is about assisting in the prevention of injury to humans as 
the primary motivation, with an additional benefit of assisting in decreasing the financial burdens 
of managing these errors within the health system. 
 
The key barrier to the use of this methodology in a business context raised by Hughes and 
Wood-Harper (1999) was the time taken to do the analysis, and the additional costs associated 
with that increased time.  This issue appears to be less applicable to a decision domain that 
relates to public health, than it is when commercial motivators are the driving force behind 
systems development. 
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The papers reviewed in chapter two did not discuss the implication of the theoretical perspective 
or the epistemology underpinning their work.  In the information systems (IS) literature 
generally, there is a discussion of the epistemology underpinning grounded theory, but this was 
not discussed in relation to the practical impact this has on the results of their work.  It appears, 
therefore, that their contribution is the use of grounded theory to allow ideas about the 
requirements to emerge, but use a framework that suggests each core concept has a single 
understanding for multiple users. 
 
As stated in the previous section, the use of a social constructionist epistemology with a 
symbolic interactionist theoretical perspective permits and expects that different individuals and 
different groups within society will construct meaning from the symbols and language used 
within their environments.  The case studies used within the work include multiple perspectives 
of a single ADR, providing an opportunity to understand the different meanings each participant 
and group of participants have for the language used within the ADR decision domain.  These 
perspectives can then be triangulated to provide a more complete understanding of this multi-
dimensional decision domain, highlighting the areas where there is common understanding, 
areas where there is understanding within each group, and areas where the understanding is at 
the level of the individual participant. 
 
Systems that are developed based on a single perspective, or based on an assumption that there 
is a single understanding of the core concepts, are likely to provide only a partial solution to a 
complex domain area.  The use of grounded theory within this work, in conjunction with social 
constructionist and symbolic interactionist perspectives provides a framework for analysing the 
similarities and differences in perspectives between participants. 
                   
3.5. Methods – Case study analysis 
This section provides an overview of the methods used within this work.  It includes an 
overview of case study analysis (section 3.5.1), the processes of recruiting participants (section 
3.5.2), challenges in recruiting participants (section 3.5.3), the processes used to collect the data 
(section 3.5.4) , and discussion of the analysis (section 3.5.5).  Throughout this section, there is 
reflection of the research processes used within this work: 
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…analysis is not a structured, static or rigid process.  Rather, it is a free-flowing and creative 
one in which analysts move quickly back and forth between types of coding, using analytic 
techniques and procedures freely and in response to the analytic tasks before analysts 
(Strauss & Corbin, 1998, p. 58).   
 
Ezzy (2002) also writes about the non-linear process of data analysis:  
 
For many people discovery occurs in writing as much as it does during the task of data 
analysis.  Writing is not simply about transferring ‘results’ to a written page.  Writing is as 
much about creating ‘results’ as it is about reporting them (p. 138). 
 
3.5.1. OVERVIEW OF CASE STUDY ANALYSIS 
The original research plan was to conduct a thematic analysis of the interview data, focusing on 
the views of the consumer, medical practitioner, and expert of a single instance of an ADR.  The 
GP view of the de-identified cases in a GP forum was also to be used. Using a thematic analysis, 
the aim was to collect enough participants to obtain saturation. Strauss and Corbin (1998) define 
saturation below: 
 
A category is considered saturated when no new information seems to emerge during coding, 
that is, when no new properties, dimensions, conditions, actions/interactions or 
consequences are seen in the data (p. 136). 
 
It became obvious, however, that although some interesting ideas evolved from the analysis of 
each participant group, the strength of the data came by viewing a single case.  This provided 
insight that could not be seen by combining and grouping the data.  Once the data had been 
combined into single cases, it became clear that the 15 cases collected, provided significant 
insight into this research problem. This was supported by Miles and Huberman’s (1994) 
description of qualitative research that uses case study methods:  
 
With high complexity, a study with more than 15 cases or so can become unwieldy.  There 
are too many data to scan visually and too many permutations to account for…Still we’ve 
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seen multiple case studies in the 20s and 30s.  The price is usually thinner data.  And at 
some point you say Why not do a survey? (p. 30) 
 
We are generalising from one case to the next on the basis of a match to the underlying 
theory, not to a larger universe.  The choice of cases is usually made on conceptual grounds, 
not on representative grounds….  If you look at the cells of the sampling frame, each is 
essentially unique (p. 29) 
 
For the purposes of this research, a case has been given the following boundaries.  A single case 
may comprise of two or more of the following perspectives of a single incident of a suspected 
ADR: a consumer, one or more medical practitioner and two experts.   
 
Case studies can be analysed using a variety of methods.  Three methods have been used, an 
individual case level (a single incident of an ADR from the consumer medical practitioner and 
expert perspective), an analysis of the data in participant groups (consumers, medical 
practitioners, and experts), and an analysis that views the case studies and groups of data 
together. 
 
Rather than using a single method of analysis, three levels of analysis have been used to extract 
the richness that the case studies provided and each level provides insight into a different set of 
research questions.  The research questions that focus on the interaction, or differing opinions 
of participants within a single case study, have been addressed through the individual case study 
analysis. Patterns between case studies developed into emerging themes or theory when these 
have been viewed when combining the case studies.  The questions that pertain specifically to a 
group of participants (consumers, medical practitioners, or experts), have been addressed in the 
analysis at the group level.    
 
The table below (Table 3-1) lists the research questions in column one, and in column two lists 
the method of analysis that was used to address each question.  Some questions were addressed 
using only one method, others were informed using several methods. 
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3.5.2. RECRUITING PARTICIPANTS  
Four groups of people were requested to participate in this study, consumers who believe they 
may have experienced an ADR, the medical practitioner or clinicians for each of these 
consumers, ADR experts and a group of GPs to participate in a GP forum. The aim was to 
collect four views of the one incident of a suspected ADR to form cases.  Sections 3.5.2.1 to 
3.5.2.4 describe how each group of participants were recruited. 
 
Research questions  Method of 
analysis 
1) Who are the decision-makers in the ADR domain?      Group level 
2) What decisions are made by each decision-maker?      Group level 
3) What do decision-makers understand by the term ADR?  Group level 
4) DO ALL DECISION-MAKERS AGREE ON A DEFINITION OF AN ADR?    Between group 
5) How are ADR decisions made? 
                 
Group level, 
case level  and 
combined analysis 
6) What problems occur when making ADR decisions? 
            
Group level and  
case level analysis 
7) What resources are used by decision-makers: information and knowledge sources and 
content? 
Group analysis 
8) How do decision-makers contribute to the creation of new knowledge at an individual, 
national and international level? 
Group and 
combined level 
analysis 
9) How do ADRs affect people and how does this impact on decision-making? Group level and case 
level analysis 
Table 3-1 Method of analysis used to address each research question 
3.5.2.1. Group 1: Consumers who have experienced a suspected ADR. 
Consumers who believed they may have experienced an ADR within the past 12 to 18 months 
either answered an advertisement that was placed in a local Ballarat newspaper, or one placed to 
staff and students at the University of Ballarat, via a research newsletter and via a university wide 
e-mail. Twenty consumers responded, 15 met the selection criteria and were interested in 
participating in the study.   The characteristics of each of the participants has been discussed in 
section 4.2.2. 
 
These criteria state that the consumer: 
 
 is over 18 years old; 
 suspects s/he has experienced a moderate to severe ADR within the past six to 12 
months; 
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 has no disability that affects cognition or language; 
 does not have a psychiatric history that may interfere in their ability to perceive and 
accurately report their experience and; 
 is not taking recreational drugs. 
 
The rationale for these criteria was to: 
 
 ensure participants have the ability to report their experience of an ADR; 
 ensure participants are old enough to provide consent to access their medical records; 
 screen for psychiatric disorders as some psychiatric disorder may affect a person’s ability 
to perceive and report accurately their experience of an ADR; 
 screen for recreational drug usage as recreational drugs are likely to compound the 
problem and are out of scope of the study. 
 
Each consumer responded by telephone or e-mail.  Each potential participant was provided with 
an overview of the project via the telephone, was posted a plain language statement written for 
consumers (Appendix B), and a copy of the consent form (Appendix C), prior to the interview.   
 
3.5.2.2. Group 2: The clinicians who treated the consumer participants 
The consumer participants provided details of each medical practitioner and clinic attended 
throughout the experience of a suspected ADR.  These medical practitioners may have been 
from any health service within the study region.  A decision was made to limit recruitment of 
hospital medical practitioners to the study region, as ethics clearance had been obtained by the 
hospitals involved.  Two medical practitioners from private practice who lived outside of the 
region were requested to participate in the study.   
 
The medical practitioners named by the consumers were approached individually to request 
participation in the study.  An information package was sent to each medical practitioner.  The 
information package included an introductory letter (Appendix D), a plain language statement 
that had been written specifically for medical staff (Appendix F), a copy of the consent form 
signed by the consumer (Appendix C), and a blank consent form for the medical practitioners to 
sign if they decided to participate in the study (Appendix F).  The medical practitioners were 
99 
CHAPTER THREE: THE RESEARCH PROCESS 
offered a payment of one hundred dollars per hour to compensate them for time they put into 
the study.   
 
3.5.2.3. Group 3: Members of ADRAC who are experts in the area of ADRs 
The chief medical officer for the adverse drug reaction unit at the Therapeutics Goods 
Administration (TGA) was approached for assistance with this study.  Two members of 
ADRAC volunteered to participate in the study in the role of ADR experts. One member was 
unable to continue with the study, and so a third member volunteered.  Of the three experts, 
two have medical training, and one has a science background. Throughout the data collection 
phase of the study, one of the experts was unable to continue with the role and so another 
volunteer was requested who continued with the role of expert.  This third expert had a medical 
background. 
 
3.5.2.4. Group 4:  General Practitioners to participate in a forum 
GPs for the planned GP forums were recruited through a Division of General Practitioners.  
Leading up to the request, several articles were written for the division newsletter over a period 
of three months, to alert medical practitioners to the existence of the project.   
 
The forums were developed in collaboration with the GP division and a TGA medical officer 
and were packaged in the form of ADR training.  The Royal College of General Practitioners 
approved the forums as a professional development activity, which allowed the medical 
practitioners to gain professional development points for attendance.  The planned forums 
included a meal, and the GPs were also offered a financial incentive to attend. 
 
The aims of the GP forums included the following: 
 to inform the GPs of  the research being conducted at the University of Ballarat; 
 to present of a number of the case studies collected in this work for the GPs to discuss in 
small groups.  The case studies were to be presented by the principal investigator, and the 
initial learning was to be from discussion with each other about the likelihood the symptoms 
were caused by the suspected drug and the processes surrounding this decision-making; 
 the cases were to be presented a single view at a time, and the GPs would have the 
opportunity to make a diagnosis initially based on one view only of the case study.  This was 
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to be followed by the  presentation of the second view and then finally the third view of the 
data collected.  The aim was to determine if the additional information available from each 
view made a difference to diagnosis, and to understand more about the impact it had; 
 to review of the case studies with a medical officer from ADRAC, who would: 
o answer GP questions about the cases; 
o highlight key factors within the case studies; 
o provide general information about methods of preventing and detecting adverse 
drug reactions in their patients; 
o provide general information about ADRAC voluntary adverse drug reaction 
reporting processes. 
 
The responses from the GPs throughout the forum were to be recorded, de-identified, and with 
GP consent, used as the forth phase of data collection in the work of this thesis. 
 
The forums were advertised via a ‘fax out’ process used regularly by the BDDGP.  This process 
was conducted twice.  GPs who had not previously been involved in the study as medical 
practitioners were requested to participate in the study.  Three GPs from the division 
volunteered to participate.  Following a discussion with the BDDGPs, the ADRAC medical 
officer and the research team, it was decided to cancel the forums due to insufficient numbers. 
 
3.5.3. CHALLENGES IN THE RECRUITMENT PROCESS 
3.5.3.1. Challenges in recruiting consumers 
Significant thought was put into an effective method of recruiting ADR cases.  As the goal was 
to collect four views of a single suspected ADR, the choices ranged from attempting to capture 
ADRs as they occurred to requesting the consumers to recall their ADRs retrospectively.  It was 
decided that it was not practical to observe consumers in a clinical environment and collect cases 
of ADRs as the incidence of ADRs is sparse compared with the number of cases seen within a 
practice.  It was decided, therefore to collect retrospective case studies. 
 
There were a number of options regarding who to approach to gather the case studies such as 
beginning with the consumer and tracing back to the medical practitioners, beginning with the 
medical practitioners and tracing back to the consumers or beginning with hospital records and 
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tracing back to both consumers and medical practitioners.  It was decided to begin by recruiting 
consumers and then trace back to find the medical view for two main reasons: 
 
 In order to collect the data, consumer consent was required. Beginning with a self-
selection process ensured consumer consent was obtained, and assisted in maintaining 
privacy.  
 
 Medical staff could have been approached and asked to put forward cases of consumers 
who may have experienced ADRs. Issues raised by medical staff to this proposal 
included the following:  
 
o Some consumers may not be aware they have experienced an ADR. 
o The medical staff and/or hospital would need to contact each of these people to 
see if they are prepared to participate in the study maintaining strict 
confidentiality, until such time as the consumer signs a consent form to release 
their details to the research team, which is time consuming for medical staff who 
are already time constrained. 
o Medical litigation may result from drawing attention to suspected ADRs, 
especially in light of the fact that the cases at that stage are suspected rather than 
confirmed, and in the majority of cases the probability that a particular drug is 
associated with a symptom or set of symptoms is less than 100%.  
 
Thought was also put into the specific type of ADRs to target.  An initial suggestion was to 
collect a homogeneous group of suspected ADRs, such as ADRs from a particular drug, or 
reactions of a particular type such as allergic reactions.  Given the complexity in collecting case 
studies described in section 3.5.4, it was decided that choosing a subset of ADRs would have 
added to the complexity of data collection, and decreased the usefulness of the results.  If a 
common ADR had been chosen, one which was well known by the medical and perhaps the 
consumer community, decision-making is likely to have been different compared with an ADR 
that is less well known.  If a rare ADR had been chosen, the numbers would have been sparse, 
and collecting a large enough sample, would have been more complex.  If an ADR diagnosis had 
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been one of the selection criteria, the case studies where there is no clear diagnosis would have 
been missed.   
 
As a result of the complexities above, it was decided to begin with consumers who were self-
selected, and allow the spread of ADR types to be determined by who volunteered, rather than 
choose not to study this domain due to the difficulties in data collection. 
 
The self-selection process may have resulted in attracting a subgroup of consumers who met the 
criteria. The consumer group appeared to be particularly analytical, as several of the participants 
maintained detailed diaries over a number of years, and the majority used logical processing to 
determine the likelihood that the medication taken caused the suspected reaction.  
 
It is also possible that the consumers volunteered for the study because they were particularly 
concerned, angry or frustrated by their suspected reaction. As can be seen from section 4.2.2 
referring to participant characteristics, the group did have a significant level of concern, with 
67% displaying a high level of concern as observed by the principal researcher. It is not known if 
this level of concern is due to self-selection, or whether it is representative of consumers who 
have experienced a suspected reaction to a medication.  
 
3.5.3.2. Challenges in recruiting medical practitioners 
Usually, when requesting participation in a research study, a selected sample is chosen as a 
subgroup from a wider population.  In this case, participation was requested from particular 
individuals.   
 
It may have been possible to collect more case studies which included the medical view, if a 
process had been followed of recruiting the consumer participants then contacting the medical 
practitioners to request participation prior to interviewing the consumers.  In-depth interviews 
would only have been conducted, then, in cases where the medical practitioner had agreed to 
participate.  This method, however, may have excluded case studies that were of particular 
interest to the study, and excluded consumers who particularly wanted to participate. 
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The GPs involved in the forums conducted in the preliminary background studies (O'Brien & 
Yearwood, 2002) stated that although they consider ADRs a problem which need to be 
addressed, their perception is that ADRs occur infrequently within the GP context and so are a 
lesser priority for training purposes than issues that occur more frequently. 
 
There were several challenges in recruiting GPs.  The GPs have stated that they have high work 
demands, and are frequently requested to participate in research projects, and professional 
development, and so they need to prioritise according to what they perceive to be their highest 
needs. Many of the GPs within the division had already participated in ADR research: eight GPs 
from the division participated in the forums for the preliminary background studies, which were 
four forum sessions of one hour each; four GPs participated in the larger research project as 
medical practitioners; and three more GPs were interested in attending the GP forums.  Projects 
in the area of ADRs have also been occurring within the same region and so it is possible that 
the GPs who do have a specific interest in ADRs had already contributed.   
 
3.5.3.4. Challenges in recruiting GPs 
 
One potential difficulty may have been location of the experts as they are based in Canberra, 
Australia.   Due to effective e-mail and telephone contact and face-to-face meetings throughout 
the research process, the distance has not been an issue. 
3.5.3.3. Challenges in recruiting ADRAC experts 
 
By using the approach taken there are two distinct groups of case studies, those, which include 
the consumer, medical and expert views, and those, which include only the consumer and expert 
views.  This provided insight into the value of consumer only views of ADRs, which would not 
have been as clear if all case studies had included a medical view. 
 
 
An overview of the data collection process is presented in Figure 3-1. 
3.5.4. DATA COLLECTION  
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Medical view of a suspected ADR - interview with medical practitioner/s
Medical History Episode of care about ADR Episode of care about ADR Episode of care about ADR
ADRAC ADR expert opinion of the
de-identified data
GP Forum expert medical opinion of the
de-identified data
Consumer experience of ADR incidence.
Data Sources Methods
In-depth Interview
taped and transcribed
Time-line
Direct Transcription
Questionnaire for each case history.
GP Forums where GPs will be shown each episode of care for
each case, individually in a time sequence.
Consent Forms
Consumer Experience of ADR
Structured time line of the
events surrounding the ADR
e.g. clinics, diagnoses, treatments
medications, doses, symptoms,
as viewed by the Consumer
Data
Specific consent to
access medical records,
show de-identified data to
ADRAC and to present at
a GP forum.
Interview with the medical practitioner about
the suspected ADR, including the medical practitioner's
interpretation of case notes.
This may be for one or more
dates, in one or more medical clinics.
ADRAC opinion about the
diagnosis, degree of certainty of
the diagnosis, critical factors in
the diagnosis, based on the consumer time-line
and the medical record data.
Pre-morbid condition/s
Past suspected ADRs
Any other significant history as determined
by the GP.
Medical view of de-identified cases where the medical practitioner
can view multiple episodes of care and the consumer
view of the data collection.
Determine the benefits available to a GP when multiple
components of the medical history are available rather
than documentation from a single episode of care
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Figure 3-1 Methods of intended data collection
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3.5.4.1. Choice of evidence 
According to Yin (2003), one attribute of a ‘good’ case study has, multiple forms of evidence 
available to build the case, and as much evidence as possible, within the case boundaries has 
been collected. (Yin, 2003) 
 
Considerable thought was put into methods of collecting evidence or data.  The broad goal was 
to collect data about the suspected ADR from the consumer perspective.  Maintaining 
consistency with the symbolic interactionist theoretical framework, the aim was for the 
consumers to talk about the aspects of the event that were important from the consumer 
perspective, and so an in-depth interview was selected.  As a secondary aim was to collect some 
specific factors about the case such as relevant dates and medications, the in-depth interviews 
were semi-structured in nature to allow specific information to be collected, as well as allowing 
the consumer to direct the interview in the direction important to him or her.  The time-line of 
events (Appendix I), a more structured form of data collection, had the aim of assisting with 
recall, but also collecting the medical ‘facts’ to assist in locating the relevant components of the 
medical history, and to assist the experts in making a medical diagnosis. 
 
The next type of evidence to be considered was the medical record.  The initial goal was to 
access the medical record directly.  There were some issues with this approach.  These include 
consumer privacy, in particular surrounding notes in the case history that were not relevant to 
the suspected ADR, and also reliable interpretation of the notes.  As the researcher collecting the 
data was not medically trained (although a professional in allied health), it was decided that 
asking the medical practitioner to interpret the notes, would be a more reliable method of 
accessing the medical records.   
 
It was decided, therefore, for the medical records to be accessed via an in-depth semi-structured 
interview with the medical practitioner.  The semi-structured interview type was again used, to 
allow the medical practitioner to direct the interview to information considered relevant and 
important to the medical practitioner.  Again, because the secondary aim was to collect the 
medical ‘facts’ of the case, specific questions were asked.  A secondary benefit of the semi-
structured interviews was the ability to follow up on emerging themes from the consumer data 
collection, and from previous interviews with medical practitioners.  In some cases, the medical 
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practitioner, having interpreted the case notes, photocopied relevant documentation such as lab 
reports for the study. 
 
All of the data collected were imported into and stored in the NVivo software program 
described in section 3.5.5.  An inventory of the data included in that database can be found in 
Appendix J.   
 
The fourth form of data collection was the opinion of ADR experts.  A questionnaire with 
specific questions and open-ended questions was developed to access information from the 
ADR experts.  There were a number of reasons for this approach.  Two experts were asked to 
participate in each of the 15 case studies, and so the time required of the experts was 
significantly higher than the other participants.  In-depth interviews about each case appeared to 
be a method that would be too time-consuming for this group of participants.  Open-ended 
questions were included to allow the experts to comment on issues they felt were relevant that 
had not been asked by the previous questions.  The primary limitation to this method was the 
extraction of the reasoning behind the expert’s opinion.  In some cases the expert provided an 
explanation, and at other times, further explanation was required.  The experts were then 
prepared to answer questions via e-mail to clarify any issues.  The e-mails with the experts have 
either been stored as memos in NVivo, or have been appended to the end of the questionnaire 
file. 
 
Another data type collected from the experts was a trail of what they considered to be the key 
data used in decision-making.  Each expert was asked to use a highlighter pen to select the data 
used when making a differential diagnosis.  As previously stated, the case studies were compiled 
attempting to include the most relevant components of the data.  These highlighted pieces of 
text, collected from the experts, were used to check that the data considered relevant to 
differential diagnosis, by the experts, was included in the case studies.  
 
3.5.4.2. Methods of data collection 
The data were gathered and analysed one group at a time.  The initial set of data, the consumer 
data, was collected, de-identified, verified and analysed, prior to collecting the second group of 
data.  The next group of data to be collected was the medical practitioner data, which again, was 
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collected, de-identified, verified, and partially analysed prior to sending the de-identified case 
studies to the experts for an expert opinion.  There was no overlap between collecting the 
consumer data and the medical data, however, the majority of the medical data were collected 
and sent to the experts. In two cases, it was following the expert data collection that some more 
medical data were collected, and then these two cases were sent to the experts for an opinion at 
a later date.   
 
It was a conscious decision to collect the consumer data prior to collecting the medical 
practitioner data, for two key reasons.  The first reason was to allow time to sit with and identify 
with the consumer group in order to understand their unique issues prior to collecting medical 
data, which may contradict, or provide information that altered our understanding of what was 
being said by the consumer group.  The second reason was to allow time for themes to emerge 
from the consumer group so these themes could be included in the interviews with the medical 
practitioners.  An example was the issue of consumer access to ADR information.  A theme that 
emerged was that the consumers, as a group, wanted more information about potential ADRs 
prior to commencing a drug, but had experienced difficulty accessing that information from the 
medical practitioner.   
 
The case studies collected would have been different if the interviews had been gathered from 
the medical view initially.  By beginning with the consumer view, some case studies were 
collected where the consumer suspected an ADR, however the medical practitioner and/or the 
experts disagreed that the symptoms were likely to have been related to the drug.  This subset of 
case studies provides insight into the decision-making processes surrounding ADRs, when there 
is a difference in understanding of the series of events between decision-makers.  If the case 
studies had all the participants in agreement about the ADRs prior to data collection, the 
information relating to the processes surrounding differential diagnosis may have been less 
detailed. 
 
If the data collection had commenced with the medical view, it would have been possible to 
determine if the consumer was prepared to participate in the study prior to the initial data 
collection, and therefore there may have been a larger percentage of case studies obtained that 
included the consumer, medical practitioner and expert view, whereas with this design, only 66% 
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of cases include all three views.  Also, all of the cases would have been local to the study region, 
and presumably if the medical practitioners were prepared to participate in the study initially, 
each case would have included the medical practitioner perspective.  By collecting data beginning 
with the consumer, as stated previously, the consumers may have been a particular subgroup of 
consumers who have experienced a suspected ADR.  The same can be said for the medical 
practitioners, there may have been a particular subgroup of medical practitioners who 
volunteered for the study providing a limited view of how medical practitioners in general 
approach this problem.  As a consequence, whichever way the data might have been collected, 
there would have been benefits and limitations.  
 
3.5.4.3. Group 1: Data collection from consumers. 
Each consumer participant was asked to do the following: participate in a single in-depth semi-
structured interview with the principal investigator, assist in completing a time line of events 
surrounding the suspected ADR and sign a consent form for participation in the study, and to 
provide permission for the medical practitioners to be contacted regarding their participation in 
the study. 
 
The interview took place in a private office at the University of Ballarat or in the participant’s 
home.  The participant chose the location of the interview. The interviews were tape-recorded.  
 
In-depth semi-structured consumer interviews 
The interviewer and the participant sat at a table, with the tape recorder between them, but to 
one side.  A micro-tape recorder was used with an external stand-alone microphone to ensure 
clarity of the recording.  The tape recorder was small and unobtrusive however the external 
microphone was more obtrusive.  Some participants appeared to be very aware and self-
conscious of the microphone.  One participant spoke directly into the microphone, and asked 
several times if she was ‘doing it right’.  A less obtrusive microphone may have assisted in 
providing a more relaxed atmosphere. 
 
The interviewer disclosed the following during the introduction to the study: 
 The Therapeutics Goods Administration and a division of GPs were involved in and 
supporting the study.  
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 The medical practitioners would be asked to be interviewed about the medical view of 
the suspected ADR. 
 The interviewer is not medically trained, but interested in the broader view of the ADR 
experience than purely the medical acts of the case. 
 
The effect of this disclosure appeared to be three fold.  Firstly, the consumers being aware that 
the interviewer was not medically trained, named specific drugs, but then explained their 
understanding of the reason they were taking the drug and their medical condition. One 
consumer said that she felt comfortable knowing that the interviewer was an impartial observer 
rather than a medical practitioner.    
 
The second effect appeared to be that the study took on credibility in the eyes of the consumer, 
knowing that it was supported by the medical community, and that they were interested in 
finding out more about the consumer’s experience. 
 
The third effect appeared to be that some consumers were slightly guarded in their discussion 
about their relationship with their medical practitioner.  When asked a question about whether 
there was anything they would have liked their medical practitioner to have done differently, 
several appeared quite defensive, and then explained how supportive their medical practitioner 
had been, even though prior to the question, they had been quite critical of some aspects of their 
care.  One consumer was very open about the relationship with his medical practitioner, but 
then checked with the interviewer that his medical practitioner would not have access to the 
transcript. 
 
A goal of a semi-structured interview is to have some specific questions to ask each participant, 
but also to have the freedom within the interview to explore issues raised by the participant that 
were not previously considered by the interviewer.    
 
The qualitative research approach also encourages the researcher to collect some data, do some 
analysis, and on the basis of the analysis, modify the questions for the next group of participants 
to explore newly raised issues. 
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An initial list of questions were used, that came from the preliminary background studies and the 
research questions.  Refer to Appendix H for the list of questions asked. 
 
The questions were not asked in any particular order.  Sometimes the consumer answered a 
question without it specifically being asked. The interviewer intentionally attempted to create a 
sense of a conversation about what happened, rather than the feeling of an interview, to 
encourage the participants to ‘chat’.  This allowed issues important to the consumer to be raised, 
even if, on the surface, they did not appear to be directly relevant to the study.  Some of those 
issues have become important components of the study, such as in one case, an elderly man was 
speaking about his progressive disability, and how quickly he had lost mobility.  He progressed 
to speaking about the challenges he and his wife were experiencing as they both have a disability.  
This then provided a context for the impact of the suspected ADR.  Without the life context, 
the impact on the consumer would have been understood differently.  This outcome of the 
interviews is not something that was anticipated by the interviewer prior to conducting the 
interviews. 
 
Questions asked and issues that were explored in later interviews due to the responses from the 
earlier interviews can also be found in Appendix I. 
 
The interviews ranged in time from half an hour, to two hours depending on the level of 
complexity of the case. 
 
Time-line of events 
A second strategy used to assist with memory recall, was to work with the participants to 
complete a timeline of events (Appendix I).  The aim of this timeline was to ensure that the 
sequence of events surrounding the suspected ADR was clearly recorded, with dates when 
available, so that the medical practitioners would be able to locate the episode of care within the 
consumer case history.  This was a method of ensuring all of the medical ‘facts’ of the case were 
pieced together, including dates, symptoms, medical practitioners, drugs and dosages. 
 
In some cases, the interviewer had enough information from the interview to complete the time-
line of events and so did not ask the consumer to do what would have been a repeated activity.  
111 
CHAPTER THREE: THE RESEARCH PROCESS 
In other cases, the act of filling in the time-line with the consumer prompted the consumer’s 
memory, and additional information was raised.  In two of the cases, the details of the case were 
so complex, that the interviewer decided to attempt to do the time-line independently based on 
the information obtained from the interview, and then sent the time-line back to the consumer 
with the interview for verification.  In one case the consumer then contacted the interviewer and 
asked to discuss the time-line one more time.  Modifications to the time-line were made during 
the second interview.  Although the consumer continued to discuss the case in the second visit, 
the interview was not tape-recorded, as the interviewer had not anticipated this additional 
discussion and did not have the tape recording equipment with her. 
 
Each participant was asked to complete a consent form either prior to or during the interview, 
with the medical practitioner’s names and the address of each clinic.  Most participants came to 
the interview with the consent form completed. 
 
In some of the cases, the consumers provided specific dates of the consultations.  In these cases 
where there was also a medical view for the case, the dates provided by the consumers were 
accurate.  In the cases where the consumer was only able to provide an approximate date, it 
directed the medical practitioner to a section of the medical history, and then the medical 
practitioner was able to locate the specific consultation referred to by the consumer.  There were 
no cases where the consumer indicated a date or approximate date, and the medical practitioner 
was unable to locate the specific consultation being referred to by the consumer, within the 
consumer’s health record. 
 
Transcribing and de-identifying consumer interviews 
Approximately 80% of the tapes were transcribed by an external transcriber, who signed a 
confidentiality agreement.  The remainder were transcribed by the research team.  The 
transcriptions were then validated by listening to each tape and checking the transcription for 
errors. The tape recordings were de-identified in the following ways:  
 
 The transcriptions were labelled with codes.  For example, consumers were labelled in 
the following way C01, C02, C03. 
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 For each consumer, there may have been a number of consultations.  Each interview 
with a medical practitioner was identified as belonging to a particular consumer, 
identified by the clinic type (hospital, GP), and according to their sequence.  For 
example, if consumer C01 had indicated she attended three clinics GP1, GP2, H3. The 
code for the second clinic would be C01GP2.  All of the data collected that related to the 
consumer 01, would begin with C01. 
 All medical personnel’s names were removed and replaced with a code.  For example, Dr 
x may be replaced with D1.  These codes were then replaced with pseudonyms in the 
case studies and analysis of the case studies sections. 
 All consumer names were removed and replaced with a code.  These codes were then 
replaced with pseudonyms in the case studies and analysis of the case studies sections. 
 All references to relatives were removed and replaced with a code. For example, a wife’s 
name may be replaced with W. 
 In some cases the description given by the participant about his/her work environment 
was detailed enough to identify the participant.  In these cases wording was changed 
from specific details to general, and then checked with the consumer to ensure meaning 
was not changed. 
 Dates were changed, maintaining original spacing between the dates. 
 All drug names were checked against a drug dictionary to ensure the drug specified by 
the consumer was spelt correctly.  Misspelling can result in a misidentification of the 
drug, as different drugs exist with similar spelling.  In some cases, the consumer spelt the 
drug name for the principal investigator, but when the drug was checked the spelling was 
incorrect.  Drug names were then checked first by the consumers when the 
transcriptions were verified, and then by the experts when the de-identified cases were 
being reviewed by the experts. 
 
Verification of the transcripts by the consumer participants 
Transcripts and completed time-line of events were sent back to the consumers for verification 
in all cases except one.  One participant was an elderly lady who had expressed at the time of the 
interview that she had been very upset by the suspected ADR, and that she wanted to hand the 
information over to the researcher as a way of ‘letting go’.  There was a nine-month gap between 
the interview and when the transcript was ready for verification due to an interruption to the 
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research process.  It was decided not to send the transcript back to this consumer as it was felt 
that it may arouse the feelings surrounding the suspected ADR again.    
 
Thirteen of the 14 participants acknowledged that they had received the transcript by either 
posting or e-mailing it back, or by phone call and either made some changes or confirmed that it 
was representative of the interview.  One consumer did not respond. 
 
Two participants chose to make significant changes to their transcripts.  One participant chose 
to re-write the interview, and one asked for a second meeting with the researcher to clarify some 
dates and events in the timeline of events.  
 
3.5.4.4. Group 2: Data collection for medical practitioners 
The data collection process for the medical practitioners followed a similar path to that of the 
consumers.  Each medical practitioner who chose to be involved, participated in an in-depth 
semi-structured interview with the interviewer, in the medical practitioner’s work place.  Initially 
the plan was to ask the medical practitioner to fill in a time-line of events.  It became obvious 
fairly soon within this phase, however, that the medical practitioner accessed the medical record 
based on the consumer time-line, and so adding to the consumer time line with information 
such as specific dates or dosages that the consumer may not have recorded, and compiling a 
combined time-line was more useful. 
 
In-depth semi-structured medical interviews 
Each medical practitioner was asked if he4 would be prepared to have the interview tape 
recorded.  Three of the eight medical practitioners chose not to have the interview tape 
recorded, the remainder agreed.  The interviews where a tape was used were longer and more 
detailed.  The interviews where the interviewer was unable to tape were briefer, as the recording 
of the interview was in the form of note taking, which restricted the level of detail that could be 
recorded and also restricted the flow of the interview.  Also, the medical practitioners tended to 
use extensive medical terminology in the interview, and some spoke very quickly limiting what 
                                                 
4 Generally when referring to participants the term “s/he” has been used to indicate gender.  As each of the medical 
practitioners in the study are male, when referring to the medical practitioners, the term “he” will be used. 
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could be recorded.  When the interviews were tape recorded, the interviewer could listen 
multiple times and check the terminology to ensure accuracy. 
 
A list of questions was compiled based on the research questions, the background preliminary 
studies, the literature, and the results of the consumer interviews.  Several of the medical 
practitioners asked to see the list of questions either prior to the interview, or prior to consenting 
to having the interview tape recorded.  As in the consumer interviews, the tone of the interview 
was kept conversational to encourage issues not directly asked by the interviewer, but seen as 
important by the medical practitioner, to emerge. 
 
The list of questions about the suspected ADR did not alter significantly throughout this phase 
of the data collection.  Some questions were asked explicitly, some were answered throughout 
the course of the interview, some were not relevant based on the answer to the previous 
question, and some over the course of the interviews became less relevant. 
 
Transcribing, de-identifying and verifying medical interviews 
Each tape was transcribed, de-identified, and returned to the medical practitioner for 
verification, unless the medical practitioner had stated specifically that he did not want to check 
the transcription.  All interviews that were recorded by notes were sent back for verification.   
 
Each interview was de-identified using the same methods as described in section 3.5.4. 
 
3.5.4.5. Group 3: Data collection for experts 
Once the data from the consumers and medical practitioners had been collected and de-
identified, the data were sent to the participants from ADRAC for an expert opinion.  The data 
had been organised into cases, and so for a single case, the experts received the consumer 
interview, the time-line of events and, if available, the medical interview.  The experts, therefore 
offered an opinion on all case studies, those with both the consumer and medical perspectives 
and those with only the consumer perspective. 
 
The ADR experts were asked to read each interview, highlight using a highlighter pen, which 
pieces of information within the case study they used to make their decisions, and then fill in a 
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questionnaire about each case study.  A copy of the questionnaire can be found in Appendix G.  
The experts were asked to use whatever resources they would normally use when attempting to 
determine if they believed a set of symptoms are associated with a medication, however they 
were asked not to discuss the case studies with each other. 
 
The experts then e-mailed back a soft copy of their interviews so they could be easily imported 
into the analysis software, and posted back the original interviews with the highlighting. Minimal 
de-identification was required for these data, as the experts analysed data that had been de-
identified.  Each expert was allocated a code, and so the experts were identified by code rather 
than by name.  Each expert was allocated a code, E1, E2, and E3. 
 
3.5.5. METHODS OF ANALYSIS  
The analysis of these data was performed using three methods: individual case study analysis; 
analysis of participant groups (consumers, medical practitioners and experts); and a combined 
analysis viewing all of the data together. 
 
The analysis was conducted in a different order to that in which it is presented.  The group 
analysis of the consumers was conducted as the consumer data was collected.  This was followed 
by a group analysis of the medical practitioners and then experts.  The individual data analysis 
was performed at the same time as creating the case study documents, and following the group 
analyses.  The combined analysis occurred as the final phase of analysis.   
 
The group analysis extracted results that could only be seen when viewing that particular group 
of data, such as insights provided by the consumers.  Once the group analysis had been 
completed, themes began to emerge.  The analysis of the individual case studies highlighted 
issues specific to that individual case study; some of which were seen in other case studies, and 
some which were unique to that case study.  It also replicated results that had been revealed 
during the group analysis.  The combined analysis provided themes that were only visible when 
viewing the themes from the group data and those emerging from the case study data together, 
and in some cases evolved into emerging theory. 
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The analysis process was not linear.  One form of analysis triggered insights into other forms of 
analysis.  Some insights at the combined analysis level emerged throughout the data collection, 
others became clearer when writing a set of results or a research paper, and others emerged 
when specifically focusing on this form of analysis. 
 
The group analysis involved coding the data and then observing patterns and emerging themes, 
which are described in section 3.5.5.1.  The case study analysis was performed using a less formal 
method, and is described in section 3.5.5.2.  The combined data collection method is described 
in section 3.5.5.3.  As stated above, the order of presentation of the results is different to the 
order the data were analysed, and this has been explained in the introduction of chapter four.  
 
3.5.5.1. Group analysis 
The process of coding involves attaching codes to data.  In this case the data comprises the 
consumer and medical practitioners’ interviews, the expert questionnaires, and additional 
documentation such as letters or notes from medical files.  Miles and Huberman (1994) describe 
codes: 
 
Codes are tags or labels for assigning units of meaning to the descriptive or inferential 
information compiled during a study.  Codes usually are attached to “chunks” [of text] of 
varying size – words, phrases, sentence, or whole paragraphs, connected or unconnected to 
a specific setting.  They can take the form of a straightforward category label or a more 
complex one (e.g. a metaphor) (p. 56).  
 
According to Strauss and Corbin, it is not necessary to code every interview in minute detail, but 
important to perform very detailed coding at the beginning of the analysis process, in order to 
establish the key concepts held within the data, and then to scan the remaining data for new 
ideas or concepts that had not been previously captured,  (Strauss & Corbin, 1998).  Miles and 
Huberman (1994) warn that it is easy to be overloaded with the enormity of the task, and the 
very large quantity of data that can be generated.  They, therefore, suggest being selective in the 
process of coding, using research questions and the conceptual framework to hone in on the 
relevant concepts and ideas. “You may never have the time to condense and order, much less to 
analyse and write up, all of this material” (p. 55). 
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Following Miles and Huberman’s (1994) recommendations, the coding was begun with a set of 
codes that were derived from the research questions, the preliminary background studies, and 
the literature.   
 
The data analysis tool, NVivo 2.0 (QSR, 2002) was used to assist with the initial coding of the 
data.  NVivo is a software package designed to assist with the process of coding, it does not do 
the coding for the analyst.  Some features of NVivo that were extremely useful during the coding 
process were the ability to generate codes and store them electronically, attach code tags to the 
data, with the ability to code the same data in different ways (sometimes a phrase or paragraph 
can relate to more than a single concept.). 
 
In the purest form of grounded theory, ‘free nodes’ are created and the codes are then grouped 
and clustered in the second phase of analysis to form tree structures, or hierarchies.  The codes 
naturally developed into hierarchical structures, which were represented within NVivo as tree 
structures, and so allowed this process to naturally occur.   
 
Themes emerged from these codes that relate to each of the research questions.  As will be 
explained in detail in the results chapters (chapters four and five), the results will be presented 
using the research questions as the primary structure, followed by the themes at the second level. 
 
3.5.5.2. Individual case study analysis 
The individual case studies were analysed using a less formal method than the group analysis.  
The individual case studies were compiled from the raw data, and are presented in chapter four.  
Throughout the process of creating the case studies, insights into the decision-making processes 
within the case study emerged.  At an individual case study level, all that can emerge is a concept 
or idea that relates to that case study.  It cannot be a theme at this stage, as it has only occurred a 
single time.  As each case study was compiled and analysed, themes between the individual case 
studies began to emerge.  These themes could then have been re-presented in a results section 
looking at the between case study themes, but rather than introducing this repetition, the 
emerging themes at this level are re-presented in chapter five, which discusses the results in the 
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context of the entire set of results and comparing it with current knowledge found in the 
literature. 
 
The repetition between the individual case studies indicated triangulation between the individual 
case studies.  As the individual case study analysis revealed some concepts that had already 
emerged in the group analysis, the only ideas to be presented in this section are those that were 
unique to the individual case study analysis, and were not revealed in the other forms of analysis. 
 
3.5.5.3. Combined methods analysis 
The combined analysis primarily occurred whilst conducting the other two forms of analysis.  
There were themes which arose from either the group analysis, or gradually when doing the 
individual case study analysis, that when combined produced either more detailed themes, and in 
some cases emerging theory.  These results were only visible when all of the data and the results 
of the previous forms of analysis, were combined.  These are presented in section 5.5. 
 
3.5.5.4. Triangulation 
Triangulation is a term which is often used to support evidence.  Patton (1987), cited in Yin 
(2003) describes four types of triangulation.  These include triangulation: 
 
 of data sources (data triangulation); 
 among different evaluators (investigator triangulation); 
 of perspectives to the same data set (theory triangulations); and,  
 of methods (methodological triangulation)  (pp. 98-99). 
 
The analysis of case study data was triangulated in a number of ways.  The triangulation “of data 
sources” (Patton, 1987 cited in Yin, 2003, p. 98), included triangulating the views of the 
consumer, medical practitioners and experts.  In some cases, there was “convergence of 
evidence” (p. 100) described by Yin (2003).  This term meant that when multiple sources of 
evidence are used, they can confirm or validate a ‘fact’.  The use of triangulation for this purpose 
fits within a positivist theoretical framework, as the goal is to find a single understanding for a 
concept.  The data have been triangulated within these case studies using a symbolic 
interactionist theoretical framework.  Rather than using multiple sources of evidence to confirm 
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a ‘fact’, multiple sources of evidence have been used to reveal differences in understanding 
between individuals within a single case study, and between the groups. 
 
Another example of triangulation was when the individual case studies revealed themes that were 
repetitive.  Rather than describing each of these repeating themes within the individual case 
study analysis, these themes were extracted and reported using the group and combined methods 
of analysis. 
 
These uses of triangulation added strength to the results of these three methods of data analysis. 
 
3.6. Ethical considerations 
The University of Ballarat Human Research Ethics Committee reviewed the research proposal, 
and due to the complexities of the project and the sensitivity of the data, agreed to a meeting to 
discuss and work through ethical concerns.  Following the discussion, the ethics committee 
requested that some additional measures be taken to ensure participant safety, and for the 
project to be re-submitted for consideration following these changes.  The second time the 
project was submitted, it was approved on 27th June 2002, subject to the approval of the Ballarat 
Health Services and St. John of God Health Services, Combined Hospitals Ethics Committee.  
The research proposal was approved by the Ballarat Health Services and St. John of God Health 
Services, Combined Hospitals Ethics Committee on 26th August 2002. 
 
The University of Ballarat Human Research Ethics Committee also required that the other 
participating bodies, put in writing that they did not need the project to be approved by their 
own ethics committees.  
  
Ethics approval was obtained by all of the organizations involved in the study, as requested by 
the University of Ballarat Human Research Ethics Committee.  Care has been taken to ensure 
that all of the requirements of each of the ethics committees were adhered to, and to avoid 
ethical issues that may impact on any of the participants. 
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One unanticipated ethical issue that arose was the issue of de-identification of case study 
material when it was presented within the thesis in individual case study format.  The consumers 
were told by the interviewer that the contents of their transcript would not be discussed with the 
medical practitioner, and that the interview with the medical practitioner would not be discussed 
with the consumer.  The consumers were aware that the information recorded within the time-
line of events (containing the medical ‘skeleton’ of the cases) would be disclosed to the medical 
practitioner, to assist in the location of the particular episode of care within the consumer’s 
medical case history.  The consumer consent form included a request for the consumers to give 
the interviewer permission to contact the medical practitioners who were involved in the 
suspected ADR.   Care was taken throughout the interview process to ensure information other 
than what was included in the time-line of events, was not disclosed to the medical practitioner.  
Case study analysis, however, meant that the individual interviews were situated next to each 
other as a component of the research analysis.  The data have been carefully de-identified, 
including changing names, locations, and dates (but maintaining relationships between dates), 
and at times aspects of the interview that would identify a participant, such as comments about 
work environment.  This issue was particularly important when studying people from a regional 
centre.  This process has minimized the likelihood that someone outside of the case study would 
identify the participants.  The participants themselves, however, if reading the results of this 
study, would potentially be able to identify themselves within the study.   
 
Advice was sought regarding this issue, and a number of possible suggestions were raised.  These 
included: further de-identification of the case studies; removing the individual case study analysis 
and using only combined case study analysis and the group analysis; an embargo; or restructuring 
the thesis so the case study data is in a separate volume within limited access.  Each of these has 
been discussed below. 
 
3.6.1.1. De-identify the case studies  
The suggestion was to de-identify the case studies to the point that the individual (consumer 
and/or medical practitioner) who participated in the research cannot identify his/her own case.  
As there are only 15 case studies, using the process of elimination, the participants can 
reasonably work out which is their case. 
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The method used within this research of interviewing the medical practitioners rather than, as 
initially proposed, collecting the medical view from the consumer medical histories, was to 
ensure medical integrity of the data.  The medical experts involved in the study, ensured 
terminology was correctly used, and explanations based on the medical data were credible.  The 
‘skeleton’ of each case study includes the medical details such as the drug names, dosages, 
symptoms, and temporal relationship between these factors. The decisions and interactions 
between the decision-makers, which form the main body of the discussion and conclusion, 
‘hang’ off this skeleton.   Each case, at this level, is unique, and therefore potentially identifiable 
by the consumer who participated in the interview.   
 
Another suggested method of assisting with the de-identification process was to remove the 
drug names.  The participants, however, would still be able to identify his or her own case by 
other factors within the case study.  To illustrate, below is a small segment of one case study. 
 
Joanne, a 29-year-old woman, who works in a health profession, has a significant history of 
allergies, in particular an anaphylactic reaction to nuts.  Joanna experienced three suspected 
ADRs, the most severe one a suspected photosensitivity reaction to Celebrex, which 
resulted in ongoing photosensitivity for at least two years.   
 
Below is the same segment from a case study.  The gender age and occupation have been 
changed and drug names removed: 
 
Ray, a 35-year-old man has a significant history of allergies, in particular an anaphylactic 
reaction to nuts.  Ray experienced three suspected ADRs, the most severe one a suspected 
photosensitivity reaction to Drug A, which resulted in ongoing photosensitivity for at least 
two years.   
 
Joanna would still identify her case from this segment as there is no other case study where the 
consumer within the set of case studies who had a history of a significant allergy to nuts and 
experienced a suspected photosensitivity reaction that lasted several years. 
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3.6.1.2. Removing individual case-study analysis 
The intention was always to triangulate the multiple perspectives of the consumer, medical 
practitioner and expert.  This was made explicit to the participants.  What was not considered at 
the commencement of this work was how the case studies would be presented within the thesis, 
without allowing the consumers to have access to the medical practitioner view and vice versa.   
 
The individual case study analysis is an integral component of this work, and accounts for more 
than half of the results within the thesis.  Removing the individual case study analysis and 
analysing the case studies at a multiple case study level would severely compromise the results of 
the thesis.   
 
3.6.1.3. Restructure of the thesis  
A final suggestion was to re-structure the thesis into two volumes.  Volume one to contain the 
main body of the thesis, and Volume two to contain the details of the case studies.  Following 
examination, the second volume would not be available to the general public. 
 
A combination of the above suggestions has been used within this work.  The thesis has been 
structured into two volumes.  The case studies have been removed from Volume one, but the 
analysis of the individual case studies remains.  In chapter five, which presents the group analysis 
of the case studies, at times the participant’s pseudo name has not been used, and at times the 
drug name has been removed.  The case studies allow insight into the human side of ADRs.  
 
There does not appear to be a totally satisfactory solution to this ethical issue. A balance, 
therefore, has been attempted between removing some detail to make it more difficult for a 
consumer who has identified his or own case, to determine the medical data that pertains to his 
or her case, and maintaining the human side of these cases. 
 
3.7. Summary of  research process 
This study is situated in a social constructionist epistemology, with a theoretical perspective of 
symbolic interactionism.  Case studies of consumers with suspected ADRs have been collected, 
which include two or more perspectives from consumer, medical practitioner and experts.  
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These case studies have been analysed using a grounded theory methodology, and methods have 
included an analysis of each participant group (consumers, medical practitioners, and experts), 
individual case study analysis, and analysis combining the case study and group analysis results. 
 
Significant ethical issues were raised by two ethics committees, but were eventually worked 
through and resolved.  Issues surrounding confidentiality of the data that emerged throughout 
the research process have been discussed. 
 
Considerable thought went into the complex task of collecting data for this study, given the 
ethical and logistic issues that surrounded the data collection.  Eventually the method of data 
collection included advertising for consumers who believe they may have experienced an ADR, 
contacting the medical practitioners and asking for their participation in the study, and passing 
the de-identified case studies to two ADR experts.  GP forums were organised as a fourth phase 
of data collection, however due to a lack of numbers were cancelled. 
 
The consumers and medical practitioners each participated in an in-depth semi-structured 
interview, and were asked to participate in the creation of a time-line of events.  These interviews 
were recorded via tape recording or note taking.  The tapes were transcribed, de-identified and 
passed to the experts.  The experts highlighted on each of the transcripts the pieces of 
information they considered important, and filled in a questionnaire. 
 
The data were analysed using three methods.  The participant data were grouped into consumer, 
medical practitioner and experts and each set of data coded using the NVivo analysis software to 
assist with this process.  The data were also analysed at an individual case study level and then 
finally by combining all of the data, and the results of the two previous forms of analysis. 
 
The results of the analysis are presented in the next two chapters.  Chapter four includes an 
overview of the data collected followed by the individual case study analysis.  Chapter five 
includes the group analysis at the consumer, medical practitioner and expert levels, and also the 
results of combining the data. 
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 CHAPTER FOUR 
4. Results: Data Overview and 
Individual Case Study 
Analysis 
4.1. Introduction 
The results are presented in two chapters, chapters four and five, followed by a third chapter, 
chapter six, that integrates the results and discusses them in the context of past literature.  The 
first of the results chapters (chapter four) includes an overview of the data followed by the 
individual case study analysis.  The individual case studies have been divided into three groups, 
the case studies which include a consumer, medical practitioner and expert view, and there is a 
high likelihood that the consumer has experienced an ADR, the case studies which include again, 
all three groups, but where the likelihood that the consumer experienced an ADR is low, and the 
final group which are case studies which only include a consumer and expert view and there is a 
high likelihood that the consumer has experienced an ADR. 
 
The second results chapter (chapter five) includes the group analysis which is divided into the 
group analysis for the consumer data, the group analysis for the medical practitioner data and the 
group analysis for the expert data.  This is followed by the analysis when viewing all of the data. 
 
4.2. Overview of  data 
This section summarises and describes the data, to provide an overview of what was collected 
prior to delving more deeply.  This section describes the participants for each case (section 
4.2.1), followed by the characteristics of each participant (section 4.2.2) and then the 
characteristics of the ADRs (section 4.2.3). 
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Case ID Consumer GP Specialist Hosp  ADRAC  
     Expert 1 Expert 2 Expert 3 
C02 C02    Female C02GP1 Declined1 NA2 C02TGA1 C02TGA2  
C04 C04    Female Declined NA NA C04TGA1 C04TGA2  
C05 C05    Female NA C05SP1 C05H1 C05TGA1 C05TGA2  
C06 C06    Female NA NA C06H1 C06TGA1 C06TGA2  
C07 C07   Female Declined C07SP1 NA C07TGA1  C07TGA3
C08 C08   Female Declined NA OL3 C08TGA1 C08TGA2  
C09 C09   Male C09GP1 NA NA C09TGA1 C09TGA2  
C10 C10   Male Declined NA NA C10TGA1 C10TGA2  
C11 C11   Female Declined C11SP1 NA C11TGA1 C11TGA2  
C12 C12   Male NA NA OL C12TGA1 C12TGA2  
C13 C13   Female C13GP1 NA NA C13TGA1 C13TGA2  
C14 C14   Male Declined NA NA C14TGA1 C14TGA2  
C15 C15   Female NA NA OL C15TGA1 C15TGA2  
C16 C16   Female NA OL OL C16TGA1  C16TGA3
 C16 Family4       
C17 C17 Male C17GP1 NA NA C17TGA1 C17TGA2  
Table 4-1 Participants for each case study 
1. Declined – each of these participants were sent an information package and requested to participate 
in the study, followed by a phone call. The participants either chose not to participate or did not 
respond to the request. 
2. NA – not applicable.  The participant did not use this service throughout the suspected ADR. 
3. OL – The medical practitioners were based in a hospital outside of the regional area.  These medical 
practitioners were not approached as ethics clearance was only for specific hospitals. 
4. In this case, the consumer’s husband was interviewed, as the consumer was not fully aware during 
the suspected reaction. 
 
4.2.1. PARTICIPANTS FOR EACH CASE 
Each case study comprises interviews from two or more perspectives.  Table 4-1 lists the 
interviews that were obtained for each case study.  In total the data collection comprises 25 in-
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depth interviews (15 consumers, one family member and nine medical practitioners) and 30 
questionnaires (two expert views for each case study) 
 
Three experts are listed in Table 4-1 because of the two experts who initially volunteered for the 
study one was unavailable to review the final two case studies.  As a consequence a third 
member of ADRAC offered to provide an expert opinion for the remaining two cases, and is 
labelled as ‘Expert 3’. 
 
The codes used to indicate the participant and participant type were described in section 3.5.4.3.  
To remind the reader: consumers were labelled in the following way C01, C02, C03. For each 
consumer, there may have been a number of consultations.  Each interview with a medical 
practitioner was identified as belonging to a particular consumer, identified by the clinic type 
(hospital, GP), and according to their sequence.  For example, if consumer C01 had indicated 
she attended three clinics GP1, GP2, H3. The code for the second clinic would be C01GP2.  
Each case study was reviewed by two experts, with the code TGA1, TGA2 or TGA3 to identify 
the expert.  The interview data relating to the first expert’s evaluation of C05’s case therefore is 
C05TGA1. 
 
4.2.2. PARTICIPANT CHARACTERISTICS 
In order to understand who the participants were, their characteristics have been described in 
this section.  Sections 4.2.2.1 to 4.2.2.3 describe the characteristics of the consumers, medical 
practitioners and experts respectively.   
 
4.2.2.1. Consumer characteristics 
Twenty consumers inquired about the study and 15 chose to participate.  There were four 
consumer participants who entered the study without meeting one of the criteria.  Two with 
diagnosed depression were entered into the study, the first because the diagnosis was not 
disclosed by the participant but was disclosed by the medical practitioner after the consumer 
interview had been completed, and the second, because it did not become apparent that the 
person had this disorder until partially through the in-depth interview.  In two more cases, the 
time since the suspected reaction was greater than 18 months.  It was decided to enter these four 
case studies into the study as they added additional information.  In the cases of the depression, 
CHAPTER FOUR: RESULTS: DATA OVERVIEW AND INDIVIDUAL CASE STUDY ANALYSIS 
128 
in one case it was being treated, and in the other case, it did not appear to affect the participant’s 
ability to report their experience. 
 
The 15 consumer participants had the following characteristics:  
 
 Age range of 29 to 76, with the following breakdown: 
o four aged 21-40, eight aged 41-60, three aged 61-80.  
 ten female, five male.  
 six from the University of Ballarat, nine from the community. 
 
4.2.2.2. Medical practitioner characteristics 
If, when requested to participate in the study by mail, there was no response from the medical 
practitioner, a follow up phone call was made to the medical practitioner’s clinic.  Of 16 medical 
practitioners approached, nine agreed to participate. 
 
The medical practitioners had the following characteristics: 
 
 half the medical practitioners approached were prepared to participate. 
 nine male, none female. 
 three medical specialists, four general practitioners, two hospital based medical 
practitioners. 
 two hospital based, seven community based.  
 
Information about age was not collected however the estimated age range is 30 to mid 50s. 
 
4.2.2.3. Expert characteristics 
ADRAC (Adverse drug reaction advisory committee) is the central body in Australia for 
collecting reports of suspected ADRs and determining the likelihood that the drugs are 
associated with the newly presenting symptoms.  This committee is considered, within Australia, 
as an expert committee in ADR detection.  The experts within this work are professionals 
working within the ADRAC Secretariat. 
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Two experts initially volunteered as expert participants in the study.  Throughout the study, one 
was unable to continue with the project, so a third volunteered.  The three male experts are 
members of ADRAC.  Two of the experts are medically trained, and one is a scientist. 
 
4.2.3. SUSPECTED ADR CHARACTERISTICS 
Table 4-2 describes the characteristics of the suspected ADRs, including the reaction type 
classification. Reaction types were described in detail in the literature review chapter (section 
2.2.4).  Below is a summary of the definitions to assist in the interpretation of the information 
presented in Table 4-2. 
 
Case ID No. 
drugs 
Drug Symptoms 
Consumer view 
Suspected 
ADR Type 
Expert view 
C02 (Single) Single Tegretol1 Severe flu style illness Type B 
C04 (Multiple) Multiple tramadol hydro- 
chloride 
Itchy/skin crawl, in absence of 
rash 
Type A 
C05 (Single) Single Generic  
sodium valproate
Grand Mal first for 18 years. Type F 
C06 (Single) Single Panadeine Forte Convulsions Type B 
C07 (Multiple) Multiple tamoxifen Aches in legs, and nausea Type A 
C08 (Single) Single Inderal Slow heart rate and slow 
recovery from epidural 
Type E 
C09 (Single) Single Zyban Bell’s Palsy Type B 
C10 (Multiple) Multiple Efexor Vomiting after second dose, for 
two weeks 
Type B 
C11 (Multiple) Multiple hydralazine Drug induced lupus Type B 
C12 (Single) Single Panadeine Forte Felt ill enough to miss work, 
nausea, generally feeling unwell 
Type A 
C13 (Multiple) Multiple Celebrex Photo-sensitivity – pustule rash Type D 
C14 (Multiple) Multiple Vioxx Photo-sensitivity – itchy rash Type D 
C15 (Multiple) Multiple Maxolon Double vision Type B 
C16 (Multiple) Multiple Sabril Induced severe seizure – similar 
to psychotic episode. 
Type F 
C17 (Single) Single Lipitor Restless Legs, unwell, pain in 
legs and hip 
Type B 
Table 4-2 Characteristics of the suspected ADRs 
1.  Drug proprietary (trade) names have been capitalised, and generic names have not been capitalised.  
The consumer used either a proprietary name or generic name.  The term used by the consumer has been 
used in the thesis. 
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 Type A, predictable events or reactions, pharmacological reactions or expected events or 
reactions, common and are accounted for by a drug’s known pharmacological properties, 
(Kalachnik, 1999). 
 Type B, unpredictable events or reactions.  Also referred to as idiosyncratic or 
unexpected events or reactions, uncommon and independent of a drug’s known 
pharmacological properties (Kalachnik, 1999).  This group includes hypersensitive 
reactions.  A person may have a slight reaction the first time they are in contact with the 
drug, but may react more severely with each subsequent contact.  
 Type C, dose related and time related. Uncommon and related to the cumulative dose,  
 Type D, delayed. Uncommon, usually dose related and usually becomes apparent some 
time after the use of the drug,  
 Type E, withdrawal. Uncommon, occurs soon after the withdrawal of the drug and  
 Type F, unexpected failure of therapy. Common, dose related and often caused by drug 
interactions. (Edwards & Aronson, 2000) 
 
Table 4-2 lists the suspected drug name, whether the consumer was taking a single drug or 
multiple drugs at the time of the suspected reaction, and the suspected reaction type using the 
definitions above, from the expert perspective.  In summary, the suspected ADRs experienced 
by the participants have the following characteristics: 
 
 Type of medication – 15 prescription, no non-prescription, no complementary.  
 Number of medications - seven single medication, eight multiple medications.  
 three Type A, seven Type B, no Type C, two Type D, one Type E, two Type F. 
 Suspected interaction between multiple drugs, one case study. 
 
4.3. Introduction to individual case studies 
As stated in the previous chapter, the process of analysis and recording results is a different 
process from writing the results and assisting the reader gain an understanding of the key 
concepts, themes and emerging theory.   
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The results from the individual case studies are presented first.  Some of the case studies 
describe more than one suspected ADR, however each case study has a primary focus on one of 
them.   The case studies have been presented in Appendix A in Volume two of this thesis5   
 
Following the individual case study results, are the results from the group analysis, which are 
presented in chapter five.  These results include any emerging themes that were viewed by 
analysing the consumer data, medical practitioner data and expert data separately from each 
other.  This is followed by results that emerged when the data were combined and the results of 
the individual case study analysis and group analysis is combined. 
 
A secondary element to this order of presentation of the results relates to the strength of the 
emerging results.  The individual case studies provide insight into concepts, the group data 
presents emerging themes, or conceptual ordering, to use Strauss and Corbin’s terminology 
(Strauss & Corbin, 1998).  The final section that reports on results obtained by combining the 
data and previous results begins to describe some possible explanations emerging from the data, 
which becomes emerging theory.   
 
The results have been presented using the research questions and emerging themes as a structure 
as illustrated in Table 4-3.  Column one lists each of the research questions and the key themes 
that have emerged from each question.  The second column indicates the primary method of 
analysis that was used to inform each research question.  The structure is a guide only, as there 
were times when one method of analysis provided a small insight into a research question, an 
insight that was not visible when viewing the data using the primary form of analysis, and so was 
included, but is outside of this overriding structure.  Throughout the remainder of the 
document, the structure of each section will include the research questions and themes that are 
relevant to that section. 
 
Eight of the case studies include a consumer, one or more medical practitioners and two expert 
views.  The remaining seven cases include only the consumer and expert view.  In two of the 15 
 
5 As explained in detail in section 3.6, the individual case studies in volume two will not be available to the public 
due to the sensitive nature of the data, and the inability to protect the participants through de-identification. 
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case studies, both of the experts agreed that the medication was unlikely to be associated with 
the symptoms.  In the remaining 13 cases, at least one expert agrees that there is a significant 
likelihood that the drug was associated with the symptoms.   
 
Research questions and key themes  Method of 
analysis 
Who are the decision-makers (defined by the participants) in the ADR domain? 
              Multiple decision-makers. 
Group level 
What decisions are made by each decision-maker?  
              Decision types.  
              Consumers as diagnostic decision-makers. 
              The role of the pharmacist 
Group level 
What do decision-makers understand by the term ADR?  
‘Side effect’ as an attribute of a drug 
‘Side effect’ as an expected but non-therapeutic effect of a drug 
‘Reaction’ describing the experience of the consumer 
‘Allergy’ as a type of reaction 
Terminology used when quoting a health professional 
Group level 
Do all decision-makers agree on a definition of an ADR? 
                Differences in understanding 
Group level 
How are ADR decisions made? 
                Differential diagnosis – Consumer 
                Differential diagnosis – Medical practitioner 
                Differential diagnosis – Expert  
                Differences between GPs and specialists 
                Medical practitioner/consumer decision-making models 
Group level, 
case level and 
combined analysis. 
What problems occur when making ADR decisions? 
               Medical practitioner/consumer relationship 
               Decision-making with partial knowledge 
               Decisions that may contribute to an ADR 
               Complexities in the ADR decision domain 
Group level and  
case level analysis 
What resources are used by decision-makers? 
                List of resources used – Consumer 
                List of resources used – Medical practitioner 
                List of resources used – Expert 
Group analysis 
How do decision-makers contribute to the creation of new knowledge at an 
individual, national and international level?  
                 Reporting suspected ADRs to ADRAC 
                 Reasons for low levels of reporting 
                 Concerns about a lack of reporting 
                 Impact on individual decision-maker learning 
Group analysis and 
combined analysis 
How do ADRs affect people and how does this impact on decision-making? 
                  Impact on the medical practitioner/consumer relationship 
                  Perception of the severity of the suspected ADR 
                  The importance of life context 
                  Differences between expected versus unexpected symptoms 
Group level and 
case level analysis 
Table 4-3 Method of analysis used to address each research question 
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4.4. Case studies of  suspected adverse drug reactions: high 
likelihood of  an ADR from the consumer, medical and 
expert views 
 
The following five case studies include the consumer, medical and expert perspectives of a single 
ADR, the case studies of Toni, Helen, Irene, Joanna and Paul.  The age range is from 29 to 64 
years of age.  In each of these case studies, both of the experts believe there is a likely association 
between the suspected drug and the newly developed symptoms.  The case studies have been 
presented in Volume two of this thesis.  Below are the results of the individual case study 
analysis. 
  
4.4.1. ANALYSIS OF TONI’S CASE STUDY (C02) 
Toni experienced a suspected reaction to Tegretol, a reaction that resembled the symptoms of a 
‘flu like’ virus.  This case study includes the view of Toni the consumer, her general practitioner 
Dr Barns, and two experts.  The specialist who prescribed the drugs chose not to participate in 
the study.  In this case, all participants agree that there is a high likelihood that the symptoms are 
related to the drug Tegretol.  The details of Toni’s case study can be found in Volume two, 
section 1.2.1. 
 
4.4.1.1. How are ADR decisions made? 
Differential diagnosis 
ADR resembles another disease 
The symptoms of this uncommon ADR closely resembled a common disease, an influenza type 
of virus.  It appears that the first time Toni went to see her GP, the most likely cause of the 
symptoms was diagnosed and it was not until the condition progressed in an unexpected way for 
the initial diagnosis that a second diagnosis was considered. 
 
According to the experts (from the group expert data), in order to differentially diagnose 
between an ADR and another disease, the decision-maker/s need to be aware that a differential 
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diagnosis is required, and that it is important to have a drug reaction as one of the possibilities in 
mind at the beginning of the decision-making process.  It appears that in this case, the diagnosis 
on the first day was a virus.  It appears from this case study that differential diagnosis did not 
begin until the second consultation, and according to the medical practitioner the rash was what 
signalled the possibility of an ADR.   
 
According to one of the experts awareness that the drug Tegretol has a potential reaction that 
resembles a virus, would have assisted in the diagnosis of this ADR two days earlier.  The 
second expert said that he believes that the reaction was detected as soon as was feasibly 
possible given the similarity of the two conditions. 
Novel versus pattern matching 
In this case, there is a difference of opinion about how the diagnostic decisions surrounding the 
suspected ADR were made. According to Toni, Dr Barns had begun to suspect the ADR on the 
second visit, as he ceased the Tegretol, and was differentially diagnosing between an ADR and a 
virus, using temperature as a key factor.  According to Toni, he stated that because Toni had a 
temperature, the symptoms were unlikely to have been related to an ADR.  By the third 
presentation, the rash had developed, and Dr Barns requested liver function tests and rang the 
specialist, two actions to determine if the symptoms were related to an ADR. 
 
According to Dr Barns, he recognised the ADR as an allergic reaction, based on the look of the 
rash.  He said “it looked like a reaction”, indicating he used a pattern matching style of decision-
making.  From this case study, therefore, it is not clear which style of decision-making was used, 
and perhaps there was a combination of styles. 
Diagnosis based on probabilities rather than absolutes 
Based on the combined accounts of Toni and Dr Barns, above, it appears that the initial 
diagnosis was a virus, and that the possibility of a second diagnosis required a differential 
diagnostic process to occur, and by the third visit, the second diagnoses became more likely than 
the first diagnosis, illustrating clearly that in this case, diagnosis was about weighing up 
possibilities with a level of probability, rather than black and white certainties. 
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4.4.1.2. What problems occur when making ADR decisions? 
Medical practitioner/consumer relationship 
Medical practitioner’s awareness of the experience of the ADR 
Within this case study, there are multiple instances where Toni described one experience, and Dr 
Barns described what he believed to be Toni’s experience, with a significant discrepancy between 
perceptions: 
 Dr Barns thought that the specialist had warned Toni of the potential problems with 
Tegretol, when according to Toni, he did not warn her. 
 Dr Barns thought that Toni was aware that the symptoms were probably caused by an 
ADR, when Toni reported that she was not aware of this.   
 Dr Barns believed that Toni recovered quickly, when Toni did not feel she made a full 
recovery for ten weeks. 
 Dr Barns believes that the medical specialist reported Toni’s case to ADRAC, however, 
he did not know for certain. 
 
Decision-making with partial knowledge 
Partial knowledge of ADRs 
In this case, there were two key impacts of not providing Toni with information about suspected 
ADRs.   
 
Toni reported that she specifically asked the specialist if the medication may cause problems that 
she should be aware of.  According to Toni, the response of the specialist was for Toni to not 
worry about it.  Dr Barns stated that he believed the specialist would have warned Toni about 
possible reactions, as reactions are more common with this group of drugs.  One of the experts 
believed that if Toni had been aware that a symptom of an ADR could resemble a virus, it would 
have been detected and managed earlier resulting in a less severe reaction. 
 
In the absence of reliable medical information, Toni used less reliable information sources such 
as discussions with family and friends.  Information gathered about the “reputation” of Tegretol 
added to Toni’s anger at not being told about potential ADRs associated with this drug, 
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especially when her perception was that those around her were aware of the potential dangers of 
this drug, but when she asked for this information, she was not given it. 
Treating medical practitioner different to the prescribing medical practitioner 
Toni’s specialist prescribed the drug, but Toni sought treatment from her GP rather than the 
prescribing medical practitioner.  In the preliminary background studies (O'Brien, 2001) the GPs 
stated that they use a ‘preferred list’ of drugs.  This is a method they use to manage the large 
number of drugs available on the market. Rather than attempting to know all drugs on the 
market, they limit the drugs they use regularly.  The drug prescribed by the specialist, may not be 
a drug that is one regularly used by the GP.  According to Toni, Dr Barns requesting 
confirmation of the diagnosis from the specialist, indicating that the specialist had more 
familiarity with this drug than the GP.   
 
4.4.1.3. How do ADR decision-makers contribute to new ADR knowledge? 
Impact on individual decision-maker learning 
Lack of feedback to prescriber from consumer 
In this case study, Dr Barns believed that Toni recovered quite quickly.  As Toni did not 
feedback to Dr Barns that she took ten weeks to recover from this reaction, and Dr Barns did 
not follow up with Toni regarding her recovery, he did not have the opportunity to develop 
more of an understanding about this specific ADR. 
 
4.4.2. ANALYSIS OF HELEN’S CASE STUDY (C06) 
Helen had a mole removed in day surgery at about four o’clock in the afternoon under local 
anaesthetic.  Following surgery she took Panadeine Forte for the pain, which resulted in her 
feeling nauseated, fainting and convulsing. The treating medical practitioner and experts agree 
that the symptoms are highly likely to be associated with the drug Panadeine Forte.  The details 
of Helen’s case study can be found in Volume two, section 1.2.2. 
 
CHAPTER FOUR: RESULTS: DATA OVERVIEW AND INDIVIDUAL CASE STUDY ANALYSIS 
137 
4.4.2.1. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
The impact of partial knowledge 
Helen chose to take a medication not prescribed for her, a medication that resulted in a 
suspected ADR.  The circumstances surrounding this decision, however, included a lack of 
information.  Helen took this medication, because the pain she experienced was severe, it was 
the middle of the night, and she had no other medication in the house.  She said that she did not 
expect to experience such a severe level of pain, and if she had been aware, she would have 
ensured she had what she needed available to her. 
 
Helen also commented that she felt unwell when she left the surgery, but because she did not 
expect to feel unwell, she had her children with her and drove.  She may have made a different 
choice if provided with information about the possible outcomes post surgery. 
 
As the surgeon did not participate in the study, it is not known whether the medical practitioner 
could have predicted these symptoms and provided prior warning to Helen to assist with these 
issues. 
Impact of no diagnosis 
At the time of interview, Helen was not certain of the diagnosis.  It is well known that often it is 
difficult to provide a clear diagnosis for a suspected ADR but it appears in this case the medical 
practitioner did make a diagnosis.  Two impacts of not knowing about this diagnosis, have been 
identified from this case study.   Because Helen has not been provided with a diagnosis, it is 
possible that she will take the medication again, even though, in the interview, the medical 
practitioner stated that there is a high chance that Helen would experience the same reaction 
again, and should avoid the drug.  The second impact was that in order to understand the cause 
of her experience, she sought other sources of information that may be less reliable, because the 
people she asked did not have access to all of the information.   
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4.4.2.2. Decisions that may contribute to an ADR 
Taking a prescription drug prescribed for another consumer 
As stated previously, Helen chose to take a medication that was not prescribed for her.  
According to one of the experts, Helen’s decision to take a prescription medication prescribed 
for someone else, may have contributed to the occurrence of the ADR. 
 
4.4.3. ANALYSIS OF IRENE’S CASE STUDY (C11) 
Irene has a significant history of ADRs.  She spoke in detail about a suspected reaction to a drug 
hydralazine, which was associated with drug-induced lupus.  Irene expressed concern about her 
failing memory combined with her history of multiple suspected reactions.  In order to manage, 
she maintains detailed diaries of her care, which are the equivalent of her own personal medical 
record.  Irene’s specialist Dr James located the key information within his own medical history 
about the suspected ADR using Irene’s dates to guide him.  Dr James and experts agreed with 
Irene that there is a high likelihood that the drug was associated with the symptoms.   
 
Irene’s GP responded to the request to participate in the study by return mail.  He chose not to 
participate in the study, however, due to a lack of time, stating that Dr James, Irene’s specialist,  
would have the same information that he would have.  The details of Irene’s case study can be 
found in Volume two, section 1.2.3. 
 
4.4.3.1. How ADR decisions are made? 
Prescribing decisions 
History of ADRs 
According to Irene, she has a significant history to ADRs, and so provides any new medical 
practitioner with a list of past suspected ADRs so the medical practitioner can use this 
information when making decisions about drugs to prescribe.  The experts stated that this 
history is an indicator that she is likely to be “sensitive” to future drugs.  One of the experts 
stated, during a discussion, that if a person has a slow metabolism, they can have an 
accumulation of the drug.  He said consumers can be tested for a slow metabolism. 
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Changes in drug sensitivity due to age 
Irene is aware that as she has grown older, some additional issues have arisen due to age.  One 
issue is that she is less able to rely on her memory, and more reliant on her diaries.  The second 
issue is that she is aware that drug sensitivity can increase with age. As a consequence, she begins 
with a lower than recommended dosage of any prescribed drugs. 
 
4.4.3.2. What problems occur when making ADR decisions? 
Medical practitioner/consumer relationship 
Different understandings of a set of events 
In this case study, the consumer, treating medical practitioner and experts, each have very 
different views about Irene’s condition. 
 
According to Irene she has a significant history of reactions to medications.  She maintains 
detailed diaries to assist in recalling the medications she has trialled, the dosages she has taken 
and any reactions she has experienced.  She passes this information on to prescribing medical 
practitioners, so they can take it into account when making prescribing decisions. 
 
Dr James said that he believes Irene had no underlying disorder that may have been responsible 
for the perceived hypersensitivity to drugs, apart from anxiety.  According to Dr James, some of 
the medications taken by Irene are below a therapeutic dose, and as a consequence are unlikely 
to be effective.  He reasoned that if she did require a lower than therapeutic dose, he would 
expect to see her hypertension controlled.  He said, however, in the ten years of treating her, it 
has never been well controlled, supporting his belief that she is taking drugs at an ineffective 
dosage.  Although not stated explicitly, Dr James appears to be suspecting that Irene is 
experiencing a number of nocebo effects rather than symptoms that are associated with the 
drugs in question. 
 
According to one expert “it is well known that patients who develop ADRs tend to do so 
frequently and appear to be ‘sensitive’ to many drugs”, and as mentioned above, she may have a 
slow metabolism resulting in an accumulative dosage of the drug, a characteristic that can be 
tested. 
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As can be seen, Irene and her medical practitioner, in particular, have very different 
understandings of what the underlying cause of Irene’s apparent sensitivity to medications, and 
as a result make decisions based on this difference in understanding, resulting in an 
uncoordinated approach.  Dr James indicated that his goal is to gain control of Irene’s 
hypertension, and views her behaviour as obstructing that process by not complying with the 
recommended dosages.  Irene indicated that she is attempting to maintain her detailed diaries, to 
keep information that she can pass onto prescribers to keep herself safe, due to the complexity 
of her case, and her own detailed knowledge of her history.  She is, however, aware that medical 
practitioners do not always value that information. This lack of a common understanding may be 
contributing to the management of this condition. 
 
Decision-making with partial knowledge 
Partial knowledge of consumer and medical history 
Continuing from the previous section, Dr James indicated concern about the emphasis Irene 
places on “illness”, and felt she needed to focus on other aspects of life.  When asked about the 
suspected reaction to hydralazine, however, Dr James was unable to state an opinion, as the case 
notes in his file were not summarised.  Irene’s detailed diaries, however, were used to locate the 
consultations in Dr James’ medical record.  Dr James upon reviewing the case notes agreed that 
the symptoms of lupus are likely to be associated with the drug hydralazine.  He said that one of 
the reasons it was not suspected was because although hydralazine is associated with drug-
induced lupus, it is usually at dosages significantly higher than the dosage that Irene was on, a 
factor that to Dr James was perplexing, but to the experts was consistent with a person with an 
underlying condition of increased sensitivity to medications.   
 
In this case study, Irene has the details of dates associated with a suspected ADR, Dr James had 
the medical details of the episodes of care, and the experts have information about a condition 
that could explain Irene’s condition.  Each party has partial information, that when combined 
results in an additional possible explanation for the events. 
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Another issue was highlighted in this case related to partial medical history.  Decision-making 
with only components of information may be because a person does not have access to all of the 
information required to make a decision.  In this case, however, partial information appears to 
be more related to the weight placed on information that is available.  As indicated above, Dr 
James and Irene have each interpreted the events surrounding Irene’s condition differently, and 
so information collected by Irene is likely to be given less weight by the medical practitioner due 
to his understanding of the condition. 
Treating medical practitioner different to the prescribing medical practitioner  
In this case the specialist prescribed the drug, but the consumer initially sought treatment from a 
number of GPs rather than the prescribing medical practitioner.  The several GPs did not detect 
the ADR and it was recognised by the specialist. The GP who was contacted to participate in the 
study stated that the specialist and he have the same information about this suspected reaction, 
indicating that he had received feedback from the specialist about the ADR. 
 
4.4.4. ANALYSIS OF JOANNA’S CASE STUDY (C13) 
Joanne has a significant history of allergies, in particular an anaphylactic reaction to nuts.  Joanna 
experienced three suspected ADRs, the most severe one a suspected photosensitivity reaction to 
Celebrex, which resulted in ongoing photosensitivity for at least two years.  Joanna’s GP and the 
experts agree that the reaction is highly likely to be associated with the Celebrex.  In this case, 
although Joanna was treated for the reaction in its acute phase, the association with the drug was 
not suspected until several weeks later, and the initial diagnosis was made by Joanna.   
 
Joanna’s specialist chose not to participate in the study, and the hospital staff were not contacted 
as they were outside of the ethics approval region.  The details of Joanna’s case study can be 
found in Volume two, section 1.2.4. 
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4.4.4.1. What problems occur when making ADR decisions? 
Medical practitioner/consumer relationship 
Consumer choice to accept or reject advice 
Dr Casey, when making a general comment about providing ADR information to consumers, 
said that he believes there are problems in providing people with too much information about 
the possible reactions of medications.  He stated that it may cause a person to choose not to take 
a medication, which is an important medication for their health.  Joanna did not have access to 
information, and so she used the Internet to access the information she required in order to 
make a diagnosis.  Joanna stated that if she were to re-live this experience, she would choose not 
to take the medication, but look for alternative methods of managing her injury.  According to 
the experts, Joanna’s choice not to take the medication would have been the “correct” decision 
for Joanna and her specialist to make, given her allergic history.  This case study illustrates, not 
only the consumer’s ability to make a diagnostic decision about a suspected ADR, but also the 
ability to make the decision not to take a particular medication based on preferences for 
treatment, and knowledge of her own case history. 
 
Decision-making with partial knowledge 
Impact of partial knowledge 
Joanna stated in her interview, that she continued to take the Celebrex after the initial 
consultation for her symptoms in the acute phase.  This implies that the treating hospital 
clinician either did not suspect the Celebrex as a possible cause for the reaction, or did not 
communicate this with Joanna.  Joanna reported that she did some research on the Internet and 
then found listed in the product information a link between the drug and her symptoms.  
Although not explicitly stated, this implies that the specialist who first prescribed the reaction 
did not provide information about the possible reactions to the drugs prescribed. 
 
According to the experts, if Joanna had access to that information earlier, she would have ceased 
the medication earlier, which may have reduced the severity of her symptoms.   
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Impact of no diagnosis 
As stated in the previous section, Joanna continued taking the Celebrex for several weeks after 
the onset of the reaction, and after seeking treatment for the reaction.  According to Joanna, at 
this stage, she was still unaware that the reaction may have been linked to the medication. It was 
not until several weeks later when she wondered if there was a link that she looked up the 
medication on the Internet.  In this case, not having a diagnosis may have increased the severity 
of the reaction. 
Advantages of sharing knowledge 
Joanna’s case study explores three suspected reactions.  The ‘facts’ of the third suspected 
reaction were shared with Dr Carey, by the interviewer, in order to understand this suspected 
reaction in more detail.  
 
In this case study, Joanna was the first to suspect the association between Flexitone and a mild 
skin condition.  Joanna ceased the two preparations she was on at the time, the Flexitone and the 
beta-carotene, and then re-challenged herself with the beta-carotene, with no further reaction.  
She then concluded that the glucosamine within the Flexitone was responsible for the skin 
condition.  The experts agreed with Joanna. 
 
At the time of interview, Dr Carey was not aware of the reaction to the Flexitone.  He did have 
some additional information that Joanna did not appear to have, however and that is that 
Flexitone has two key ingredients, glucosamine and Boswellia.  She also did not appear to realise 
that a reaction may be caused by an interaction between two medications, as this did not enter 
into her reasoning.  According to Dr Carey, it is still not known which of these two ingredients 
Joanna has reacted to.  
 
Because Joanna did not share this information with Dr Carey, Dr Carey was unable to provide 
the additional information required by Joanna to make a complete diagnosis.  Due to the mild 
nature of this reaction, this issue was not critical in this case, but illustrates the advantage of 
sharing information between consumers and medical practitioners for ADR diagnostic decision-
making. 
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Treating medical practitioner different to the prescribing medical practitioner 
This is another case study where the medical practitioner who prescribed the drug, is a different 
medical practitioner to the medical practitioner treating the suspected reaction.  Dr Carey 
indicated that he was not aware that Celebrex could be associated with photosensitivity 
reactions, and so the act of Joanna coming to the consultation with a diagnosis meant that Dr 
Carey was able to make his diagnostic decision based on a clear hypothesis, rather than 
attempting to make a novel decision. 
 
Complexities in the ADR decision domain 
Joanna had two complexities in her case study that were not illustrated in any of the other case 
studies, the issue of a consumer being in a heightened state of reactivity, and the notion that 
there may be a hierarchy of drugs that are more or less likely to result in an ADR for consumers 
with particular conditions.  These issues are discussed in the following two sections. 
Heightened state of reactivity 
Dr Carey discussed a report from the allergist.  According to this report Joanna had an IGE 
reading of 1734 indicating an increased level of reactivity.  Dr Carey said that he does not know 
whether this is Joanna’s habitual state, or if it was raised due to one or more of the reactions.  It 
is also unclear if the first reaction to naproxen raised Joanna’s IGE levels, which resulted in an 
increased chance of a reaction to the second reaction, and if she had taken this medication 
without the initial reaction whether she would have experienced the second reaction.  This case 
study highlights a need to understand this area, and possibly make this type of information 
available to prescribing medical practitioners. 
Likelihood that a drug will be associated with a reaction 
The second complexity is whether there is a hierarchy of drugs more likely to cause a reaction.  
Based on descriptions by Dr Carey and also the experts, it appears that some drugs are known to 
be less likely to cause a reaction.  The preliminary background studies (O'Brien, 2001) 
highlighted the difficulty of determining the risk that any individual will experience a reaction to 
a drug, because not all reactions are reported, and the number of people who have taken the 
drug are factors that are unknown.  It does appear, however, that although a percentage may not 
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be available to prescribers, it may be possible to develop a hierarchy of likelihood, another issue 
to be explored further. 
Prescribing a drug which is contraindicated 
In this case, Dr Carey was aware of Joanna’s significant allergic history, but did not prescribe the 
drugs.  As the specialist who prescribed the drugs did not participate in the study, it is not 
known if he was aware of this history.  According to the experts, the class of drugs NSAIDS, 
should not be prescribed to a consumer with an anaphylactic reactions to nuts.   Both the 
naproxen and the Celebrex are both drugs of this class. 
 
4.4.4.2. How do ADRs affect people? 
Impact on the medical practitioner/consumer relationship 
Dr. Casey stated that in the end, nothing worked, there was no solution found to this problem, 
even though many paths were explored.  Joanna appeared to have faith in Dr Carey, and be 
working co-operatively with him despite the lack of a result, indicating that a result is not the 
only factor a consumer requires when seeking medical treatment. 
 
4.4.5. ANALYSIS OF PAUL’S CASE STUDY (C17) 
Paul, experienced a suspected reaction to a cholesterol reducing drug, Lipitor.  The low level 
symptoms that lasted approximately three years impacted significantly on Paul’s quality of life.  
This case study includes the views of Paul, his GP, and two experts.  The details of Paul’s case 
can be found in Volume two, section 1.2.5. 
 
4.4.5.1. How are ADR decisions made? 
Differential diagnosis  
It appears from the case study, that an ADR to the drug Lipitor was not considered in the 
differential diagnostic process until other diagnoses had been exhausted.  Dr Kent went through 
a series of possible diagnoses.  When Paul asked Dr Kent if he thought the symptoms may have 
been related to the drug, Dr Kent said that it was a possibility, but suggested exhausting other 
hypotheses first. It also appears from Dr Kent’s interview, that he eliminated the possibility that 
the symptoms were related to the drug, due to the unilateral nature of the hip pain. 
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4.4.5.2. What problems occur when making ADR decisions? 
In this case study, the suspected reaction is one that has been well documented, the mechanism 
for the reaction is well understood, and relatively common, yet was not detected by the medical 
practitioner despite a past history of an ADR to the same class of drugs.  Some of the reasons 
for this occurring have been explored in the following sections. 
 
Decision-making with partial knowledge 
Impact of partial knowledge 
Paul was not provided with information that listed the possible ADRs associated with Lipitor.  
He accessed information that linked the drug to the symptoms from the Internet.  According to 
the experts, Paul should have been warned that muscle aches and pains are a common ADR to 
this class of drugs and if they did not go away after a while he should return for a change in 
drug.  One expert said that “if the patient had been properly warned he would have associated 
the symptoms with the drug much more quickly, and the symptoms would have been recognised 
as an ADR sooner” 
 
Another impact relates to sharing of knowledge between the consumer and medical practitioner.  
Although Paul did ask Dr Kent if he felt the symptoms could be associated with the drug on one 
occasion, after doing some investigations, he chose to manage the suspected ADR himself rather 
than discuss this with his GP.  According to the experts, “more open communication” may have 
assisted in earlier detection of the ADR. 
Consideration of test results in the context of a specific consumer 
Dr Kent was aware that hepatic dysfunction is associated with this class of drugs, however 
decided that Paul’s enzymes were not elevated significantly enough to cause suspicion.  It was 
after Paul had ceased the Lipitor and Paul’s enzymes lowered, in combination with raised 
cholesterol that assisted the diagnostic process.   
Partial case history 
In this case study, Paul previously experienced an ADR to the same class of drugs, information 
that possibly was in the case history.  It is not known if Dr Kent had access to this information.  
According to the experts, the reaction could have been prevented if the fact that Paul had 
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previously experienced an ADR to a drug from the same class, had been taken into 
consideration when making the prescribing decision, and a drug from another class had been 
prescribed.   
 
Complexities in the ADR decision domain 
Generalised symptoms 
The symptoms expressed by Paul are general symptoms that could be attributed to multiple 
disorders including life style.  At the time of diagnosis, according to Dr Kent, Paul was in the 
process of changing jobs and his wife was unwell, life style factors that could also have 
contributed to the generalised symptoms.  As a result, it is difficult to know which symptoms are 
part of the syndrome and which are not, especially as the problem built up over a number of 
years.   
 
4.4.5.3. How do ADRs affect people? 
Impact on the medical practitioner/consumer relationship 
Consumer lost faith in medical practitioner 
Dr Kent considered several possible diagnoses for the symptoms.  When Paul suggested the 
possibility of an ADR, according to Paul, Dr Kent considered it briefly, but wanted to exhaust 
the other possibilities first.  When Paul then did his own investigations, and found information 
that supported his hypothesis, he lost faith in his medical practitioner and decided to manage the 
symptoms himself rather than seek further advice from the medical practitioner.  This loss of 
faith, which resulted in a communication breakdown, may have also delayed the detection of the 
ADR. 
Crossing of professional boundaries 
Dr Kent and Paul knew each other and were friends outside of the clinical setting. Paul and Dr 
Kent both spoke about whether this prior friendship may have had a negative impact on their 
interaction.   
 
Paul explained that because he and Dr. Kent knew each other, they were particularly friendly, 
which he felt may have contributed to the communication problem.  He also said that because 
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Paul was from the medical field, perhaps Dr Kent overestimated his knowledge and ability to 
make these decisions.   
 
When asked if Dr Kent would do anything differently using the advantage of hindsight, he said 
that he would be more aware.  He explained that he is a friend of Paul’s wife, and he wondered if 
this relationship had an impact on hearing what Paul was saying.   
Awareness of consumer experience 
Dr Kent said that he believed the symptoms were not a significant problem for Paul.  When 
asked if he would treat the situation differently if Paul had been extremely bothered by them he 
answered, “Yes definitely, of course I would have…” He said “it is extremely difficult to know 
how a consumer feels”.  Paul felt he had expressed the level of misery and frustration he was 
feeling to the medical practitioner, and felt that Dr Kent did not take the problem seriously 
enough.  When Paul read that sometimes reactions to this class of drugs results in a permanent 
injury, he was even angrier that the problem was not being taken seriously enough 
 
In this case, again a communication breakdown appeared to exacerbate the problem.  Paul 
believed he had expressed the impact of the ADR on his life, and so needed a solution, and Dr 
Kent believed the problem was a small irritant to Paul, and so over time attempted to eliminate 
possible causes in order to manage the symptoms. 
 
4.4.5.4. How do decision-makers contribute to new ADR knowledge? 
The impact of the research process 
Although Paul did not disclose to Dr Kent that he believed he had experienced a suspected 
ADR, the research process alerted Dr Kent to this factor.  Paul provided the researchers with 
permission to interview his medical practitioner.  Through the interview process, and the 
reflective thinking about the case and the advantages of hindsight, Dr Kent revised his initial 
diagnosis. 
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4.5. Case studies of  suspected adverse drug reactions: low 
likelihood of  an ADR from the consumer, medical and 
expert views 
This section includes the second group case studies.  This set of case studies include ADRs that 
are suspected by the consumer, however the experts believe that there is a low chance that the 
symptoms are associated with the drug.  This set includes Kay, Mary and Tim’s case studies.  
These cases include the consumer, medical practitioner and expert perspectives.  The age range 
is from 29 to 70. 
 
4.5.1. ANALYSIS OF KAY’S CASE STUDY (C05) 
Kay had epilepsy, which is controlled with medication.  In this case, rather than the drug in 
question being suspected of causing additional symptoms, Kay’s suspicion, is that a generic 
formulation of the drug, was ineffective, and as a result she experienced a grand mal seizure, the 
first in 18 years.  This case study includes the views of Kay the consumer, Dr. Nash Kay’s 
regular specialist, Dr. Green the medical practitioner in the hospital, and the view of two experts.  
The details of Kay’s case can be found in Volume two, section 1.3.1. 
 
4.5.1.1. How are ADR decisions made? 
Differential diagnosis 
This case study includes the reasoning of two medical specialists and two experts regarding the 
differential diagnosis process that occurred in this situation.  The process appeared to include 
holding multiple possible diagnoses, gathered information to support or eliminate each diagnosis 
(factors about the consumer, factors about drug behaviour, knowledge of epilepsy), considered 
the possible diagnoses separately, but also in combination with each other, and then eventually 
came to a diagnosis they believe is most likely. The other possible hypotheses do not appear to 
have been eliminated, but just have a lower weighting than the preferred diagnosis. 
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4.5.1.2. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Partial knowledge of drug behaviour and ADRs 
According to the medical practitioners, one method of determining the effectiveness of a drug is 
to measure the levels of the drug in the blood when the level is expected to be at its peak (fully 
absorbed).  In this case, medical knowledge that was missing concerned the level of the sodium 
valproate in the blood serum.  Dr Green determined when the blood needed to be taken for a 
meaningful reading, however according to Dr Green’s interpretation of the medical file, they 
were not taken at the times requested. 
Another aspect related to knowledge of ADRs.  One of the experts said that the impact of a 
change of medication would be obvious in three to four days according to the Australian 
Medicine’s Handbook, indicating that as the seizure occurred approximately ten days after the 
change of the brand of the drug, that the drug change is unlikely to be associated with the 
seizure.   
 
Dr Nash said his normal procedure is to check drug levels in the blood after 14 days of 
commencing a new drug.  According to the experts, checking after 14 days would not have 
detected a problem in the generic brand quickly enough to have prevented the seizure, if the 
problem had been the formulation of the medication. 
Partial knowledge of the consumer and consumer history 
It was not known by anyone whether Kay forgot her evening dose of her medication.  Kay was 
not sure, and the level of the sodium valproate in the serum was inconclusive.  Again, as a result 
of this lack of information, differential diagnosis was more difficult, and according to Dr Nash, 
not possible, as a missed dose is a hypothesis that cannot be confirmed or eliminated. 
 
It is also unknown if in the past 18 years, whether the same set of factors, being premenstrual, 
sleep deprivation and alcohol have occurred at the same time in the past, to indicate if this 
combination may have been the cause. 
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Inconsistencies between decision-makers 
Another factor was that according to Dr Nash, the blood levels did not drop below the 
therapeutic range, and he therefore eliminated the generic brand and the missed dose as 
probably causes.  Dr Green, however, said the dose did drop below the threshold, but due to 
when the readings were taken, the accuracy of those results were in question. 
 
This lack of information had an impact on differential diagnosis.  According to Dr Green, it 
meant that it was not possible to be sure if the blood levels dropped below the therapeutic 
threshold, a factor which may have been able to determine if the seizure was as a result of a 
lower than expected drug level, or factors such as the sleep deprivation and alcohol. 
 
Medical practitioner/consumer relationship 
Differences in understanding 
Kay believed that the diagnosis made by the medical practitioner was that the seizure was caused 
by the generic brand of Epilim, because if there was no reason for the seizure, she would have 
had to stop driving for three years, but because there was a reason, she only had to stop for one 
month.  Dr Nash, however said the clear reason for the seizure, which allowed him to 
recommend she stops driving for one month rather than three years, was the lack of sleep. 
 
Although Kay’s explanation indicated that she believed the diagnosis was the change of brand of 
drug, she also appeared very shaken by the seizure, and described changes in her behaviour such 
as not driving if she has a lack of sleep, or if she experienced petti mals in the morning, 
indicating she realised the seizure may have been more related to the lack of sleep. 
 
Complexities in the ADR decision domain 
ADR resembles another disease 
The primary complexity in this case was that the symptoms could have been caused by a number 
of factors, a “Type F” ADR, as suspected by Kay, a missed dose, or a lowering of Kay’s 
threshold due to the factors such as a lack of sleep.  There were too many unknown factors to 
make a diagnosis. 
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Reasons a consumer may choose to blame drug 
One expert said that he feels that Kay may have been more prepared to accept the possibility 
that the seizure was caused by a drug rather than accepting that her epilepsy may be becoming 
more unstable. 
Relationship between medical practitioner and pharmacist 
One of Kay’s medical practitioners mentioned that one problem in the communication between 
medical practitioners and pharmacists, is that some pharmacists will change a drug brand 
without consulting a medical practitioner, which means that the monitoring throughout the drug 
change cannot be performed. 
 
4.5.2. ANALYSIS OF MARY’S CASE STUDY (C07) 
Mary suspects she may have experienced a reaction to tamoxifen, a long term medication which 
was used to prevent the reoccurrence of cancer following a mastectomy and chemotherapy.  
This case study includes interviews with Mary, her specialist, Dr O’Neil and two expert views.  
Mary explained the events, but did not have specific dates.  Dr O’Neil provided specific dates 
for the events described by Mary, as well as providing additional details from the case history, 
and his medical opinion.   
 
In this case, Mary suspected she experienced an ADR to tamoxifen.  Dr O’Neil believes the 
symptoms may be partially due to the tamoxifen, but primarily due to a pre-existing condition.  
One expert agrees with Mary, and one expert agrees with Dr O’Neil, indicating the complexity 
of this case. The details of Mary’s case can be found in Volume two, section 1.3.2. 
 
4.5.2.1. What problems occur when making ADR decisions? 
Medical practitioner/consumer relationship 
A key issue for Mary was her sense of disempowerment within the medical 
practitioner/consumer relationship.  She mentioned several incidences of feeling “fobbed off”.  
She also referred to other instances of care when she did not feel she was provided with 
information about her care that she was entitled to. 
 
CHAPTER FOUR: RESULTS: DATA OVERVIEW AND INDIVIDUAL CASE STUDY ANALYSIS 
153 
Mary decided to access information about the next drug Dr O’Neil was considering Arimidex 
from a hospital pharmacist. 
 
Throughout the interview, Mary expressed feelings of anger at not being supported in her search 
for a diagnosis for her condition, and frustrated by the lack of information which she felt she 
was entitled to, at a stage when she felt too unwell to go through this process. 
 
It is difficult to know the source of these feelings expressed by Mary.  Possible sources include 
her frustrations of not being supported by the medical profession and family, an undiagnosed 
ADR, the processes described by Dr O’Neil that are associated with the realisation she had 
survived a life threatening illness, or depression, or some combination of these factors. 
 
Different understandings about a set of events 
There are several examples in this case study, of differences of understanding, and as a 
consequence, it is not possible from the information obtained in this case study, to determine a 
clear diagnosis.  In addition to multiple possible causes of the symptoms, there were several 
interventions implemented within a similar time frame; the cessation of the tamoxifen, the 
commencement of an anti-depressant, and the commencement of psychotherapy.  There are also 
different reports of the same events. Mary said she felt that after she came off the tamoxifen that 
her aches and pains were much improved, whereas Dr O’Neil said they were still there following 
the cessation of the tamoxifen, but ceased following the psychiatric intervention. 
 
The experts emphasised different components of the case study.  The first expert explained the 
aches and pains as a symptom of the depression.  The second expert focused on the report that 
the aches and pains diminished following the cessation of the tamoxifen, and therefore 
associated the two. 
 
Mary was frustrated by the lack of diagnosis, and the movement from one possible explanation 
to another without an explanation of all the possible causes of the symptoms, however in this 
case it appears it was very difficult for the medical staff to do more than work through a list of 
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possible causes.  Possibly what Mary required was a discussion of the multiple possibilities that 
were being considered, so she could also work through each of them. 
 
Complexities in the ADR decision domain 
Mary’s case is complex due to the number of possible factors in the equation.  She has 
experienced a life threatening illness of cancer, and has survived, she has a history of depression, 
she is on multiple medications, and she has a history of musculoskeletal disorders such as a 
childhood accident, arthritis and degeneration of the spine.  Attempting to make an association 
between symptoms and a cause is extremely difficult.  This point is emphasised by the 
differences in understanding between Mary, Dr O’Neil and the two experts, and in the case 
study, the experts disagree on a diagnosis. 
 
Reasons a consumer may choose to blame drug 
Dr O’Neil explained that Mary may have preferred to blame the drug rather than accept her 
depression.  At the time of Mary’s interview, however, the diagnosis of depression had not been 
made.  Dr O’Neil’s interview, however, was following this diagnosis.  He also said that it may 
have been a cry for help, and ceasing the tamoxifen as a way of indicating there was a problem 
that needed to be addressed. 
Differences in understanding 
Continuing from the previous section, the interview with Mary appeared to indicate that Mary 
had been trying to get help for her condition for several months, but did not feel she was being 
heard or taken seriously.  Dr O’Neil said “I think when someone stops a drug before they see a 
doctor it usually means they’re serious about it.  So no matter what I was going to say.”  
 
4.5.3. ANALYSIS OF TIM ‘S CASE STUDY (C09) 
Tim made the decision to stop smoking, and used Zyban to assist with this process.  Tim’s case 
includes the consumer, medical practitioner and expert perspectives.  In this case study, Tim 
experienced nausea and vomiting which are known ‘side-effects’ of the medication then 
developed Bell’s Palsy.  Both the medical practitioner and the expert believe that the Bell’s Palsy 
was co-incidental, and unlikely to be related to the medication, however the experts stated that 
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they cannot be sure it is not a rare, previously unreported reaction. The details of Tim’s case can 
be found in Volume two, section 1.3.3. 
 
4.5.3.1. How are ADR decisions made? 
Differential diagnosis 
This case highlights two factors that need to be taken into consideration when making an ADR 
diagnosis.  As highlighted in section 4.5.3.5, one of the experts highlighted the need to consider 
the symptoms from the drug compared with those caused by the withdrawal of nicotine.  The 
second factor was the possibility that the Bell’s Palsy occurred by chance. 
 
The effect of the research process on decision-making 
At the time of interview, Dr Price said that he did not report the suspected ADR to ADRAC as 
he did not believe the symptoms were associated with the drug.  Using the interview to reflect 
back on the case, he said that using hindsight, he would report this incident in the future, 
because although there appeared to be no link between the two, he could not be sure. 
 
4.5.3.2. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Partial knowledge of drug behaviour and ADRs 
According to Dr Price, Tim did not mention the other side effects he had experienced due to the 
Zyban. Tim said that he did mention the headaches and vomiting, and continued with the 
medication based on Dr Price’s reassurances. Tim’s reasoning, included his experience with the 
onset and cessation of the vomiting and headache which coincided with the commencement and 
cessation of the Zyban.  Dr Price appeared to believe there was a virus also involved because 
Bell’s Palsy is known to occur in the presence of a virus.   
 
Another aspect of partial knowledge was that Dr Price’s decision-making processes were around 
the assumption that when reflecting back, an ADR makes sense in some way, that is, it is related 
to a known pharmacological property of the drug.  What he may not be aware of, is that only 
Type A ADRs have this characteristic, and that Type B reactions are unrelated to the drug’s 
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known pharmacological properties.  It appears from this interview that he considered the 
possibility that an ADR may be a Type A reaction, but not a Type B reaction. 
 
4.6. Case studies of  suspected adverse drug reactions: high 
likelihood of  an ADR from the consumer and expert 
views only 
This set of seven case studies includes, Julie, Belinda, Edward, James, Bob, Kerry and Robyn.  
aged between 35 and 70. In three of the cases, the medical practitioner chose not to participate 
in the study and in the remaining four cases the medical practitioners for the suspected ADRs 
were based in a hospital outside of the ethics approval area.  
 
In each of these cases, at least one of the experts agreed with the consumer that there is a high 
likelihood that the symptoms described by the consumer were associated with the suspected 
drug.    
 
As these case studies include only the consumer and expert views, most of the results emerged at 
the group data level, when analysing the consumer only and expert only data.  The descriptions 
of the results of these case studies, therefore, are significantly shorter than the previous cases. 
 
4.6.1.    ANALYSIS OF JULIE’S CASE STUDY (C04) 
Julie’s case study illustrated the challenges of living with chronic pain, the difficulties in finding 
drugs or combinations of drugs that effectively manage the pain, and the increased risk of ADRs 
that result from particular individual drugs or interactions with drugs.  Julie has a good working 
relationship with her medical practitioners where they work as a team to balance the risks and 
benefits of medications, knowing that due to the number of drugs and high doses of drugs she is 
taking, the goal is to minimize rather than eliminate ADRs.  Julie’s GP and specialist were both 
invited to participate in the study, but declined. The details of Julie’s case can be found in 
Volume two, section 1.4.1. 
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4.6.1.1. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Impact of partial knowledge 
According to Julie, she requested a consumer information sheet from the pharmacist, but one 
was not available. A new box of medication did not include product information, she accessed 
the Internet and found the product information, but did not find the association.  It was found 
that the product information did describe the suspected reaction, but it was labelled “pruritis”, a 
name not recognised by Julie. The experts said that if she had been warned that itching may have 
been associated with the Tramal, the reaction may have been detected earlier. 
 
Several times throughout the interview Julie commented on the role of information and how it 
allowed her to feel empowered.  Without this information, she felt she had less control and 
limited ability to participate in discussions and decision-making with her medical practitioners. 
Partial knowledge of drug behaviour and ADRs 
One expert commented that rather than ceasing the Tramal, perhaps there was another 
antihistamine that could have been used to control the itching, but that would not have caused 
the drowsiness.  As the expert mentioned, the GP may have had a reason for this decision, but 
as he chose not to participate in the interview and so his reasoning cannot be included in the 
study.  It does highlight, however, that another source of knowledge is the knowledge of a broad 
range of drugs.  The preliminary background studies (O'Brien, 2001) found that GPs have a 
group of drugs that they know well.  They call this their ‘preferred list’ of drugs, because it is not 
possible to keep up to date with all of the drugs available on the market.  Lack of awareness of 
drugs outside of the ‘preferred list’ may be another source of partial knowledge. 
 
Complexities in the ADR decision domain 
Julie’s complex case history increases the difficulty of prescribing decisions.  Below are two 
examples. 
Weighing risk versus benefit of drug therapy 
The ADR to Tramal was treated with Periactin.  Julie then experienced a second ADR to the 
Periactin.  According to the experts, if the initial ADR had not been treated with a drug, the 
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second ADR would not have occurred.  In this case, however, the benefits of the Tramal were 
so significant to Julie, that treating the ADR was preferable to ceasing the medication. 
Multiple medications 
Julie has a history which includes chronic pain, psychological issues and polycystic ovary 
syndrome, and is therefore on multiple medications all of the time.  Management of the pain is 
difficult, and so combinations of medications are often trialled.  When trialling a new 
combination of drugs, Julie and her medical practitioner do not expect to eliminate ADR 
completely, but aim to maximize the therapeutic benefits whilst minimizing the ADRs. 
 
4.6.2. ANALYSIS OF BELINDA’S CASE STUDY (C08) 
Belinda whilst having knee surgery under an epidural, experienced a very slow heartbeat, felt 
“spaced out” and was very cold, a reaction she believes, to the Inderal, symptoms which lasted 
three days.  
 
Belinda’s surgery occurred in a hospital outside of the area studied, and so the medical 
practitioners were not contacted for medical records.  Belinda also saw a GP who assisted in the 
management of her migraines, who was contacted to participate in the study, however he did not 
respond to the request.   This case study therefore includes only Belinda and the expert views.  
The experts both agree that there was a likely interaction between the Inderal and one or more 
of the drugs used during the surgery, resulting in bradycardia, dissociation and anomia but 
without access to the medical record were unable to determine which drugs were involved. The 
details of Belinda’s case can be found in Volume two, section 1.4.2. 
 
4.6.2.1. How are ADR decisions made? 
Prescribing decisions 
Accurate drug history information 
This study illustrates the difficulties in making a diagnosis without information about drug/s and 
dosages, and consumer information such as age, body weight.  In this case study, the consumer 
was able to provide detailed information about her experience, but did not have the details of 
her case history.   
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4.6.2.2. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Prevention of future ADRs 
As a diagnosis has not been made, if Belinda were to have further surgery future medical 
practitioners would also not be able to use this information to prevent future ADRs.  Because 
Belinda does not have this information and unless she went to the same hospital, the 
information would not be available in order to prevent the reaction happening a second time.  
Because Belinda was concerned about future surgery, she chose to work with her GP to cease 
the Inderal. 
 
Partial knowledge of drug behaviour and ADRs 
According to the experts, the staff treating Belinda did not appear to be aware of the potential 
ADRs associated with beta blockers, prior to the surgery, and so according to Belinda, did not 
determine the reason for her symptoms immediately. 
 
4.6.3. ANALYSIS OF EDWARD’S CASE STUDY (C10) 
In this case there is a clear temporal link between the drug and the reaction, especially because 
when Edward took the drug a second time he experienced the same reaction a second time 
(referred to by medical practitioners as a rechallenge).  The unique aspect of this case is that the 
impact was more severe due to the context of Edward’s life, rather than the immediate effects of 
the ADR.   
 
Edward’s GP chose not to participate in the study. The message conveyed by the medical 
practitioner’s receptionist was that even though Edward had given his permission for the 
medical practitioner to discuss the case, he was not prepared to as he felt the study was an 
invasion of the medical practitioner/consumer relationship. The details of Edward’s case can be 
found in Volume two, section 1.4.3. 
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4.6.3.1. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Management of ADRs 
In this case, the management of the ADR was rest.  The experts stated that another medication 
could have been used in an attempt to stop the second bout of vomiting, however Edward 
believed that if the Stemetil had not stopped the vomiting, other medications would also be 
ineffective.  One expert said that hospitalisation would be expected because of the risk of renal 
failure and dehydration, in a person of Edward’s age. As the medical practitioner was not 
interviewed, the reasoning behind this decision is not available. 
Partial knowledge of drug behaviour and ADRs 
Edward attributed all of his symptoms to the ADR.  The experts said that the initial vomiting 
had a high probability of being associated with the drug, but the prolonged vomiting was 
probably caused by another illness. 
 
Impact of partial knowledge 
If Edward had been aware that a second dose of the drug may have caused a second bout of the 
vomiting, he stated that he would not have chosen to take a second dose, a decision that would 
have prevented the second ADR.  According to one expert, there was a high probability that the 
second dose would result in a second bout of vomiting.  The lack of information impeded 
Edward’s ability to make a decision that would have prevented the ADR. 
 
4.6.4. ANALYSIS OF JAMES’ CASE STUDY (C12) 
James experienced a series of suspected reactions that occurred over several years in hospitals 
outside of the study region.  As he did not report these symptoms and suspicion of ADR to the 
hospitals or his GP, the medical staff were not contacted to participate in the study. 
 
This is the only case where the diagnostic decision-making was made entirely by the consumer 
with no input from medical practitioners. The details of James’ case can be found in Volume 
two, section 1.4.4. 
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As this case study includes primarily the consumer view, most of the results of this case study 
have been reported in the combined group analysis in chapter five.  The only additional result 
from this case study is one about partial knowledge, below. 
 
4.6.4.1. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Partial knowledge of drug behaviour and ADRs 
James made the differential diagnosis himself, a diagnostic decision that was supported by the 
experts. James said that he would have liked to have been warned that it is possible to have 
reactions to medications, so that this information could have been taken into consideration in 
his own decision-making. 
 
4.6.5. ANALYSIS OF BOB’S CASE STUDY (C14) 
Bob experienced a suspected ADR to Vioxx, in the form of a mild photosensitivity reaction.  It 
was over time that Bob noticed the association between the sun and the redness and itching, but 
at the time of interview, he was attempting to establish if there was a link between the symptoms 
and the rash.  Bob’s GP chose not to participate in the study.  One expert believes there is a high 
likelihood that the symptoms are associated with the drug, and the second expert believes there 
is a very low likelihood of an association. The details of Bob’s case can be found in Volume two, 
section 1.4.5. 
 
4.6.5.1. What problems occur when making ADR decisions? 
Decision-making with partial knowledge 
Impact of no diagnosis 
Due to the irritating nature of this reaction, Bob initially requested advice from his medical 
practitioner, but eventually concluded, “he probably won’t know.”  He then went on to access 
information from his wife, his wife’s cousin, his daughter, the family pharmacist, and then chose 
to participate in this study in an attempt to gather further information.  His medical practitioner 
suggested he stop the Vioxx, which according to Bob he had already done, and suggested some 
treatments that Bob did not feel were practical or effective.   
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4.6.5.2. How do ADRs affect people? 
Impact of an ADR 
Mild but irritating reaction 
Although this ADR was relatively mild, it appeared to be causing Bob significant annoyance, 
possibly due to not knowing what was causing it, and also, because of the impact it was having 
on his enjoyment of outdoor or recreational activities.  This was illustrated when Bob said “ I 
work inside all the time and I like to…I don’t like extreme hot weather, but I like to get out.  
Like I said, I do a bit of fishing and that.  I like to get the shorts on and all that…” 
Impact on medical practitioner/consumer relationship 
As a consequence of this consultation, Bob appeared to loose faith in his medical practitioner. 
The fact that the two experts disagreed on a likely diagnosis for the symptoms indicates that this 
case is difficult to diagnose, so even though the GP attempted to manage the ADR, the lack of 
diagnosis appeared to be the key issue. 
 
When the transcript was sent to Bob for verification, he telephoned to report some additional 
information about his case.  He said that his medical practitioner at that stage suspected an 
environmental irritant in Bob’s work place and was investigating that further.  No additional 
information about this was provided by Bob.  Bob’s medical practitioner chose not to participate 
in the study, and so no further information was accessible via him either. 
 
4.6.6. ANALYSIS OF KERRY’S CASE STUDY (C15) 
In this case study, the particular ADR described in the case study, and Kerry’s history of ADRs 
are all associated with the experience of anaesthetic drugs and surgery.  The cumulative effect of 
multiple ADRs has been a fear of surgery, limiting Kerry’s therapeutic choices in the future. 
 
The ADR reported in this case study occurred in a hospital outside of the study region, and so 
the medical practitioners were not contacted for their input into the study.  The experts agree 
that there is a moderate likelihood that the drug Maxolon is associated with the symptoms of 
visual disturbances. The details of Kerry’s case can be found in Volume two, section 1.4.6. 
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4.6.6.1. How are ADR decisions made? 
Differential diagnosis  
In this case, there were multiple events occurring at the same time, making it difficult to 
determine which drug was responsible for the visual disturbances.  The experts used factors 
outside the case study situation, such as other case studies in the ADRAC database, and the 
history of anaesthetics without this particular reaction to hypothesis about which agent was most 
likely responsible for the reaction.   
 
4.6.6.2. What are the problems when making ADR decisions? 
Impact of partial knowledge 
Kerry expressed fear associated with surgery based on her complex medical history and several 
ADRs following surgery.  She wanted to discuss her concerns with the anaesthetists prior to 
surgery, but found she was unable to due to the time the medical practitioners had available.  
The inability to discuss the procedures prior to the surgery, and her history of ADRs related to 
anaesthetic drugs, added to her anxiety and fear of future surgery. 
Partial knowledge of consumer and consumer history 
Kerry has had several operations at various hospitals.  Her medical file, therefore is spread over 
multiple sites.  Kerry has a lay person’s view of what happened, but it appears that each time she 
has another operation, she needs to spend time passing on her complex history to the new team 
of medical practitioners. Within this single interview, there are inconsistencies in what Kerry 
describes, indicating that she is not clear herself what happened post surgery, and appeared to be 
attempting to make sense of what happened.  
 
4.6.6.3. How ADRs affect people? 
Impact of ADR 
This is another ADR where the impact is more significant than the immediate impact.  In this 
case, the ADR is added to other negative experiences, resulting in Kerry being extremely fearful 
of anaesthetics.  As explained by the expert, when a person is unable to use a particular drug or 
undertake particular interventions, their options are restricted.   
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An additional outcome of this reaction expressed by one of the experts is that “this experience 
has reinforced her fear of surgery and anaesthesia, which may have the effect of further limiting 
future therapeutic options.” 
 
4.6.7. ANALYSIS OF JOAN’S CASE STUDY (C16) 
Joan heard about this study and volunteered even though she lived outside the study area.  The 
interview was conducted via telephone.  When the transcript was sent back to Joan, she chose to 
type her response to the questions and asked for her written interview to be used rather than the 
verbal one. 
 
Joan has severe epilepsy which has been difficult to control.  When the epilepsy is not controlled 
she has periods of time when she is not aware of what she is doing or where she is going.  The 
ADR she described in this case study occurred when Joan’s husband, Ron, was at home.  Joan 
was in an altered state of consciousness at the time of the suspected ADR, and therefore 
suggested Ron be interviewed as well. This case study, therefore, includes the consumer view, 
and also the view of her husband. The details of Joan’s case can be found in Volume two, 
section 1.4.7. 
 
4.6.7.1. How are ADR decisions made? 
Differential diagnosis 
ADR resembles the pre-existing disease 
This case study illustrates the complexity of differentially diagnosing ADRs when there are 
multiple medications, and where the symptoms from the ADR are similar to a worsening pre-
existing condition.   
 
Weighing risks versus benefit 
According to the experts, the commencement of the drug Sabril was temporally related to the 
symptoms described by Joan.  The condition worsened because of the medical decision to 
continue with the drug, despite Joan’s reports of worsening symptoms as the dose increased.  
According to Joan, the medical decision was based on another case where the Sabril improved 
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another consumer’s condition significantly, a consumer with an apparently similar profile to 
Joan’s.  In this case, the medical practitioner, weighing up the risks and benefits appeared to be 
putting a significant weight on the possible positive benefits of the Sabril, compared with the 
risks of the ADR. It was when Joan decided that the risks outweighed the potential benefits that 
the drug was ceased. 
 
4.6.7.2. What Problems occur when making ADR decisions? 
Decisions that may contribute to an ADR 
According to the experts, one reason why the Tegretol was not detected as contributing to the 
problem in controlling the epilepsy earlier, was because Joan chose not to participate in “video 
monitoring” assessment, where all drugs are withdrawn and then gradually introduced under 
controlled conditions.   
 
In this case, the ADR, rather than producing the required effect, produced an unwanted 
reaction, actually produced the opposite effect from what was expected from the drug.  Rather 
than reducing the epilepsy, it made it worse. 
. 
4.7.   Conclusion 
Analysis of 15 individual case studies has been presented in this chapter, eight that include the 
consumer, medical practitioner and expert perspectives, and seven that include only the 
consumer and medical practitioner perspectives.   
 
The first set of five case studies included the consumer, medical practitioner and expert view, 
and each participant agreed that there was a high likelihood that the symptoms were associated 
with the suspected drug/s.  The second set of three case studies, included all three perspectives 
again, but the experts believe there is a low likelihood that the suspected drug was associated 
with the consumer’s symptoms.  The final set included only the consumer and expert 
perspectives, and in each of these cases, the experts agreed that there is a likelihood that the 
symptoms are associated with the suspected drug. 
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As can be seen from the summaries of each section, a large number of results have emerged 
from this method of analysis.  Below are the key results: 
 
• Diagnostic processes included the use of pattern matching or recognition that a set of 
symptoms are associated with a medication due to past experience, hypothesising a 
number of possible diagnoses, and using knowledge and information sources to alter the 
weights associated with each possible diagnosis and logic and reasoning including the 
temporal relationship between the commencement of a drug and the onset of the new 
symptoms.  In some cases an ADR was in the list of possible hypotheses, and in other 
cases it was not considered until later in the diagnostic process.   
 
• For each of the case studies that did not include a medical practitioner perspective, at 
least one expert agreed that the symptoms were likely to be associated with an ADR, 
strengthening the view that consumers can play an important role in the reporting of 
ADRs.  In many of the case studies, the consumer was the first to detect the suspected 
ADR, and in most of these cases the experts agreed with this diagnosis.  This indicates 
that consumers play an important role in the detection of ADRs. 
 
• The largest problem in the ADR decision domain highlighted by this set of data, and not 
seen from the group data analysis, was the issue of partial knowledge.  Each of the 
participants held a particular set of knowledge and accessed information from multiple 
sources.    The consumers had knowledge of their own body, awareness of what is in 
their medical history, and awareness of their own preferences.  The medical practitioners 
had expertise in disease diagnosis and management, and access to information about the 
consumer contained in the medical file and shared by the consumer, and some 
knowledge of drugs.  The experts had expertise in drugs and ADRs, and access to the 
content of the case studies. The pharmacists knowledge was often not included.  A 
theme arising from these data is that access to only a component of the knowledge and 
information available relating to the suspected ADR appeared to contribute to the 
incidence, and delayed detection of ADRs. 
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• An emerging theme relating to the consequences of decision-making using partial 
knowledge related to the consumer’s ability to participate in decision-making.  A lack of 
information about potential ADRs made it difficult for the consumers to participate in 
the ADR decision-making, resulting in either a prolonged ADR or impeding the 
consumer’s ability to make an informed decision about whether or not to take a 
medication. 
 
• New knowledge about ADRs is created at a national level through spontaneous 
reporting and at an individual level by accessing national and international data, but also 
through personal experience.  An emerging theme from these data was that the medical 
practitioner did not receive feedback that a drug they prescribed resulted in a suspected 
ADR, inhibiting individual learning.  In two cases the research process of using reflective 
thinking assisted the medical practitioners to re-evaluate their decisions and change their 
conclusions. 
 
The following chapter includes the results from the group analysis and from the analysis 
combining the group and individual case study analysis. 
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 CHAPTER FIVE 
5. Results: Group Analysis and 
Combined Methods Case 
Study Analysis 
5.1. Introduction 
The previous chapter presented the analysis of the data at an individual case study level.  This 
chapter presents the results that emerged when viewing the data at a group level, that is the 
consumers as a group, the medical practitioners as a group and the experts as a group.   
 
As described in the chapter three, one aim of using several methods of analysis was to extract 
the maximum from the data, but present them with minimal repetition.  Following the group 
analysis is a section which presents the results obtained combining the group and individual case 
study data together. 
 
The structure of this chapter is similar to that of the previous chapter.  Again, research questions 
have been used to structure each section, and the key themes that have emerged that relate to 
each research question are used as subsections.   
 
5.2. Group analysis - Consumer view 
The consumer group analysis included the analysis of the consumer interviews in isolation 
without considering the medical practitioner or expert perspectives.  This analysis, therefore, 
includes the 15 consumer interviews, and also includes the interview of Joan’s husband, Ron as  
Joan was not fully conscious of what happened during her suspected ADR. 
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5.2.1. WHO ARE THE DECISION-MAKERS IN THE ADR DOMAIN? 
A key aspect of this exploratory research is to understand more about the decision processes 
surrounding ADRs.  A logical question, therefore, is who are the decision-makers within this 
domain?  As described in the review of the literature (chapter two), the majority of decision 
support has been developed for the medical practitioner, however the preliminary background 
studies (O'Brien & Yearwood, 2002) indicated that there may be others involved in the decision-
making processes surrounding ADRs.  The consumer data provided the following insights. 
 
5.2.1.1. Multiple decision-makers  
Within the 15 case studies, according to the consumers, the people involved in decision-making 
(either making decisions or providing observational input into the decision-making) included, the 
prescriber who was either the GP or a specialist, the consumer, members of the consumer’s 
family and the consumer’s friends, the pharmacist and/or other health professionals such as a 
naturopath. Table 5-1 describes for each of the suspected ADRs, the symptoms, suspected drug, 
level of certainty that the drug is associated with the symptoms, the sources of knowledge used 
to make the diagnosis, who make the diagnosis and the impact of the suspected ADR, all from 
the consumer only perspective. As will become clear later in this chapter, the medical 
practitioners and experts did not agree with these forms of analysis in all cases.  Table 5-1, 
column five shows that from the consumer’s perspective, the consumer was involved in the 
diagnostic decision-making process; one type of decision-making, in 11 of the 15 cases and in 
seven of the 15 cases described this decision as collaborative.  The collaboration is with a family 
member in four of these cases and with the medical practitioner in three cases. 
 
5.2.2. WHAT DECISIONS ARE MADE BY EACH DECISION-MAKER? 
5.2.2.1. Types of decisions made by consumers 
Table 5-1 above, explores the diagnostic decision type of “suspecting a drug to have caused a 
reaction”.  Other decisions made by the consumers within these 15 cases are described in Table 
5-2. 
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Consumer 
Code 
Symptoms Drug Level of
Certainty
 Source of knowledge 
used by consumer and 
medical practitioner as 
perceived by 
consumer. 
Who 
diagnosed 
Impact 
Toni  
C02 
Severe influenza 
style illness 
Tegretol    High GP consulted specialist Medical
practitioner 
“I really felt like I couldn’t 
drive, I was feeling really 
miserable.” 
“he said (GP) “you are 
seriously ill”” 
Julie  
C04 
Itchy in absence of 
rash 
tramadol hydro-
chloride 
High Internet, observation and 
asking the medical 
practitioner. 
Medical 
practitioner 
Concerned and confused 
not knowing the cause 
Kay  
C05 
Grand Mal first for 
18 years. 
Generic brand of 
sodium valproate 
Consumer 
High 
Elimination of other 
possible factors 
Consumer and 
medical 
practitioner 
“the impact for me 
personally was huge” 
Helen  
C06 
Convulsions Panadeine Forte Medium Advice from medical 
practitioner 
Medical 
practitioner 
“I won’t take it again, just 
in case.” 
Mary  
C07 
Aches in legs, 
nausea 
tamoxifen High Consumer’s reflection and 
specialist’s medical 
knowledge 
Consumer 
suspected 
medication and 
the medical 
practitioner 
confirmed 
“I just felt I was getting 
weaker and sicker and I 
was angry by this stage 
too…I felt that I was bit 
fobbed off” 
Belinda  
C08 
Slow recovery 
from epidural 
Inderal Medium Observation and prior 
knowledge of medication. 
Consumer and 
GP suspected 
“I don’t want to be 
prescribed drugs again if 
it’s not necessary.” 
Tim  
C09 
Bell’s Palsy Zyban Mod High Observation and 
elimination of other 
possibilities. 
Consumer “I was nearly in tears, I 
didn’t know what was 
wrong” 
Edward 
C10 
Vomiting after 
second dose for 
two weeks 
Efexor  High Symptoms immediately
following taking the drug.  
Re- challenged 
 Consumer, 
confirmed by 
GP 
“Nobody on earth could 
talk me into trying it 
again.” 
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    Irene 
C11 
Drug induced 
lupus 
hydralazine High Observation, Internet. Consumer,
confirmed by 
medical 
practitioner. 
“I was just in agony” 
James  
C12 
Felt ill enough to 
miss work. 
Panadeine Forte High Observation. Several uses 
over time. 
Consumer and 
wife 
“It delayed my return to 
work” 
Joanna  
C13 
Photo-sensitivity – 
pustule rash 
Celebrex High Observation and the 
Internet 
Consumer “The impact was major.  
For the period of the 
reaction I was miserable.” 
Bob  
C14 
Photo-sensitivity – 
itchy rash 
Vioxx    Low Observation and
information from friends 
Consumer, wife, 
wife’s cousin 
and daughter. 
Searching for an 
explanation for the 
symptoms for 18 months. 
Kerry  
C15 
Double vision Maxolon High Medical practitioner 
referred to ADR reference 
material. 
Medical 
practitioner 
“I’m terrified of having 
any more surgery 
absolutely terrified” (after 
a series of unpredictable 
reactions to drugs) 
Robyn  
C16 
Induced severe 
seizure – similar to 
psychotic episode. 
Sabril High Timing of medication with 
suspected reaction. 
Consumer and 
husband 
“was terrifying” “It did 
shatter me 
psychologically” 
Paul  
C17 
Restless Legs, 
unwell, pain in legs 
Lipitor High Observation by the 
consumer and his wife, 
own medical knowledge, 
Internet. 
Consumer “I’m miserable….  [its] the 
decrease in the quality of 
life” 
Table 5-1 Detecting suspected ADRs from a consumer’s perspective
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These consumer data indicate that consumers are involved in a wide range of decisions 
surrounding suspected ADRs, broader than the treatment decisions and diagnostic decisions 
discussed in the literature review (sections 2.3.2 and 2.3.3).  These results also indicate that the 
decision types made by consumers are significantly broader than the current ADR decision 
support focus. 
Decision Type Decisions made by consumers 
Diagnostic 
decisions 
Suspect a drug of causing a reaction 
 Suspect a class of drugs of causing a reaction. 
 When given a diagnosis by a medical practitioner, whether to accept the diagnosis 
Treatment 
decisions 
Whether to use drug therapy 
 Which medication to take – prescription, non prescription or complementary 
 Whether to take prescribed medication 
 To take a medication prescribed for a family member or friend. 
 Decision to request a specific drug from a medical practitioner 
 Decision between multiple suitable drugs 
 Decision to take medication prescribed for self, for a previous illness. 
 When to begin or cease a drug. 
 Frequency of drug 
 Whether to follow recommendations by medical practitioner or product information. 
 Whether to accept a side effect because of the benefits of the medication. 
Information sharing Whether to report a suspected reaction to a medication practitioner 
 Whether to report new symptoms to a medical practitioner 
 Which information to share with a medical practitioner 
 Whether to request specific information about a drug 
 Determine the priority for treatment 
 Inform medical practitioner of ceasing a medication 
 Inform a medical practitioner of ‘non-compliance’ – eg higher dose than 
recommended. 
 When to report a suspected reaction to a medical practitioner 
Seeking information Who to seek information from; medical practitioner, pharmacist, naturopath, friend, 
family 
 When to seek information.   
 Where to seek information – Internet, person, media, drug product information 
Table 5-2 Decisions made by consumers during a suspected ADR from a consumer perspective 
 
5.2.2.2. Consumers as diagnostic decision-makers 
As described in chapter two, the majority of decision support has focused on the prescriber, and 
decision support that includes consumers is mainly for treatment decisions.  These consumer 
data revealed that in 11 of the 15 cases, the consumer was involved in the diagnostic decision-
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making process.  In seven of those 11 cases, the consumer believes that s/he made the diagnosis 
without the assistance of the medical practitioner.  (O'Brien & Yearwood, 2003) 
5.2.2.3. The role of the pharmacist 
Three case studies included the role of the pharmacist in ADR decision-making.  The decision 
types made by the pharmacist are listed in Table 5-3 below. 
 
Pharmacist decision Case study 
Recommend changing drug from branded drug to generic. Kay 
Provided information about drug properties Kay 
Provided information about potential ADRs associated with drugs Julie 
Advised consumer to seek medical assistance Toni 
Table 5-3 ADR decisions made by pharmacists 
5.2.3. WHAT DO DECISION-MAKERS UNDERSTAND BY THE TERM ADR?   
The terms side effect, reaction and allergy have all been used by the consumers in the interviews.  
It is not the intention of this study to do an in-depth linguistic analysis of the use of these terms, 
however some understanding of how people use particular terms is important in order to 
understand their intention. 
 
A direct question about the difference in meaning between side-effect and reaction was not 
asked to many consumers, and many of those who were asked, did not appear to have a clear 
explanation.  One participant, however, offered an explanation of her understanding of the term 
‘side effects’:  
 
I suppose I don’t see side effects as necessarily being that negative if you can cope with 
it…I mean if it’s a side effect it’s, I think if it can be handled otherwise I don’t necessarily 
see it as negative because it’s just part of it…  
 
Another method of determining the meaning attributed to these terms is to observe how the 
term is used in conversation.  One pattern that appeared to emerge where the term ‘side effect’ 
was primarily used to refer to an attribute of the drug, where as the term ‘reaction’ appeared to 
be used to refer to the experience of the consumer.  Another pattern was the combined use of 
‘side effect’ and ‘reaction’.  Reaction was used as something more severe than a side effect that 
was unexpected and more severe.   
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5.2.3.1. ‘Side effect’ as an attribute of a drug 
The following extracts illustrate the use of the term ‘side effect’ as an attribute of the drug: 
 
 I’d be discussing probably now [following the suspected ADR] with my GP what the 
options are and going through all the side effects. 
 
…looking up the [drug] on the computer wondering what sort of side effects it had. 
 
So he called me on a Saturday morning and said I will send you a prescription and you can 
start taking that and I said are there any side effects… 
 
No [I didn’t see the Dr] because it’s, headaches are one of the side effects of [the drug] is 
throwing up, it’s, they were both side effects of [the drug] 
 
They list every conceivable side effect that anyone’s ever had. 
 
In each of these cases ‘side effect’ was used as a general term which did not appear to reflect 
severity. 
 
5.2.3.2. ‘Side effect’ as an expected but non-therapeutic effect of the drug 
In the examples below, the consumer has experienced symptoms s/he has attributed to non 
therapeutic effects of the drug that do not appear to be of a major concern to the consumer, 
possibly because the cause of the symptoms is known. In these examples, the term ‘side effect’ is 
still used as an attribute of the drug, but as can be seen, the side effect appears to be something 
that is expected, by at least one party, either the consumer, medical practitioner and/or 
documented in the product information: 
 
I was experiencing very severe headaches, migraines averaging about one to two a week and 
I was throwing up about once a week and I continued with it, the doctor said no, no, no 
that’s all right it’s just side effects [of the drug] so I continued. 
 
I told the doctor I was getting bad dreams and apparently that is one of the side effects of it 
[the drug]. 
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5.2.3.3. ‘Reaction’ describing the experience of the consumer 
The term ‘reaction’ appeared to be the term most often used when referring to the consumer’s 
experience of the symptoms.  Some examples follow: 
 
…just because on a previous occasion I had a bad reaction. 
 
I mean it wasn’t that I has having fever or anything I was simply throwing up and I was 
getting headaches and it was the fact that was happening so regularly over the period that to 
me said it wasn’t so much a viral infection I was just having a normal reaction to the drug. 
 
Well I have a reaction to a lot of things. 
 
…if somewhere the fact that some people have a reaction to either Panadeine Forte or 
Tramal or whatever it might be would be useful to know that so it could be taken into 
consideration. 
 
This use of the term ‘reaction’ did not appear to be related to the severity or whether the 
symptoms were expected.  It seemed to be used generally to indicate the person’s experience. 
 
5.2.3.4. ‘Allergy’ as a type of reaction 
The term ‘allergy’ was used by eight of the consumers. In the majority of cases, the consumer 
had been told by a medical practitioner that s/he had an allergy, and so used the same term.  
Edward used the term ‘allergy’ as a term meaning ‘reaction’ Other consumers appeared to use 
the term as a subtype of allergy, which is consistent with the expert definition. Some examples 
have been listed below: 
 
I must be allergic to Codeine. 
 
…[the] doctor has said that it was an allergic reaction and to stay off the [drug].   
 
I had an allergic reaction. 
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Whether if I’d gone to casualty they might have given me Maxolon or something else that 
might have worked I don’t know.  I got the impression not. You’re stuck with a total 
allergy…Well again, if I got an allergic reaction like that nobody on earth could talk me into 
trying it again. 
 
As a child I had an allergy to eggs. 
 
I think he also did a blood test if I remember and it did show that I could have had an 
allergy but he thought it was more like an environmental allergy. 
 
5.2.3.5. Terminology used when quoting a health professional 
At times the consumer referred to a diagnosis made by a medical practitioner.  In these cases, it 
appears that the consumer uses the terminology used by the medical practitioner.  As it is not 
possible to know what terminology was used by the medical practitioner, this can only be a 
suggestion at this stage: 
 
[Quoting a medical practitioner in an emergency clinic] “I know what you’ve come for, 
you’ve got an allergy to…”, that was a definite allergy. 
 
The other possible complexity related to the use of terminology, is that the term ‘reaction’ or 
‘suspected reaction’ was used consistently by the interviewer throughout the interview process.  
It is possible that the consumers, having answered an advertisement for people who believe they 
may have experienced an adverse drug reaction, to have adopted this terminology for the 
purposes of the study. 
 
5.2.4. WHAT PROBLEMS OCCUR WHEN MAKING ADR DECISIONS? 
5.2.4.1. Medical practitioner/consumer relationship 
Responsibility of health care 
The consumer group raised concerns about their care throughout their suspected ADR.  Using 
hindsight, they would have liked the following changes in their care. They would have liked: 
 
 not be told, do not worry, it is nothing to worry about, it will pass;  
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 additional information about the suspected ADR to assist with giving the consumer 
ownership of their condition; 
 for the medical practitioner to take more responsibility for ensuring diagnosis is correct; 
 for the medical practitioner to not take responsibility for what the consumer does or 
does not need to know; 
 for the medical practitioner not to patronize; 
 for the medical practitioner to take this information the consumer had collected about 
her own experiences into consideration when making future treatment 
recommendations. 
 
The consumer choice to accept or reject advice  
Several consumers said that using hindsight they would not necessarily have followed the advice 
given by the medical practitioner, or may have requested more information to clarify the 
recommendation before making a decision about whether to follow it or not. 
 
 one consumer said he would not have taken the medical practitioner’s advice to take a 
second tablet when there had been a significant reaction to the first dosage; 
 two consumers said they would not have taken a non-essential medication. These 
consumers would have looked for an alternative to drug treatment, 
 one comment was that agreeing to take a medication means fully understanding the 
possible consequences of this agreement.  This consumer said she needed to know more 
about what she was agreeing to regarding drug treatments; 
 one consumer would not have taken the generic brand of a medication suggested by the 
pharmacist. 
 
Consumer satisfaction with episode/s of care surrounding suspected ADR 
When asked, again using hindsight, what the consumers would have liked their medical 
practitioner to have done differently, there were many positive comments from the consumer 
group.  Two have been listed below: 
 
I know from past experience if my GP’s felt he hasn’t been able to cope with the situations 
he’s … sent me back to [Perth] so I suppose when you know he was clear about this well 
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you know it’s not like I had to question whether you know he wouldn’t do the best for me 
because I knew he would and I knew that he would send me back to [the specialist] if there 
wasn’t anything that could be done. 
 
…even the GP was because of the high temperature was saying I don’t think it can be and 
you know then went ahead and checked it up and realised it was.  I mean he’d told me to 
come off it already so he was terrific). 
 
One issue raised by several consumers was the issue of access to information.  Eight of the 
consumers expressed a desire for more information about possible reactions to drugs, or about 
disease and disease processes.  Following are two lists, the first is a list of information the 
consumers would have liked access to about drugs, and the second about diseases. 
 
5.2.4.2. Decision-making with partial knowledge 
Information about drugs and ADRs 
A discussion of the differences between information and knowledge can be found in section 
2.3.4.4.  This section refers to information sources the consumer’s would have liked.  The 
consumer group indicated that they would have liked access to the following information about 
drugs and potential ADRs.  These included: 
 
 a discussion of possible side effects to a drug prescribed for them;   
 warnings of what to look out for and when to seek medical treatment, particularly when 
a potential reaction could look like another common illness; 
 written information about possible ADRs using common language that is easy to 
understand without technical jargon, from either the medical practitioner or pharmacist  
For example, pruritis = itchiness, but the consumer did not recognise it as such; 
 clear information about the positive and negative effects of drugs so consent to take the 
medication is informed; 
 an explanation of the cause of new symptoms and the likely course of the suspected 
reaction, as it is likely to be a disease process not previously experienced by the 
consumers.  
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Information about disease and treatment options 
The consumer group indicated that they would have liked access to the following information 
about diseases and treatment options.  These included: 
 
 a warning that post-surgery the consumer may feel unwell and therefore need 
medication, allowing the consumer to plan and purchase a suitable drug rather than take 
an inappropriate drug that was readily available; 
 all of the possible sources of the symptoms rather than just providing a single suggestion, 
so the consumer is aware of what options are being considered; 
 information about what is likely to happen during a surgical procedure. 
 
As can be seen from section 5.2.2, consumers in this study were actively involved in making a 
wide variety of decisions within this domain and without information this task was more 
difficult.  At the time of the suspected ADR, the consumer may not have realised it was required, 
in retrospect they see it would have been useful.  It is also about providing information that is 
directly requested by the consumer using language that is understandable by the consumer.  In 
several cases when information was requested directly, it was not provided. 
 
5.2.4.3. Decisions that may contribute to an ADR 
Ignoring recommended dose 
In two cases, the consumers chose to ignore the recommended dose of a medication that may 
have contributed to the prolongation of their ADRs.   
 
Julie initially chose not to tell her GP that she was taking a higher than recommended dose of 
the Periactin to manage the ADR to Tramal, because the Tramal was the only drug she had 
found that managed the pain and did not cause drowsiness.  She was concerned that informing 
her medical practitioner would mean that she would have to stop the Tramal which she found 
very effective in managing her pain.  Taking a higher than recommended dose of the Periactin to 
assist with the management of the initial ADR, resulted in a second ADR , one which is a Type 
A reaction which is dose related.  The second ADR, therefore, was unlikely to have occurred if 
Julie had not exceeded the dosage. 
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Toni chose to take a higher dosage of Aspro Clear than was recommended to manage the 
increasingly severe symptoms due to high work and family commitments. At the time, she 
believed she had a cold or flu, a disease she was familiar with.  Her decision to seek medical 
assistance was delayed due to her choice to put family and work commitments before her health.  
This delay in seeking medical treatment may have resulted in a delay in diagnosis of the ADR. 
 
Decision not to share information with medical practitioner 
In six case studies, the consumer chose not to share information with either the medical 
practitioner or the prescribing clinician.  In two cases, the consumer was prescribed the drug by 
one medical practitioner, but another medical practitioner was the treating medical practitioner, 
and so the consumer did not have a reason to speak with the prescribing medical practitioner.  
In two more cases, the suspected ADR occurred post surgery, but because there was not surgical 
follow up consultation, again, there was no reason for the consumer to make an appointment 
with the prescribing clinician.  In one case, the consumer lost confidence in the medical 
practitioner and so decided not to go back, and in the final case, the consumer did not want to 
share with the prescriber that she was experiencing an ADR, because the medication was 
working well in treating the original condition. 
 
5.2.4.4. Complexities in the ADR decision domain 
Essential versus non-essential medications 
In most of the case studies, the medication taken by the consumer was a non-essential 
medication, and so the decision to cease the medication was not critical.  In Joan’s case, 
medication is essential for controlling her pre-existing condition of epilepsy, and so the decision 
to cease one medication, meant that another medication was needed to replace it immediately, 
making the decision to cease a medication more complex.  In contrast, the medications taken by 
James were non-essential medications and the symptoms were not severe, and so the risks 
associated with this diagnostic decision were low.   
 
5.2.5. WHAT RESOURCES ARE USED BY DECISION-MAKERS? 
5.2.5.1. Information, knowledge sources and content used by the consumers 
Information and sources of knowledge that were used by the consumers when making decisions 
surrounding ADRs were extracted from the interviews during the coding process.  Below are 
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three lists, one of information sources used, and the second of knowledge sources used and the 
third one the types of information gathered. 
 
The sources of information used by the consumers included:  
• the product information sheet;  
• consumer drug information sheet from the pharmacist; 
• personal diaries; 
• the Internet; 
• advice from medical practitioner;  
• advice from a family member; 
• observations of self; 
• family and friend’s observations of consumer’s symptoms; 
• family and friend’s recollections of past events; 
• hearing about case studies similar to own; 
• family friends; 
• the pharmacist. 
 
Sources of knowledge used by the consumers included: 
• past experience with medicines; 
• past experience with particular diseases, including suspected ADRs; 
• their own behaviour surrounding medications such as when medications were 
commenced and/or ceased. 
 
Content of information and knowledge used by the consumers: 
• general information about drugs;  
• general information about diseases; 
• classes of drugs; 
• alternative drugs for a similar treatment; 
• potential ADRs associated with drugs; 
• dosage;  
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• time required for medication to reach therapeutic level; 
• characteristics of own body. 
 
As can be seen by the lists above, the consumer group accessed information from a variety of 
sources and on several topics, as well as accessing their own knowledge.  Only one source of 
information was from a medical practitioner.   
 
5.2.6. HOW DO ADRS AFFECT CONSUMERS AND HOW DOES THIS IMPACT ON 
FUTURE DECISION-MAKING?  
A component of gaining insight into ADRs, is to understand the impact they have on a person’s 
life.  This section discusses three key themes that emerged on this topic.  Section 5.2.6.1 explores 
the consumers’ perception of the severity of their ADR experience, section 5.2.6.2 discusses the 
importance of including a life context when attempting to understand the impact of ADRs, and 
finally section 5.2.6.3 looks at the impact of experiencing symptoms that the consumer expected 
versus those that were totally unexpected.  
 
5.2.6.1. Perception of the severity of suspected ADRs  
Although the suspected reactions reported by the consumers are not life threatening and did not 
cause death or permanent physical injury, each consumer found the suspected reaction 
distressing.  The impact of the ADRs as described by the consumers appeared to fall into five 
key categories: the immediate impact of a suspected ADR; the impact after a drug has been 
ceased; the impact on the medical practitioner/consumer relationship; the impact on trust; and 
finally the impact on lifestyle. 
 
Immediate impact of a suspected ADR 
The first two quotes, below, indicate the impact on the consumer whilst experiencing the 
suspected reaction: 
 
I got home but I had to go to work for half an hour so my husband was going to drive me 
there because I really felt like I couldn’t drive, I was feeling really miserable. 
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I said [to GP] I’m miserable, I said my legs, I said I’ve got pain, I’ve got this restless legs, 
I’ve got this thigh pain around here and stuff like that and I said I’m miserable you know I 
really am. Is this the way life’s supposed to be? 
 
Toni had eight weeks of illness and said she didn’t feel completely well again for ten weeks.  Paul 
indicated that the symptoms had persisted for three years progressively getting worse. 
 
Impact of a suspected ADR after the drug has been ceased 
The following quote indicates how a suspected reaction may have an initial impact, but then has 
a longer-term impact such as increased sensitivity to the sun, impacting on lifestyle for a number 
of years: 
 
I would say the impact was major.  For the period of the reaction I was miserable.  I needed 
to miss work because of it.  I felt sick with it as well.  So from that point of view that 
episode was major.  It impacted on my holiday.  And then I had had subsequent episodes 
with Ultra violet light exposure, since then.  So to me, that’s a major impact, because I enjoy 
the sun, I enjoy being outside, and I enjoy outdoor activities.  It means that I have to be 
extremely careful with exposure to the sun, wear sunscreen, cover up, that sort of thing. 
 
Impact on medical practitioner/consumer relationship 
In two of the case studies, the consumers said that although a drug had been associated with a 
reaction, it did not impact on the medical practitioner/consumer relationship in a negative way.  
In Julie’s case, although she was frustrated by not being able to access information about Tramal 
and determine the cause of her itching, and would have liked to have been warned that the drug 
may have particular side effects, it did not appear to affect her trust in her medical practitioners 
or her decision to trial future medications.  James spoke of his suspected ADRs saying that he 
was not particularly concerned that he had experienced ADRs, and felt that nothing could have 
been done to prevent them.   
 
Impact on trust 
Kay was a person who had experienced uncontrolled epilepsy as a child, but over the past 18 
years had lived without experiencing grand mal seizures.  The impact related to Kay’s 
confidence, the fear of future episodes of epilepsy, the impact on her family, and the inability to 
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drive a car. Although the experts and medical practitioners do not believe the epileptic fit 
experienced by Kay was related to the effectiveness of the generic brand of Epilim, the impact 
of the episode has decreased Kay’s confidence in trialling new medications. 
 
Impact on lifestyle 
In Joanna’s case, as well as the impact on her physical health, a secondary impact of the 
suspected ADR was the fact that her holiday was affected, and had to be cut short, and then 
subsequently, her outdoor recreation had been affected because she is unable to enjoy outdoor 
activities in the way she used to. 
 
5.2.6.2. The importance of life context 
When reading about ADRs in the literature, there is significant emphasis on ADRs that causes 
death or significant injury.  An impact may be significant to the consumer without resulting in an 
injury that is medically significant.  The impact of Edward’s ADR was broader than the 
immediate symptoms of vomiting due to Edward and his wife’s disabilities, the fact that Edward 
was the primary carer for his wife with Alzheimer’s disease, and Edward’s age.  Life context 
assists in understanding the impact, but it also provides additional forms of understanding.  
 
Julie has a history of chronic pain, Robyn has severe long term uncontrolled epilepsy, and Irene 
has a history of uncontrolled blood pressure which is complicated further by a significant history 
of suspected ADRs.  In each of these cases, the pre-existing disease is extensive and complex.  It 
is not just a matter of making a diagnosis, and prescribing a drug.  In each of these cases, 
multiple drugs have been trialled over time, and combinations of drugs are juggled in order to 
maximize the treatment effectiveness.  In each of these cases, although ideally the chronic pain, 
epilepsy and blood pressure would be completely controlled, however due to the complexity of 
the case, this is unlikely.  In each of these cases, therefore, the risk of ADRs is extremely high 
due to the strength and combinations of medications for Julie and Robyn, and the increased 
sensitivity to drugs in Irene’s case, and so a realistic expectation for these people is to minimize 
ADRs, but not to eliminate them. 
 
For two consumers, some level of ADR is acceptable.  The aim is to maximize the therapeutic 
benefits, and minimize the reactions, rather than expect to have no reactions.  Each time a new 
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drug is trialled, which may be a new drug on the market, they know that there is a significant 
chance of a reaction, but are prepared to take the risk in an attempt to manage their condition: 
 
I suppose I don’t see side effects as necessarily being that negative if you can cope with it.  I 
mean I’ve got tinnitus which they seem to think is from medication and I’ve got other 
problems that have come from the medication and that’s I mean I have a lot of constipation 
problems, I’ve got fatty liver problems, I’ve got these but I suppose it’s weighing up 
whether it’s worth coping.  I mean, I mean if it’s a side effect it’s, I think if it can be handled 
otherwise I don’t necessarily see it as negative because it’s just part of it, if you know where 
it’s coming from well that’s fine I mean I know when I did go on the Tramal that my ring in 
my ears got worse and I just said to the doctor just check that there wasn’t wax in it and he 
said no and I thought oh well it must be the tinnitus and that’s fine. 
 
One consumer talked about her awareness of the risks and the process she goes through when 
attempting to decide whether to risk trialling a new medication: 
 
I was used to the fact that there are new drugs being discovered all the time and he [medical 
specialist] had told me, and we’d discussed it, that it might have an adverse effect.  I read the 
information that came with the [the drug] because I like to do that.  Sometimes I read it for 
any medication and won’t take it after all.  I think that maybe I can’t stand all those possible 
side effects.  If the information warns about depression I get worried.  In fact I’ve just 
started a drug called [drug name] which is for severe untreatable acne rosacea. There was a 
whole book on what would go wrong.  In the end I decided to have the [drug name] 
because the acne was getting quite bad.  Yet none of the warnings have happened to me.  
However, when you’re dealing with neurochemistry anything could happen so trying any 
drug is a bit of a danger. 
 
In contrast, because another consumer has her medication for her epilepsy working extremely 
effectively, she is not at all prepared to risk changes in medications that may results in an ADR: 
 
There is some discussion at this point where he [the medical practitioner] wouldn’t mind 
changing me onto another medication, but that’s another issue.  And I need to decide when 
and if I want to do that, because I risk, having another one of these [seizures] and not being 
able to drive, and that’s something that I need to do when I haven’t got any stresses in my 
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life, which I can’t imagine that happening (laugh)…….And whilst things are ok, if 
something’s not broke, why fix it.  So I’m a bit hesitant there.  I think, well this has agreed 
with me for so long. 
 
In another consumer’s case, her history with ADRs in association with anaesthetic drugs has 
resulted in a significant fear of surgery.  The following two consumers are very hesitant to try 
new drugs due to a fear of something going wrong, a fear based on previous negative 
experiences associated with drugs: 
 
I’m terrified of having any more surgery, absolutely terrified.  What ever it is, I’ll try any 
other means.  I’ve just had too many bad experiences.  In fact I have a problem with my 
nose where I can’t breathe properly, and I’ve been told I really should have surgery for that, 
but there’s no way I’m having it.  I’ll put up with anything, I’m just too nervous about 
surgery now. 
 
One consumer’s concern is about working with a new medical practitioner to explain her 
complex history, and to convince him/her of her history of suspected ADRs: 
 
Yeah, yeah I do I just hate going to a new doctor because and the older I get the more you 
forget so if I haven’t got it written down, you know, I forget to tell them so yeah I hate it 
for (laugh) that reason and then to show them all this [past history of ADRs] I hate doing 
that too (laugh). 
 
For each of these consumers weighing up the risks versus the benefits of taking a medication is 
based on their life context.  The context may include a complex pre-existing disease that has a 
significant impact on life, and so trialling new drugs is better than living with the pre-existing 
condition, versus someone with finely balanced medications, where the risk of upsetting the 
balance is more of a problem than the possible improvement of a new drug.  Someone else may 
have a life where an illness that interrupts that life has a significant impact on people other than 
the person taking the drug, and for people who have had such negative experiences in the past, it 
is important to minimize that risk.   
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Another aspect of life context is that the ADR may have been more or less severe depending on 
where the consumer was at the time of the suspected ADR.  In the case of Helen, the fainting 
was less severe because she was at home.  It could have been significantly more severe if driving 
a car.  This same issue is shared by Kay.  If the fit had occurred whilst driving, it would have had 
a significantly greater impact, than having a fit at home. 
 
These are factors that are essential to consider when assisting a consumer make risk benefit 
decisions about drugs. 
 
5.2.6.3. Differences between expected versus unexpected symptoms   
In a few cases the consumers were accepting of uncomfortable symptoms that they expected but 
were distressed when they did not know the cause of symptoms.  One example was the 
consumer who suspected Zyban of causing Bell’s Palsy.  The quote below indicates an 
acceptance of some symptoms that were severe enough to stay home from work: 
 
Headaches are one of the side effects of [the drug] as is throwing up…they were enough to 
prevent me from working, lying in bed in darkness…The doctor said no, no, no that’s 
alright. It’s just side effects so I continued. 
 
The following two quotes indicate the stress associated with not knowing the cause of the 
symptoms of the suspected ADR: 
 
I think that if I’d known that that was possibly a side effect it would have been less 
traumatic because it was really quite stressful not knowing why. 
 
The double vision was distressing, because I’d never had it before, and didn’t know why I 
had it. 
 
The consumers were asked if they would do anything differently or would have liked the medical 
staff to do anything differently if they were to face the same circumstances again, using the 
advantage of hindsight.  The majority of the participants indicated they would have liked to have 
been warned that the medication they were taking may result in a reaction.  Some also indicated 
that some idea of when to seek medical advice would have been useful. 
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5.2.7. SUMMARY OF CONSUMER GROUP ANALYSIS 
The consumer group analysis included analysis of the consumer interviews.  It provided insight 
about the decision-makers in the ADR domain, and the decision types made by consumer 
decision-makers, how consumers use terms such as ADR, side effect and allergy, some problems 
when making ADR decisions, the resources used by consumers when making ADR decisions, 
and how ADRs affect consumers and the impact this has on future decision-making.  The key 
results have been summarised below: 
 
• This set of data indicates that consumers are decision-makers in the ADR decision 
domain, and make a wide variety of decisions including diagnostic decisions, treatment 
decisions and decisions surrounding information sharing and information seeking. 
 
• ADR decision support includes medical practitioner only decisions.  These data suggest 
that consumers are also actively involved in this decision domain, and play an important 
role in the detection of ADRs. 
 
• The consumers used the terms ‘reaction’, ‘side effect’ and ‘allergy’.  They appeared to use 
the term ‘side effect’ to describe a drug, and ‘reaction’ to describe a consumer 
experience.  They also appeared to view a ‘side effect’ as a known and tolerable non-
therapeutic effect of a drug.  ‘Allergy’ was used as a type of ‘reaction’. 
 
• Issues surrounding the medical practitioner/consumer relationship related to ownership 
and responsibility issues surrounding health care.  The consumers as a whole would have 
liked to take more responsibility for their health care and the decisions surrounding their 
treatment.   
 
• The consumers expressed that they would have liked more access to information about 
prescription drugs and/or the pre-existing condition, to assist in their ability to make 
informed decisions.   
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• The consumers made some decisions that may have contributed to the existence of their 
ADRs including ignoring recommended dosages and choosing not to share particular 
information with their medical practitioners.   
 
• This set of data highlighted some of the impacts of the suspected ADR other than the 
immediate impact on the consumer.  Other impacts included a continuation of the ADR 
after the drug had been ceased, the impact on the immediate family, the impact on the 
medical practitioner/consumer relationship, and on trust and lifestyle. 
 
• When making decisions surrounding prescribing this set of data highlighted a need to 
consider life context.  For some consumers some level of ADR is acceptable due to the 
complexity of the case and the difficulties surrounding controlling the pre-existing 
condition, where as for other consumers their medications are finely balanced and so any 
ADRs may have a negative impact.  For some, having had significant negative 
experiences with drugs, it is important to minimize the risk of future ADRs due to the 
impact on future decision-making. 
 
• The final result from this group of data was that consumers appeared to be more 
accepting of non-therapeutic symptoms associated with drugs when they were aware that 
they may occur, than when they appeared with no apparent cause.  This may be another 
factor to support the argument that providing information to consumers assists in the 
management of ADRs. 
 
The following section presents the results from the analysis of the medical practitioner data. 
 
5.3. Group analysis - Medical practitioner view 
The medical practitioners, who were approached to participate in the study, were asked to 
discuss the ADR suspected by the consumer by referring to their medical notes, and providing 
an interpretation as required.  As well as discussing the specific ADR in the case study, the 
medical practitioners were asked some general questions to explore reasoning behind their 
clinical decisions and to provide some insight into the medical perspective of some issues raised 
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in the consumer interviews.  This section includes the results of the medical practitioner data 
only. 
 
Seven of the 15 case studies included a medical practitioner perspective, with one case including 
two medical practitioner perspectives.  In total, therefore, this group data includes the views of 
eight medical practitioners comprising four GPs, three specialists, and one hospital based 
medical practitioner. 
 
This section, again, follows the general structure of the research questions, followed by the key 
themes that have emerged from the data analysis.   
 
5.3.1. WHAT DECISIONS ARE MADE BY EACH DECISION-MAKER? 
The decisions made by the medical practitioners were identified by the processes of coding 
described in section 3.5.5.1.  Table 5-4 includes a general decision type description in column 
one, and the decisions made by the medical practitioner group in column two. 
 
The contents of Table 5-4 reinforces the view that decision-making surrounding ADRs is 
complex, and involves a range of decision types which are more extensive than the medical 
decisions currently supported in ADR decision support systems. 
 
5.3.2. WHAT DO DECISION-MAKERS UNDERSTAND BY THE TERM ADR? 
The medical practitioners used the same set of terms used by the consumers, ‘side effect’, 
‘reaction’ and ‘allergy’ to describe symptoms that were associated with drugs. In addition, they 
also referred to ‘significant reactions’ and ‘significant side effects’. Below are some meanings that 
have emerged from this set of data. 
 
5.3.2.1. ‘Side effects’ as an attribute of the drug and a description of the consumer’s 
experience 
The consumers referred to side effects as an attribute of the drug as in section 5.2.3.1.  The 
medical practitioners also described side effects as an attribute of the drug.  For example, Dr. 
Price referred to the “…side effects of Zyban…”  
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Decision 
Type 
Decisions 
Prescribing 
decisions 
Decision to use drug therapy 
 Determine drug to prescribe 
 Determine dosage and duration of drug therapy 
 Cease a medication 
 Continue with medication, even if reaction present 
 If decision to cease medication, decide the time required to cease a medication (slowly 
decrease one and increase the other; stop one and start another; stop one, wait and 
then start another.) 
Diagnostic 
decisions 
Determine a range of possible diagnoses for symptoms, and to determine the most 
likely diagnosis/es. 
 Determine if one of the possible diagnoses is an ADR 
 Determine which symptoms are likely to be associated with which diagnosis 
 Whether tests are required to assist with diagnosis 
 Which tests to order or conduct 
 Determine the severity of the reaction and the likely progression 
 Determine whether treatment is required for an ADR 
 Whether to consult information to assist with diagnosis, and if so, which source of 
information 
 Determine which pieces of information are relevant and those that are not relevant to 
the diagnostic decision. 
Treatment 
decisions 
Whether to treat the ADR, or allow it to resolve itself. 
 Whether to access an external source of information to make treatment decisions 
(database, text, colleague) 
 Determine the amount of investigation to conduct whilst working within ethical limits
 Decide how often the consumer needs to be monitored, and the frequency of 
monitoring 
Reporting 
decisions 
Whether to report a suspected ADR to ADRAC 
 Which information to report 
Seeking 
information 
Determine when to seek further information and who to seek it from (such as 
consumer, text book, colleague, database, pharmacist) 
 Determine which information to seek from each source 
Sharing 
information 
Determine the information to share with the consumer, and the level of information 
to share.  
 Determine a method of conveying information to consumers to avoid information 
overload, but provide information requested and required by consumers. 
Table 5-4 Decision types made by medical practitioners 
 
The medical practitioners also referred to ‘side effects’ as symptoms experienced by the 
consumer.  One medical practitioner used the following phrase. “I just think that she was 
certainly having side effects of [the drug].”  
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5.3.2.2. ‘Side effects’ as unwanted, known or expected, non-therapeutic effects of 
medications 
In addition to the terms as attributes of drugs and or consumers, most of the medical 
practitioners used the term ‘side effect’ to describe non-therapeutic effects of a drug, that have a 
known set of attributes such as a set of symptoms, the consumer group likely to experience 
ADRs, and an expected time frame.  Some examples are listed below: 
 
It’s unusual in the post menopausal women to have these side effects.  It’s usually with 
younger women that are pre-menopausal. 
 
Side effects of [the drug] are usually on mental function rather than nerve function. 
 
[I] did the liver tests to check for hepatitis, which is a possible side effect of the group of 
drugs, know as statins. 
 
My only experience with all that is that when women usually get with those sort of things, 
they get it earlier on, they don’t get it two years after starting tamoxifen…  
 
…sometimes what I do is print out a list of known side effects of medications. 
 
The above examples use the term ‘side effect’ as a set of symptoms known to be related to a 
drug.  Dr James, however, used the term ‘side effect’ to describe symptoms associated with the 
drug that are not well known.  He was talking about when ADRs should be reported to 
ADRAC.  “I just stop the drug and change things around, but if it’s a side effect of the drug, 
which is uncommon, or it may not have been described, well you should report those.” 
 
5.3.2.3. ‘Significant side effects’ 
Several medical practitioners referred to ‘significant’ side effects.  The implication appears to be 
that a significant ‘side effect’ may be one that has an impact on the consumer, as opposed to 
insignificant side effects which can be tolerated, or which will not prevent the consumer from 
continuing to take the medication.  One medical practitioner used the term as follows.  “…she 
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started off on the [the drug] and she didn’t have any significant side effects for the first six to 
eight months.”  
 
5.3.2.4. Differences between the terms ‘side effect’ and ‘reaction’ 
Some of the medical practitioners made a clear distinction between the term ‘side effect’ and 
‘reaction’. 
  
I’m not sure if there was a reaction, but I just think that she was certainly having side-effects 
of [the drug].  And it’s well recognised that a proportion of patients just can’t tolerate [the 
drug]. 
 
5.3.2.5. ‘Reaction’ as an attribute of the drugs and description of the consumer’s 
experience 
Although some medical practitioners distinguished between ‘side effects’ and ‘reactions’, they 
appear to have been used in a similar way.  Like the term ‘side effect’, ‘reaction’ was used as an 
attribute of the drug, such as “…it’s a known medication to have potentially significant 
reactions”. It was also used as a description of the consumer’s experience such as “…she has 
had adverse drug reactions to [reading a list of drug names] …” 
 
One medical practitioner said that he sees ‘side effects’ and ‘reactions’ as different terms to refer 
to the same concept. 
 
5.3.2.6. ‘Significant reaction’ 
The term ‘significant’ was also used with the term ‘reaction’, for example “even though it was a 
quite significant reaction, I think it responded reasonably quickly.” 
 
Another similarity between the term ‘side effect’ and the term ‘reaction’ was that reactions were 
also used to describe non-therapeutic symptoms that were associated with a drug, which had 
particular characteristics.  Some examples are below: 
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[The medical practitioner] said that normally a reaction to a medication would cause pain on 
both sides of the body and be constant pain, where as [the consumer] experienced the pain 
only on the right side, and the pain was worse with specific activities such as driving. 
 
[The medical practitioner] said he has seen reactions to [drug class] in the past, and the 
person usually has pain down both of the large muscle groups in the legs often unable to 
stand up. 
 
I don’t think there is evidence that [this drug] causes this sort of reaction. 
 
Although the terms ‘side effect’ and ‘reaction’ have been described as being different terms, they 
appear to be used the in same way, and have the same characteristics.  The only difference may 
be severity, with ‘reactions’ as more severe than ‘side effects’, however as the term ‘significant’ 
was used with both terms, it appears that there can be more severe and less severe ‘side effects’ 
and ‘reactions’.   
 
There are not enough examples within these data to determine if the terms are used to mean 
similar concepts, or whether different medical practitioners have different understandings and 
uses of the term.   
 
5.3.2.7. Allergies 
The term ‘allergy’ was only used by three of the medical practitioners and appeared to refer to a 
specific type of reaction.  Of the case studies with a medical view, there were only two that were 
described by the medical practitioners and experts as being classified as an ‘allergy’.   
 
The term ‘allergy’ is defined in the Medline Plus online encyclopaedia as follows: 
 
Allergy is caused by an oversensitive immune system, which leads to a misdirected immune 
response. The immune system normally protects the body against harmful substances, such 
as bacteria and viruses. In contrast, an allergic reaction is when the immune system reacts to 
substances (allergens) that are generally harmless and in most people do not cause an 
immune response (Medlineplus). 
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This term appeared to be consistent with how it was used by these medical practitioners.  In 
most cases the medical practitioners referred to drug allergies, but Dr Carey also referred to 
Joanna’s allergy to nuts. 
 
One medical practitioner referred to the diagnosis of an allergic reaction, as having particular 
characteristics that can be recognised: 
 
 It looked like an allergy.  She had inflamed eyes on that day as well.  It just looked like an 
allergic reaction. Particularly two days later when she had the rash, it was definitely an 
allergy, but even on the first presentation, it looked like an allergy. 
 
5.3.2.8. Misunderstandings related to terminology 
One medical practitioner referred to confusion in the terminology between medical practitioners 
and consumers.  He was referring to consumers who come to the medical practitioner with a 
suspected ‘allergy’ to a drug: 
 
…most of those are not allergies, they’re nausea, and some tummy upset, that’s quite 
possible without an allergy, but it’s difficult to know, sometimes if they are truly allergic, or 
whether they’re getting some significant side-effects, or whether it’s, having read it, it’s the 
way they believe it’s gone, or whatever.  It’s hard to tell. 
 
Interestingly, it appears that the consumers referred to by this medical practitioner are using the 
term ‘allergic’ as a general term to mean ‘symptoms associated with the drug’, and he 
understands them to literally mean an allergy, rather than using the term ‘allergy’ to mean the 
more generic terms of ‘reaction’ or ‘side effect’. 
 
The statement quoted by one medical practitioner earlier, “I’m not sure if there was a reaction, 
but I just think that she was certainly having side-effects of [drug name],” may indicate that the 
medical practitioner was using the term ‘reaction’ to mean ‘allergic reaction’ and again, the 
symptoms suspected by Mary were not ‘allergic’ in nature, but she did feel may have been 
associated with the medication. 
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This section indicates that there appears to be some confusion in the terminology.  In some 
cases, the terms ‘side effect’ and ‘reaction’ appear to be largely interchangeable, with the term 
‘allergy’ referring specifically to an immunological response.   
 
In chapter six, the use of these terms will be discussed to determine if there is an impact of 
different groups using terminology differently, as it relates to the detection and management of 
ADRs, and implications for decision support.  
 
5.3.3. HOW ARE ADR DECISIONS MADE? 
The primary decision type described by the medical practitioners during their interviews was the 
differential diagnosis between one or more suspected conditions. A condition may include the 
pre-existing disease, and newly developing disease, an ADR or a combination of these. 
 
5.3.3.1. Differential Diagnosis 
The analysis of the medical practitioner data revealed some strategies medical practitioners used 
when attempting to differentially diagnose an ADR.  The strategies discussed in this section 
include novel decision-making and the use of negative knowledge, pattern matching, and the 
differences between specialists and GPs. 
 
Novel decision-making and lack of knowledge 
In some of the case studies, the medical practitioner indicated that he6 had little or no experience 
with a suspected ADR by either stating it directly, or by seeking advice from colleagues or 
information sources, appeared to have little or no previous experience. 
 
As an example, one medical practitioner stated that he had not seen photosensitivity linked to 
NSAIDs:   
 
 
6 When referring to the group of medical practitioners, rather than using the term s/he as previously used in this 
document, as all medical practitioners are male in this study, the term he will be used. 
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I’ve seen photosensitivity reactions to things like tetracyclines.  I certainly haven’t seen it to 
an NSAID.  I’ve seen it with St John’s wort.  The short answer is, no, I haven’t seen it to 
that group of medications.  In my experience, this is not a common problem. 
 
In two cases, the consumer indicated that the medical practitioner sought advice from either a 
colleague or a database, indicating it was a novel diagnosis, not one that was immediately 
recognised by the medical practitioner.   
 
One of the strategies that appeared to be used when making a novel decision was the use of a 
process of elimination.  One medical practitioner described this process: 
 
Her regular routine hadn’t altered, and so, because that is a known side effect and she 
consulted the literature herself, you know, being in the medical field she’d gone straight to 
the literature, she’d made that diagnosis and conclusion herself.  I was happy to go along 
with that.  That seemed reasonable…It was a severe photosensitivity reaction, so it wasn’t as 
if it was a rash, a mild rash by a viral illness, or a brief rash you might get for a week or two 
that would occur perhaps after an anti-biotic.  She hadn’t been unwell in any other way.  
That was the only change to the routine, so it’s highly probably that that was the cause of 
the problem. 
 
Pattern matching 
In some of the other cases, when asked if the medical practitioner used an external source of 
information to assist in the diagnostic process, he stated that he was very familiar with the ADR 
due to years of medical experience.  One medical practitioner said “I know about [the reaction] 
because I’ve seen it.  I’ve experienced it.” Another one stated, “[I have] a lot of experience with 
these drugs, I’ve had many years of experience, most of my patients are on [this drug].” 
 
One medical practitioner used pattern matching, also as a method of eliminating possible 
diagnoses.  “My only experience with [this drug] is that when women usually get with those sort 
of things [symptoms described by consumer], they get it earlier on, they don’t get it two years 
after starting [the drug], you know”. 
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One medical practitioner also began with a familiar diagnosis, but there was a variation of the 
details of the diagnosis for this specific consumer.  In this case the medical practitioner said that 
he was familiar with the suspected, reaction, however not at the dose the consumer was taking. 
“In my experience most people who got drug induced lupus from [drug name] were taking 
200mg three or four times a day, not 50mg twice a day which is what [the consumer] was 
taking.” 
 
5.3.3.2. Differences between GPs and specialists 
The use of pattern matching for ADRs was stronger from the group of medical specialists, 
compared with the GPs.  Each of the specialists interviewed, when asked if they accessed 
additional resources to assist with their decision-making, said that they were very familiar with 
the drug and class of drugs in question.  Of the GPs, however, there was only one that indicated 
the diagnosis was made through recognition, “it looked like an allergy”.  Each of the others 
described a diagnostic process of considering multiple options, and weighing up the likelihood 
of each option.   
 
The analysis of the medical practitioner data has provided some insights into methods used by 
the GPs and specialists when attempting to differentially diagnose between an ADR and a 
disease.  Nine clinicians provided some insight, however when attempting to look at the 
differences between GPs and specialists, the groups contained only four cases, making it difficult 
to do more than suggest these processes be explored further in future research. 
 
5.3.4. WHAT PROBLEMS OCCUR WHEN MAKING ADR DECISIONS? 
The medical practitioner data provided some insights into some of the problems surrounding 
ADR decisions.  This section discusses the information needs of consumers, and the concerns of 
medical practitioners surrounding information, and the use of the term ‘compliance’ and the 
implications of this term in this decision domain. 
 
5.3.4.1. Information required by consumers 
The analysis of the consumer data highlighted the issue that consumers would like more 
information about potential ADRs associated with prescribed medications.  This issue was 
discussed with the medical practitioners, and the following concerns emerged. 
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Medical practitioners view of providing ADR information to consumers 
Several of the medical practitioners interviewed discussed a concern about providing ADR 
information to consumers.  One medical practitioner articulated this concern below: 
 
Information is given.  They go to a chemist.  The pharmacist gives them an enclosed 
brochure.  Now for some people that’s just terrific, and for some people it’s a disaster. 
 
The medical practitioner’s expressed a belief that some consumers will over estimate the risk of 
taking a medication, compared with the risk to their health of not taking the medication or not 
treating the underlying condition.  The concerns appeared to fall into two categories;  those 
related to a consumer choosing not to take a medication, and concern that providing 
information will result in a nocebo effect.  These are discussed below. 
 
Consumers choosing not to take a medication 
Two of the medical practitioners spoke of their concerns surrounding consumers choosing not 
to take medications when provided with detailed ADR information: 
 
They just, every symptom they believe will potentially happen to them, and some of these 
things, in the ultimate, they can be very very nasty reactions.  The one I was talking about 
with the hepatitis, that person was really quite sick, but it’s one in whatever it is rare, and but 
people, some people don’t like taking medication say, right well I’m not taking the 
medication, when they truly need the medication.  That sort of person is not getting the 
benefit you thought might be worthwhile…The old power of suggestion is pretty strong.  
And if you’re wanting someone to really take a medication for some serious problems and 
they don’t then you’ve lost the opportunity you had. 
 
I think it depends on the particular individual.  For some people, knowledge is power, and 
for some people knowledge is destructive, and unfortunately there are a group of people in 
whom, if you provide them with the prescribing information and the side effect profile of a 
medication, they’ll flatly refuse to take it, even though the chances of them having those side 
effects are miniscule, simply because the drugs sound far too dangerous.  On the other hand 
there are a group of people who, when they have that information, they just say, that’s ok, 
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that’s interesting, I’ll see what happens.  You can’t predict which way people are going to 
respond.   
 
According to one medical practitioner, the product information provides the reader with 
information about the types of symptoms that may be associated with the drug, but not a clear 
indication of the likelihood.  He also stated that the risk of taking the drug needs to be weighed 
against the risk of not taking the drug, something he feels the consumer does not do, if provided 
with the information about possible reactions. 
 
The nocebo effect 
The second concern raised by the medical practitioners was that information may result in the 
consumer experiencing a nocebo effect.   
 
The nocebo effect was described in the literature review (chapter two).  The nocebo effect is 
when a consumer takes a substance that does not cause harm, such as a sugar tablet, but when 
the consumer believes it may cause harm, s/he experience harmful effects, which are perceived 
to be due to the drug.  It is a concept described also as a negative placebo effect. 
 
Some of the medical practitioners indicated the difficulty in differentially diagnosing a reaction to 
a medication versus a nocebo effect: 
 
I’m just thinking about one person…they imagine every side effect possible…They are not 
all realistic side effects…it’s difficult to know, sometimes if they are truly allergic, or 
whether they’re getting some significant side-effects, or whether it’s, having read it, it’s the 
way they believe it’s gone, or whatever.  It’s hard to tell… The old power of suggestion is 
pretty strong . 
 
The medical practitioners did not offer a solution about how to make this differential diagnosis, 
apart from being aware that it can happen, and to limit the level of detailed information provided 
to consumers. 
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Using information to support medical reasoning 
One medical practitioner said that he uses information to reassure consumers that a medication 
is not associated with a drug, when they have heard from friends and/or family that:  
 
…sometimes what I do is print out a list of known side effects medications.  It’s mainly just 
to reassure them, it’s not related to a drug but sometimes they get a bee in their bonnet that 
they don’t want to take a drug, because they had one of their friends on it, and it wasn’t 
good, you know, caused something terrible, and you know and then they want to get off it. 
 
5.3.4.2. Medical practitioner/consumer relationship 
Many issues related to the medical practitioner/consumer relationship were highlighted in either 
the individual case study analysis, or the analysis of the consumer only data.  One issue related to 
the use of language raised in the medical practitioner data, was the issue of ‘compliance’, and the 
problems perceived by medical practitioners when consumers are ‘non-compliant’ surrounding 
prescription medications. 
  
Compliance 
Compliance and non-compliance were terms used by the medical practitioners, but were not 
found in the consumer interviews.  The term non-compliance appears to imply that the medical 
practitioner has made a recommendation for a drug therapy, and the consumer has either not 
taken the drug/s, or has not taken the drug/s using the recommended instructions (time of day, 
dosage).  The previous section showed that medical practitioner’s were concerned that providing 
detailed ADR information may cause non-compliance, that is, a consumer choosing not to take a 
medication recommended by the medical practitioner, for a reason the medical practitioner 
considered is based on misunderstanding information.  The text below describes one medical 
practitioner’s concerns over non-compliance: 
 
And the other one [issue] is just ordinary compliance.  People saying they’ll do it, but they 
don’t do it, either by forgetfulness or deliberately not wanting to take it, and you think they 
are taking it. 
 
 I don’t know how to get over the compliance factor apart from talking to people and 
hopefully they see it as being important…you don’t know whether to increase medications.  
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You assume things are being done…So you’re not sure whether the medication’s not 
working, or whether the medications not being taken. 
 
An additional issue highlighted by one medical practitioner above, is the lack of honest 
communication between the medical practitioner and the consumer.  He expressed frustration in 
attempting to determine if a drug is working or not, as he is not sure if the consumer has taken 
the drug or not. 
 
Compliance will be discussed further when examining medical practitioner/consumer decision 
models in section 6.3.2. 
 
5.3.4.3. Complexities of diagnosis 
The medical practitioner data highlighted two factors that add to the complexity of ADR 
diagnosis, whether a medication is essential or non-essential, and the factor that diagnosis is an 
inexact science. 
 
Essential versus non-essential medications 
Managing an ADR from a non-essential drug appeared to be less complex than when managing 
a drug that is essential. 
 
One medical practitioner suggested that consumer’s decision to cease the drug was a much 
simpler decision because the medication was non-essential.  This contrasts with the decision 
made by another medical practitioner, who felt the drug could be a very important medication 
for this consumer, and so the decision to cease the medication was a much more difficult 
decision given her complex history. 
 
The likelihood that a drug is associated with a medication 
As discussed in chapter two, the results of the diagnostic process usually include a likelihood that 
a drug is associated with a set of symptoms.  Causation is rarely stated.  The experts classified the 
ADR according to either, a percentage likelihood, or a level of certainty.  Two medical 
practitioners, below, talk about cases when they do not believe diagnosis is possible, and provide 
their reasoning. 
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The first medical practitioner stated that he didn’t believe he could make a diagnosis, and that 
any attempt to do so would be supposition.  He said that when there are confounding factors, a 
diagnosis is not possible: 
 
I don’t think you can, that’s the problem.  I don’t think you can decide.  We just know the 
facts that she had the sleep deprivation, she changed brands and then she had a fit.  So 
putting them all together is supposition.  And sometimes, there is more than one factor, and 
sometimes, a little bit in the presence of the other thing can go a long way, so that if she 
hadn’t had the sleep deprivation, maybe the drug change would not have made a difference. 
 
The second medical practitioner referred to another situation where diagnosis was not seen as 
possible: 
 
In a totally separate situation I have a patient at the moment, that is convinced, or the family 
are convinced that some inhaled medication caused a coma.  Now, I can find no reference 
to that anywhere in the world literature.  They could still be right.  I mean, she might be the 
only case where it has ever happened.  So you just can’t be absolutely certain, but you can 
only base what you do on the information that’s available. 
 
5.3.5. WHAT RESOURCES ARE USED BY DECISION-MAKERS? 
The information and knowledge sources used by the medical practitioners when making 
decisions surrounding ADRs were extracted from the interviews during the coding process.  
Below are three lists, one of information sources used, the second of knowledge sources used 
and finally, the content of the information sources used by the medical practitioners.   
 
The same definitions for knowledge and information are used in this section, as in the section 
describing the resources and information used by consumers. 
 
The sources of information used by the medical practitioners included: 
• test results (allergy testing, liver function, blood serum, patterns in anti-nuclear 
antibodies); 
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• drug companies; 
• ADRAC; 
• desk top prescribing software; 
• databases of medical information (natural health program and the Cochrane Library); 
• drug product information; 
• opinions of other professionals including: 
o Pharmacists; 
o referrals to medical specialists;  
o consultation with colleagues. 
• reference books including: 
o Mims (drug product information); 
o a reference book describing drug levels (when a drug will peak in the blood 
serum). 
• consumer and/or the consumer’s family; 
• the consumer’s medical history. 
 
Sources of knowledge used by the medical practitioners included: 
• medical knowledge of diseases such as: 
o symptoms known to be associated with particular diseases; 
o typical progression of a disease. 
• knowledge of drugs and drug behaviour including the temporal relationships between 
drug and onset of symptoms; 
• knowledge of ADRs (theoretical and from experience); 
• knowledge of consumer (from time spent interacting with a single consumer and many 
consumer’s over time); 
• observation of symptoms when commencing drug, and when ceasing drug; 
• knowledge from experience as a medical practitioner with other consumers; 
 
Content of information and knowledge used by the medical practitioners 
• about the consumer included: 
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o results of tests (blood serum levels, liver enzymes, allergy); 
o level of drug in consumer’s blood serum at a particular point in time; 
o medical history that was:  
• stored by their own clinic or hospital; 
• reported by another medical practitioner; 
• reported by the consumer, including a history of ADRs. 
o dates and times drugs were given and symptoms appeared; 
o individual characteristics of a particular consumer;  
o information about events surrounding commencement of symptoms conveyed 
by the consumer and/or consumer’s family; 
o likely problems associated with particular groups of consumers (eg with a 
particular condition such as pregnancy or diabetes); 
o consumer preferences for particular treatment options. 
• about drugs included: 
o ADRs known by drug companies or ADRAC; 
o ADRs documented in drug product information; 
o therapeutic levels of drugs; 
o prescription, over the counter and complementary medicines. 
• about ADRs included: 
o known ‘reactions’ associated with particular drugs. 
• about diseases included: 
o possible diagnoses for a set of symptoms; 
o possible tests available, what they will show and the time taken to receive the 
results; 
o factors that differentially diagnose two possible diseases. 
 
The sources of information available were not always complete sources of information, because 
either one party did not share all available or relevant information, or did not have the time/take 
the time to access the available information.  This issue is discussed further in the analysis of the 
individual case studies in the previous chapter, and again in the discussion of the results in the 
following chapter. 
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5.3.6. HOW DO DECISION-MAKERS CONTRIBUTE TO THE CREATION OF NEW 
ADR KNOWLEDGE? 
New drugs are constantly appearing on the market.  Each new drug has the potential to 
individually contribute to ADRs, and also to interact with other drugs currently available.  As 
explained when reviewing the literature in chapter two, before a new drug is released on the 
market, drug trials are done to determine the safety of the drug, and identify any common and 
rare ADRs.  Because this trial is done with a subset of the community, at the time the drug is 
released onto the market, all the likely ADRs from the drug are not known.  Drug surveillance 
programs, therefore, are in place to detect and then document additional ADRs associated in 
particular with new drugs on the market, and to detect any changes in drugs which may be 
related to the manufacture of the drug, or due to an interaction with a new drug. 
 
The medical practitioners were each asked if they reported the suspected ADR to ADRAC, and 
to provide a reason for their response.    
 
5.3.6.1. Reporting suspected ADRs to ADRAC 
Table 5-5 lists the case studies which include a medical practitioner perspective.  Two medical 
practitioners were involved in Kay’s case.  Of the nine medical practitioners who participated in 
the study and treated eight consumers with suspected ADRs, none of them reported the 
suspected ADR.  For three of the consumers, the medical practitioners did not believe the 
suspected ADR was likely to be an ADR and so did not report it.  For the remaining five 
consumers, three medical practitioners indicated that the ADR was well documented and well 
understood, and of the five, three indicated that the process of reporting to ADRAC is very time 
consuming and so they would only be likely to report when a suspected ADR had not previously 
been documented and/or is not well known, or in serious circumstances. 
 
The reasons the medical practitioners gave for not reporting have been discussed in detail below. 
 
5.3.6.2. Reasons for low levels of reporting 
The medical practitioners provided three key reasons for not reporting; the reporting processes 
are complex, the medical practitioner did not believe there is a high likelihood that the 
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symptoms were associated with the drug, and the suspected ADR has been previously 
documented and is well understood. 
 
Complexities of reporting 
Three medical practitioners expressed that in the past, they have reported suspected ADRs, and 
although the actual reporting process was not time consuming, it was the level of detail required 
Case 
Code 
Medical 
practitioner 
Report to 
ADRAC? 
Reason 
Toni 
C02 
C02GP1 
Dr Barns 
No Not the prescribing medical practitioner.  Thought the 
prescribing Dr may have reported it.  Also negative past 
experience with reporting. 
Kay 
C05 
C05SP1 
Dr Green 
No Unlikely to be an ADR, confounding issues 
 C05H1 
Dr Nash 
No Unlikely to be an ADR 
Helen 
C06 
C06H1 
Dr Stevens 
Not asked Dr Stevens indicated that this reaction is very common. 
Mary 
C07 
C07SP1 
Dr O’Neil 
Not asked Unlikely to be an ADR 
Tim 
C09 
C09GP1 
Dr Price 
No Unlikely to be an ADR 
Irene 
C11 
C11SP1 
Dr James 
No ADR previously well described and understood (although not 
at the dosage taken by this consumer) 
Joanna 
C13 
C13GP1 
Dr Carey 
No Probably should have reported it.  Didn’t due to being busy 
and focus on consumer management. 
Paul 
C17 
C17GP1 
Dr Lang 
No ADR previously well described and understood.  ADRAC 
processes too time consuming to report well documented 
ADRs 
Table 5-5 Reporting of suspected ADRs to ADRAC 
when staff from ADRAC followed up the suspected ADR that was the concern.  Two examples 
follow: 
 
Well, I reported one. I can remember one case I reported of a serious reaction. And it had 
to be reported, it should have been reported, it needed to be reported, but the amount of 
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detail that they wanted, it made it, you thought, gee you wouldn’t do this unless you really 
had to do it, unless it was very important, because you couldn’t answer some of it. You 
didn’t know some of it, so much detail. Sure necessary detail but some of it, it would be nice 
to have it all, but sometimes you just haven’t got that.  All we are saying is look I think this 
is a serious reaction, it was hepatitis that developed from this, but I don’t know why, you 
know, they wanted to know this and that, liver biopsy, no I haven’t done a liver biopsy.  I’m 
telling you about this, if you want to know any more, you follow it up, so it was a little bit 
demanding [laugh].  I do it for serious things.  It really has to be a serious reaction. 
 
I mean, certainly I have reported things in the past, and essentially it’s, well, it’s a bit of a 
rigmarole…The rigmarole tends to be, not the initial reporting of it, but then the follow up.  
Often they will come back with follow up questions, and then you have really got to go 
through even more of the history and all the rest of it, which I understand from their point 
of view is part of the process, but yes, it’s not so much just the initial filling in the blue form 
and sending it away. 
 
Unlikely to be an ADR 
The second reason given for not reporting an ADR was that the medical practitioner believed 
the symptoms were more likely to be associated with another condition, than with the suspected 
drug.  One medical practitioner commented that if he had been certain that the symptoms were 
associated with the suspected ADR, he would have reported it, however because there were 
confounding factors that may have contributed to the incident, the decision was not to report.   
 
Oh no, I think if I had believed it, you know, I would have reported it.  I believe there was a 
definite reaction.  I must say, I tend not to report things that I think are confounded.  If she 
hadn’t had the sleep deprivation and had had it, I’d definitely report it; but no, not with the 
other things.  This was also complicated by me not seeing her at the time.  I saw her, a 
couple of months later. 
 
ADR previously documented and well understood 
A final reason the medical practitioners said they did not report the suspected ADR, was because 
it had already previously been well documented and described.   
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I would normally report unusual reactions.  I wouldn’t normally report reactions which have 
previously been well described, and therefore, I don’t think need to be.  For instance, this is 
a recognised situation.  If someone is on lipid lowering therapy and they develop myositis,
  muscle aches and pains and their CPK level goes up, it’s a recognised complication of 
[the drug], so do you notify? Well I don’t, I just stop the drug and change things around, but 
if it’s a side effect of the drug, which is uncommon, or it may not have been described, well 
you should report those.  That way a database is built up. 
 
The medical practitioners each provided one of the above reasons for not reporting the 
suspected ADR.  The next section discusses some implications for this lack of reporting. 
 
5.3.6.3. Concerns about a lack of reporting 
In this study, none of medical practitioners reported suspected ADRs for a variety of reasons.  
As discussed when describing the processes surrounding ADR reporting, a key method in 
detecting ADRs associated with a drug that were not detected in the initial drug trials, is through 
voluntary reporting processes.  If the following ADRs that were not reported had been reported 
by either, the medical practitioner, the prescribing clinician or the consumer, the following 
contributions would have been made to new knowledge: 
 
 Hydralazine: The link between hydralazine and lupus has been well documented, but not 
at the dosage taken by the consumer. 
 Zyban: The results of this case study suggest it is unlikely there is an association between 
Zyban and Bell’s Palsy.  Zyban, however, was a new drug on the market, and Bell’s Palsy 
may have been a rare ADR associated with Zyban not yet recognized and documented.  
One method this association would be made is if cases from around Australia and the 
World were reported, which would result in a signal in the ADRAC database.  If, 
because it is unlikely, it is not reported, new signals cannot be generated. 
 
The following reactions, due to their severity, if reported, would assist ADRAC in monitoring 
the occurrence of severe reactions, and monitoring the extent to which prescribers use ‘known’ 
information when prescribing.  As well as documenting new ADRs that have not previously 
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been described, ADRAC at times notices reports of drugs that have been described, and include 
a reminder to ADR decision-makers: 
 
 Tegretol was associated with a severe reaction that looked like flu symptoms.  Has been 
previously documented, but the medical practitioner did not recognise it.  Reporting may 
have prompted ADRAC to publish a reminder in The Australian Adverse Drug Reaction 
Bulletin. 
 Celebrex was associated with a severe photosensitivity reaction that has had an impact 
on the consumer for the past two years was not reported.  Although the association 
between Celebrex and photosensitivity reactions is documented in the product 
information, the medical practitioner was not aware of this association.  Again, this may 
have indicated to ADRAC that a reminder may be useful. 
 
5.3.7. SUMMARY OF THE MEDICAL PRACTITIONER GROUP ANALYSIS 
The medical practitioner data comprised four GPs, four specialists and one hospital medical 
practitioner.  The nine medical practitioners were the medical practitioners for eight cases, as 
one case study includes two medical views.  Below is a summary of the results from this section: 
 
• The data suggest that medical practitioners are involved in decision types broader than those 
currently supported by ADR decision support.  The decision types included diagnostic 
decisions, prescribing decisions, treating decisions, decisions surrounding ADR reporting, 
information sharing and information seeking. 
 
• The terms ‘side effect’, ‘reaction’ and ‘allergy’ were used by the medical practitioners.  
Although they indicated that there is a difference between ‘side effect’ and ‘reaction’, the 
uses of the terms were similar.  ‘Allergy’ was used as a subtype of ‘reaction’.  These data also 
implied that differences in terminology between medical practitioners and consumers may 
result in misunderstandings between decision-makers. 
 
• This set of data highlighted some methods used by the medical practitioners when 
attempting to differentially diagnose between ADRs and other conditions.  In some cases, 
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the medical practitioners made novel decisions having never seen the symptoms associated 
with a drug in the past, and in other cases they appeared to have used a pattern matching 
approach when making familiar diagnostic decisions.  The specialists in the study all used a 
pattern matching diagnostic style, and most of the GPs used diagnostic processes associated 
with novel decision-making. 
• The medical practitioners were concerned that providing detailed ADR information to 
consumers may result in them either choosing not to take an essential medication due to 
their inability to weigh up the risks of taking a medication compared with the risks of not 
treating a disease.  They were also concerned that the detailed information may result in 
some consumers experiencing a ‘nocebo’, or negative placebo effect. 
 
• The term ‘compliance’ was used by medical practitioners, but was not a term used by the 
consumers.  Two issues associated with compliance and ADRs raised by the medical 
practitioners were that detailed ADR information may be associated with ‘non-compliance’, 
and ‘non-compliance’ makes it difficult for medical practitioners to determine if the drug 
therapy is not working or if the consumer is not taking the medication.   
 
• Two complexities in the diagnostic process raised were the issues of essential versus non-
essential medications, and difficulties of making inexact diagnoses, and in some cases 
diagnoses were not seen as possible. 
 
• The final result from this section were issues surrounding reporting of ADRs to ADRAC.  
In this study, none of the suspected ADRs were reported to ADRAC.  Three reasons were 
provided by the medical practitioners; the reporting processes are complex and time 
consuming, that the medical practitioner did not believe the symptoms experienced by the 
consumer were likely to be a suspected ADR, and finally that the ADR was well documented 
in the literature and well understood.  
 
5.4. Group analysis – expert view 
The expert views alone, provided significantly less insight when analysed as a group, than when 
analysed at a case level.  The key results from this chapter include insight into the definitions 
CHAPTER FIVE: RESULTS: DATA OVERVIEW AND INDIVIDUAL CASE STUDY ANALYSIS  
213 
used by ADRAC, and some factors the experts believe may have assisted in the prevention, early 
detection and/or management of ADRs. 
 
5.4.1. WHAT DO DECISION-MAKERS BELIEVE IS AN ADR? 
ADR definitions were discussed when reviewing the literature (section 2.2.1).  The experts use 
the World Health Organization (WHO) definitions.  According to WHO, the term ‘unexpected’ 
has been included to indicate the subset of ADRs of most interest to drug surveillance programs. 
 
Side effect 
Any unintended effect of a pharmaceutical product occurring at doses normally used in man 
which is related to the pharmacological properties of the drug (WHO, 2004). 
 
According to WHO the term ‘side effect’ is an old term that includes positive and negative 
unexpected effects.  It is used synonymously with the term ‘ADR’, but is less specific.  They 
recommend the term ADR is used instead as it is more specific. 
 
A discussion with one of the experts about the differences between an ‘ADR’, a ‘side effect’ and 
an ‘allergy’ revealed the understanding that an allergy is a subset of an ADR.  One complexity 
discussed was that the expert’s perspective was that a consumer may use the term ‘allergy’, when 
meaning an ‘ADR’, but a medical practitioner may hear ‘allergy’ and not understand that the 
consumer really means the generic form of an ‘ADR’. 
 
The expert said that he believes people may use the term ‘side effects’ to describe common 
ADRs that are generally  well understood and well documented.  He said he believes that Type A 
reactions, which are dose related, are commonly referred to as side effects. 
 
5.4.2. FACTORS THAT WOULD ASSIST IN THE PREVENTION, DETECTION OR 
MANAGEMENT OF ADRS 
Table 5-6 lists each of the case studies, and summarises whether the experts believe the 
suspected ADR fits the WHO definition of an ADR, whether prevention was possible and 
whether earlier detection was possible. Reasoning and complexities have also been included in 
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this table.  In most cases, using the advantage of hindsight, the experts believe that something 
could have been done to either prevent or detect each of these suspected ADRs earlier. 
 
5.4.3. SUMMARY OF THE EXPERT GROUP ANALYSIS 
The analysis of the expert questionnaires provided results that relate to the use of terminology 
surrounding ADRs, factors that occurred in the case studies that may have resulted in a 
preventable ADR, or delayed detection of an ADR, and the complexities that make ADR 
diagnosis difficult. 
 
The experts had the advantages of hindsight, and of viewing both the consumer and medical 
data for a case.  Neither the consumers nor the medical practitioners had access to all of the 
information.  The results from this section, therefore, cannot reasonably state what each party 
should have done, all they can suggest is that certain behaviours may have contributed to the 
occurrence of, or delayed detection of an ADR, but with the acknowledgement that the 
decision-makers at the time did not have access to the information available to the experts. 
 
The experts used the WHO definitions for ‘reaction’ and ‘side effect’, which have been re-
iterated in this section.  Implications of each participant group using these terms differently will 
be discussed in the following chapter. 
 
The expert data provided insight into factors that may have prevented or detected suspected 
ADRs in these case studies.  The factors can be summarised as follows: 
 
• Awareness of drugs which are contraindicated for particular groups of consumers. 
• Awareness by the consumer and/or medical practitioner that a possible diagnosis for a 
set of newly presenting symptoms is an ADR.   
• Providing consumers with warnings about suspected ADRs and/or written information 
about known risks of medications. 
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5.5. Combined methods case study analysis 
There are several results which were not able to be satisfactorily presented by either viewing 
them at the case study level, or at the group level.  When they were discussed using the group 
and individual case study results together, they provided a meaningful result.  The two sets of 
results in this section include a discussion of how consumers contribute to diagnostic decision-
making, and medical practitioner/consumer decision-making models. 
 
5.5.1. HOW ARE ADR DECISIONS MADE? 
Understanding how ADR decisions are currently made can assist in understanding why ADRs 
continue to occur, and determining gaps that, if filled, may assist in the prevention, detection or 
management of ADRs.  The consumer interviews provided insight into the information and 
knowledge sources used in order to make their ADR decisions, and also some understanding of 
the difference between traditional medical diagnostic decision-making, and ADR diagnostic 
decision-making.  This consumer group information, however, is more meaningful when in the 
context of the expert and medical practitioners is included, and it is therefore included in this 
section of analysis. 
 
5.5.1.1. Differential diagnosis - Consumers 
Past literature supports the notion that consumers are becoming more involved in medical 
treatment decisions (as discussed in chapter two) however diagnostic medical decision-making, is 
generally considered a task for medically trained personnel.  Some of the consumers in this 
study, believe they have been involved in diagnostic decision-making, as previously discussed.  It 
is interesting to consider, therefore, whether diagnostic decision-making in the area of ADRs is 
different to traditional diagnostic decision-making. 
 
Table 5-7, includes the consumers who believe that s/he was the person who initially suspected 
that the drug was associated with the symptoms.  In each of the cases, two experts provided an 
opinion about whether they believe the symptoms were associated with the suspected drug.  In 
several of these interviews, the consumer described the reasoning behind their suspicion.  
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 ADR? Prevention? Earlier
detection? 
Suggestions to prevent or detect 
ADR earlier 
Complexities in each case 
 E1   E2 E3 E1 E2 E3 E1 E2 E3  
Toni  
C02 
Y  N    N N    Y N  If consumer had sought advice earlier. 
If consumer had been warned that a 
“flu like virus” can be an ADR.   
If medical practitioner had recognised 
possible ADR earlier and done tests 
to support this. 
Symptoms of suspected ADR very similar 
to symptoms of influenza virus.   
Possible that consumer had virus AND 
ADR. 
Julie  
C04 
Y  Y        Perhaps treat pruritis with a different 
anti-histamine 
Provide consumer with ADR 
information 
Chronic pain very difficult to manage 
Often can’t avoid ADRs 
Kay  
C05 
N  N         General suggestions for prevention of 
epilepsy included avoidance of alcohol, 
and sleep deprivation. 
Helen  
C06 
Y  Y    Y Y    N N  Not to take drug prescribed for 
someone else 
 
Mary  
C07 
N   Y    N   Y Earlier consideration that the 
symptoms may have been caused by 
the tamoxifen 
Another possible diagnosis that also fits 
the symptoms 
Belinda  
C08 
Y  Y  Not
sure 
 N   Not
sure 
Y  Medical staff could be more aware of 
possible complications with Beta 
Blockers 
Likely to be an interaction, but unsure of 
which drugs were interacting due to lack 
of medical information 
Tim  
C09 
N  N         Difficult to determine the effects of the 
nicotine withdrawal compared with the 
effects of the Zyban. 
Edward  
C10 
Y  Y    Y N    N N  Vomiting could have been treated 
Possible hospitalisation for consumer 
of this age. 
Second ADR could have been 
avoided with recognition of first 
ADR. 
Second bout of vomiting significantly 
more severe that would be expected from 
ADR alone.  Suspect another 
complication. 
Irene Y  Y    N N    Y Y  ADR well documented and Very generalised symptoms may have 
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C11 understood 
Consumer history of ADRs known to 
be “sensitive to many drugs”. 
Earlier testing for lupus or cessation 
of drug. 
made detection complex 
James  
C12 
Y  Y    N N    N N  Multiple instances of the reaction 
assisted with detection 
 
Joanna  
C13 
Y  Y    Y Y    Y N  NSAIDs should be avoided with 
Joanna’s history of anaphylactic 
reaction to nuts. 
Used physical therapies rather than 
drug therapies 
Seek medical assistance earlier 
 
Bob  
C14 
Y  N   N    N     
Kerry  
C15 
Y  Y    N N    N N   This experience has reinforced her fear of 
surgery and anaesthesia which may have 
the effect of further limiting future 
therapeutic options. 
Robyn  
C16 
Y    Y N    N N  N  “…the specialist was kept appraised but 
elected to continue this therapy 
notwithstanding the symptoms reported 
by the patient.”  This was because he 
believed this medication may be useful 
once ADR settled. 
Paul  
C17 
Y  Y    N N    Y Y  “…if the patient had been better 
warned, the association would have 
been more quickly recognised and 
management (by stopping the drug) 
would have occurred much more 
quickly.” 
Better communication between 
medical practitioner and consumer. 
The symptoms were general, and could 
have been attributed to a number of 
factors. 
Significant difference between the 
consumer’s perception of the severity and 
the medical practitioner’s.  
Table 5-6 Expert opinion on the prevention and detection of suspected ADRs
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Paul and Joanna both have backgrounds in a medically related field and so will not be included 
in this section, as the aim is to understand about how diagnostic decisions have been made by 
non-medical personnel in the area of ADRs.  The remaining consumers in Table 5-7, suspected a 
relationship between the drug and symptoms without medical training.   
 
Temporal relationship between drug onset and symptoms 
In six of the eight cases in Table 5-7 there was a clear relationship between the time the 
consumer took the drug and the onset of the symptoms.   
 
Tim had headaches and vomiting that were known reactions to Zyban, and when he ceased the 
drug, the headaches and vomiting stopped.  It was at this time that he also developed Bell’s 
Palsy.  Due to the temporal relationship between the commencement of the drug and the onset 
of symptoms, Tim concluded that there was a relationship between the two: 
 
I’m certain within my mind that there’s a connection simply because it was the only thing 
that had changed and the sicknesses that I’d had had only been when I was on Zyban and 
when I stopped Zyban I stopped getting headaches and I stopped throwing up and 
everything else that was happening. 
 
It is useful to note at this stage, that Tim’s medical practitioner believes the Bell’s Palsy was 
related to a virus, and the headaches and vomiting experienced by Tim were partially related to 
the drug, but coincidently partially related to a virus; an opinion which is supported by the 
experts. 
 
Edward had a four hour gap between commencing the drug, and the onset of symptoms.  This 
relationship was confirmed in Edward’s case, as he took a second dose after the initial symptoms 
had passed, and experienced a similar reaction.  Medical practitioners refer to this as a 
rechallenge: 
 
I took one tablet…About four hours after I took it I was vomiting and then I went on from 
there dry reaching for about four hours. 
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Code Drug Who first suspected 
ADR? 
ADRAC view of whether the 
symptoms are likely to be 
associated with an ADR. 
Temp 
Relationship
Multiple 
instances
Past 
ADRs
Process of 
elimination 
Tim  
C09 
Zyban      consumer Very Low x x
Edward 
C10 
Efexor consumer High (suspect ADR in conjunction 
with another condition) 
x    x x
Irene 
C11 
hydralazine  consumer, confirmed
by medical practitioner 
Very high   x x 
James  
C12 
Panadeine 
Forte 
consumer and wife High x x  x 
Joanna 
C13 
Celebrex consumer confirmed by 
GP 
Very high x  x x 
Bob  
C14 
Vioxx consumer, wife and 
daughter 
Very Low/ 
Very High 
    x x
Robyn  
C16 
Sabril consumer and husband 
confirmed by medical 
practitioner 
Very high x  x x 
Paul  
C17 
Lipitor       consumer Very high x x
Table 5-7 Consumer diagnostic decision-making
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I had rung the doctor in between and I said, “Will I call the [hospital]”, he said “No it might 
be the drug”.  I tried Stemetil suppository and it had no effect whatsoever and he said, I 
rang him the next day and said, “I seem to have got over it” and he said “Right well leave it 
for 48 hours and try another one.  Sometimes you get, only get the one reaction”. That was 
the second disaster.  The second one lasted a fortnight; bouts of vomiting and reaching 
went on for nearly a fortnight. 
 
Edward’s medical practitioner did not participate in the study, however the experts stated that 
they believe there is a high likelihood that the symptoms were associated with the drug, however 
they said that the symptoms were more severe than would be expected for an ADR, and suspect 
that there may have been another complication not identified by Edward. 
 
Multiple instances of a drug associated with a set of symptoms 
James’ case differed slightly from Tim and Edward’s cases.  The first time he experienced the 
symptoms, there was more than one factor involved, multiple drugs including anaesthetic drugs.  
It was not until a situation occurred when the symptoms were, again, temporally related to the 
drug, in the absence of any other likely cause for the symptoms, that James and his wife 
suspected the drug.  They used their observation of the temporal relationship, but also memory 
of similar symptoms in a past situation: 
   
I thought I’ve had these symptoms before and I thought back with my wife who’s fairly 
methodical too and worked out that’s what it was so because the symptoms were the same 
and it’s only when I took it so right that’s why I’ve been ill after those operations, it wasn’t 
the general anaesthetic it was the Panadeine Forte so I must be allergic to Codeine. 
 
Bob experienced the same symptoms several times.  He initially came up with a hypothesis that 
the rash was associated with the garden, and then when he experienced the same set of 
symptoms, in a different context, he began to suspect a photosensitivity reaction to the sun, 
which lead him to suspecting the drug:   
 
And I thought, oh…I just had a scratch and I thought, it’s something in the grass… a 
reaction….Like, after work in the garden, I was going down the garden of a night to water, 
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then I started on the legs, you know, which I sort of blamed just being in the garden.  But 
since then, it’s definitely the sun. 
 
In the car, the sun coming through the window.  That’s happened several times.  Well, even 
one day, I left work to pay a bill or I’m not sure now, but to go somewhere.  It might have 
been the water board or something like that.  By the time I got there I was scratching all 
around here (indicating leg).  It was the sun just through the windscreen. 
 
The temporal relationship was less clear, as Bob had ceased the drug but continued to 
experience the symptoms. As can be seen from Joanna’s case a photosensitivity reaction can 
continue for several years after the drug has been ceased. 
 
It is interesting to note that in this case, the link was made between the sun and the rash, 
however, no clear link was made between the drug and the photosensitivity.  The experts 
differed in their opinion.  One expert believed strongly that the symptoms were associated with 
the drug, and the second expert believed strongly that the symptoms were not associated with 
the drug.   
 
Edward’s case was clearer, because he took the medication, experienced a suspected reaction, 
took the medication a second time, and experienced the same reaction a second time, clearly 
indicating a relationship between the drug and symptoms. 
 
Past experience with suspected ADRs 
In Robyn’s case, as a person with severe epilepsy, she had past experience with reactions to 
medications, and so when she experienced what appeared to be a severe epileptic fit, similar to 
psychosis, and due to the close temporal relationship between the commencement of the drug 
and the onset of the symptoms in the absence of any other drug or environmental changes, she 
suspected the drug.  This suspicion, again, was confirmed by the experts. 
 
Irene’s case was significantly more complex, due to the large number of drugs she takes 
regularly.  Irene, however, has experienced suspected reactions to medications many times, and 
maintains detailed diaries of medical consultations, drugs, drug dosages and symptoms.  She 
appeared to use her awareness that drugs can be associated with symptoms, the Internet to 
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search for a link between the drug and the symptoms, and again the temporal relationship 
between the drug commencement and onset of symptoms, and very careful observation and 
recording of those observations in order to detect the link. 
 
Irene’s specialist confirmed that there is a high likelihood that the drug was associated with the 
symptoms.  The interesting thing about this case was that Irene used observation, logic and 
reasoning to suspect the ADR, accessing medical information from the Internet to assist her, 
whereas the medical practitioner said that he did not suspect the ADR because the symptoms 
are not usually associated with the drug at doses so low.  Irene was aware that she sometimes 
requires a lower than recommended dosage based on past experience and knowledge of herself, 
information not used by the medical practitioner. 
 
Process of elimination 
In each of these cases, an analytical process of eliminating other possible diagnoses occurred, 
leaving the suspected ADR as the final diagnosis in the minds of the consumers.  For Tim, 
Edward, Joanna and Robyn, there had been no other significant change to their life style.  In 
James case, the first time the reaction occurred there were other factors, such as surgery and 
anaesthetic drugs, but in the second case, these confounding factors were not present.  In Paul 
and Irene’s case, there was a process of considering alternative, and gradually eliminating them, 
until the suspicion of the drug was one of the few possibilities left.  Both located information to 
support this growing hypothesis. 
 
Skills used by consumers in the detection of suspected ADRs in the absence of medical 
knowledge 
The skills used by these consumers to make these diagnostic decisions appear one or more of 
the following: 
 
 a clear temporal relationship between the commencement of the drug and the onset of 
symptoms, the absence of any other possible cause such as another disease or other 
medications; 
 a recognition from past experience;  
 multiple experiences of the same drug/symptom relationship and; 
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 elimination of other possible diagnoses, leaving a suspected ADR as the final hypothesis. 
 
Of the 15 cases, there were three where the experts and medical practitioners agreed that there 
was another diagnosis that was more likely to be associated with the newly presenting symptoms, 
than a drug.  In these three cases, the knowledge used by the experts and medical practitioners 
was a broad knowledge of disease, information not available to the consumers.  In the remainder 
of the cases, when the consumer was the first to suspect the ADR, the skills used by the 
consumer was sufficient to detect a suspected ADR.  This illustrates the role of the consumer in 
the diagnostic decision-making, and the importance of making these diagnoses in conjunction 
with a medical practitioner.  
 
5.5.1.2. Medical practitioner/consumer decision-making models 
Medical practitioner/consumer decision-making models were discussed in the chapter two.  To 
re-iterate,  (Scott & Lenert, 2000) refer to four models of medical practitioner/consumer 
decision-making.  Paternalistic, Informed, Collaborative or Deliberative models which originally 
were described by (Emanuel & Emanuel, 1992).  Paternalistic decision-making is defined as a 
model where by the clinician has complete authority to make decisions on behalf of the 
consumer.  Informed decision-making is defined as a model where the consumer makes 
completely autonomous decisions.  Collaborative decision-making is defined as a model where 
the consumer relies on the health provider to provide information, but also to facilitate the 
decision-making processes.  The final model is described as Deliberative.  In this model, the 
health provider attempts to convince the consumer of the best outcome for their health, based 
on what the medical practitioner believes is in the consumer’s best interests.   
 
Each of the medical practitioners in the study have been classified into one of Emanuel and 
Emanuel’s classifications in Table 5-8. 
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Description of the decision-making model Emanuel and 
Emanuel’s model 
(1992) 
“Most people still say “what do you think?”  “I’ll go with your thoughts”  And 
then you have to say “well if it was me, and you’ve done all these right things, and 
it’s still there, I’d treat it.”  So more people are like that.” 
“…sometimes you know you are in for a real fight about what you are going to 
do either to convince them to take it, or to convince them that they don’t need to 
take it. And that’s difficult too. And talking people out of it, when they think they 
need it.” 
Combination of 
collaborative and 
deliberative. 
“[the model used included] a bit of both (medical practitioner and consumer) [the 
consumer] wanted to get to the bottom of why she had experienced the grand 
mal.  She initiated going back onto the [the drug], and initiated checking her 
blood levels.  She was concerned about losing her licence. 
Combination of 
informed and 
collaborative 
“[The medical practitioner’s] normal style is to make a suggestion and for the 
patient to agree with it.  He said he hopes he involves the patient in the decision-
making process.  He said it is important to get the patient involved as it impacts 
on compliance.  In situations such as Cholesterol, the patient does not feel sick, 
they have to trust that if Cholesterol is not controlled now, there could be a major 
impact ten years down the track.  It is particularly important to have patient 
compliance with these medications.” 
Collaborative, 
moving towards the 
deliberative model 
“[One medical practitioner] feels that he is an advisor only.  He described his role 
as to provide a service, and to provide guidance in decision-making, but that the 
consumer is the decision-maker ultimately.” 
Informed 
“Yes, it’s interesting actually, my [experience] is that often the patients have very 
firm views about it [the relationship between a drug and an ADR], and it’s often 
the patients who make the decision rather than the medical practitioner.” 
Medical 
practitioner’s view 
that consumers 
often use the 
Informative model.  
Unclear whether the 
medical practitioner 
agrees with this. 
“And she just made a decision that she felt that the benefits of being on the 
[drug], weren’t good enough for her to be able to keep on with it.  So she was 
aware of that, and so she decided to stop taking the drug, which she did.  She 
then went on to some other forms of homeopathy, to help her with her 
symptoms which she didn’t fill me in on.” 
“…she had already made up her mind because she stopped it the day before she 
saw me, so she had already made up her mind to get off the [drug], and therefore 
was not open to any negotiation really when she came in [laugh].  I think when 
someone stops a drug before they see a medical practitioner, it usually means 
they’re serious about it. [laugh].  So no matter what I was going to say.” 
“Well, look if it was her only treatment, for instance if she hadn’t had 
chemotherapy, I would be wanting to change her onto something else” 
Consumer using 
Informed model, 
Medical practitioner 
preferring the 
paternalistic or 
deliberative model. 
“I think the patient presented with the symptoms and the medical practitioner 
quite reasonably concluded it might be the medications.  I can’t be sure that [the 
consumer] didn’t come out and say “I’ve got joint pains and skin rash and I think 
it’s my [drug]”, but she might have.  But [unintelligible] patients don’t do that, 
patients tend to come out and say this is what’s wrong with me, and it’s usually a 
drug they’ve been taking for quite some time, and it’s only in retrospect that it’s 
realised it may be medication related.” 
Paternalistic 
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“…it gave us more options of things to try,”  [The medical practitioner’s] use of 
“us” referring to himself and [the consumer], implies a partnership. 
“I certainly wouldn’t have been giving her, because I know she likes to do things 
in as natural a way as possible, so I would not have been giving her an anti-
inflammatory drug…in the first instance.  You know I would have been 
suggesting she tried other means” 
Collaborative as 
defined by us rather 
than Emanuel and 
Emanuel. 
Table 5-8 Medical practitioner/consumer decision models based on Emanuel and Emanuel’s 
(1992) model  
 
Expansion of the medical practitioner/consumer decision-making model 
Further analysis of the consumers and medical practitioner’s decisions revealed seven 
classifications of medical practitioner/consumer decision models, expanding Emanuel and 
Emanuel’s (1992) model.  Some of the models suggested by Emanuel and Emanuel (1992) have 
been split into two models in the classifications listed below:   
 
• Consumer decision-making with no consultation with medical practitioner. 
• Consumer decision-making informing the medical practitioner of decisions. 
• Consumer decision-making and the medical practitioner provides advice. 
• Consumer and medical practitioners as partners in decision-making. 
• Medical practitioner decision-making considering consumer preferences. 
• Medical practitioner decision-making informing or convincing the consumer of the 
decisions. 
• Medical practitioner decision-making with no consultation with consumer. 
 
These have been described below using examples of decisions for illustration. 
Consumer decision-making with no consultation with medical practitioner 
This model includes decisions made by the consumer only.  Once the consumer made the 
decision, it was not discussed with a medical practitioner for verification.  This model, in 
combination with the following model is equivalent to Emanuel and Emanuel’s (1992) Informed 
model. 
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James reasoned that he does not see his GP very often, and he is confident of his decision that 
the symptoms were related to the Panadeine Forte and Tramal.  The experts agreed with his 
decision.  
 
Kay made the decision, with the pharmacist to change brands of the drug sodium valproate, 
without consulting or informing her medical practitioner.  It appears that she was not aware that 
monitoring this change may be important. 
 
Consumer decision-making and informed medical practitioner of decisions 
This model includes decisions where the consumer made a decision, and then informed the 
medical practitioner once the decision had been made.  The decision was made with no 
consultation with a medical practitioner. This model, in combination with the previous model, is 
equivalent to Emanuel and Emanuel’s (1992) Informed model. 
 
Dr O’Neil said that Mary came to his consulting rooms having already made the decision to 
cease tamoxifen.  She had ceased the drug the day before.  She reported that she discussed it 
with him.  From Dr O’Neil’s perspective, Mary had made the decision independently, and 
informed him. 
 
Another example of a consumer making a decision and informing the medical practitioner is 
when James informed the hospital that he had a reaction to codeine, but did not discuss with 
them the process of deciding whether he had or had not experienced an ADR. 
 
Consumer decision-making and medical practitioner provide advice 
In this model the medical practitioner acts as a consultant to the consumer providing 
information, but the consumer makes the final decision.  This model is equivalent to Emanuel 
and Emanuel’s (1992) Collaborative model. 
 
In Paul’s case, Dr Kent provided information about possible reasons for the set of symptoms 
Paul was experiencing.  Paul was the person to make the decision to cease the Lipitor.  Dr Kent 
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said that his usual model is a consultative model where he provides information to the 
consumer, but the consumer can make their own medical decisions. 
 
Consumer and medical practitioners partners in decision-making 
In this model, the consumer and medical practitioner work together in partnership, in a similar 
way to colleagues. This model does not have an equivalent model in Emanuel and Emanuel’s 
(1992) system. 
 
Dr Green said that he felt that in the hospital the decision-making model was of shared decision-
making.  He illustrated this point by referring to Kay’s request for specific tests and asked to be 
put back on the Epilim brand of sodium valproate. 
 
Julie was given a range of medications she could use to manage her pain.  She had broad 
guidelines about which medication to use, when and the dosage.  As long as she worked within 
these guidelines, she has a high level of discretion about the use of drugs.  In this case, Julie was 
encouraged to make decisions about when to take certain medications, and the dosage she 
required at the time.  Julie also said that when her GP was unsure about how to proceed, he 
would consult the specialist.  It appears the team of medical practitioners were partners with 
Julie in managing her condition. 
 
Joanna and Dr Carey worked together in an attempt to manage the suspected ADR.  
Throughout the interview, Dr Carey referred to “we”, Joanna and himself when discussing the 
management strategies that were trialled. 
 
Medical practitioner decision-making considering consumer preferences 
In this model, the medical practitioner makes the decisions based on the consumer’s preferences.  
This model is the equivalent of Emanuel and Emanuel’s (1992) Paternalistic model.  There are 
no examples of this type of decision-making in the data. 
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Medical practitioner decision-making informing or convincing the consumer of the decisions 
In this model, the medical practitioner makes the decisions and either informs the consumer of 
the decision, or convinces him/her of the decision that has been made.  This model is the 
equivalent of Emanuel and Emanuel’s (1992) Deliberative model.   
 
In Edward’s case the medical practitioner provided reasoning as to why Edward could safely try 
the drug a second time, however the decision to take a second dose appeared to be the medical 
practitioner’s decision, and he convinced Edward of his reasoning. 
 
Another decision made in this style was the decision to commence the Efexor.  According to 
Edward he did not feel he needed medication for depression however the medical practitioner 
made the decision and persuaded Edward to try the medication. 
 
Kay’s medical practitioner made the decision for Kay not to drive for a month following her 
epileptic seizure.  This however was a medical decision guided by a law; a decision where the 
medical practitioner had no discretionary power beyond deciding if there was a likely cause for 
the epilepsy.  In this case Kay was informed rather than consulted. 
 
Medical practitioner decision-making with no consultation with consumer  
In this model, the medical practitioner makes decisions with no consultation with the consumer.  
This is the equivalent of Emanuel and Emanuel’s (1992) Paternalistic model. 
 
In Kerry’s case, she was in hospital for a surgical procedure.  Decisions about the surgical 
procedure and which drugs would be used were made without discussion with Kaye, or 
informing her pre or post surgery.  This is possibly a typical scenario in surgical cases. The 
complexity in Kerry’s case was that due to her history of problems with anaesthetic drugs, she 
wanted to have a discussion with the anaesthetist prior to surgery, but due to the time 
constraints, was unable to do so. 
 
The above examples suggest that the range of models suggested by Emanuel and Emanuel’s 
(1992) can be expanded to include more models. 
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5.5.2. HOW DO DECISION-MAKERS CONTRIBUTE TO THE CREATION OF NEW 
KNOWLEDGE?  
5.5.2.1. Individual decision-maker learning 
New ADR knowledge can be generated at a national and international level.  New knowledge 
and/or understanding can also occur at an individual decision-maker level.  The analysis of the 
medical practitioner data suggested some problems surrounding individual learning. 
 
Lack of feedback to prescribing and medical practitioners 
In several cases, the clinician prescribing the drug was a different medical practitioner to the 
clinician treating the consumer.   
 
In Irene’s case, several GPs were involved in Irene’s medical management while she was 
experiencing the reaction to hydralazine, but did not associate the symptoms with the drug.  In 
this case the specialist prescribed the drug, but the consumer sought treatment from her GP 
rather than the prescribing medical practitioner.  Once a diagnosis had been made by the 
specialist, it is not clear whether the GPs received feedback from this specialist. 
 
In Joanna’s case, she did not report her suspected reaction back to the prescribing clinician, and 
again, it is not clear if the medical practitioner sent a report to the prescriber or not. 
 
James and Helen both experienced their suspected ADRs following surgery.  Neither of them 
had a follow up visit with the surgeon or with a GP.  Because they don’t regularly need to visit a 
GP, they did not have an opportunity to report the suspected ADR back to the prescriber. 
 
At the time of interview, Paul had not reported back to Dr Kent that he had ceased the Lipitor.  
He also had not reported that he had commenced an alternative non-drug treatment, and that he 
chose not to follow up on the referral to the orthopaedic surgeon.   
 
In the preliminary background studies (O'Brien & Yearwood, 2002), an issue raised by the GPs 
in the GP forum, was that they do not perceive that they see ADRs frequently.  In each of these 
cases, a prescribing or treating medical practitioner did not, or may not have received feedback 
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about the suspected ADR, affecting both their perception of the frequency of suspected ADRs, 
and their individual learning about the effects of drugs on particular individuals. 
 
Lack of feedback to ADRAC impacts individuals learning 
Another impact on individual learning is the lack of feedback to ADRAC.   
 
Dr Carey believed he ‘should’ have reported the case to ADRAC. “…it is pretty slack not to 
report it”.  He went on, however to discuss his priorities, and the issues with the ADRAC 
reporting process as reasons for not reporting the suspected reaction.  Given that this was a 
reaction that was unfamiliar to Dr Carey, it is likely that it will be unfamiliar to other GPs also.  
By not reporting the reaction, this information is not conveyed to the TGA to add to the 
national and international database, but also not highlighted for other individual GPs to assist in 
their learning. 
 
5.5.3. SUMMARY OF COMBINED GROUP ANALYSIS 
The combined group analysis section produced results that could be seen when viewing the 
individual case study and group analysis results together.  This section revealed strategies 
consumers use when making diagnostic decisions surrounding ADRs, an expansion of Emanuel 
and Emanuel’s (1992) medical practitioner/consumer decision-making model, and issues 
surrounding ADR reporting that impact on individual decision-maker learning. 
 
5.6.   Conclusion 
This chapter has described results from the group analysis of the consumers, medical 
practitioners, and experts, and results from combining the group data with the individual case 
study data.  The consumer analysis included analysis of the 15 consumer interviews plus the 
single interview of Joan’s husband. The medical practitioner analysis included analysis of 
interviews from nine medical practitioners from eight of the case studies. The expert analysis 
included analysis of 30 questionnaires, two per case study.  The combined group data analysis 
revealed results that emerged only when combining each set of data. 
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The results from these three levels of analysis, the individual case study analysis, the group 
analysis and the combined analysis, have been summarised below: 
 
• These data suggest that consumers and medical practitioners make decisions surrounding 
ADRs, and the decision types made by each include diagnostic decisions, treatment 
decisions, information sharing and information seeking decisions.  The medical 
practitioners also made decisions about prescribing and ADR reporting; two decision 
types not made by the consumers. 
 
• The term ‘side effect’, ‘reaction’ and ‘allergy’ were terms used by the consumers, medical 
practitioners and experts.  The medical practitioners also used the terms ‘significant 
reaction’ and ‘significant side effect’, terms not used by the consumers.  The experts used 
the terminology defined by the World Health Organization (WHO).  An additional term 
used by the experts is ‘unexpected ADR’.  Each group used these terms differently, and 
the difference appeared to result in miscommunication in some cases between the 
consumer and medical practitioner. 
 
• The consumers and medical practitioners each used differential diagnostic strategies to 
determine if the newly presenting symptoms were associated with a disease or a drug.  
The medical practitioners appeared to either diagnose an ADR by using past experience 
and a pattern matching style of diagnosis, or hypothesising a number of possible 
diagnoses, and gathering information to strengthen or eliminate each hypothesis.  The 
medical practitioners appeared to use their knowledge of medicine and disease to 
determine which disease/s was most likely to be associated with the set of presenting 
symptoms.   The consumers used a different set of strategies to detect a suspected ADR, 
such as using the temporal relationship between drug onset and symptoms, multiple 
instances of a drug associated with a set of symptoms, past experience with ADRs and 
process of elimination. 
 
• The consumers expressed that they would like more information about potential ADRs 
known to be associated with medications, and about the pre-existing disease.  The 
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medical practitioners expressed a general concern that providing detailed ADR 
information to consumers may result in consumers either choosing not to take an 
essential medication due to their inability to weigh up the risks of taking a medication 
compared with the risks of not treating a disease.  The experts said that for some cases, 
providing the consumers with warnings about suspected ADRs and/or written 
information about known risks of medications may have resulted in earlier detection of 
the ADRs. 
 
• None of the suspected ADRs in this study were reported to ADRAC.  The reasons 
provided by the medical practitioners included the reporting processes are complex and 
time consuming, the medical practitioner did not believe the symptoms experienced by 
the consumer were likely to be a suspected ADR, and that the ADR was well 
documented in the literature and well understood.  In many cases prescribers and/or 
medical practitioners did not receive feedback from the consumer or medical practitioner 
once a diagnosis had been made, impacting on individual learning. 
 
• Emanuel and Emanuel (1992) describe four medical practitioner/consumer decision 
models; paternalistic, collaborative, deliberative and informed.  The data from this study 
have expanded on this model, and suggests the seven decision-making models, which 
will be discussed in detail in 6.3.2: 
 
o Consumer decision-making with no consultation with medical practitioner. 
o Consumer decision-making and informed medical practitioner of decisions. 
o Consumer decision-making and medical practitioner provide advice. 
o Consumer and medical practitioners as partners in decision-making. 
o Medical practitioner decision-making considering consumer preferences. 
o Medical practitioner decision-making informing or convincing the consumer of 
the decisions. 
o Medical practitioner decision-making with no consultation with consumer. 
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Each of these results will be discussed in the following chapter in relation to the pre-existing 
literature and the implications for consumers, medical practitioners and experts when attempting 
to prevent, detect and manage ADRs; and concepts to consider regarding decision support. 
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 CHAPTER SIX 
6. Discussion 
6.1. Introduction 
The previous two chapters described the results that emerged from three forms of analysis: 
analysis of the individual case studies; the groups of data; and the combined analysis.  These 
chapters were structured according to the research questions.  This chapter moves away from 
this structure so the results can be integrated into emerging theory that crosses multiple research 
questions. 
 
Concepts are the building blocks of theory.  The work of this thesis commenced with an 
understanding of some concepts within the ADR domain, which were described in chapter two.   
 
This chapter begins with a discussion of the concepts in the ADR decision domain (section 6.2) 
which includes: concepts that were defined within this work to accommodate multiple 
perspectives; concepts with multiple definitions that were informed by the data; and concepts 
with single definitions that have been applied to a domain with multiple perspectives.   This is 
then followed by a discussion of the contributions this work has made to theory (section 6.3).  
These contributions include: the use of multiple perspectives and triangulation to inform systems 
design; medical practitioner/consumer decision models; ADR differential diagnosis; the role of 
the consumer in ADR decision-making; problems with generating new ADR knowledge; and 
ADR decision-making based on partial knowledge as a contributor to the incidence of ADRs.  
The final section of this chapter, section 6.4 is a discussion of the limitations of this work. 
 
6.2. Concepts in the ADR decision domain 
The concepts from the ADR domain, which were described in chapter two, were defined from a 
medical perspective.  An example is the concept of an ADR which was defined according to the 
World Health Organization (WHO) definition.   
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The positivist theoretical perspective that has underpinned past work within this domain has the 
focus of finding a single understanding of core concepts.  The use of a symbolic interactionist 
theoretical framework, not only permits, but expects any concept or symbol within a specific 
domain to have different meanings for different groups.   
 
The methodology used within this work, and in particular the collection of three perspectives of 
a single instance of an ADR has provided additional insight into many of these concepts due to 
this addition of multiple views of each concept.  A contribution of this work, therefore, is an 
expansion in understanding of some of the core concepts in this domain, and in particular the 
move from a single understanding to multiple understandings of some concepts.   
 
Each of the primary concepts used within the ADR decision domain has been listed in one of 
the four tables below, including a brief definition. The concepts have been divided into four 
groups, which are represented by four tables.  The first table (Table 6-1)  includes the actors or 
decision-makers within the ADR domain.  This group of concepts were discussed in chapter two 
and so will not be discussed further in this section.  The second table (Table 6-2) includes 
concepts that have been defined by the study to accommodate multiple perspectives.  The third 
table (Table 6-3) includes concepts that have been defined by the preliminary background work 
and the literature.  These concepts began with a single meaning but have been informed by this 
work, providing a new understanding based on the multiple views obtained within the data.  The 
fourth and final group (Table 6-4) also includes concepts that have been defined by the 
preliminary background work and the literature that began with a single meaning, but when used 
across multiple groups with this assumed single meaning appear to add to miscommunication 
between decision-makers.  A discussion of the contribution this work has made to the 
understanding of these groups of ADR decision domain concepts follows these tables. 
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Actors or decision-makers 
in the ADR domain 
Brief definition 
Consumer The purchaser and/or recipient of medical services  
Medical practitioner A ‘doctor’ who has been consulted by a consumer for a medical 
condition.  Includes a GP, specialist, or medical practitioner working 
in a hospital setting.  
Expert A member of the Australian adverse drug reaction advisory committee 
(ADRAC) who has agreed to participate in this study as an ADR 
expert. 
Pharmacist Within the context of this work, a pharmacist refers to a community 
pharmacist who has been consulted by a consumer. 
Table 6-1 Actors or decision-makers in the ADR domain 
 
Concepts that 
accommodate multiple 
perspectives 
Brief definition 
Suspected ADR A set of symptoms that any decision-maker believes may be associated 
with a therapeutic drug 
Table 6-2 Concepts that were defined to accommodate multiple perspectives 
 
Concepts that have been 
informed by the data that 
have multiple definitions 
Brief definition 
Adverse drug reaction 
(ADR) 
Refer to section 6.2.2.1 for a detailed discussion of this concept 
Side effect Refer to section 6.2.2.1 for a detailed discussion of this concept 
Allergy Refer to section 6.2.2.1 for a detailed discussion of this concept 
ADR decisions or decision 
types 
Refer to section 6.2.2.3 for a detailed discussion of this concept 
ADR decision-maker Refer to section 6.2.2.2 for a detailed discussion of this concept 
Diagnosis The most likely explanation for a set of symptoms.  This concept will 
be defined further when discussed in the section 6.3.3 on emerging 
theory of ADR diagnosis. 
Differential diagnosis Determining which of two or more possible explanations for a set of 
symptoms is most likely. This concept will be defined further when 
discussed in the section 6.3.3 on emerging theory of ADR diagnosis. 
Impact of an ADR Refer to section 6.2.2.4 for a detailed discussion of this concept 
ADR context Refer to section 6.2.2.5 for a detailed discussion of this concept 
Table 6-3 Concepts with multiple definitions that were informed by the data 
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Concepts with single 
definitions that add to 
ambiguity in a domain 
with multiple decision-
makers 
Brief definition 
Known ADR Symptoms associated with a therapeutic drug that have been 
documented 
Unknown ADR Symptoms associated with a therapeutic drug, that have not yet been 
documented. 
Preventable ADR An ADR caused by a drug being prescribed to a consumer with: 
A known contra-indication 
A known allergy to the drug or class of drugs 
A drug known to cause an interaction with another drug the consumer 
is concurrently taking. 
Allergy – known A consumer has experienced an allergy to a particular drug or class of 
drugs in the past. 
Allergy – unknown An allergy a consumer has to a drug, which has not been identified or 
documented. 
Contraindication A drug that either ‘should not’ or ‘must not’ be taken by a consumer 
with a particular condition. 
Drug interaction Drug interactions are ADRs that may be caused by a drug/drug 
interaction, or a drug/food interaction (Kalachnik, 1999). 
Medical error Misdiagnosis 
Improper choice of treatment 
Failure to avoid drug interactions 
Failure to detect if the drug treatment is not working 
Failure to detect if the drug is causing further injury 
Failure to avoid allergic reaction (Woodstock, 2000) 
Compliance Term used by the medical practitioner, which refers to whether a 
consumer follows a regime either constructed by the medical 
practitioner, or constructed through a collaborative process between 
the medical practitioner and consumer. 
Nocebo effect “…‘non-specific side effects’ are symptoms or physiological changes 
that cannot be explained on the basis of the known pharmacology of 
the drug and are idiosyncratic and not dose dependent.  In theory non-
specific side effects may be positive and beneficial or negative and 
adverse” (Barsky, Saintfort, Rogers & Borus, 2002). 
Table 6-4 Concepts with single definitions applied to a domain with multiple perspectives 
 
6.2.1. CONCEPTS THAT WERE DEFINED TO ACCOMMODATE MULTIPLE 
PERSPECTIVES 
In this work, there was a single concept that was defined to accommodate multiple perspectives; 
a ‘suspected ADR’.  Rather than defining an ADR based on the initial WHO definition, a 
decision was made to allow the consumer who volunteered for the study to determine if s/he 
has experienced a suspected ADR.  By beginning with a single perspective from one of the 
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participant groups, one definition and explanation of that definition was collected initially.  By 
then asking the medical practitioner/s and then experts whether they agree with the consumer 
perspective, a second and third perspective of the definition of an ADR emerged.  Not only did 
the definition emerge, but the beliefs and reasoning behind the definition emerged.   
 
6.2.2. CONCEPTS WITH MULTIPLE DEFINITIONS THAT WERE INFORMED BY 
THE DATA 
6.2.2.1. ADR, side effects and allergies 
The data that informed the concepts ‘ADR’, ‘side effect’ and ‘allergy’ and the results were 
presented in section 5.2.3. 
  
To summarise, the experts, representatives of ADRAC, use the World Health Organization 
definition of ADR, and view the term ‘side effect’ as an outdated term that is better replaced 
with the term ADR.  They refer to ‘serious’ and ‘unexpected’ ADRs to describe the subset of 
ADRs they are most interested in collecting via the spontaneous reporting processes. 
 
The medical practitioners in the case studies used the terms ‘reaction’ and ‘side effect’.  They also 
referred to ‘significant reactions’ and ‘significant side effects’.  Although some of the medical 
practitioners made comments indicating there was a difference in meaning between these terms 
such as “I’m not sure if there was a reaction, but I just think she was certainly having side effects 
…” the use of each term within the case studies did not reflect this.  The use of the word 
‘significant’ appeared to be what determined if the medical practitioner needed to act upon the 
set of symptoms by either treating them or withdrawing the drug, regardless of whether s/he 
was referring to a ‘reaction’ or ‘side effect’. 
 
The consumers appeared to refer to a ‘reaction’ as something a person experienced and a ‘side 
effect’ as an attribute of the drug but otherwise used the terms interchangeably. 
 
It appears from the data that despite the differences described, each group use the terms ‘side 
effect’ and ‘reaction’ to mean non-therapeutic symptoms associated with a medication.  In the 
cases when a participant attempted to differentiate between the terms, it also appeared that the 
term ‘side effects’ referred to the symptoms expected or known to occur in some people with a 
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particular reaction, and ‘reaction’ as something unexpected or more serious, however this was 
not consistently apparent.  To take this further, a ‘significant side effect’ may mean a known and 
expected ADR that a consumer cannot or chooses not to tolerate, and a ‘significant reaction’ 
may mean an unexpected or less predictable reaction that resulted in a change of treatment. 
 
The consumer appeared to have a general term for “non therapeutic symptoms associated with a 
drug”, that is, some thing is happening that should not be happening.  The medical practitioners 
appear to be more specific, with a clear distinction between ‘allergy’ and a more general term of 
‘side effect’ or ‘reaction’, and with the qualification of ‘significant’.  The experts, however, had a 
specific definition, classifying ADRs as Type A to E and including contraindications, interactions 
and product manufacturing faults, also as important information. 
 
The formal product information found in electronic prescribing products refers only to adverse 
drug reactions, (Medical Director, 2003).  The Consumer Medicine Information (CMI) (Better Health 
Channel, 2003) refers to ‘side effects’, implying a side effect is a more general term and ‘adverse 
drug reaction’ a more medically based term. 
 
When attempting to determine the incidence of ADRs, terminology differences between adverse 
drug reactions, adverse drug events, adverse events, medication errors and medical errors, were 
used inconsistently in the literature.   
 
The term ‘allergy’ appeared to be used by all participants as a sub type of either ‘reaction’ or ‘side 
effect’ related to a hypersensitivity reaction to a particular drug.   
 
It appears, therefore, that the definition of these terms is broad rather than precise, and that the 
general meaning of these terms is similar between participants.  The problem in communication 
appeared to be when one participant was more specific in his or her usage of the term, such as 
when Mary approached her medical practitioner with what she believed was a suspected 
reaction, and he said “no, not a reaction, but could be a side effect”. Another example is when 
one of the medical practitioners referring to the problem of providing consumers with ADR 
information said:  
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I see far more of the anxiety from the person that comes in with the sheet, having 
underlined every symptom and, if they’ve taken it, I’ve had that, that, that and that, and 
most of those are not allergies, they’re nausea, and some tummy upset, that’s quite possible 
without an allergy, but it’s difficult to know, sometimes if they are truly allergic, or whether 
they’re getting some significant side-effects. 
 
The consumer in this example, appeared to be saying s/he was experiencing some new 
symptoms, “nausea and tummy upset”, but labelled them as an ‘allergy’.  The medical 
practitioner appeared confused because the consumer’s description, in his mind, was not an 
‘allergy’.  If the medical practitioner heard this as ‘something is wrong and I think it’s related to 
my medication’ rather than specifically an allergy, the communication may be clearer.   
 
The data found in these case studies cannot provide a definitive understanding of these terms.  It 
can, however, provide some insight into how the terms appear to be being used, and suggest 
some problems that may be occurring due to differences in terminology between groups, when 
there is an expectation of a single understanding.   
 
In the few case studies where a consumer or medical practitioner was asked about the definition, 
their response did not match their usage, indicating they are not cognitively aware of their usage 
of these terms. It is unlikely, therefore, that a study designed to specifically ask participants how 
they use the term, would provide data on their actual use of these terms, only what they believe 
they understand.  In order to learn more about the inconsistencies in these terms, a study would 
need to be designed specifically to elicit the use of these terms. 
 
The development of decision support within this domain using a positivist framework may result 
in a solution that involves choosing a single definition or understanding of these terms, and 
educating all ADR decision-makers to have a single understanding.  This idea has been illustrated 
in Figure 6-1.   
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Definition of an
Consumer Medical
Practitioner
ADR
Expert Pharmacist
The aim of decision support is to use a single
understanding of the concepts within the
ADR decision domain, and use concepts such
as education to move all decision makers to
a single understanding
Positivist perspective
 
 
Figure 6-1 Positivist theoretical framework to develop decision support 
 
The development of decision support using a social constructionist epistemology, and symbolic 
interactionist theoretical framework, however, points to a solution of accepting and valuing the 
diverse range of understandings, and encouraging ADR decision-makers to recognise different 
people use the same terms for different meanings.   
 
One of the fundamental aspects of symbolic interactionism is that meaning is created through 
interaction with other members of the social group.  The interaction, in many of the case studies, 
between the medical practitioners and the consumers was limited, limiting the opportunity to 
develop a shared understanding.  Rather than making an assumption about the meanings, taking 
the time to understand what the individual consumer or medical practitioner means by each 
term, may be a role for ADR decision support.  This notion has been illustrated in Figure 6-2. 
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ADR decision support using a
Consumer MedicalPractitioner
Expert Pharmacist
Recognition that each group will have a different
understanding of the concepts within the ADR
communication between decision-makers to
develop a shared understanding.
symbolic interactionist
theoretical perspective
domain.  The goal of decision support is to facilitate
 
ure review identified a number of methods that have been used to reduce ADRs. We 
ps in chapter two.  They are: drug surveillance programs in 
ed; and increasing awareness, through education and training.  These 
ystems focused primarily on supporting decisions from a single perspective, the perspective of 
Figure 6-2 Symbolic interactionist theoretical framework to develop decision support 
 
6.2.2.2. Decision-maker/s 
The literat
classified these into five grou
Australia; drug surveillance at an international level; computerised clinical guidelines; 
incorporating decision support modules into prescribing software tools; early warning ADR 
systems that are hospital bas
s
the medical practitioners.  The results of this study as discussed in section 5.2.1, indicate that the 
medical practitioner is only one decision-maker in a decision domain that includes many 
different decision-makers including the consumer, the consumer’s family and friends, and to a 
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lesser extent, community pharmacists and other health professionals such as naturopaths.  This 
has been illustrated in Figure 6-3.  The dotted lines indicate infrequent communication. 
 
General
Practitioner Consumer
room
GP Consulting
Consumer
family
Consumer
friends
Other health
professionals
Pharmacist
Specialist
Colleagues
Actors in the ADR decision domain
Specialist
consulting
room
ADRAC
bulletin
ADRAC
Consumer
Medicines
Information Line
 
Figure 6-3 The actors or decision-makers in the ADR decision domain 
solution. 
 
The focus of providing ADR information and resources to prescribers, and building decision 
support to assist with the medical practitioner’s decisions, appears to be a group of ADR 
solutions that are tailored to only part of the decision-making team, and only supporting some of 
the ADR decisions, which is likely to result in a partial rather than a complete decision support 
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s of the consumer data indicated that not only are consumers involved in the 
DR decision domain, they play a significant role in this area, making a wide variety of decision 
consumers in this work (described in section 5.2.2) included 
iagnostic decisions, treatment decisions, decisions about which information to share and what 
sec
AD cisions.  Although the consumers cannot prescribe drugs, and 
inp
suspected ADRs, however, the introduction of the consumer medicines information line (section 
ph
consumer’s family and friends assisted the consumer with each of their decision types.  Although 
an
ver focuses almost exclusively on treatment 
ecisions.  This study suggests that treatment decisions are only one decision type made by 
de
tre
6.2
Th  section relate to understandings at a group level.  That is, 
hat the consumers understand compared with what the medical practitioner’s understand.  
6.2.2.3. ADR decision types 
The group analysi
A
types surrounding ADRs.   
 
Decision types made by the 
d
information to seek.  The medical practitioners also made a variety of decisions (described in 
tion 5.3.1) including the four types of decisions made by the consumers and decisions about 
R reporting and prescribing de
so did not make prescribing decisions, they do make decisions about treatment, and so have 
ut into prescribing decisions.  The consumers in these case studies did not report their 
2.2.6.9) has resulted in Australian consumers taking a larger role in ADR reporting.  The 
armacists were primarily involved in the role of providing information to the consumer.  The 
there are variations in the actual decisions and the sources of information used by the consumers 
d medical practitioners, the role division is not as significant as the literature suggests.   
 
There is a growing body of literature about the consumer role in medical decision-making, which 
was discussed in chapter two.  Within this body of literature, there is beginning to be a focus on 
consumer decision support.  This literature howe
d
consumers, and that consumers play an important role in the detection and diagnosis of ADR 
cisions, challenging the belief that decision support for consumers will be restricted to 
atment decisions. 
 
.2.4. Impact of an ADR 
e concepts described in the previous
w
These next two sections, the impact of an ADR, and the importance of life context are related to 
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everity of each ADR associated with a medication.  This information could then 
e used to asses the risks associated with the drug compared with the benefits of the drug for a 
his terminology arose from forums with a single group of decision-
e impact of a suspected ADR.  For example, in Kerry’s case she experienced a 
suspected reaction to Maxolon; double vision following surgery which resolved to blurred 
 the impact of a drug after the drug has been ceased.  For example, in Joanna’s case, she 
 
 the impact on lifestyle.  For example, in Joanna’s case, again, her holiday was cut short, and 
 
Th
pe
consumer.  Two cases that illustrate this point are: 
the individual circumstances surrounding an individual consumer, rather than consumers as a 
whole. 
 
The GP forums conducted in the preliminary background work (O'Brien, 2001) revealed an 
informal scale used by medical practitioners to indicate severity of ADRs.  This was a factor the 
GPs considered important to include in ADR decision support, so the prescriber was aware of 
the likelihood a s
b
particular consumer.  T
makers, the GPs. 
 
The consumer group data revealed another dimension related to severity, and that was impact of 
the ADR on the consumer.  These results were discussed in section 5.2.6.  To summarise these 
results, the impacts included:  
 
 the immediat
vision that lasted several days; 

continued to experience a photosensitivity reaction for several years after having ceased the 
suspected drug; 
the impact on trust in drugs and/or medical procedures.  For example, in Belinda’s and 
Kerry’s cases, there was significant fear of future surgery, due to past incidences of ADRs 
whilst undertaking surgical procedures; 

her enjoyment of outdoor activities was affected by the continuing effects of the ADR. 
e second aspect of severity and impact that was highlighted by the data was the differences in 
rceptions between decision-makers about the impact the suspected ADR had on the 
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n weeks. 
 Paul’s case, where the medical practitioner believed the impact of the suspected ADR on Paul 
tremely distressed and felt his quality of 
life had been significantly affected. 
 
In this second case, Dr Kent said that if he believed the ADR had been a problem to Paul, his 
management would have been different.  To Dr Kent, the symptoms were low grade, and 
general indicating a low level of severity.  To Paul, the symptoms were insidious and constant, 
affecting his sleep and impacting his overall quality of life. 
 
The dimension of ‘impact’ emerged from the consumer data.  The term ‘severity’, used by the 
medical practitioners, was a less complete indicator of the level of intervention required than the 
terms ‘severity’, from the medical practitioner data and ‘impact’, from the consumer data, when 
used together.   
 
6.2.2.5. ADR context 
S  
drug, some impacts cannot be known u er is actually experiencing a suspected 
nce of understanding the impact of an ADR 
To summarise, the key factors included the following: 
 Whether the drug in question is essential or non-essential.  If a drug is considered essential, 
 Toni’s case where the medical practitioner believed Toni recovered quickly from the 
suspected ADR to Tegretol, based on the fact that Toni did not go back for further 
consultations.  Toni said that she did not feel completely well for te

was at the level of an irritation, where as Paul was ex
ome of the factors that are likely to impact on a consumer are known prior to commencing a
ntil the consum
ADR.  The previous section discussed the importa
on the consumer.  This section explores the factors known about the consumer prior to 
prescribing a drug that may be important to take into account when weighing up the risks and 
benefits of drugs versus treatments.  The results that relate to context have been written in 
section 5.2.6.2. 
 
 
there may be an increased chance that a consumer is prepared to accept the risk of an ADR, 
than for a non-essential medication.  In Julie’s case, drugs and combinations of drugs that 
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ore of some irritating but minor ADRs such as tinnitus. 
negative experiences with drugs in the past.  A consumer who 
Minimal life
assist in managing her pain are essential for her to participate in her daily activities.  She is 
tolerant, theref
 
 Whether the person has had 
has a significant fear of experiencing further ADRs may be less prepared to risk an ADR in 
the future.  In Kerry’s case, she has had so many negative experiences with surgical 
procedures which were drug related, that her preference would be to have no surgery than to 
risk another potential ADR. 
 
 Whether the person has factors in his or her life that would be severely impacted if an ADR 
were to occur.  In Edward’s case, the ADR not only had an impact on his own health, it had 
an impact on his ability to care for his wife with a severe disability. 
 
These three factors have been illustrated in Figure 6-4.   
 
Essential
Non-essential
Fear of future ADRs
Acceptanc
of ADRs
Significant life
responsibilities
e
responsibilities  
Figure 6-4 Life context factors to consider when weighing up the risks versus the benefits of a 
drug therapy 
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.2.3. CONCEPTS WITH SINGLE DEFINITIONS THAT ARE APPLIED TO A DOMAIN 
gle definition.  This assumption has created ambiguity 
ithin this multi-decision domain. These concepts and the resulting lack of clarity have been 
e, but are 
sed as the basis of many other concepts.  Each of the definitions of ADR types that were 
al error’, ‘preventable ADR’, ‘contraindication’, and ‘drug interaction’ 
re also all based on an understanding of what is ‘known’ or ‘unknown’.   
ed blood level or tissue level of the 
rug/s, or an additive effect.  The complexity is when classifications of ‘medical error’ or 
hich 
teracts with another drug the consumer is currently taking, resulting in a ‘known’ reaction, this 
The development of weighted factors surrounding risk may bring to consciousness some of the 
factors that need to be considered when weighing up the risks versus the benefits of drugs, 
which may be useful when designing a decision support system, or may just be useful to facilitate 
a discussion between the consumer and medical practitioner about risk and benefits. 
 
6
WITH MULTIPLE PERSPECTIVES 
Some concepts within the ADR decision domain have either not been defined clearly, or defined 
with the assumption that there is a sin
w
described below. 
 
6.2.3.1. Known and unknown  
The concepts, ‘known’ and ‘unknown’ have not been clearly defined in the literatur
u
described in section 2.2.1, use the term ‘known’ as a component of the decision.  An example is 
the definition of a Type A reaction.  “Predictable events or reactions, pharmacological reactions 
or expected events or reactions.  Type A reactions are common and are accounted for by a 
drug’s known pharmacological properties” (Kalachnik, 1999).  The concepts of ‘known allergy’, 
‘unknown allergy’, ‘medic
a
 
The implicit definition of what is ‘known’ is that knowledge has been discovered about an aspect 
of a drug and/or ADR associated with a drug, and that this knowledge has been documented.  It 
is not clear where this new knowledge needs to have been documented in order for it to be 
considered ‘known’.  The second aspect of this definition which is ambiguous is when ‘known’ is 
applied to another definition, such as a ‘known drug interaction’.  Drug interactions were 
described in section 2.2.4.4.  In summary drug interactions may be classed as pharmacokinetic or 
pharmacodynamic, resulting in an increased or decreas
d
‘preventable’ come into play.  If a medical practitioner prescribes a drug for a consumer w
in
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 Woodstock’s (2000) definition, as medical error, and is also 
is ‘known’ but in a location not accessible to the decision-makers, can it still 
e considered a preventable ADR?  It could be considered a preventable ADR if the information 
 
community are having, maintaining up to date 
 build on these concepts.  Further work is 
. 
n 
that does not fit within other models.   
The term compliance was defined in
the term co tion for 
t recommendation.  A 
The consumer did not have an equivalent term.  The consumer spoke of making various choices, 
compliance only holds where there is an assumption that 
is considered according to
considered preventable.  
 
The significant question in this situation, however, is ‘known by whom?’  Where does this 
information need to be located for a consumer and/or medical practitioner to have access to this 
information?  If it 
b
about this interaction was available to the decision-makers at the time of making a decision.  
 
An issue raised in the GP forums conducted as a part of the preliminary background studies 
(O'Brien & Yearwood, 2002, 2005), and has been re-enforced in recent health informatics 
conferences,  is the difficulty the medical 
knowledge, due to the increasing number of publications within this area. This problem adds to 
the ambiguity of what is considered ‘known’. 
 
This lack of a clear definition or set of definitions of the terms ‘known’ and ‘unknown’ has 
resulted in ambiguity surrounding the terms that
required to clarify these core concepts
 
6.2.3.2. Compliance 
Compliance was a term used by the medical practitioners, but was not used by the consumers.  It 
 of the medical practitioner/consumer decisioappears to be a concept that fits within some
models (described in section 6.3.2), but a term 
 
 the results section (section 5.3.4.2).  To remind the reader, 
mpliance was used when a medical practitioner made a recommenda
treatment, and the consumer did not follow, or ‘comply’ with tha
consumer is said not to comply, when they choose not to follow either the recommended, or the 
agreed course of action.  
 
and/or making decisions.  The term 
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e medical practitioner is the primary decision-maker, and it is up to the consumer to follow 
dical practitioner is an advisor 
ho works with the consumer to make decisions, and that both parties have the right to make 
a re not fit with medical ‘best practice’, but makes sense to the consumer in 
.2.3.3. The nocebo effect 
sion domain 
n the previous section, the concepts, or building blocks within the ADR decision domain have 
erton developed the middle range theory as a solution to a 
end of social research where the focus of theory development was to either develop grand 
s focussed on the very 
pecific domain of ADR decision-making.  The emerging theories, however, tap into current 
th
what is recommended.  When the assumption is made that the me
w
decisions, ‘non-compliance’, becomes, ‘the consumer changed his or her mind’ for some reason; 
ason that may or may 
some regard which may or may not be medically related. 
 
The use of this term is inconsistent with our definition of a partnership in decision-making. 
 
6
The nocebo effect or nocebo phenomenon is a term used within the literature, but was not used 
by any of the participants within this work.  The concept underlying these terms, was used by 
the medical practitioners and alluded to by the consumers, however they did not attach this label 
to it.  This term is discussed in detail when describing ADR differential diagnosis, and so will not 
be described here. 
 
6.3. Contribution to theory in the ADR deci
I
been discussed.  The use of these building blocks to form and develop pre-existing theory will be 
described in this section. 
 
The level of theory derived from this work matches Merton’s middle range theory (Blaikie, 
2000).  According to Blaikie (2000), M
tr
theories, which aimed to generalise to an entire society; or micro theories, that did not generalise 
beyond the immediate work.   
 
The theory discussed in this section was derived from work which ha
s
more substantive theories within the domains of decision theory and decision support.  
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 the use of multiple perspectives and triangulation to inform systems design; 
 ADR decision-making based on partial knowledge as a contribution to the incidence of 
olic interactionist theoretical perspective.   
The development of ADR decision support systems have used knowledge of the ADR decision 
d  
w  
provided insight based on the perspectiv sumer, medical practitioner and expert.  
ng 
as been developed to include multiple perspectives and to create multiple understandings which 
 
of a
incr
This work contributes to theory development in the following areas: 
 

 medical practitioner/consumer decision models; 
 ADR differential diagnosis; 
 the role of the consumer in the ADR decision domain; 

ADRs; 
 creation of new ADR knowledge.  
 
Each of these will be discussed in detail in the following sections. 
 
6.3.1. THE USE OF MULTIPLE PERSPECTIVES AND TRIANGULATION TO INFORM 
SYSTEMS DESIGN 
The methodology used within this work to inform the pre-requirements analysis phase of 
systems design was a grounded theory analysis of case studies.  Each of these case studies 
included multiple views of a single ADR.  The underlying epistemology was social 
constructionism with a symb
 
omain that was primarily based on the perspective of the prescriber.  The methodology used
ithin this work to inform the requirements analysis phase of decision support development,
es of the con
Knowledge that was developed using a single perspective and based on a single understandi
h
has resulted in a significantly greater insight into this decision domain. 
Knowledge of the ADR domain was primarily situated in a positivist school of thought.  The use 
 social constructionist school of thought in combination with triangulated data, has lead to 
eased understanding of the differences between decision-makers, and the contribution of 
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to t
The
AD opment of ADR decision support.  
urther work will be required to consolidate and test this theory.  The grounded theory 
tion 
systems, based on assumptions about the industry, such as who the key stakeholders are, and 
their primary information needs.  Development f decision support may rely on the existence of 
he following sections discuss the emerging theory that either expands on current theory, or 
contributes a new understanding, that has arisen from this research approach. 
 
6.3.2. MEDICAL PRACTITIONER/CONSUMER DECISION MODELS 
A medical practitioner/consumer decision model developed by Emanuel and Emanuel (1992), 
was first discussed in chapter two.  Figure 6-5 is a graphical representation of this model, 
including the percentage of consumers who prefer each of these models based on Scott and 
Lenert’s (2000) work.  It is important to note that these models are based on how medical 
practitioners and consumers currently make medical decisions, not based on what is considered 
‘best practice’.  These models, therefore, are based on Carroll and Johnson’s (1990) definition of 
descriptive decision theory. 
those differences to the misunderstanding that occur within this domain and their contribution 
he continuing incidence of ADR. 
 
 work of this thesis has made progress towards the development of theory underpinning 
R decision-making, providing a solid basis for the devel
F
approach provided a method of eliciting new theory within this domain. 
 
A requirements analysis exercise elicits information that can be used to develop informa
o
theory and a detailed understanding of the decision domain.  Traditional requirements analysis 
methodologies do not explore the decision domain in this level of detail. 
 
The research methodology used within this work, therefore, has contributed significantly to the 
understanding of the ADR decision domain providing a solid basis for the development of ADR 
decision support that is grounded in theory that has been derived from real world data.   
 
T
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Medical
Practitioner Consumer
Paternalistic Model
(3-8%) Informed Model(20-30%)
Collaborative Model
(50-60%)
Deliberative Model
(10-20%)  
sion-making Figure 6-5 Medical practitioner/consumer deci models described by Emanuel and 
Emanuel (1992).  The percentage of consumers who would prefer each model from Scott et al.’s 
(2000) work. 
92) defined each of these models as follows: 

 
preferences, and making the final decision.  
 Collaborative decision-making
 
 
Charavell et al.’s (2001) expansion of these decisi
They viewed the paternalistic and informative models described by E  
on, where as the collaborative and deliberative  
To remind the reader, E
 
manuel and Emanuel (19
 Paternalistic decision-making is defined as a model whereby the clinician has complete 
authority to make decisions on behalf of the consumer.   
Informed decision-making is defined as a model where by the consumer makes 
completely autonomous decisions.  The role of the clinician is to provide medical 
information, but it is assumed that the consumer is responsible for determining their own 
  is defined as a model where the consumer relies on the 
health provider to provide information, but also to facilitate the decision-making processes.   
Deliberative decision-making is defined as a model where the health provider attempts to 
convince the consumer of the best outcome for their health, based on what the medical 
practitioner believes is in the consumer’s best interests.   
on models was also discussed in chapter two.  
manuel and Emanuel
(1992) as reducing the exchange of informati
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nsumer.  The medical practitioner would elicit 
references from consumer and assist in the decision-making process, and also state their own 
models attempt to increase the exchange.    They suggested an additional model, the shared 
decision-making model, which sits between the collaborative and deliberative models.  This new 
model includes the medical practitioner conveying information about the condition, including 
risks and benefits of various options to the co
p
preferences for the consumer.  Charavell et al.’s (2001) suggestion has been incorporated into 
the figure illustrating the medical practitioner/consumer decision models in Figure 6-6.  
 
Medical
Practitioner Consumer
Paternalistic Model Informed Model
Collaborative Model
Deliberative Model
Shared Model  
Figure 6-6  Medical practitioner/consumer decision-making models described by Emanuel and 
Emanuel (1992).  Charavell et al. (2001) add an additional model, the ‘shared decision-making 
ecision-making model; 
nd a model where the consumers and medical practitioners are partners in decision-making 
model’ 
 
The results from this work described in section 5.3.4.2 suggest another expansion of this set of 
decision-making models.  The additional models are: a consumer only d
a
which have been illustrated in Figure 6-7.   
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Medical
Practitioner Consumer
Consumer only
Consumer only
and inform
Medical Practitioner
(Informed)
Medical Practitioner only
and convince the
consumer
(Deliberative)
Partners
in decision making
in decision making.
(Shared)
Medical Practitioner considering
consumer preferences
(Collaborative)
Consumer considering
medical advice and
with Medical Practitioner to assist
Medical Practitioner only
(Paternalistic)
Medical Practitioner
only and
inform consumer
 
Figure 6-7 Medical practitioner/consumer decision-making models described by Emanuel and 
Emanuel (1992).  Additions to this model include ‘medical practitioner only but inform 
consumer’, ‘consumer only decision-making’, and ‘consumers as decision-making partners with 
medical practitioner’ 
 
These models have been defined as follows: 
 
 Consumer only decision-making is defined as a model where by the consumers make 
independent medical decisions without discussion with a medical practitioner.  An example 
of this model was in James case, where James and his wife diagnosed two ADRs; the first to 
Panadeine Forte, and the second to tramadol hydrochloride.  The experts who reviewed this 
case study agreed with James’ diagnosis supporting the notion that not only did he make this 
diagnosis, but that the diagnosis was accurate. 
 
 Partners in decision-making is defined as a model where by the consumer and medical 
practitioner are partners in medical decision-making.  This model parallels the model of 
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Joanna’s case, where Dr Carey and Joanna jointly made decisions about the management of 
Joanna contributed knowledge of the past 
cott and Lenert (2000) stated that they do not believe consumers are capable of shared medical 
 that consumers do not have, and that it is not until all of the 
formation has been conveyed and the risks and benefits have been weighed that a consumer 
 have access to medical 
g a medical 
decision, co u d discussed prior to 
making AD
to make an ADR diagnosis.  A key point, however, is that whether authors believe consumers 
 
em.  As stated previously, the original work by Emanuel and Emanuel (1992) uses descriptive 
ether they 
should be used. The data from this work suggests that some consumers do make independent 
medical decisions, and they do participate in partnership with their medical practitioners.  It can 
then be decided that consumer’s ‘should not’ participate in these types of decisions because of 
their limitations, or it can be realised that some consumers do participate in these types of 
decisions, and so working together with these consumers to enhance their participation is likely 
to enhance medical decision-making rather than detract from its effectiveness. 
 
One further expansion of the original model by Emanuel and Emanuel (1992) is to suggest an 
expansion to the Paternalistic model.  According to Emanuel and Emanuel (1992) the 
decision-making that is likely to be used between two colleagues of equal standing, but who 
contribute different perspectives to a decision domain.  An example of this model was in 
her suspected ADR to Celebrex.  In this case, 
history of the case and her analysis and reasoning to date.  Dr Carey contributed medical 
knowledge and access to medical resources and some additional medical reasoning. 
 
S
decision-making because they have limitations such as education, numeracy, problem solving 
and understanding their own preferences.  Charavell et al. (2001) stated that medical 
practitioners have information
in
can contribute to the decision-making process. 
 
The results of this work suggest that although medical practitioners
information and diagnostic expertise that needs to be considered prior to makin
ns mers also have information that needs to be considered an
R decisions, and that both sets of information are equally important when attempting 
are capable of making medical decisions is a different issue to whether they are actually making
th
decision theory, describing decision-making styles that are currently being used, not wh
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Paternalistic decision model is defined as a model where by the clinician has complete authority 
to make decisions on behalf of the consumer.  This model may include:  
 
 decisions made by the medical practitioner without informing the consumer, such as 
which anaesthetic drugs to use during surgery;  
 decisions made by the medical practitioner where the medical practitioner informs 
the consumer of the decision that has been made, such as a change to a surgical 
procedure that happened during surgery, based on what was found at the time of surgery. 
 
Another dimension to these models is the consideration of matching the decision model used by 
each of the decision-makers.  In the case study of Paul, Dr Kent used Charavell et al.’s (2001)’s 
shared decision-making model.  Dr Kent’s expectation was that he would provide information 
and Paul would make his own decisions.  Paul, however, expected and wanted to be using a 
collaborative model, where the medical practitioner would make the decisions having discussed 
the issues surrounding the decision with Paul.  The result of the mismatch between the models 
each decision-maker expected to use contributed to a breakdown in the medical 
practitioner/consumer relationship.  The implication of this is that a discussion between 
decision-makers about the preferred model of decision-making may assist with this problem
 
A final dimension to these models is that different circumstances allow or require different 
decision models.  Clearly decisions made within surgery cannot be made in conjunction with the 
consumer at the time of decision-making.  A plan can be made between the decision-makers 
prior to surgery, but in some cases the plan will need to be changed according to the 
circumstances, especially in emergency situations.  Similarly, decisions about when to seek 
medical assistance, and which medical practitioner to consult, fall clearly in the domain of 
consumer only decision-making.  The more complex the medical situation and the more time 
constrained the decisions are, the more likely the decision model most appropriate to the 
situation will move towards the medical practitioner’s end.  Decisions that are more the right and 
responsibility of the consumer that require skills that are used outside the decision domain, such 
as logic and reasoning, the more likely the most appropriate decision model will be to the 
consumer end.  It is the models in the middle that are likely to be preference related, and 
therefore require negotiation between decision-makers. 
. 
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n the literature about the role consumers are capable of taking, 
tion that consumers are all individuals, and 
ticipate in the medical decision domain, and 
tow sidering consumer’s contribution to medical decision-
aking is important.  Considering the impact of excluding the consumer’s contribution is also 
 models suggested from this work indicate that the role consumers 
ing is broader than is being described in the literature, and 
needs is an important factor to be taken into account when making ADR decisions. 
The results of this work revealed a number of strategies used by the participants, including the 
 
his model illustrates some of the complexities surrounding the diagnosis of an ADR.  The key 
ristics listed below. 
Ch
 Matching a set of symptoms to the most likely diagnosis/diagnoses. 
 
There is significant discussion i
and want to be taking.  These data support the no
different consumers have different abilities to par
different levels of interest in taking responsibility for their health care.  With the movement 
ards evidence based practice, con
m
important.  The additional
currently take in medical decision-mak
the acknowledgement of that, and the recognition that individual consumers have differing 
 
6.3.3. ADR DIFFERENTIAL DIAGNOSIS  
consumers and medical practitioners, when making a differential diagnosis.  Figure 6-8 is a 
model of the strategies used. 
T
concepts within the model are diagnoses, symptoms and drugs.  Each of these concepts has a list 
of characte
 
aracteristics of diagnoses 
 Considering a set of possible diagnoses. 

 Gathering information to support or eliminate each diagnosis.  Information may: 
o be purposefully gathered (asking questions, ordering tests); 
o appear over time (multiple incidences of a suspected ADR, progression of a 
condition or disease). 
 Holding one or more possible diagnoses at any one time. 
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Figure 6-8 An e  model of differential diagnosis
C
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 Symptoms can start and stop along the timeline. 
 Drugs have a dosage which can change over time.  The dosage may be increased, decreased 
 complementary medicine. 
 The medical practitioner may know about all or none of the drugs the consumer is taking at 
igure 6-8 attempts to illustrate these emerging differential diagnostic processes, whilst 
 and 
 
Characteristics of symptoms 

 Symptoms can increase or decrease in severity. 
 Symptoms can be: observed by medical practitioner; reported by a consumer or family 
member, or come from test results. 
 
Characteristics of drugs 
 Drugs can be started and stopped. 

or remain static. 
 The number of drugs a consumer is taking at any time can be from none to multiple. 
 The drug may have been prescribed by the medical practitioner, another medical practitioner 
or self-medicated (non prescription). 
 The drug may be a prescription drug, an over the counter drug or a

any time. 
 
As well as including individual concepts, this model illustrates some relationships between these 
concepts: 
 A set of symptoms may be as a result of one or more possible diagnoses (some symptoms 
associated with one diagnosis and other symptoms associated with a different diagnosis).  
 Multiple symptoms may result in a single diagnosis. 
 
F
highlighting the complexity of this decision type.  This figure has four potential diagnoses down 
the left side: a complication of one or more pre-existing diseases or conditions; one or more 
newly presenting diseases or conditions; an adverse drug reaction or interaction; or a nocebo 
effect.  One or more of these possible hypotheses is matched with a set of symptoms.  The 
methods of matching the diagnoses with the symptoms included hypothesis testing, pattern 
matching or observing multiple instances of the same set of symptoms.  The section on the right 
of this figure, illustrates the complexities of symptoms and drugs.  Drugs are commenced
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eased at various times within a person’s life.  The dosage may be stable, increasing or decreasing 
ing, decreasing, intermittent or stable.  
t is most likely to explain the set of symptoms at 
ny point in time. 
Th
multiple participants.  No single participant used all of the strategies within this model, however 
s, and therefore the 
ons of 
DR decision-making, and description of when ADR decision-making was ineffective, or less 
c
at any moment in time.  The symptoms may be increas
Knowledge of symptoms and drugs, therefore, requires an understanding, not only of what is 
presented at the time, but also the history of their progression. 
 
The process of differential diagnosis, according to this emerging theory, is the matching of one 
or more symptoms or patterns of symptoms (observed or reported) to one or more possible 
diagnoses, and determining the diagnosis tha
a
 
is model of ADR decision-making is an amalgam of decision-making strategies articulated by 
it appears that thorough diagnosis would include each of these strategie
model illustrates a prescribed decision-making process which was derived from descripti
A
than effective. 
 
Table 6-5 highlights some of the differences observed between the strategies used by consumers 
compared with those used by the medical practitioners when making ADR diagnostic decisions. 
 
Medical practitioner diagnostic strategies Consumer diagnostic strategies 
Hold multiple hypotheses Work with a single hypothesis at a time 
Aware of a range of possible diseases or conditions Searching for any possible diseases or conditions 
that may account for symptoms 
May have seen the symptoms and/or condition in 
other consumers, self, family or friends. 
May have seen the symptoms and/or condition in 
self, family or friends. 
Table 6-5 Differences between consumers and medical practitioners in diagnostic strategies 
 
The ADR differential diagnostic strategies that have emerged from the case study data, 
 individually are not new.  The methods of selecting an option from a set of hypotheses and
pattern matching (described in section 2.3.5.2) fit with Elstein and Schwarz’s (2002) descriptions 
of hypothetic deductive reasoning and pattern matching.  The idea that different methods are 
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y O'Neill et al., (2005). 
mplication for a decision support system designed to support differential diagnostic 
ecisions, therefore, would be the use of a combination of theories, for multiple decision-makers 
.3.3.1. Utility Theory 
-makers in case studies presented in 
ation was gathered to 
upport or eliminate each hypothesis, and as new evidence was presented or gathered, the 
, Dr Barns added an additional hypothesis to the list of possible hypotheses, an ADR, 
us.  After obtaining the test results, 
th the specialist, it appears the hypothesis of a virus had a lowered weighting 
 allergic reaction to the Tegretol increased.  Dr Barns said “Sometimes 
ou are saying what’s more likely, rather than really being certain.” 
used by different decision-makers depending on the circumstances of the decision was reviewed 
in section 2.3.5.2 and was described b
 
Other methods of ADR diagnosis have included strategies for a single rather than multiple 
decision-makers, and have used hypothetico-deductive rule based methods rather than including 
the role of pattern matching in this form of diagnosis, (American Society of Consultant 
Pharmacists, 1998; American Society of Health-System Pharmacists, 1995; Naranjo et al., 1992; 
VDUAC, 1999; WHO, 2002).  Also these methods have included the differential diagnosis 
between an ADR and a disease or condition, but have not included the hypothesis of a nocebo. 
 
The i
d
and the inclusion of the four possible hypotheses rather than two or three that are usually 
considered.  The following sections revisit the decision theories described in chapter two, that 
might be useful in developing a decision support system of this type. 
 
6
Utility Theory was described in section 2.3.5.3.  The decision
chapter four, appeared to be holding one or more hypotheses at any point in time, and were 
adjusting the weights of each hypothesis.  At any point in time, a series of hypotheses were being 
considered, and each had a weighting or likelihood attached to it.  Inform
s
weightings changed.  The medical practitioner’s did not make definite statements about which 
was the ‘correct’ hypothesis, just which hypothesis was most likely. 
 
In Toni’s case, the hypothesis with the highest weighting was a “flu like virus”.  After Toni 
presented a second time, with a newly presenting symptom of a rash, “that looked like an 
allergy”
and increased its weight compared with the weight of the vir
and a discussion wi
and the weighting of an
you are really guessing. Y
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ing is that rather than only using cases within a person’s own experience, 
ases can be stored in a database and shared with other decision-makers.  This method can be 
sist in 
making a diagnosis that may be novel to this decision-maker, but is not novel to a group of 
est practice’. 
is work referred to past cases they had 
 with hydralazine.  In these past cases, the dosage of the medication was 
ignificantly higher than in Irene’s case.  This case was similar to past cases, which appeared to 
this particular consumer. 
 
6.3.3.2. Case-based reasoning for familiar diagnoses 
Case-based reasoning, discussed in section 2.3.5.5, is a method of solving new problems by 
accessing a database of old problems.  The medical practitioners referred to past cases within 
their own experience that assisted in making decisions about the case in question.  An advantage 
of case-based reason
c
used in several ways to assist with diagnosis: 
 
 Cases can be collected and stored so that decision-makers can find similar cases to as
decision-makers. 
 Cases can be used to either support a diagnosis or eliminate a diagnosis. 
 Cases can be combined to form a ‘typical’ case that can then be used as ‘b
 
In some situations, the medical practitioners within th
experienced which either added additional weight to a particular hypothesis, or lowered the 
weighting of a particular hypothesis.  Dr James said that he has seen similar cases of drug 
induced lupus associated
s
bring the past cases into consciousness for consideration.  This case, however, had a key 
difference to the past cases, the difference in dosage, which appeared to reduce the weighting Dr 
James placed on this hypothesis.  The other hypothesis Dr James appeared to be holding was 
that the symptoms were as a result of a Nocebo effect, based on Irene’s past history of multiple 
suspected ADRs, which it appears, Dr James believed were partially due to a Nocebo effect.  
This appears to be a second use of case-based reasoning, considering this diagnosis against the 
results of past diagnoses for 
 
6.3.3.3. Cognitive theory for novel diagnoses 
Another aspect of ADR decision-making appeared to be related to a more cognitively driven 
decision-making process, where the decision-maker actively seeks and tests one or more 
hypotheses.  This appeared to be the process when the medical practitioner did not have a past 
CHAPTER SIX:  DISCUSSION 
265 
t did not appear that any of the decision-makers began with all four types of hypotheses 
ypothesis was 
hallenged by another decision-maker as in Mary’s case; or new symptoms appeared as in Toni’s 
.3.3.4. Idiosyncratic characteristics of ADR diagnoses 
 symptoms. 
case that matched the current case providing a clear initial hypothesis, indicating the diagnosis 
was a novel, or unfamiliar diagnosis. 
 
I
indicated in Figure 6-8 at the beginning of the decision-making process.  It appears that they 
began with one or two possible hypotheses, and only introduced a new hypothesis if something 
about the condition changed, resulting in the need to reconsider the possible hypotheses.  This 
may have been because: a treatment did not work, as in Paul’s case; the condition did not 
progress as expected based on the first hypotheses, as in Toni’s case; the h
c
case. 
 
A single decision strategy, therefore, does not appear to account for the multiple facets of 
decision-making in this small but complex domain.  Multiple decision strategies appear to be 
being used at different stages of the decision-making process, indicating the need for multiple 
theories to underpin the development of a decision support solution within this domain. 
 
6
ADR diagnostic decision-making appears to be different to traditional medical decision-making, 
as consumers untrained in medicine have made diagnostic decisions that have been supported by 
ADR experts.  This provides additional insight into this decision domain. 
 
In cases where there was a clear temporal link between the commencement of the drug and the 
onset of the symptoms, with no other concurrent conditions or diseases, the diagnosis required 
only observation, logic and reasoning.  In this set of cases, medical knowledge was not required.  
Medical knowledge would have allowed the decision-maker to eliminate other possible diseases 
that could also have resulted in a similar set of symptoms, but was not required to suspect an 
ADR. 
The diagnosis becomes more complex with multiple factors: 
 multiple drugs; 
 multiple conditions; 
 multiple
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ated with a newly 
eveloping disease. 
tant when making this type of diagnosis. 
It app here 
medic ome 
limite
 
.3.3.5. The nocebo effect as a possible hypothesis 
e symptoms were caused by a nocebo effect, or 
egative placebo effect. 
if the symptoms are not symptoms known to be associated with the drug or set of 
rugs suspected, and no other cause can be found, it may be a nocebo effect; or if the consumer 
the first strategy relates to the complexity of developing knowledge of 
reviously undocumented ADRs.  If no explanation for the symptoms is found and so the 
 
In cases where there was a newly presenting condition or disease, the diagnosis was complicated 
by determining which symptoms were associated with the drug, and which symptoms were 
associated with the other condition or disease.  In Paul’s case, Dr Kent believed that some 
symptoms were associated with the drug, and some symptoms were associ
d
 
 In cases where there were multiple conditions and multiple drugs, sorting out which symptoms 
are associated with which hypothesis is difficult, and knowledge of diseases and the patterns of 
symptoms associated with those diseases is impor
 
ears, therefore, the consumers in this work made ADR diagnoses in situations w
al knowledge is not required.  They also appeared to be able to make diagnoses with s
d medical knowledge based on their own investigations or experience. 
6
When attempting to differentially diagnose an ADR from a pre-existing or newly developing 
disease, one hypothesis in Figure 6-8 was that th
n
 
Within this work, no clear set of strategies emerged for differentially diagnosing between a 
nocebo effect and some other possible explanation of the symptoms.  Two possible strategies 
did emerge: 
d
is a person who appears anxious about taking medications and is what the medical practitioners 
consider overly anxious about the possibility of experiencing an ADR, the symptoms are more 
likely to be a nocebo effect. 
 
The difficulty with 
p
medical practitioner assumes the symptoms to be associated with a nocebo effect, it will not be 
reported to ADRAC.  Symptoms that have not previously been associated with a particular 
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ledge. 
 has experienced many ADRs 
nd has developed a fear, or has a particular ‘sensitivity’ to medications, as described by the 
 
ical changes that result directly from the specific biological and pharmacological 
tivity of the drug a b pr is the 
 Type A r ctions described section 2.2.4.1.  T second set of s ptoms 
as “ ‘non-spe ic side effects’ ar mptoms or physio gical changes th  cannot 
n the basis o the known pharm logy of the drug and are idiosyncratic and not 
ent.  In theory on-specific side cts may be positive and beneficial or negative 
Type B reactions are uncommon and independent of a drug’s known 
 properties They are consid red the most serious and are poten
 (Kalachnik, 1999).  The ‘non-specific side effects’ described by Barsky et al. (2002) 
ition of a Type B reaction, except for the expected level of severity.  Barsky et 
al.’s (2002) definition includes milder symptoms were as the Type B definition describes serious 
reactions. 
medication, and no other possible diagnosis has been found, may be a previously undocumented 
ADR associated with the medication, and unless medical practitioners report this type of case, 
this knowledge will not be added to the developing body of ADR know
 
The difficulty with the second strategy is that the person who is anxious and very focused on the 
possible ADRs associated with medications, may be a person who
a
experts, which may mean they are more likely to experience ADRs to medications.  No clear
strategy in determining which explanation is most likely emerged from this study. 
 
Another complexity of the nocebo effect, is that the symptoms medical practitioners sometime 
believe are the results of a nocebo effect, are symptoms known to be associated with a particular 
drug, and the belief is that because the consumer is aware that this set of symptoms may be 
associated with a particular drug, it is these symptoms they develop as a nocebo effect.  It is not 
clear from the case studies how a medical practitioner can make a differential diagnosis between 
a set of symptoms known to be associated with a drug which are caused by a drug, and which 
are caused by a nocebo effect. 
 
An article by Barsky et al. (2002), discusses the issue of the nocebo phenomenon associated with 
medications.  They categorise two sets of symptoms “ ‘specific side effects’ are symptoms or 
physiolog
ac nd tend to e dose-dependent and edictable.”  Th  definition is 
equivalent of the
they describe 
ea  in he ym
cif e sy lo at
be explained o f aco
dose depend  n effe
and adverse.”  
pharmacological .  e tially life 
threatening
fit with the defin
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largely accounted for by the 
ocebo effect.  When a drug trial occurs, one control group receive the drug and the control 
gh incidence of ADRs reported by 
 future work incorporate: 
he letters rsky et al. (200 wever, this 
y be all but impossible to make”. 
in not identifying a nocebo effect is that drugs are attributed with ADRs incorrectly, 
se of a pote lly useful therape tic tool.  The danger in incorrectly diagnosing 
 nocebo effect is that the consumer experiencing the symptoms may be nosed 
. 
ithin this work that illustrates the problem is Irene’s case.  Without explicitly 
stating his reasoning, D ne’s symptoms were a 
nocebo effect rather than effects of the drugs based on behaviours that did not appear logical to 
 
having experienced multiple ADR due to an underlying metabolic condition that has not been 
 
Barsky et al. (2002)  argue that the ‘non-specific side effects’ may be 
n
group receive a placebo.  Barsky et al. (2002) highlight the hi
participants receiving the placebo, which they attribute to the nocebo effect.   
 
Publication of this paper resulted in several letters to the editor in response. Within these letters 
an issue was raised that a placebo is a compound.  It is possible that a consumer has had a 
reaction to the compound used within the placebo drug (Golomb, 2002). Another respondent 
(Caspi, 2002) suggested
  
…a 2 x 2 matrix comprising four conditions in which subjects are (1) told they will get a 
drug and receive a drug, (2) told they will get a drug but receive a placebo, (3) told they will 
not get a drug but receive the drug in a disguised form, and (4) told they will not get a drug 
and receive a drug (p. 2502). 
 
In response to t
distinction ma
, Ba 2) concede “…in clinical practice, ho
 
The danger 
limiting the u ntia u
symptoms as a
incorrectl
diag
y
 
One case study w
r James appeared to be suggesting that some of Ire
him.  Irene fits the personality characteristics described by Barsky et al. (2002), and it is possible 
that this is the case. 
 
It is also possible that Irene’s anxiety and focus on her health is based on a fear that has evolved
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.3.4. THE ROLE OF THE CONSUMER IN THE ADR DECISION DOMAIN 
dec aker participates in.  This table was 
n from this table, the medical practitioner makes the majority 
f the decisions within this environment, with the lower case indicating a partial role.  The 
Medical Practitioner ADR Expert Pharmacist 
diagnosed, as suggested by one of the experts.  Diagnosing a nocebo when there is an underlying 
condition is clearly not a diagnosis that most serves the consumer.  Diagnosing ADRs that are 
actually the result of a nocebo effect also have negative connotations.   
 
A key implication here is that further research is required to understand this phenomenon more 
clearly to assist in the process of differentially diagnosing ADRs.  
 
6
In chapter two, a table (Table 2.3) was presented that illustrated the decision-makers in the ADR 
ision domain, and the types of decisions each decision-m
derived from the literature, the preliminary background work to this thesis, and analysis of the 
current ADR decision support systems designed to assist decision-makers with ADR decision-
making.  This table has been included again, below, to remind the reader of its content. Table 
6-6 includes the primary decision-makers within the ADR domain, and the decision types within 
the ADR decision domain that were identified through the literature and the preliminary 
background studies.  As can be see
o
consumers, therefore, participate in the treatment decisions and make decisions about life style 
and when to seek treatment.  The diagnostic decisions are the domain of the medical 
practitioners with the ADR experts, and the information supplied by ADRAC, assisting in this 
process. 
 Consumer
D
D
etecting and 
iagnosing 
 X X  
Treatment  x X   
Prescribing  X   
Reporting x X  X 
Seek treatment 
(Broadst
Michie, 2000) 
X   X 
ock & 
Lifestyle 
decisions 
(Broadstock & 
Michie, 2000) 
X   X 
Table 6-6 Decision types made by each decision-maker 
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he results presented in chapters four and five suggest that in the area of ADRs, consumers 
make decis
 
6.3.4.1. Co
The results fro
detected their 
experts, strengthening the argument that these consumers had the ability to recognise a set of 
symptoms 
existing disease ferred to in the medical community as 
differential
 
able 6-7 illustrates the additional consumer decisions illustrated by this work.  The sections in 
pre
maker that were found in this work. 
Consumer Medical Practitioner ADR Expert Pharmacist 
T
ions that are broader than those illustrated in Table 6-6.   
nsumers as ADR diagnostic decision-makers 
m the work of this thesis indicate that the consumers in this study not only 
suspected ADRs, but in many cases their suspicions were confirmed by the 
as being likely to be associated with a drug rather than symptoms of either a pre-
 or a newly developing disease, a process re
 diagnosis. 
T
an font that is not bolded, indicate the decision types made by each decision-maker that were 
viously known, and the bolded sections represent the decision types made by each decision-
 
Detecting 
Diagnosin
 and 
g 
X X X 
Treatment  X X   
Prescribing X    
Reporting X X  X 
Informatio
sharing 
n  
X 
  X 
Informatio
seeking 
 n X   X
Lifestyle 
M
X   X 
decisions 
(Broadstock & 
ichie, 2000) 
Table 6-7 Consumer role in ADR decision-making 
 
As can be seen
decision, treatm n type 
of informat
 
 from Table 6-7, the decision types made by the consumer include diagnostic 
ent decisions, information seeking and information sharing.  The decisio
ion sharing is an additional decision type that emerged from these data. 
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sion models in 
ection 5.5.1.2, the discussion of ADR diagnostic decision-making in section 5.2.2.2, the results 
de
AD
we lustrating how they did 
it. 
ION-MAKING BASED ON PARTIAL KNOWLEDGE WHICH 
CONTRIB
The results s of the single case 
studies.  It was this level of analysis, where mu ple views of a single instance of an ADR, that 
nowledge unknown to the other decision-makers and some that is 
 
and the relative proportion 
kn owledge of diseases and 
onditions; and knowledge of consumer behaviour and the consumer medical history (recorded 
th partial knowledge.   Partial knowledge has several dimensions.  It may 
clude: 
When combining the discussion of the medical practitioner/consumer deci
s
that discussed the strategies consumers used to make ADR diagnostic decisions, and the various 
cision types discussed in this chapter, there is mounting evidence of the role consumers play in 
R diagnosis.  Not only did consumers make ADR diagnostic decisions within this work, and 
re capable of making those decisions, a set of strategies also emerged il
 
6.3.5. ADR DECIS
UTES TO THE INCIDENCE OF ADRS. 
 that informed partial knowledge came only from the analysi
lti
the differences in understanding, at an individual level, were most apparent.  These results 
suggest that ADR knowledge is distributed between multiple decision-makers and each decision-
maker has access to some k
shared between decision-makers.   
Figure 6-9 illustrates knowledge within the ADR decision domain 
each decision-maker has to each of the three sources of knowledge.  The three sources of 
owledge include: knowledge of drugs and drug behaviour; kn
c
history and unrecorded history). 
 
It appears from this work, that most ADR decisions are made with only partial knowledge.  This 
work illustrated some problems that arose in the decision domain which appeared to result from 
decision-making wi
in
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ledge between participant groups.Different levels of know
ADRAC
Medical Specialist
General Practitioner
Consumer
Knowledge of
consumer
behaviour
and their history
conditions
and diseases
Knowledge of
drugs and drug
behaviour
Knowledge
of medical
 
Figure 6-9 Knowledge in the ADR decision domain 
 access to only some of the available ADR knowledge: 
 
o consumers with limited knowledge of potential ADRs to drugs; 
o consumers with limited knowledge of the likely progression of ADRs; 
o consumer’s awareness of the risks of a drug compared with the benefits of the 
treatment and the risks of not treating the disease. This result has been discussed 
in detail in a recent health informatics conference paper (O'Brien & Yearwood, 
2004); 
o medical practitioners unable to keep up-to-date with the large number of drugs 
o different decision-makers placed emphasis on different knowledge sources, 
resulting in different preferred decisions. 
that are introduced into the market place; 
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ledge used in ADR decision-making is at 
any point in time (That is, partial awareness of what knowledge exists that the decision-maker 
ilable knowledge about 
potential and preventable ADRs; 
tives of ADR concepts: 
is not an ‘allergy’, meaning ‘it is another type of ADR, but not an allergy’; 
o the consumer’s level of concern compared with the medical practitioner’s 
hase pain 
killers.  In the middle of the night, the only pain killers in the house were Panadeine Forte 
rom the same drug 
      resulting in frustration of symptoms that have no diagnosis. 
 
 partial awareness of the completeness of the know
is not aware of): 
 
o medical practitioner’s awareness of the consumer case history; 
o medical practitioner’s awareness of the consumer’s concerns, fears, perceptions, 
impact of an ADR; 
o medical practitioners limited knowledge of all ava
o consumer’s awareness of the reliability of the information s/he accesses; 
 
 knowledge of one definition or understanding of a concept and lack of knowledge or 
understanding of the other perspec
 
o consumers labelling a set of symptoms, for example, as an ‘allergy’ (using a term 
to mean ‘symptoms associated with a drug’, and the medical practitioner saying it 
awareness of the consumer’s level of concern. 
 
The impact of partial knowledge in the ADR decision-making domain included: 
 
 consumers making decisions based on incomplete knowledge.  An example was Helen was 
not aware that her pre-existing condition may cause severe pain, and so did not purc
prescribed for her husband, and so she chose to take that medication; 
 a break down in trust between the consumers and medical practitioners; 
 prescribing a drug for a consumer that was contra-indicated according to the experts 
 a lack of diagnosis: 
o leaving the consumer open to experiencing a second ADR f
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l records, and 
bringing this information to the attention of the decision-makers. 
nic records are central to a medical service rather than centralised for a 
onsumer.  This technology may be useful in the future when the sharing of electronic medical 
is the central body in Australia 
r collecting reports about potential ADRs.  A figure that has been used extensively when 
rrent knowledge of ADRs to inform the process of differential diagnosis.  The idea 
e medical practitioners were diagnosing a set of symptoms that may be a previously 
undiagnosed ADR did not appear to be a factor considered in most cases.  The hypothesis that   
 
The implications of this emerging theory, is that if partial knowledge does contribute to the 
incidence of ADRs, and the ability to detect and manage them quickly, roles for ADR decision 
support may be to assist in: 
 storing all this information centrally, a solution that has been a focus of centralised medical 
records; 
 facilitating sharing of this information between decision-makers; 
 accessing relevant information from within complex computerised medica
 
Intelligent software agents (ISA) described in chapter two, have the ability to perform functions 
such as these.  Limitations at this stage are that most medical records at this stage are still paper 
based, and electro
c
data is established. 
 
6.3.6. PROBLEMS WITH GENERATING NEW ADR KNOWLEDGE 
The final set of results emerging from the case studies relates to developing new ADR 
knowledge.  As described in the introductory chapter, the TGA 
fo
discussing this work has been included below (Figure 6-10).  
 
As can be seen from this figure, the process of developing new ADR information is via reports 
from consumers and medical practitioners.  These reports are reviewed by ADRAC and are 
stored in the ADRAC database. 
 
Within the case studies, the medical practitioners and consumers used existing knowledge to 
make decisions about suspected ADRs.  If they could not locate information about a suspected 
ADR, they were more likely to decide that the drug and symptoms were not related.  That is, 
they used cu
that th
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TGA ADR
Database
ADR Bulletins
Blue Card
Consumer
One or more
Medical Staff may
 Complete
Blue Card
Therapeutic Goods
Administration reviews
data on Blue Cards
and then stores in
database
ADR Bulletins are posted out
and are available on the Web
Medical staff
 gather
information
from consumer
and detect
a suspected ADR
Data analysed
extensively by
Therapeutic Goods
Administration
 staff and ADRAC
ADRAC committee
+/or +/or committee
rmation to be
shed in the
R bulletins
ADRAC committee
determine critical
info
publi
AD
Consumer experiences
a suspected ADR.  The only
person to view the entire
ADR.
General
Practitioner
Partial
Medical
history
Emergency
Clinic
Partial
Medical
history
Hospital
may include
Pharmacists or
Medical
Practitioners
Partial
Medical
history
 
Figure 6-10 Collection and dissemination of ADR information by ADRAC 
 
the symptoms were a nocebo, or belonged to a pre-existing or newly developing disease 
 
s in this work reported the suspected ADR.  
& Yearwood, 2002, 2004), found that the number 
f reports sent to the TGA are likely to be significantly lower than the number of suspected 
appeared to be a more likely diagnosis, in their minds. 
None of the medical practitioners nor consumer
Three reasons were given by the medical practitioners: it is a known ADR as is well documented; 
it is unlikely to be an ADR; the reporting processes are too complex. Although consumer 
reporting has been available in Australia for many years, it has not been promoted and a 
dedicated consumer reporting service has only been introduced within the past year.  The data 
collected for this work occurred prior to the promotion of this service. 
 
The preliminary background studies (O'Brien 
o
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ecause the TGA promotes the reporting of serious or 
own to them, or there is a variation in this particular case compared with what they 
reviously knew about this type of case; or they believe there is unlikely to be a relationship 
he decision support systems described in chapter two, used within a hospital setting to alert 
ecords in the community settings at this stage are still primarily paper 
ased, and may be stored by multiple medical practitioners in multiple locations.  
ADRs that occur.  One reason for this is b
unexpected reactions to new drugs.   
 
Of the three reasons, the ADRs that are known and have been well documented, did not need to 
be reported.  The other two groups, however, would have assisted in developing the ADRAC 
database.  
 
The paradox of this situation is that the medical practitioners and consumers rely heavily on 
what is currently known about ADRs, but unless they report cases where: the suspected ADR 
was unkn
p
between the suspected drug and the newly presenting symptoms, but there is some doubt; this 
knowledge, which decision-makers in this domain depend on, will remain out of date. 
 
Another problem that emerged from these case studies, was that even when an ADR was 
described by a medical practitioner as ‘known’, the medical practitioner did not recognise it as an 
ADR within the clinical setting.  This indicates that perhaps documenting ‘unknown’ ADRs is 
not enough, and that the medical practitioners may benefit from a decision support system that 
assists in recognising ADRs, regardless of whether they are known or not. 
 
T
hospital staff that a consumer may be experiencing an ADR, used rule-based engines to 
recognise a subset of possible ADRs.  This issue suggests that medical practitioners and 
consumers within a community setting may benefit from technology that performs a similar 
function. As the context is different, the system would need to work differently.  These hospital 
based systems used information that was available in their centralised electronic hospital medical 
record.  The medical r
b
 
The results relating the development of new ADR knowledge, however, highlight the 
importance of resolving the problems of non-reporting, and suggest that documenting 
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were discussed in chapter 
e of the population of ADR case studies.  The 
re cannot be generalised to the wider ADR population. This work is 
ed 
 the data and can be tested using qualitative research methodologies to determine the extent 
mine the degree that they are present in the wider 
opulation. 
.4.2. CONSUMER VOLUNTEERS 
rep
bu
of medical practitioners who declined may have had a particular set of characteristics. 
a  C reactions were 
presented within this group of case studies.  It is not known if the distribution is typical of the 
 
knowledge about ADRs is not enough, and that decision support may have a role in detecting 
suspected ADRs. 
 
6.4. Evaluation of  the research process 
The results that have emerged from these case study data that were documented in chapters four 
and five, have added to current knowledge of the ADR decision domain.  These contributions, 
however, have some limitations.  Some limitations of the methodology 
three.  The implications of those limitations are discussed below. 
 
6.4.1. IN-DEPTH ANALYSIS OF FIFTEEN CASE STUDIES 
Fifteen case studies are unlikely to be representativ
result of this thesis, therefo
exploratory in nature, and so generalising the results was not a goal. A large amount of data were 
generated from this small group of case studies, and an advantage of using this smaller number 
was that very in-depth analysis could be performed.  The emerging theories have been imbedd
in
that they can be generalised.  Exploratory work is a necessary stage so that new ideas can 
emerge, which can then later be tested to deter
p
 
6
The consumers and experts were volunteers and so as a consequence are likely not to be 
resentative of all consumers, and all experts.  The medical practitioners were not volunteers, 
t from the group that were targeted, those that agreed to participate did self select.  The 30% 
 
When the cases were viewed there was significant stratification of the data, providing insight into 
wide variety of case types, (refer to Table 4-2).  All except for Type
re
population of ADR case studies. 
CHAPTER SIX:  DISCUSSION 
278 
he use of volunteers has similar implication to a small sample size.  Generalisation cannot be 
pa
 
Al y were involved in diagnostic 
ecision-making, not all consumers are.  The implication, therefore, is not that all consumers 
are capable and interested.  It is not known what proportion of all 
onsumers this relates to, but it means that this group of consumers need to be recognised 
within this domain. 
 
6.4.3. CHOICE OF PARTICIPANTS 
Consumers, medical practitioners and experts were the only participants who were interviewed.  
The data suggested that other decision-makers in this domain included pharmacists, the 
consumer’s family and friends and other health professionals.  An analysis of the roles these 
other decision-makers in this domain play, in particular the role of the pharmacist, and the role 
of the family and friends, may add additional insight not revealed by interviewing only the 
consumers, medical practitioners and experts.  The initial three, however, was a useful starting 
point. 
 
6.4.4. BIAS OF THE RESEARCHERS 
As was discussed in the introductory chapter, the use of the terms ‘consumer’ and ‘medical 
practitioner’ rather than ‘doctor’ and ‘patient’, reflect our bias towards the notion that consumers 
and medical practitioners each have a perspective that is important within any medical 
consultation.  It is also our expectation, based on a symbolic interactionist theoretical 
framework, that as well as each of the participants having a perspective based on the social 
grouping/s they belong to, the researchers within this work also have expectations.  Our biases 
come from our own experience as consumers, a belief that consumers are a valued member of 
the medical team, and experience from allied health which has a focus on family centred 
practice. 
 
T
made, and awareness that some attributes of the participants may not be typical of all 
rticipants, is necessary when interpreting the results. 
though a significant proportion of the consumers in this stud
d
have the ability to, and/or interest in participating in ADR diagnostic decisions, however, this 
work shows that some 
c
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Grounded theory, as a methodology, is based on an assumption that researchers are able to set 
aside their pre-existing ideas and allow ideas to emerge from the data.  It is recognised coming 
from a social constructionist epistemology, that this is a theoreti
cannot humanly be adhered to completely.  As an ideal, however, it allows researchers to 
become aware of their own pre-existing ideas, to a
open to newly emerging ideas.  The use of using grou
data that were in line with the preliminary thinking of the researchers, and other results that were 
 the preliminary thinking.  The use of this methodology, therefore, 
er set of researchers, conducting this study, are likely to view the results from a 
ifferent perspective.  
 than taking a 
ritical stance. These theoretical perspectives, therefore, are not sensitive to issues of power 
, reflects the researcher’s awareness of this hierarchy within the social systems this 
ork was conducted within.  The dominance of the medical view in the decision making was 
mo  within medicine.  The use of symbolic 
these issues a critical methodology would have been required. 
Th n-maker and 
eir contribution to ADR decision-making.  Although the power issues would have added an 
additional dimension to this work, they were not fundamental to the questions being asked. 
cally ideal position, one that 
cknowledge them, and then attempt to be 
nded theory revealed some results from the 
not expected, and challenged
was a useful tool to assist in understanding newly emerging themes from the data. 
 
The theories that have emerged from this work, which attempt to make sense of the results, are 
based on the results of the data combined with the perspectives of the researchers.  The 
researchers, like the consumers, medical practitioners and experts, also construct meaning based 
on their preliminary understanding of the world.  This is an expected result of the research 
process.  Anoth
d
 
6.4.5. LIMITATIONS OF THE THEORETICAL PERSPECTIVE 
Social constructionism and symbolic interactionism take a non-critical perspective.  The aim is 
that all views are equally valid and they provide an avenue to observing rather
c
between groups.  The use of first names for consumers and the title Dr. for each of the medical 
practitioners
w
reflected: within the data; within the pre-existing medical practitioner/consumer decision making 
dels; and within the current focus of decision support
interactionism, as a theoretical framework, did not highlight these issues explicitly.  To highlight 
 
e research questions within this work were about the perspectives of each decisio
th
279 
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ts within this domain are multi-
dimensional.  That is, different groups of users had different understandings of the concepts. 
The following section was a discussion of the contributions the work of this thesis made to 
 an expansion of Emanuel and Emanuel’s (1992) medical practitioner/consumer decision 
ision domain, including consumers as diagnostic 
decision-makers; 
6.5. Conclusion 
Chapter six began with a discussion of the concepts within the ADR decision domain.  Analysis 
of the case study data revealed that many of the concep
 
theory.  Contributions included the following: 
 
 the use of multiple perspectives and triangulation to inform systems design; 
 

models.  Analysis of the case study data added two additional models to this framework: 
consumer only decision-making, and medical practitioners and consumers as partners in 
decision-making; 
 
 insights into how ADR differential diagnosis occurs.  This then can be used to determine 
which decision theories and technologies can be applied to this problem; 
 
 the role of the consumer in the ADR dec
 
 the contribution of partial knowledge to the incidence of ADRs.  The consumers, medical 
practitioners and experts all had specific knowledge that was unknown to the other 
participants.  Decision-making with only partial knowledge contributed to the incident of 
ADRs and failure to detect ADRs in some of the case studies; 
 
The final section in this chapter is that of evaluating the research processes, discussing the 
limitations of this work. 
 
  
CHAPTER SEVEN 
7. Conclusion 
7.1. Introduction 
.2. Contributions to knowledge 
nding of the ADR decision domain to 
n 
This concluding chapter will outline the key contributions this work has made to knowledge. 
This will include the contributions of the research process (7.2.1) and of the emerging theory 
(7.2.2).  These contributions will then be discussed in relation to the implications for the 
prevention, detection and management of ADRs (7.2.2.1), and also the implications for the 
development of ADR decision support (7.2.2.2).  Suggestions for future work will be discussed 
in section 7.3. 
 
7
The overall aim of this thesis was to develop an understa
add to current knowledge of how ADR decisions are made, the problems that arise when 
making these decisions, the complexities and the impact ADRs have on people.   
 
This work had three key purposes, which correspond to the contributions this work has made to 
knowledge: 
 
 to add to knowledge of this domain, so that it can be used by the decision-makers to assist i
the prevention, detection and management of ADRs; 
 to provide an understanding of the domain that can be used to inform the requirements 
analysis phase of ADR decision support; 
 to determine the extent that methodology used within this work can be applied to the 
requirements analysis phase in the field of software and/or systems engineering. 
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PMENT OF DECISION SUPPORT 
he majority of systems development begins with an assumption of who the end users are, and 
s assumption.  Systems development, also, has 
one within the Information Systems (IS) community to move towards the 
se of qualitative research methods to inform the requirements analysis phase of systems 
espite significant gains in understanding of the 
omain through the use of this methodology. 
 of multiple perspectives of a single instance of an ADR.  This framework has 
ken the methodologies used within the IS research one step further.  Qualitative methods can 
Some of the findings have been previously documented in the literature.  Some outcomes, 
however, expand on current knowledge, and relate to the primary purposes, described above.  
These contributions are described below. 
 
7.2.1. THE CONTRIBUTION OF THE RESEARCH PROCESS TO THE 
DEVELO
T
scoping of an intended project based on thi
traditionally come from a positivist theoretical framework, where the aim is to provide 
information systems that are based on a uniform understanding of the core concepts.  
 
Some work has been d
u
engineering and to move towards the use of philosophical perspectives other than objectivism.  
Qualitative methodologies, including the use of grounded theory, have been used within the field 
of IS to analyse case studies as a tool for gathering requirements prior to the development of 
information systems. The concern raised by some authors has been the cost of gathering 
requirements using these methodologies, d
d
 
The work of this thesis has included a combination of a social constructionist philosophical 
perspective, symbolic interactionist theoretical framework and grounded theory analysis of case 
studies made up
ta
be used to analyse case study data, based in a positivist theoretical framework.  This work, 
however, has used triangulation of multiple perspective case studies using a theoretical 
framework that embraces understanding the differences between decision-makers rather than 
attempting to reconcile those differences.  This has added an additional dimension to current 
understanding of this decision domain.   
 
The concerns over the costs of using this type of methodology within a business context are 
likely to be different when applying it to a decision domain within the area of consumer safety.  
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ecision domain prior to, and following the work of this 
esis is compared, it can be seen that this methodology has provided additional insight that can 
 development of decision support.  As well as providing 
pter six, and so will be summarised 
elow.  This is then followed by the contribution this knowledge has made to understanding of 
ction and management of ADRs, 
r side effect’ 
ere informed by the analysis of the case study data.  For each of these concepts, multiple 
The costs of ADRs include the immediate costs of longer hospital stays, the treatment of the 
illness or injury, prescribing additional medications and lost time for the consumer in the 
workforce.  The intangible costs are associated with loss of trust between consumers and their 
medical practitioners and limiting a consumer’s treatment options based on a past injury or fear 
of future treatments.  Other costs are associated with the development of decision support 
systems that provide only a partial solution, or that may address the goals of the initial systems 
design, but may not fully address the core goal of preventing and detecting ADRs. 
 
When the knowledge of the ADR d
th
now be used as the basis for the
additional knowledge from the perspective of previous work within this area, the medical 
practitioner perspective, it has provided an integrated understanding from the perspectives of 
the consumer, medical practitioner and experts, with some additional understanding of the roles 
of other decision-makers such as the consumer family and friends, pharmacists and other health 
professionals. 
 
7.2.2. CONTRIBUTIONS TO ADR KNOWLEDGE 
The work has contributed to knowledge of the ADR decision domain from a number of 
perspectives.  These areas were described in detail in cha
b
the decision-makers that can be used in the prevention, dete
and then how it can be used to inform ADR decision support. 
 
7.2.2.1. Multiple understandings of the core concepts within the ADR decision domain 
The core concepts within the ADR decision domain were identified.  A number of these 
concepts, such as ‘reaction’, ‘side effect’, ‘allergy’, and ‘significant reaction and/o
w
definitions emerged from the multiple perspectives within the case study data.  Another group of 
concepts were defined using a single perspective, such as the term ‘known’ which came from the 
expert perspective.  The analysis of the case studies revealed the ambiguity within the domain 
that arose by using a definition that came from one perspective. 
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ionist 
pproach to identify these differences in meaning may assist in the development of any multi-
he results of the work of this thesis suggest that within the ADR decision domain, consumers 
e a number of strategies the consumers used when making a differential 
iagnosis, which relied on the partial knowledge of the ADR decision domain that the 
e not relied on the broader medical knowledge of medical 
aking them, with or without the support 
f the medical practitioners and/or decision support.  These data suggest that acknowledging 
computer repairs, the consumer may take a car or computer to an expert for a diagnosis of what 
The approach of identifying the specific meanings attributed to common terms within a multi-
user environment revealed different understandings even though the label for the term is the 
same.  This phenomenon is likely to exist in any multi-user environment, especially when the 
multiple end-users are also from multiple end user groups.  The use of a social construct
a
user system. 
 
7.2.2.2. Consumer’s role in ADR diagnosis 
A review of relevant literature revealed that medical decision-making is primarily the domain of 
medically trained professionals.  Decision support has recently moved towards including 
consumers in treatment decisions.  The role of diagnosis, however, has remained the domain of 
medical practitioners. 
 
T
play an important role in ADR detection.  In the majority of the case studies of suspected ADRs, 
the consumer was the first to suspect the newly presenting symptoms were associated with a 
drug, and in some of the cases, the consumer made a diagnosis that was later confirmed by the 
medical practitioner and/or an ADR expert. 
 
There appear to b
d
consumers have had access to, and hav
practitioners.   
 
These data do not suggest that all consumers can or would choose to be involved in ADR 
decision-making at this level, but it does suggest that not only are some consumers capable of 
making ADR diagnostic decisions, they are currently m
o
this ability and role, and working to support it, may assist in earlier detection of ADRs. 
 
In many domains, it is the expert’s role to make diagnostic decisions.  In areas such as car and 
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ithin the area of medical decision-making, 
owever, the specialist medical knowledge required for diagnosis has remained firmly within the 
 the consumer in other forms of 
 knowledge is not new.  The analysis of these case study data delineated 
e knowledge held by each of the decision-makers (Figure 6-9), and suggests, that each 
is of the case studies suggested three additional models that were observed within our 
ase study data: “medical practitioner only decision-making, informing consumers”, “medical 
practitioner and consumers as partners in decision-making” and “consumer only decision-
making” (Figure 6-7).  The analysis of the data also suggests the need to use different medical 
is wrong.  Within these fields, it is acknowledged that the consumer may also have some 
knowledge that will contribute to the diagnosis.  W
h
medical domain.  The concept of determining the role of
diagnostic decision-making, and using the consumer’s knowledge and expertise, may be of 
benefit to any domain where a diagnostic process is involved.  It is likely that in some domains 
the consumer role is less and in other domains there is more involvement, but an awareness that 
the consumer may hold partial knowledge and may be an essential contributor may be important 
to consider. 
 
7.2.2.3. Partial ADR knowledge 
This work suggests that each of the decision-makers within the ADR decision domain have 
knowledge which is important when making ADR decisions; and that most ADR decisions are 
made with only partial knowledge.  Awareness that medical decisions are often made with 
incomplete and uncertain
th
decision-maker has important information, that is largely unknown by the other decision-makers.  
It suggests that perhaps the combining of this knowledge would result in more complete 
knowledge, and that decision-making with the complete knowledge may result in more informed 
decisions than when made with less complete knowledge.   
 
7.2.2.4. Medical practitioner/consumer decision models 
A set of medical practitioner/consumer decision models was suggested by Emanuel and 
Emanuel in 1992.  These models are descriptive models, the models that have been observed as 
being used within the medical practitioner/consumer decision environment rather than models 
that prescribe best practice.  This set of models was expanded on by Charavell et al. in 2001.  
The analysis of these case study data suggests a further expansion of these models. 
 
The analys
c
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the e independent decisions about anaesthetic 
rugs which may or may not be shared with the consumer post-surgery; and non-critical 
at all decision-makers play an important role, and each have part of the ADR knowledge, 
 
rk arose from the ADR decision domain, 
agree to use within a consultation associated with ADR decision-making to decrease confusing 
decision-making.  
 
7.2.2.5.
Analysis of the medical p  
that were used by these decision-makers to make a differential diagnosis.  Combining these 
strategies resulted in an ses used to make a differential 
y presenting disease or condition; a current disease or 
lete.  The 
del as a starting point to understanding these 
n order to have a more complete understanding, this model would need to be tested 
practitioner/consumer decision models, depending on the situation.  Two examples included: 
 need for a medical practitioner in surgery to mak
d
decisions made by consumers that may or may not be shared with a medical practitioner.   
 
The data also indicated that when one decision-maker is using one decision model and another 
decision-maker is using a different decision model, miscommunication may arise based on the 
differences in expectations.  The awareness that each decision-maker has partial knowledge of 
the ADR decision domain, in combination with the emergence of the consumer’s role in 
differential diagnosis suggests the existence of a medical practitioner/consumer decision model 
which relies on partnership between the decision-makers. The use of this model acknowledges 
th
which when combined, may result in a decision made with more complete knowledge.   
Although the decision models identified within this wo
it is likely that these models will be found in other areas of medical decision-making. The 
principles of identifying the decision model the particular consumer and medical practitioner 
and miscommunication can be generalised to other aspects of medical practitioner/consumer 
 ADR differential diagnosis 
ractitioner, consumer and expert data, revealed a number of strategies
 initial understanding of the proces
diagnosis between: an ADR; a newl
condition; and symptoms arising from a nocebo effect. 
 
This emerging model of ADR differential diagnosis (Figure 6-8), is by no means comp
analysis of these case studies suggested this mo
processes.  I
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differentially diagnose an ADR and a nocebo effect. 
 differential diagnosis the 
edical practitioners in this study did not report the suspected ADRs for a number of reasons, 
 ADR knowledge. 
urrent literature highlights that ADR reporting is low and discusses the implications for the 
 
using a larger number of participants, and further work is required to understand how to 
 
7.2.2.6. Barriers to the creation of new ADR knowledge 
New knowledge about ADRs is created at an international level, a national level and at the level 
of the individual decision-maker.  Although the decision-makers, in particular, the medical 
practitioners relied on existing ADR knowledge to assist with ADR
m
and therefore did not contribute to the creation of new
 
The other barrier to the development of ADR knowledge is at an individual level.  In cases 
where the prescribing clinician and the medical practitioner were different medical practitioners, 
in many cases, the prescriber did not receive feedback that s/he had prescribed a drug that may 
have resulted in an ADR, so the prescribing medical practitioner did not have the opportunity to 
learn from the incident. 
 
C
development of new knowledge.  This work adds in a small way to this understanding showing
clearly the paradox of the medical practitioner’s reliance on current ADR knowledge, the lack of 
reporting and the apparent lack of awareness of the link between the two.   
 
7.2.2.7. Impact of ADRs on consumers and their future decisions 
Triangulation of the case study data highlighted the differences in perspective between the 
decision-makers relating to the impact and severity of the ADR on the consumer, either directly 
or indirectly.  In several of the case studies, the consumer’s reported experience, and the medical 
practitioner’s understanding of the consumer’s experience were very different.  These case 
studies demonstrate clearly this miscommunication and the direct impact of this 
miscommunication had on the medical practitioner/consumer relationship, and on future ADR 
decisions. 
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e partial 
nowledge, each participate in all decision types although they may play different roles, each has 
very different from the consumer’s perception of his/her experience.  Checking explicitly 
7.2.3. KNOWLEDGE OF THE ADR DECISION DOMAIN THAT CAN BE USED TO 
PREVENT, DETECT AND MANAGE ADRS 
 
A key theme that has arisen from the analysis of these case studies from a social constructionist 
perspective is that different decision-makers have different perspectives.  Each hav
k
a different understanding of the core ADR concepts and each will have a preferred model of 
interaction.  Awareness of these differences, and the willingness to have a meta-conversation, to 
clarify expectations and understandings, along side the conversation about the suspected ADR, 
may assist in communication that works towards combining knowledge, and understanding. The 
areas of clarification that may need to occur somewhere within the consultation include: 
 
 an agreed medical practitioner/consumer decision model.  Awareness that this model is likely 
to change in different situations, and that different consumers will prefer different models;  
 clarification of terms used by each decision-maker; 
 awareness that each decision-maker holds important knowledge;  
 active sharing of that knowledge at a level that is within the consumer’s interest and level of 
understanding; 
 awareness that the medical practitioner’s understanding of the consumer’s experience may be 
with the consumer may assist in joint understanding; 
 acknowledgment and acceptance of the range of decision types a consumer may use within a 
medical consultation, as a first step towards working in partnership with the consumer; 
 awareness that unless new ADR knowledge is developed, ADR differential diagnosis that 
relies on this information will become more difficult.   
 
A problem often raised by GPs is that of the lack of time in a short medical consultation, which 
inhibits additional discussion and clarification.  The analysis of these case studies suggests that 
not taking the time to have these discussions can also be costly. 
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MAIN THAT CAN BE USED TO 
ecision-maker responsible 
r making ADR diagnostic decisions, acknowledging and incorporating consumer knowledge 
ted by the approaches in sections 7.2.4.2 to 7.2.4.4 
ts in collaborative decision-making. Another decision support system 
at accommodates multiple perspectives is PlanIT, a system designed for land and water 
ocial constructionist philosophical 
perspective have been located, however one group of authors did use a constructionist 
7.2.4. KNOWLEDGE OF THE ADR DECISION DO
INFORM ADR DECISION SUPPORT 
 
The additional understanding of the ADR decision domain that has emerged from this work 
may be used when developing ADR decision support systems.  It is out of scope of this work to 
take the outcomes of this work and design an ADR decision support system, however the results 
point to particular solutions that will be discussed within this section. 
 
7.2.4.1. Consumer’s role in ADR decision-making 
The role of the consumer in ADR decision-making, and in particular in diagnostic decision-
making has clear implications for the development of ADR decision support.  That is, that ADR 
decision support, rather than being a single user system, would benefit from being a multi-user 
system, and rather than focusing on the medical practitioners as the d
fo
into the decision-making processes as sugges
below. 
 
7.2.4.2. Multiple understandings 
Multiple user decision support has been developed to accommodate multiple perspectives.  One 
example is a system called CUP (Collaborative Urban Planner), which has been designed to assist 
in decision-making from the perspectives of a city council, an architect and someone who has 
submitted an application for urban development (Monoharan, Taylor & Gardiner, 2002).  This 
system accommodates end user requirements from multiple groups such as the council, architect 
and applicant.  It also assis
th
resource planning.  This system is designed for end-users ranging from farmers to government 
agencies (Holyland, 2002). These systems, although catering for multiple perspectives and 
collaborative decision-making have a positivist theoretical perspective, and so assume a single 
understanding of the underlying concepts.   
 
No multi-user decision support systems based on a s
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nouns and 
erbs to search the library to accommodate the multiple perspectives found in conversation, 
cility.  This article refers to the use of the 
 end-user and is combined 
to this one database located centrally or in multiple locations.  The results from this work 
n end-users and sharing and exchange 
the 
articular decision type and/or decision context.  The agents may determine likely or possible 
ired to assist with the decision, and prompt each decision-maker for 
the specific knowledge. The knowledge that is relevant may evolve throughout the decision-
 solution would be enhanced by an electronic medical record, where the agents 
could search the electronic medical record to find relevant information and bring it to the 
attention of the decision-makers for their consideration. 
philosophical perspective for the development of multiple perspective digital libraries 
(Tuominen, Talja & Savolainen, 2003).  Their approach is to use a combination of 
v
rather than using a traditional noun based search fa
constructionist perspective in IT development, but not in the area of decision support. 
 
The results from this work, obtained using a social constructionist epistemology and applied to 
the area of decision support, suggest a different approach to the traditional multi-user approach.  
A traditional multi-user database design may include a centralised database or a distributed 
database that contains information and knowledge obtained from each
in
suggest a system that would facilitate negotiation betwee
of knowledge and the meanings attached to that knowledge, rather than pooling all of the known 
knowledge into a single database may be more useful within this domain.  Multiple users 
accessing a single database requires the database to be based on a single understanding of the 
core concepts, and an assumption that the core dataset of knowledge needed to make a 
‘completely informed decision’ is known; two assumptions that did not hold within this ADR 
decision environment, and from the social constructionist philosophical perspective, possibly do 
not hold in any multi-user decision domain. 
 
The results of this work point more towards an Agent-based system (agents were discussed in 
section 2.3.5.5). The assumption behind this suggested approach is that the decision-makers 
make the decisions, and the agents facilitate the decision-making processes. The end-users may 
be prompted to negotiate a medical practitioner/consumer decision model that suits 
p
knowledge that may be requ
making process.  The agents may prompt decision-makers to clarify meanings.  
 
This type of
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isions 
strategies to make a differential diagnosis.  Some of the 
dru rug Reaction 
cas es that have included knowledge from the 
to  attempting to make a new ADR diagnosis.  These 
based reasoning, however, at this stage, does not accommodate the issue of multiple 
us tructionist framework. 
Ar
argumentative discussion and persuasion dialogue.  As discussed previously, it can also be used 
ision-makers.  Given that each 
co
dif opinion of the importance of 
ach piece of knowledge, argumentation may be a useful approach in facilitating discussion and 
sion-makers.  Again, it may be useful in particular, when combined with 
the approaches of agents.  
tion of Flexitone.  When these pieces of information were combined 
wledge was generated. 
7.2.4.3. Using past cases to assist with new dec
One result from this work was that each decision-maker had partial knowledge, and that each 
decision-maker used a number of 
medical specialists used a pattern matching approach; recognition of a pattern of symptoms and 
gs in a past case that were similar to the case in question. The Australian Adverse D
Bulletin is also currently written in the form of cases. This result suggests there may be a role for 
e-based reasoning within this domain.  Past cas
consumer, GP, medical specialist and ADRAC, could be collated and stored within a database, 
be accessed by any decision-maker when
cases may be used as a basis of the Agent-based system described in the previous section.  Case-
understandings of core concepts.  Further thought and research is required to determine the 
efulness of this approach within a social cons
 
7.2.4.4. Combining of partial knowledge 
gumentation (discussed in section 2.3.5.6) is traditionally applied to domains which include 
to assist in facilitating the sharing of knowledge between dec
decision-maker within the ADR domain holds partial knowledge, and that even with the 
mbination of that partial knowledge, there is likely to be elements of incomplete knowledge, 
ferences of understanding of that knowledge, and differences in 
e
negotiation between deci
 
A clear result from this work is the issues that were raised by partial knowledge.  In Joanna’s case 
study, there was an example of the advantage of combining that partial knowledge (section 
4.4.4.1).  In this case study, the medical practitioner had partial information, that is, knowledge 
of the preparation of Flexitone.  Joanna also had partial information, that is, her observations of 
a reaction to the prepara
within Dr Carey’s interview, new kno
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co
 
7.2
urther development of initiatives such as HealthInsite, Health Online and MediConnect will assist in 
e 
su er consent, 
reg  
decision support would benefit from linking into these current infrastructures and initiatives to 
en  across Australia. 
A st 
ex future decisions surrounding treatment 
ecisions.  The implication this factor has for decision support is that as well as incorporating 
on  
de a in 
a d ir 
pa me and 
may change based on the situation.  The implication, therefore, is that a decision support system 
at is based on a technology such as agents may facilitate a discussion aimed at eliciting the 
his
 
7.
Th
briefly in this section. 
 
This example indicates that the use of agent technology, specifically agents that use a 
llaborative model, may be an approach to assist in combining partial knowledge.     
.4.5. Implementation of Australian initiatives 
F
providing up to date consumer information to Australian consumers.  MediConnect will provid
mmaries of medication records that a medical practitioner can access, with consum
ardless of which medical practitioner, clinic or hospital setting prescribed the drug.  ADR
sure interoperability and a co-ordinated approach
 
7.2.4.6. Impact of past decisions on future decisions 
less tangible, but important factor that has arisen from this work, is the impact pa
periences of ADRs has had upon the consumer’s 
d
the traditional medical and drug information in ADR decision support systems, including not 
ly the consumer history of past ADRs, but also the impact that history has had on future
cisions is important when making new decisions about therapy options.  Storing these dat
atabase is likely not to be useful, as the consumer’s perception of what happened during the
st experience, and their feelings towards future treatments, are likely to change over ti
th
consumer’s feelings and concerns, especially if there is a history within the consumer medical 
tory of past ADRs, so they can be taken into account when making the current decision.  
3. Future work 
is work has highlighted many possible areas for future work.  Each of these will be discussed 
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7.3.1. CONSOLIDATION OF THE RESULTS 
This work is qualitative and exploratory, which has highlighted a num
benefit from future work including: 
 a study to determine the frequency of use of each 
decision models that have emerged from this work in a variety of clinical settings; 
 a study to determine the percentage of consumers who participate in ADR diagnostic 
erred medical practitioner/consumer decision 
model and coming to an agreed model;  
 further development of the model of ADR differential diagnosis, and the testing of that 
emerging theory in clinical settings; 
 further clarification of the differences between decision-makers in understanding of the core 
concepts within the ADR decision domain; 
 understanding the role of the pharmacist in the ADR decision domain; 
 understanding further the reasons for limited reporting, and developing a strategy that will 
attempt to take into account the barriers to reporting, whilst increasing the number and 
quality of ADR reports; 
 differential diagnosis between an ADR and a nocebo effect; 
 wider use of the methodology and theoretical perspective used in this work to inform the 
development of decision support followed by evaluation to determine the effectiveness of 
this methodology in a commercial rather than research context. 
 
7.3.2. POSSIBLE DECISION SUPPORT DIRECTIONS 
As mentioned previously, it is beyond the scope of the work of this thesis to develop or design 
ADR decision support.  The analysis of the case studies, however, has suggested: a number 
general principles that may be applied to the development of ADR decision support; and also 
some research directions that may be of use within this domain.  These have been discussed 
below.  As well as developing the ideas presented in section 7.2.4, some additional ideas have 
been included below:   
 
ber of areas that may 
of the medical practitioner/consumer 
decision-making, including suspecting the ADR; 
 the impact of explicitly discussing the pref
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 Decision support may inadvertently force decision-makers into a particular decision-making 
model.  Awareness of the different decision models, that different models may be used in 
different situations, and that different decision-makers will have different preferences for the 
use of these models is important to consider when developing decision support. 
 
 A number of medical practitioners indicated that they were aware that some drugs are more 
likely to result in ADRs than others.  Determining the reliability of this hierarchy, 
documenting it and incorporating it into ADR decision support may assist by ordering drugs 
more or less likely to result in ADRs, assisting in the choice of drug to prescribe, particularly 
for consumers known to be sensitive to drugs. 
 
 One of the medical practitioners suggested providing consumers with a list of symptoms that 
they could tick whilst waiting in the waiting room, to elicit knowledge from consumers and 
facilitate knowledge sharing within a consultation.   
 
 The ADRAC database is only one source of ADR knowledge.  The medical practitioners, but 
in particular medical specialists who specialise in a particular set of drugs have seen a specific 
group of ADRs regularly, appear to have expert knowledge of particular types of ADRs.  
Accessing this knowledge and making it available to non-expert ADR decision-makers may 
be another way of gathering new ADR knowledge and disseminating it to other ADR 
decision-makers. 
 
 Develop an ADR Case Based Reasoning system to assist in real-time ADR decision-making 
and as an educational training tool.  As discussed in section 2.3.5.4, using the ADR domain, 
new cases, hypothesised by the ADR decision-makers could be tested by submitting the new 
cases to ADRAC.  ADRAC could then verify or otherwise the ‘correctness’ of the new case, 
and determine if it were to be added to the database.  If anyone were to update the database, 
there would be a risk that the integrity of the cases would be compromised. 
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 APPENDIX A  
Case Studies 
The case study data is in Volume two of this thesis.  The rea
explained in section 3.6, ethical considerations. 
soning behind this has been 
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 APPENDIX B  
Consumer plain language 
statement 
Project Explanation for Participants – Consumers 
(Plain language statement) 
Attachment 1A 
ject Title: Understanding unwanted reactions to medications. 
cipal Investigator: Michelle O’Brien 
ior Investigator: Dr. John Yearwood 
 
Pro
 
Prin
Sen
 
s people may have to 
edications in rare but serious situations. It is hoped that an in-depth understanding of these 
s present throughout the entire course of the reaction.  A Doctor may 
nly see a snap shot of the reaction. There may be more than one Doctor involved over the time 
ach person or group of people have different understandings of what is happening.  A 
throughout the entire reaction, but generally has no medical training.  A 
t 
 
Project Description 
The aim of this project is to understand more about the unwanted reaction
m
reactions will assist in the ability to prevent, detect, and if necessary manage these reactions in 
the future. 
 
This study begins with a Consumer (patient) focus. (From this point on, the Consumer or 
Patient will be referred to as the participant).  The participant who has experienced the reaction 
is the only person who wa
o
the participant experienced the reaction.  Information about the reaction may be in more than 
one medical file.  Part of it may be in the family GP’s file and some in an after hours-emergency 
clinic’s file.  The information about this reaction, therefore is spread between the participant, the 
Doctors involved and multiple medical files. 
 
E
participant is present 
Doctor is present when the participant is in his/her clinic only, but can interpret what is seen 
using an understanding of medicine.  If the reaction is serious enough, it may be sent to a group 
of experts in Canberra for their opinion.  They have expertise in reactions to medications, but 
only have access to the limited information sent to them by the Doctor, and have no access to 
e participant.  Each person or group of people only have part of the total information abouth
the reaction. 
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 In this study, we would like to gather all of the information about the reaction in order to 
understand it more fully.   We plan to interview participants who have experienced reactions to 
understand them from their point of view.  The next stage is to find all of the pieces of the 
medical history that relate to each reaction that are stored in medical files.  The third stage is to 
show this information (without identifying the participant) to a group of experts to gather their 
opinion of the reaction.  The final stage is to discuss each case with a group of General 
ractitioners.  
 a medication. 
 
cipant has any of these conditions, they will not 
icipate in the study. The first stage, therefore, will be to ask the participant, 
meet the criteria outlined in the advertisement: 
oderate to severe reaction to medication within the last 6-
e reaction; 
eational drugs either at the time of the study or at the time of the reaction; 
ditions that may affect his or her ability to report the experience.  This may 
, cognitive (processing or memory) disorders, or some psychiatric 
articipant Involvement 
incipal Investigator (Michelle O’Brien), which will be 
approximately an hour in length.  The aim of the interview will be for the participant to talk 
reaction to a medication. The interview will be tape 
Using a time line, write down the details of what happened throughout the reaction.  This 
will include symptoms, medical clinics, medications, and doses.  Obviously it may be difficult 
all of the information, but this process will assist in recalling as many facts 
 possible. 
P
 
Specifically, having gathered all of this information, we are interested in identifying the critical 
things that happened throughout the reaction, and the decisions made by the participants and 
octors, leading up to, during and following a serious reaction toD
 
The ultimate aim of this project is to use the information to develop technology that can be used 
to assist in the prevention, efficient detection, and management of reactions caused by 
edications. m
 
Participant Screening
There are some conditions that a participant may have that may make the study of an unwanted 
eaction to medication very complex.  If a partir
be able to part
y verbally, if the
 
o participate in the study, a participant will need to: T
 
suspect they have experienced a m 
12 months; 
time of th be over 18 at the 
r not be taking rec
not have any con 
include language disorders
conditions. 
 
P
Each participant, who meets the criteria, will be asked to do five things: 
 
Participate in an interview with the Pr 
about his/her experience of having a 
recorded, and then transcribed. 
 
 
to remember 
about the event as
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  Think about the events that preceded and followed the reaction, and indicate anything the 
participant would do differently if they were to have known the reaction was going to occur, 
 in the future. 
The participant will be asked to sign a consent form to allow: 
 
 the principal researcher to collect the information from the participant’s medical files on the 
dates indicated by the participant, from the clinics indicated by the participant . 
 the principal researcher to pass on the information gathered about the reaction (without 
identifying the participant), to the Therapeutics Goods Administration – Adverse Drug 
Reactions Department who are experts in identifying medications with reactions, in order to 
obtain an expert opinion on the reaction. 
 the principal researcher to show the information gathered about the reaction to a group of 
general practitioners, in order to understand which pieces of information are the most 
important to a Doctor when attempting to prevent, diagnose or manage medication 
reactions. Again the information would not include any information that identifies the 
participant.  In the case where a Doctor did recognise the history, they would be required to 
keep this information to themselves in the same way that they do not discuss information 
about their patients now. 
 
The participant will also be asked to nominate their family GP so that if there is any information 
that the participant needs to know, it can be passed onto their family GP. 
 
We understand that this information is highly confidential and will be treated accordingly. The 
only information collected will be the information that the participant has given consent to be 
collected, and it will only be used for the purposes outlined in this document.  The only person 
to have access to the participant’s identify will be the principal researcher.  The information will 
be de-identified.  That means that there will be no names and addresses stored with the 
information, just a code.  
 
At the end of the project, participants will be free to access the results of the research by 
contacting the principal researcher.  If, during the course of the project, information about the a 
reaction is discovered, that is important for the individual to know, the information will be sent 
to the family GP, and the participant will be notified so he/she can make an appointment to 
discuss this with the Doctor if required. 
 
Time commitment 
Each participant will be asked to attend a 1-hour session with the principal researcher in a 
location that is suitable.  Participants may need to be contacted and asked to attend another 
meeting if further information is required after looking in detail at the information.  One 
example may be if there appears to be some details missing. 
 
Benefits of the study 
This study will provide society with more information about what actually occurs when a 
participant experiences a serious reaction to a medication.  It is hoped that the information 
and anything they would have liked their medical practitioner to have done differently.   The 
aim of this component is to use the advantage of hindsight to find strategies to assist in the 
prevention, early detection or management of reactions
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 gained from the study will assist people developing information technology tools that will be 
more closely aligned with the needs of the Doctors and participants, specifically to prevent, 
detect early and manage more effectively reactions to medications.  It will also be used to 
provide medical practitioners with a different view of an adverse medication reaction from the 
view they usually see, which may provide them with additional insight that will assist in their 
practice. 
 
Withdrawal from the study 
Any participant is free to withdraw and/or to withdraw their permission for their interview or 
medical information to be used in the study at any point in time. 
 
Any questions regarding the project titled “Understanding unwanted reactions to medications” 
can be directed to the Principal Researcher, Michelle O’Brien, of the School of Information 
Technology and Mathematical Sciences on telephone number 041 856 8010. 
 
De-briefing support 
If, during or following the study, you felt the need to speak with a counsellor, services are 
available through one of the following sources. 
 
Clinical Health 
[clinic details] 
(To access this service you will need a referral from a General Practitioner) 
 
Or in the event of immediate support 
 
[Private psychologist’s name] 
Private Psychologist 
[Telephone details]. 
 
[Private psychologist’s name] 
Private Psychologist 
[Telephone details]. 
 
* University of Ballarat will fund debriefing if this is required.  This will include an individual de-
briefing session, and up to four counselling sessions.  If you require this service, you are free to 
access it without notifying the University. 
 
 
Thank you for your interest in the study.   
 
 
 
 
Michelle O’Brien 
Principal Researcher 
School of Information Technology and Mathematical Sciences 
University of Ballarat 
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 m.obrien@ballarat.edu.au
 
Should you (ie. the participant) have any concerns about the conduct of this research
please contact the Ex
University of Ballarat
Telephone:  (03)  532
 project, 
ecutive Officer, Human Research Ethics Committee, Office of Research, 
, PO Box 663, Mt Helen  VIC  3353. 
7 9765. 
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 APPENDIX C  
Consumer consent form 
Consumer Code:………..(For office use only) 
 
I, ……………………………………………………………………………………..…  
…………………………………………………………………………………… 
gree to the principal investigator, Michelle O’Brien: 
• speaking with each of the clinicians who treated me during the following episodes of 
care, interviewing them, and collating the medical view of the suspected reaction. 
linic                                                                                              Episode of Care (Date) 
have provided on the time-line attached, the information 
provided by the medical personnel I consulted, and showing this information that will not 
y, to the Therapeutic Goods 
tment, for an expert opinion on my case; 
 compiling the information I have provided on the time-line attached, information provided 
 identity of the clinics or Doctors involved in 
my case, to a group of General Practitioners from the Ballarat Division of General 
d that if they do, they will maintain my confidentiality in the same 
 
he research program in which I am being asked to participate has been explained fully to me, 
d 
 my satisfaction. 
 treated with the strictest 
confidence and data will be stored separately from any listing that includes my name and 
 
of……
 
a
 
 
C
…………………………………………………………………………………….……… 
…………………………………………………………………………………….……… 
 compiling the information I 
contain any information that will expose my identit
Administration – Adverse Drug Reactions Depar
 

by the medical personnel I consulted, and showing this information that will not contain any 
information that will expose my identity, or the
Practitioners.  I understand that it is possible that one of these Doctors will recognise my 
details, but also understan
way they are required to do when I visit their clinic; 
T
verbally and in writing, and any matters on which I have sought information have been answere
to
 
I understand that: 
 all information I provide (including questionnaires) will be
address 
 aggregated results will be used for research purposes and may be reported in scientific and 
academic journals 
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 I am free to withdraw my consent at any time during the study in which event my 
participation in the research study will immediately cease and any information obtained from 
sed. 
ATE: . . . . . . …….. . . .. . . . . . . .  
 
it will not be u
 
SIGNATURE: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  D
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 APPENDIX D 
Introductory letter to medical 
practitioners 
 
[D
 
 
ear Dr [medical practitioner], 
anted reactions to medications”. 
onsumer’s name], a consumer of your practice, has agreed to be a participant in the above 
ated in the first phase as outlined in the enclosed document outlining the 
 ction from a medical perspective. 
sed: - 
ld be prepared to participate, 
act me by e-mail on 
ate] 
D
 
 
Re: - the PhD study “Understanding unw
 
[C
study.  She has particip
project in detail - Attachment 1B. 
 
he project was approved by the following ethics committees: T
 [University Ethics committee] – 13th June, 2002 
 [Combined Hospitals Ethics Committee (hospitals involved in the study)] – 8th August, 2002. 
 
I am wondering if you would be prepared to participate in the second phase of the study please?  
Your participation would involve the following: - 
 
 Reviewing [Consumer’s name] case notes in relation to a suspected reaction to pain 
management medication, 
An interview with me to discuss the suspected rea
(Remuneration is available at the rate of $100/hr).   
 
bviously confidentiality and privacy are key issues within this project.  Please find encloO
 
 A copy of the consent form signed by [Consumer’s name], 
 A consent form for you to sign if you wou
 An information package for your information about the project. 
 
f you would like to discuss this further or to make a time, please contI
m.obrien@ballarat.edu.au or 041 856 8010.  I understand you are extremely busy, so if I don’t 
hear from you within a week, I will ring you to discuss this further. 
 
Thanks very much for you assistance, 
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Michelle O’Brien 
Principal Researcher 
School of Information Technology and Mathematical Sciences 
University of Ballarat 
m.obrien@ballarat.edu.au
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 APPENDIX E 
Medical plain language 
statement 
Project Explanation for Participants – Medical Practitioners 
(GPs who provide access to medical records, GPs in GP forums, and TGA personnel) 
 
Pro
 
Principal Investigator: Michelle O’Brien 
enior Investigator: Dr John Yearwood 
Pro
The s (ADRs).  At this stage, 
 
 T
 T  and may be related to the 
i
 D
u
 C
c
s
circumstances.   
bing process to inform decision support. 
focus. The person who has experienced the 
 
Attachment 1B 
ject Title: Understanding unwanted reactions to medications. 
S
 
ject Description 
 aim of this project is to learn more about adverse drug reaction
some information is known about some ADRs.  For example: 
ype A reactions are related to the pharmacology of a drug. 
ype B reactions are less predictable, generally more serious
ndividual Consumer (eg hypersensitivity) 
rug/Drug interactions occur when one drug interacts with another drug which results in an 
nwanted reaction. 
ontra-indications exist for some drugs that are known to cause problems with particular 
onditions.  Contra-indications may possibly warn against taking a particular drug, and in 
ome circumstances, certain drugs must never be taken. 
 
Most ADR information contains large amounts of uncertainty.  ADRs that have been 
documented may occur for some people with some condition in some 
 
It is also known that GPs and Hospital Doctors find it difficult to access the ADR information 
for the specific Consumer at the right time.   
 
This study will investigate the GP/Consumer decision environment to find the critical decision 
points and contexts in the prescri
 
This study begins with a Consumer (patient) 
reaction is the only person who was present throughout the entire course of the reaction.  A 
Doctor may only see a snap shot of the reaction. There may be more than one Doctor involved 
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 over the time the Consumer is experiencing the reaction.  Information about the reaction may be 
in more than one medical file.  Part of it may be in the family GP’s file and some in an after 
hours-emergency clinic’s file.  The information about this reaction therefore is spread between 
the Consumer, the Doctors involved and multiple medical files. 
 
Each person or group of people have different perspectives.  A Consumer is present throughout 
e entire reaction, but generally has no medical training.  A Doctor is present when the 
but can interpret what is seen using an understanding of 
o gather all of the information about reactions in order to understand 
e plan to interview Consumers who have experienced reactions to 
oughout the reaction, and the decisions made by the Consumers and 
octors, leading up to, during and following a serious reaction to a medication. 
There are some conditions that a Consumer may have that may make the study of an unwanted 
reaction to medication very complex.  If a Consumer has any of these conditions, they will not 
be able to participate in the study.  Before being accepted into the study, the Consumer will be 
asked verbally if they meet the criteria in the advertisement: 
 
To participate in the study, a participant will need to: 
 
 suspect they have experienced a moderate to severe reaction to medication within the last 6-
12 months; 
 be over 18 at the time of the reaction; 
 not be taking recreational drugs either at the time of the study or at the time of the reaction; 
 not have any conditions that may affect his or her ability to report the experience.  This may 
include language disorders, cognitive (processing or memory) disorders, or some psychiatric 
conditions. 
 
th
Consumer is in his/her clinic only, 
medicine.  If the reaction is serious enough, it may be sent to ADRAC (Adverse Drug Reactions 
Advisory Committee) in Canberra.  ADRAC have expertise in reactions to medications, but only 
have access to the limited information sent to them by the Doctor, and have no access to the 
Consumer.  Each person or group of people only have part of the total information about the 
reaction. 
 
In this study, we plan t
them more fully.   W
understand the reaction from their point of view.  The next stage is to find all of the pieces of 
the medical history that relate to the reaction that are stored in medical files.  The third stage is 
to show this information (de-identified) to the Therapeutics Goods Administration – Adverse 
Drug Reactions Department, for their opinion of the reaction.  The final stage is to discuss each 
case (again, de-identified) in a GP Forum.  
 
Specifically, having gathered all of this information, we are interested in identifying the critical 
events that happened thr
D
 
The ultimate aim of this project is to use the information to develop decision support 
technology that can be used to assist in the prevention, efficient detection, and management of 
reactions caused by medications. 
 
Consumer Screening 
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 Group 1. Consumer Involvement 
Each Consumer who meets the criteria will be asked to do five things: 
 
 Participate in an interview with the Principal Investigator (Michelle O’Brien), which will be 
approximately an hour in length.  The aim of the interview will be for the person to talk 
about their experience of having a suspected reaction to a medication. The interview will be 
tape recorded, and then transcribed. 
 
 Using a time line, the Consumer will be asked to write down the details of what happened 
throughout the suspected reaction.  This will include symptoms, medical clinics, medications, 
and doses.  Obviously it may be difficult to remember all of the information, but this process 
will assist in recalling as many facts about the event as possible. 
 
 The Consumer will be asked to think about the events that preceded and followed the 
reaction, and indicate anything they would do differently if they were to have known the 
reaction was going to occur, and anything they would have liked their medical practitioner to 
have done differently.   The aim of this component is to use the advantage of hindsight to 
find strategies to assist in the prevention, early detection or management of reactions in the 
future. 
 
The Consumer will be asked to sign a consent form to allow: 
 the principal researcher to collect the information from their medical files on the dates 
indicated by the person, from the clinics indicated by the person . 
 the principal researcher to pass on the information gathered about the reaction (without 
identifying the person), to a group of experts at the Therapeutics Goods Administration – 
Adverse Drug Reactions Department who are experts in identifying medications with 
reactions, in order to obtain an expert opinion on the reaction. 
 the principal researcher to show each case gathered about the reaction to a group of general 
practitioners, in order to understand which pieces of information are the most important to 
a Doctor when attempting to prevent, diagnose or manage medication reactions. Again the 
information would not include any information that identifies the person.  In the case where 
a Doctor did recognise the history, they would be required to keep this information to 
themselves in the same way that they do not discuss information about their patients now. 
 
The Consumer will also be asked to nominate their family GP so that if there is any information 
that the person needs to know, it can be passed onto their family GP. 
 
At the end of the project, Consumers will be free to access the results of the research by 
contacting the principal researcher.  If, during the course of the project, information about the a 
reaction is discovered that is important for the individual to know, the information will be sent 
to the family GP, and the person will be notified so he/she can make an appointment to discuss 
this with the Doctor if required. 
 
Group 2. Interview with Medical Personnel. 
Doctors who have treated the Consumers with suspect ADRs will be sent an information 
package including background information about the study, a consent form if they wish to 
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 participate in the study and a letter requesting information from relevant medical records or 
components of the medical records that pertain to the specific suspected ADR as identified by 
the Consumer. The GP will be asked to extract key information using the Consumer medical 
record data collection form, or to allow the principal researcher to extract these data under 
his/her supervision. Data will be de-identified before it leaves the GP’s office. The GP will be 
able to allocate codes to the data prior to releasing it. 
 
Group 3. TGA ADR involvement 
Staff at the TGA will be sent background information about the project, asked to review each 
case using their expertise in ADRs, and then to fill in a questionnaire for each case.  This 
information will be used as an “expert” view of the case.  It will also be used to determine the 
key decisions, events and pieces of data that influence the prevention, detection or management 
of an ADR, from the perspective of the expert. 
  
Group 4. GP Forums 
GPs interested in attending the GP forums will be sent background information about project 
and asked to fill in a participation consent form.  Each GP will be asked to attend a series of 
four forums of one hour each to be held at the [GP division].  The content of these forums will 
include background information about ADRs, and then each case (de-identified) will be 
presented for the GP group to comment on.  Again, the aim will be for the GPs to view the 
Consumer time lines and medical record information in order to identify key decisions, events 
and pieces of data that influence the prevention, detection and management of an ADR from 
the perspective of a GP. 
 
Privacy 
Medical records cannot be accessed for this project without written informed Consumer 
consent.  Each Consumer has been provided with background information that has been written 
in plain language text.  They have also been asked to sign an informed consent form to allow 
their data (collected in an interview, and data from their medical records) to be used in the study. 
 
The data collected for the study will only be used for the purposes disclosed the document/s 
provided to participants and so is within the privacy guidelines. 
 
Confidentiality 
Confidentiality will be maintained within this project. 
 
The Consumer participants will be identified to the medical clinics that hold their medical files in 
order to provide the consent required, and in order to access these files.  Once a case has been 
collated, this includes the Consumer view of the suspected reaction and the medical file 
information, the data will then be de-identified, so that the Consumer, medical clinics or 
individual Doctors will not be able to be identified.  The names and addresses that pertain to the 
codes will be stored separately from the data which will only be identified by codes. 
 
Each Consumer will be provided with a code eg. C10.  Each clinic for each Consumer will be 
issued a code eg. GP1.  The code for the first GP clinic this Consumer visited, therefore would 
be C10GP1. 
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The only time the codes, Consumer and medical file data will be joined together again, are if the 
TGA ADR department were to identify information about the Consumer’s condition that was 
critical for the future health of the Consumer that the GP should know about.  In this case, the 
data would be identified and provided to the TGA ADR department.  They would then maintain 
the confidentiality of these data in the same way they maintain the confidentiality of ADR 
reports that are sent to them on a regular basis. 
 
Data Storage 
During the study 
 
All original data (including tapes and medical file data) will be stored in a locked filing cabinet in 
the principal researcher’s office.  Once the data have been de-identified and transcribed, the 
original data will be stored in the data storage office (a locked office) in the school of ITMS.  
The documents linking the codes to the participants will be stored in a locked filing cabinet in 
the supervising researcher’s office – Dr John Yearwood. 
 
Following the completion of the study (all data needs to be stored for five years following the 
completion of the study) 
 
All original data (including tapes and medical file data) that have identifying data will be 
destroyed.  All transcripts that have been de-identified will be stored in a locked filing cabinet in 
a locked data storage room in the school of ITMS.  All data that have participant details and the 
associated codes will be stored in a locked filing cabinet in the principal researcher – Dr John 
Yearwood’s office. 
 
De-briefing available 
In the event that discussing an ADR results in either a Consumer or GP requiring de-briefing, 
the following supports will be available. 
 
Consumer Support 
Clinical Health 
[clinic details] 
(To access this service you will need a referral from a General Practitioner) 
 
Or in the event of immediate support 
 
[Private psychologist’s name] 
Private Psychologist 
[Telephone details]. 
 
[Private psychologist’s name] 
Private Psychologist 
[Telephone details]. 
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 (Although it is not anticipated that participation will cause participants distress, in the event that 
a participant is distressed by participating in the study, the university will fund up to four 
counselling sessions.  Participants are free to contact these services without revealing this to the 
University.  If a participant were to require further support, the psychologist the Consumer is 
seeing, will arrange a follow up service). 
 
General Practitioner’s support 
Ballarat and District Division of General Practitioners de-briefing service will be available for 
any GPs requiring support. 
 
Time commitment 
Consumers. 
Each Consumer will be asked to attend a 1-hour session with the principal researcher in a 
location that is suitable.  Participants may need to be contacted and asked to attend another 
meeting if further information is required after looking in detail at the information.  One 
example may be if there appears to be some details missing. 
 
GPs providing access to medical records. 
The time commitment may be up to half an hour per clinic per medical record accessed. 
 
GP Forums 
The time commitment will be 4x1 hour sessions plus travel time to the BDDGPs, over a period 
of four weeks. 
 
TGA ADR experts 
The time commitment will be up to one hour per case for up to 30 cases.  A possible total 
commitment of 30 hours over a period of six months. 
 
Benefits of the study 
This study will provide society with more information about what actually occurs when a person 
experiences a serious reaction to a medication.  It is hoped that the information gained from the 
study will assist people developing information technology tools that will be more closely aligned 
with the needs of the Doctors and Consumers, specifically to prevent, detect early and manage 
more effectively reactions to medications.  It will also be used to provide medical practitioners 
with a different view of an adverse medication reaction from the view they usually see, which 
may provide them with additional insight that will assist in their practice. 
 
Withdrawal from the study 
Any person is free to withdraw and/or to withdraw their permission for their interview or 
medical information to be used in the study at any point in time. 
 
Any questions regarding the project titled “Understanding unwanted reactions to medications” 
can be directed to the Principal Researcher, Michelle O’Brien, at the School of Information 
Technology on telephone number 041 856 8010. 
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Thank you for your interest in the study.   
 
 
 
 
 
 
Michelle O’Brien 
Principal Researcher 
School of Information Technology and Mathematical Sciences 
University of Ballarat 
m.obrien@ballarat.edu.au
 
 
Should you have any concerns about the conduct of this research project, please contact the 
Executive Officer, Human Research Ethics Committee, Office of Research, University of 
Ballarat, PO Box 663, Mt Helen VIC 3353.   Telephone:  (03)  5327 9765. 
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 APPENDIX F 
Medical consent form 
 
UNIVERSITY OF BALLARAT 
 
INFORMED CONSENT 
For Medical Staff who treated the Consumers in the study, 
GP Forums and TGA ADR Experts. 
 
 
 
Code number allocated to the participant (office use only)………. . . . . . . . . . . . . . . . . .  
 
 
Consent (fill out below) 
 
. . . . . . . .  . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . .  . . . . . . of . . . . . . . . . . . . . . . . . . . . . .   
. . . . . . . .  . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . 
 
hereby consent to participate in the above research study.  
 
The research program in which I am being asked to participate has been explained fully to me, 
verbally and in writing, and any matters on which I have sought information have been answered 
to my satisfaction. 
 understand that: 
all information I provide (including questionnaires) will be treated with the strictest 
confidence and data will be stored separately from any listing that includes my name and 
address 
 aggregated results will be used for research purposes and may be reported in scientific and 
academic journals 
 I am free to withdraw my consent at any time during the study in which event my 
participation in the research study will immediately cease and any information obtained from 
it will not be used. 
 
 
 
 
SIGNATURE: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  DATE: . . . . . . …….. . . .. . . . . . . . 
. . .  
 
I
 
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 APPENDIX G 
Expert questionnaire 
TGA ADR expert Questionnaire 
 
Participant code ……………………..…………………….. 
 
Please refer to background document for information about the project.   
 
Each of the cases include information the Consumer has provided about what they suspect may be an 
ADR, and the medical records for the dates the Consumer feels they experienced the ADR. 
 
For each case, can you please answer the following questions? 
 
Can you please determine a possible diagnosis/es for the symptoms described in the case? 
 
 
 
 
 
 
How certain are you of this diagnosis? 
 
 
 
 
 
 
 
 
If you consider the diagnosis to be an ADR, using the advantage of hindsight and the cumulated medical 
histories 
 
a. Are there any things that could have been done to prevent the reaction? 
 
 
 
 
 
 
b. What, if anything, could have been done to detect the reaction earlier? 
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c. What, if anything, could have been done to manage the ADR more effectively? 
 
 
 
 
 
 
 
 
What, in your opinion, are the key pieces of information, from within the case, that were used to make 
the diagnosis? 
 
 
 
 
 
 
What were the critical decisions do you feel were made throughout this process? 
 
a. By the doctor/s 
 
 
 
b. By the Consumer 
 
 
 
c. Collaborative decisions. 
 
 
 
What were the critical events you feel were made throughout this process? 
 
 
 
 
 
 
Are there any other factors in this case that you feel are significant?  If so, what are they and why do you 
feel they are significant? 
 
 
 
 
 
 
 APPENDIX H 
List of questions for consumer 
interviews 
 
Initial questions 
 Tell me what happened, leading up to, during and following your suspected reaction? 
 (Prompted for events leading up to, during and following the suspected reaction, 
including medications, dosages, clinics, doctors if required). 
 Who diagnosed the suspected reaction, and how certain is the diagnosis? 
 Was there anything that hindered or obstructed the diagnosis or management of the 
suspected ADR? 
 What communication was there between yourself and your doctors, and between the 
doctor/s and the hospital? (In cases when there was more than one doctor involved) 
 Have you had a reaction to a medication in the past? 
 How long have you been seeing your current doctor?  Do you regularly see the same 
doctor, or do you move between GPs? 
 Using hindsight, is there anything you do differently if you were faced with this situation 
again to either prevent or detect the suspected reaction? 
 Again, using hindsight, is there anything would you have liked your doctor/s to do 
differently? 
 What additional medications were you taking at the time of the suspected reaction, 
including prescription, over the counter, and complementary (herbal) preparations? 
 
Additional information gathered in later interviews 
 Asking about the history of pre-existing conditions to provide context for the experience 
of the suspected ADR, 
 exploring the risk of the medication versus the benefits of the medication weighed up 
against the risks of not treating the condition, 
 consumer doctor decision-making models, 
 feelings and impact of the suspected ADR, 
 sources of information used by the consumer to assist with decision-making, 
 consumer decision types surrounding ADRs, 
 other people in the consumer decision-making environment that were involved in the 
decision-making processes and, 
 understanding of the terminology of “side effect” versus “drug reaction” 
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APPENDIX I 
Time line of events 
       
terview:-        
         
         
                
 
Consumer ID:- 
Date of In
Date 
Event 
Description 
Treatmen
Medication/s 
Dose 
                
                
t                 
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 APPENDIX J 
Inventory of data stored in an 
NVivo database 
Document type Document Name 
Memo C02 - Memo 
Consumer Interview C02 - Toni 
Consumer Interview C04 - Julie 
 C04 - Memo 
 C04 - Memo 2 
 C04 - Memo 3 
 C04 - Memo 4 
Consumer Interview C05 - Kay 
Consumer Interview C06 - Helen 
 C06 - Memo 
 C06 - Memo 2 
Consumer Interview C07 - Mary 
Consumer Interview C08 - Belinda 
 C08 - Memo 
 C08 - Memo 2 
 C09 - Memo 
Consumer Interview C09 - Tim 
Consumer Interview C10 - Edward 
Consumer Interview C11 - Irene 
Consumer Interview C12 - James 
Consumer Interview C13 - Joanna 
 C13 - Memo 
Consumer Interview C14 - Bob 
 C14 - Memo 
 C14 - Memo 2 
Consumer Interview C15 - Kerry 
Consumer Interview C16a - Robyn 
Consumer Interview - husband C16b - Thomas 
 C17 - Memo 2 
Consumer Interview C17 - Paul 
Medical practitioner Interview Interview with C02GP1 - Dr Barns 
 Interview with C02GP1 - Memo 
Medical practitioner Interview Interview with C05H1 - Dr Green 
Medical practitioner Interview Interview with C05SP1- Dr Nash 
Medical practitioner Interview Interview with C06H1 - Dr Stevens 
Medical practitioner Interview Interview with C07SP1 - Dr O'Neil 
Medical practitioner Interview Interview with C09GP1- Dr Price 
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 Medical practitioner Interview Interview with C11SP1 - Dr James 
Medical practitioner Interview Interview with C13GP1 - Dr Carey 
 Interview with C13GP1 - Memo 
Medical practitioner Interview Interview with C17GP1 - Dr Lang 
 Interview with C17GP1 - Memo 
Expert Questionnaire TGA 3 Questionnaire C07 
Expert Questionnaire TGA 3 Questionnaire C16 
Expert Questionnaire TGA 2 Questionnaire C02 
Expert Questionnaire TGA 2 Questionnaire C04 
Expert Questionnaire TGA 2 Questionnaire C05 
Expert Questionnaire TGA 2 Questionnaire C06 
Expert Questionnaire TGA 2 Questionnaire C08 
Expert Questionnaire TGA 2 Questionnaire C09 
Expert Questionnaire TGA 2 Questionnaire C10 
Expert Questionnaire TGA 2 Questionnaire C11 
Expert Questionnaire TGA 2 Questionnaire C12 
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Expert Questionnaire TGA1QuestionsC11 
Expert Questionnaire TGA1QuestionsC12 
Expert Questionnaire TGA1QuestionsC13 
Expert Questionnaire TGA1QuestionsC14 
Expert Questionnaire TGA1QuestionsC15 
 TGA1QuestionsC15 - Memo 
 TGA1QuestionsC15 - Memo 2 
Expert Questionnaire TGA1QuestionsC16 
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Expert Questionnaire TGA1QuestionsCO2 
 TGA1QuestionsCO2 - Memo 
 TGA1QuestionsCO2 - Memo 2 
Expert Questionnaire TGA1QuestionsCO4 
Expert Questionnaire TGA1QuestionsCO5 
 TGA1QuestionsCO5 - Memo 
 TGA1QuestionsCO5 - Memo 2 
 TGA1QuestionsCO5 - Memo 3 
 TGA1QuestionsCO5 - Memo 4 
Expert Questionnaire TGA1QuestionsCO6 
Expert Questionnaire TGA1QuestionsCO8 
 TGA1QuestionsCO8 - Memo 
Expert Questionnaire TGA1QuestionsCO9 
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APPENDIX K  
Questions for medical 
practitioner interviews 
 Could you please review case notes and fill in time-line of events from medical 
perspective? (This was changed to ask if they could review the medical notes and then 
explain what they believed happened). 
 Do you feel this medication caused these symptoms?  If so, to what degree of certainty? 
 How easy or difficult was it to determine if this was an ADR, a pre-existing disease, or a 
new disease?  
 How did you come to your diagnosis?   
 What were the key factors? 
 What model do you feel was used in the diagnosis and treatment options?   
 Was it a joint decision with (consumer name)?,  
o initially observed and diagnosed by the consumer,  
o initially observed and diagnosed by you? 
 How did the consumer assist or otherwise the detection and/or management of the 
ADR? 
 What sources of information did you use? 
o External 
o From Medical knowledge 
o From knowledge of consumer 
o From Consumer 
 Were the resources used effective? 
 Were there any resources that are available that you would have liked to have been able 
to use, but were unavailable? 
 Were there any resources that are currently not available that you would like to see 
become available (some that don’t yet exist)? 
 Is there any history of reactions to medications in the file? 
 Do you see any difference between side effects and ADRs?  If so, what are the 
differences? 
 Is there anything you would do differently if faced with this same situation again using 
the advantage of hindsight? 
 Is there anything you feel you would like the consumer to have done differently if faced 
with this same situation again? 
 In the data so far, it appears that for some people, symptoms they know could be caused 
by a drug (side effects) were tolerated, but unexpected symptoms resulted in increased 
anxiety – what are your thoughts about this? 
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  Did you report this suspected reaction to TGA?   
o Why?  
o Why not? 
 What do you believe was the impact of this suspected ADR was on the Consumer?   
 How would you describe the severity of this suspected reaction? 
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